# Laparoscopic surgery for inguinal hernia repair: systematic review of effectiveness and economic evaluation

K McCormack, B Wake, J Perez, C Fraser,
J Cook, E McIntosh, L Vale and A Grant

April 2005

**Health Technology Assessment
NHS R&D HTA Programme**

HTA

Laparoscopic surgery for inguinal hernia repair: systematic review of effectiveness and economic evaluation

K McCormack,[1][*] B Wake,[1] J Perez,[2] C Fraser,[1]
J Cook,[1] E McIntosh,[3] L Vale[1,2] and A Grant[1]

[1] Health Services Research Unit, Institute of Applied Health Sciences,
   University of Aberdeen, UK
[2] Health Economics Research Unit, Institute of Applied Health Sciences,
   University of Aberdeen, UK
[3] Health Economics Research Centre, Department of Public Health,
   University of Oxford, UK

* Corresponding author

Published April 2005

This report should be referenced as follows:

McCormack K, Wake B, Perez J, Fraser C, Cook J, McIntosh E, *et al*. Laparoscopic surgery
for inguinal hernia repair: systematic review of effectiveness and economic evaluation.
Health Technol Assess 2005;**9**(14).

NHS R&D HTA Programme

The research findings from the NHS R&D Health Technology Assessment (HTA) Programme directly influence key decision-making bodies such as the National Institute for Clinical Excellence (NICE) and the National Screening Committee (NSC) who rely on HTA outputs to help raise standards of care. HTA findings also help to improve the quality of the service in the NHS indirectly in that they form a key component of the 'National Knowledge Service' that is being developed to improve the evidence of clinical practice throughout the NHS.

The HTA Programme was set up in 1993. Its role is to ensure that high-quality research information on the costs, effectiveness and broader impact of health technologies is produced in the most efficient way for those who use, manage and provide care in the NHS. 'Health technologies' are broadly defined to include all interventions used to promote health, prevent and treat disease, and improve rehabilitation and long-term care, rather than settings of care.

The HTA programme commissions research only on topics where it has identified key gaps in the evidence needed by the NHS. Suggestions for topics are actively sought from people working in the NHS, the public, consumer groups and professional bodies such as Royal Colleges and NHS Trusts.

Research suggestions are carefully considered by panels of independent experts (including consumers) whose advice results in a ranked list of recommended research priorities. The HTA Programme then commissions the research team best suited to undertake the work, in the manner most appropriate to find the relevant answers. Some projects may take only months, others need several years to answer the research questions adequately. They may involve synthesising existing evidence or designing a trial to produce new evidence where none currently exists.

Additionally, through its Technology Assessment Report (TAR) call-off contract, the HTA Programme is able to commission bespoke reports, principally for NICE, but also for other policy customers, such as a National Clinical Director. TARs bring together evidence on key aspects of the use of specific technologies and usually have to be completed within a limited time period.

Criteria for inclusion in the HTA monograph series
Reports are published in the HTA monograph series if (1) they have resulted from work commissioned for the HTA Programme, and (2) they are of a sufficiently high scientific quality as assessed by the referees and editors.

Reviews in *Health Technology Assessment* are termed 'systematic' when the account of the search, appraisal and synthesis methods (to minimise biases and random errors) would, in theory, permit the replication of the review by others.

The research reported in this monograph was commissioned and funded by the HTA Programme on behalf of NICE as project number 03/31/01. The authors have been wholly responsible for all data collection, analysis and interpretation and for writing up their work. The HTA editors and publisher have tried to ensure the accuracy of the authors' report and would like to thank the referees for their constructive comments on the draft document. However, they do not accept liability for damages or losses arising from material published in this report.

The views expressed in this publication are those of the authors and not necessarily those of the HTA Programme, NICE or the Department of Health.

Editor-in-Chief:	Professor Tom Walley
Series Editors:	Dr Peter Davidson, Professor John Gabbay, Dr Chris Hyde, Dr Ruairidh Milne, Dr Rob Riemsma and Dr Ken Stein
Managing Editors:	Sally Bailey and Caroline Ciupek

Abstract

Laparoscopic surgery for inguinal hernia repair: systematic review of effectiveness and economic evaluation

K McCormack,[1][*] B Wake,[1] J Perez,[2] C Fraser,[1] J Cook,[1] E McIntosh,[3] L Vale[1,2] and A Grant[1]

[1] Health Services Research Unit, Institute of Applied Health Sciences, University of Aberdeen, UK
[2] Health Economics Research Unit, Institute of Applied Health Sciences, University of Aberdeen, UK
[3] Health Economics Research Centre, Department of Public Health, University of Oxford, UK
* Corresponding author

Objectives: To determine whether laparoscopic methods are more effective and cost-effective than open mesh methods of inguinal hernia repair, and then whether laparoscopic transabdominal preperitoneal (TAPP) repair is more effective and cost-effective than laparoscopic totally extraperitoneal (TEP).

Data sources: Electronic databases. Conference proceedings. Manufacturers' submissions to the National Institute for Clinical Excellence (NICE) were reviewed.

Review methods: Selected studies were rigorously assessed. Dichotomous outcome data were combined using the relative risk method and continuous outcomes were combined using the Mantel–Haenszel weighted mean difference method. Time to return to usual activities was described using hazard ratios derived from individual patient data reanalysis. A review of economic evaluations undertaken by NICE in 2001 was updated and an economic evaluation was performed. The estimation of cost-effectiveness focused on the comparison of laparoscopic repair with open flat mesh. A Markov model incorporating the data from the systematic review was used to estimate cost-effectiveness for a time horizon up to 25 years.

Results: Thirty-seven randomised control trials (RCTs) and quasi-RCTs met the inclusion criteria on effectiveness. Fourteen studies were included in the review of economic evaluations. Laparoscopic repair was associated with a faster return to usual activities and less persisting pain and numbness. There also appeared to be fewer cases of wound/superficial infection and haematoma. However, operation times are longer and there appears to be a higher rate of serious complications in respect of visceral (especially bladder) injuries. Mesh infection is very uncommon with similar rates noted between the surgical approaches. There is no apparent difference in the rate of hernia recurrence. Laparoscopic repair was more costly to the health service than open repair, with an estimated extra cost from studies conducted in the UK of about £300–350 per patient. The point estimates of cost provided by the economic model also suggest that the laparoscopic techniques are more costly (approximately £100–200 more per patient after 5 years). From the review of economic evaluations, the estimates of incremental cost per additional day at usual activities were between £86 and £130. Where productivity costs were included, they eliminated the cost differential between laparoscopic and open repair. Additional analysis incorporating new trial evidence suggested that TEP was associated with significantly more recurrences than open mesh but these data did not greatly influence cost-effectiveness.

Conclusions: For the management of unilateral hernias, the base-case analysis and most of the sensitivity analysis suggest that open flat mesh is the least costly option but provides less quality adjusted life years (QALYs) than TEP or TAPP. TEP is likely to dominate TAPP (on average TEP is estimated to be less costly and more effective). It is likely that, for management of symptomatic bilateral hernias, laparoscopic repair would be more cost-effective as differences in operation time (a key cost driver) may be reduced and differences in convalescence time are more marked (hence QALYs will increase) for laparoscopic compared with open mesh repair. When possible repair of contralateral occult hernias is taken into account, TEP repair is most likely to be considered cost-effective at threshold values for the cost per additional QALY above £20,000. The increased adoption of laparoscopic techniques may allow patients

to return to usual activities faster. This may, for some people, reduce any loss of income. For the NHS, increased use of laparoscopic repair would lead to an increased requirement for training and the risk of serious complications may be higher. Chronic pain should now be addressed prospectively using standard definitions and allowing assessment of the degree of pain. More evidence is required on the loss of utility caused by persisting pain and numbness, as well as serious complications resulting from minor surgery. Prospective population-based registries of new surgical procedures may be the best way to address this, as a complement to randomised trials assessing effectiveness. Further research relating to whether the balance of advantages and disadvantages changes when hernias are recurrent or bilateral is also required as current data are limited. Methodologically sound RCTs are needed to consider the relative merits and risks of TAPP and TEP. Further methodological research is required into the complexity of laparoscopic groin hernia repair and the improvement of performance that accompanies experience.

Contents

List of abbreviations

CEAC	cost-effectiveness acceptability curve	QALY	quality-adjusted life-year
CI	confidence interval	QoL	quality of life
EU	European Union	RCT	randomised controlled trial
HES	Hospital Episode Statistics	RR	relative risk
HR	hazard ratio	SCUR	Scandinavian Clinics United Research
IPD	individual patient data		
ITT	intention-to-treat	SD	standard deviation
MRC	Medical Research Council	TAPP	transabdominal preperitoneal
NICE	National Institute for Clinical Excellence	TEP	totally extraperitoneal
OFM	open flat mesh	WMD	weighted mean difference

All abbreviations that have been used in this report are listed here unless the abbreviation is well known (e.g. NHS), or it has been used only once, or it is a non-standard abbreviation used only in figures/tables/appendices in which case the abbreviation is defined in the figure legend or at the end of the table.

vii

Executive summary

Background

This review set out to determine: (1) whether laparoscopic methods are more effective and cost-effective than open mesh methods of inguinal hernia repair; and (2) whether laparoscopic transabdominal preperitoneal (TAPP) repair is more effective and cost-effective than laparoscopic totally extraperitoneal (TEP) repair of inguinal hernia. Where data allow, the patient population has been split by whether or not the hernia is recurrent or bilateral and whether or not the patient receives general anaesthesia.

Description of proposed service

Laparoscopic inguinal hernia repair is a minimal access surgical procedure. Small incisions are made for the operating instruments and for a laparoscope. A piece of prosthetic mesh is used to close the hernia defect. Laparoscopic repair is usually undertaken by means of the TAPP or TEP repair, the main variation being whether or not the instruments enter the peritoneal cavity.

Epidemiology and background

About 70,000 surgical repairs of inguinal hernia are performed each year in England, constituting approximately 0.14% of the population each year and accounting for over 100,000 NHS bed-days. Inguinal hernia can occur unilaterally or bilaterally and can recur after surgery, necessitating reoperation. The most effective method of repair of inguinal hernia is by means of a tension-free technique involving the use of prosthetic mesh to reinforce the abdominal wall in the region of the groin. This can be accomplished by open or laparoscopic techniques. The most common open method in use in the UK is the flat mesh technique. However, about 4% of primary inguinal hernia operations are currently carried out laparoscopically.

Methods

Effectiveness

Electronic searches of 17 databases were conducted to identify reports of trials of laparoscopic inguinal hernia repair, including TAPP and TEP procedures. Systematic reviews and other evidence-based reports were also identified. In addition, selected conference proceedings were handsearched, websites were consulted, reference lists of all included papers were scanned, experts were contacted for other potentially eligible reports and manufacturers' submissions to the National Institute for Clinical Excellence (NICE) were reviewed.

All published and unpublished randomised controlled trials (RCTs) and quasi-randomised controlled trials were eligible for inclusion if they compared (1) laparoscopic inguinal hernia repair with open mesh inguinal hernia repair or (2) laparoscopic TAPP with laparoscopic TEP methods of inguinal hernia repair.

Individual patient data (IPD) were obtained, where possible, from the responsible trialist for all eligible studies. Where IPD were unavailable, additional aggregate data were sought from trialists and published aggregate data were taken from the trial reports. Two reviewers independently extracted data and assessed study quality. For each outcome the results were derived from the best available source: if IPD reanalysis was not available, information from aggregate data provided by the trialist or data from the trial publications were used. Dichotomous outcome data were combined using the relative risk method and continuous outcomes were combined using the Mantel–Haenszel weighted mean difference method. Time to return to usual activities was described using hazard ratios derived from IPD reanalysis. Predefined subgroup analyses based on recurrent hernias and bilateral hernias were also carried out.

Cost-effectiveness

A review of economic evaluations was undertaken by NICE in 2001. This review was updated from 2000 until August 2003. Identified studies were quality assessed against the *BMJ* guidelines for reviewers and narratively synthesised along with those identified from the previous health technology assessment.

In addition to the review, an economic evaluation was performed. The estimation of cost-effectiveness focused on the comparison of laparoscopic repair with open flat mesh. Estimates for open plug and mesh and open preperitoneal mesh techniques are based on very limited data and are likely to be unreliable. A Markov model incorporating the data from the systematic review was used to estimate cost-effectiveness for a time horizon up to 25 years.

Number and quality of studies and direction of evidence

Effectiveness

Thirty-seven RCTs and quasi-RCTs met the inclusion criteria on effectiveness. Thirteen of these were newly identified for this update. The RCTs were of varying, generally moderate, quality, with sample sizes ranging from 18 to 928 randomised patients and with a mean or median follow-up from 1 week to 5 years.

Cost-effectiveness

Fourteen studies were included in the review of economic evaluations, seven of which were identified from the previous health technology assessment. Two of the new studies were industry submissions and one was based on a model. Of the other five studies, two were modelled data obtained from systematic reviews; the other three studies used poor methodology and were based on non-randomised evidence.

Summary of benefits

Laparoscopic repair is associated with a faster return to usual activities and less persisting pain and numbness. There also appear to be fewer cases of wound/superficial infection and haematoma. However, operation times are longer and there appears to be a higher rate of serious complications in respect of visceral (especially bladder) injuries. Mesh infection is very uncommon with similar rates noted between the surgical approaches. There is no apparent difference in the rate of hernia recurrence.

Costs

From the systematic review of economic evaluations, laparoscopic repair was more costly than open mesh in all but two of the 14 studies. Laparoscopic repair is more costly to the health service than open repair, with an estimated extra cost from studies conducted in the UK of about £300–350 per patient. The point estimates of cost provided by the economic model also suggest that the laparoscopic techniques are more costly (around £100–200 more per patient after 5 years).

Cost-effectiveness

From the review of economic evaluations, the estimates of incremental cost per additional day at usual activities were between £86 and £130. Where productivity costs were included, they eliminated the cost differential between laparoscopic and open repair.

For the management of unilateral hernias, the base-case analysis and most of the sensitivity analysis suggest that open flat mesh is the least costly option but provides less quality adjusted life years (QALYs) than TEP or TAPP. TEP is likely to dominate TAPP (on average TEP is estimated to be less costly and more effective). The results of the base-case analysis and much of the sensitivity analysis suggest that the mean incremental cost per QALY for TEP compared with open mesh is less than £10,000 and that there is approximately an 80% chance that TEP is the most cost-effective intervention should society's maximum willingness to pay for an additional QALY be £20,000.

For recurrent hernias and treatment choice guided by gender and age, the data were sparse and results may be unreliable. In this circumstance, extrapolation from the base-case analysis for primary repair may provide the best available evidence. It is likely that, for management of symptomatic bilateral hernias, laparoscopic repair would be more cost-effective as differences in operation time (a key cost driver) may be reduced and differences in convalescence time are more marked (hence QALYs will increase) for laparoscopic compared with open mesh repair. When possible repair of contralateral occult hernias is taken into account, TEP repair is most likely to be considered cost-effective at threshold values for the cost per additional QALY above £20,000. Nonetheless, the results are sensitive to changes in estimates of prevalence and risk of progression of occult hernias, for both of which data are limited.

Sensitivity analyses

The results of the base-case analysis were most sensitive to assumptions about the disutility associated with persisting pain and numbness. When persisting pain and numbness were excluded from the analysis, then the results obtained are similar to those that formed the basis of the 2001 assessment, and it is unlikely that laparoscopic repair would be associated with an incremental cost per QALY of less than £50,000. Use of patient utility data derived from a discrete choice experiment, which put weight on avoiding rare intraoperative complications, indicated that both TAPP and TEP were unlikely to be associated with net benefits compared with open flat mesh.

Supplementary report

In April 2004, a further large trial was published. This trial reported data on 2164 randomised participants compared with the 5560 randomised participants in the 37 eligible trials considered by the main Assessment Report. The main change from the main Assessment Report is that recurrence is now statistically significantly more likely following TEP repair. The findings of the supplementary analysis for the other outcomes were essentially similar to those in the original report. On incorporation of these data into the economic model, it was found that, in terms of incremental cost per QALY, laparoscopic repair at levels of willingness to pay for an additional QALY accepted by decision-makers in the past is still likely to be considered cost-effective.

Limitations of the calculations (assumptions made)

Effectiveness

The meta-analyses were conducted using a fixed-effects model although subsequent reanalysis using a random effect model did not greatly alter effect estimates. The main limitations related to the quantity and quality of the data available. For example, few data pertaining to longer than 5-year follow up were available and only one small randomised trial was identified comparing TAPP with TEP repair.

Cost-effectiveness

The nature of the data available also had an impact on the economic evaluation, which extrapolated outcomes for up to 25 years. Assumptions were made by extrapolation about how baseline rates would change over time and about how long relative effects would persist. As far as possible these assumptions were in accordance with available data, and the results were insensitive to changes in the assumed duration of effects.

TAPP and TEP were indirectly compared. In reality, the difference in cost and outcomes between the two procedures may be much smaller than those suggested using data derived from indirect comparisons. For example, the TEP data may relate to more experienced surgeons than the data available for TAPP.

Other important issues regarding implications

The increased adoption of laparoscopic techniques may allow patients to return to usual activities faster. This may, for some people, reduce any loss of income.

For the NHS, increased use of laparoscopic repair would lead to an increased requirement for training which may be costly. During the training period, laparoscopic repair is likely to have higher costs (and hence be less cost-effective). Furthermore, the risk of serious complications may be higher, although adequate supervision and training might minimise these risks.

Notes on the generalisability of the findings

The 37 trials considered in the clinical effectiveness review were mounted in a wide range of settings. Nonetheless, very limited data were available about rare complications and for the subgroup analyses of recurrent and bilateral hernias; although data are presented, these have questionable reliability and hence limited generalisability.

Need for further research

A liberal definition of 'persisting pain' was used in the meta-analyses with the consequence of widely varying prevalence rates across trials. Ideally, the issue of chronic pain should now be addressed prospectively using standard definitions and allowing assessment of the degree of pain. Furthermore, more evidence is required on the loss of utility caused by persisting pain and numbness.

Rare, serious complications are an important consideration in the context of minor surgery. Prospective population-based registries of new surgical procedures may be the best way to address this, as a complement to randomised trials assessing effectiveness.

Further research relating to whether the balance of advantages and disadvantages changes when hernias are recurrent or bilateral is also required as current data are limited.

Questions remain about the relative merits and risks of TAPP and TEP. Ideally there should be more data from methodologically sound RCTs.

Laparoscopic groin hernia repair is technically challenging and performance is likely to improve with experience. This issue is important in its evaluation and further methodological research related to this is warranted in the context of both trials and meta-analyses of trial data.

Chapter 1

Aim of the review

The aim of this review is to determine:
(1) whether laparoscopic methods are more effective and cost-effective than open mesh methods of inguinal hernia repair; and
(2) whether laparoscopic transabdominal preperitoneal (TAPP) repair is more effective and cost-effective than laparoscopic totally extraperitoneal (TEP) repair of inguinal hernia. Where data allow, the patient population has been split by whether or not the hernia is recurrent or bilateral and whether or not the patient receives general anaesthesia.

Supplementary report

In April 2004, a further large trial was published. This trial reported data on 2164 randomised participants compared with the 5560 randomised participants in the 37 eligible trials considered by the main Assessment Report. The main change from the main Assessment Report is that recurrence is now statistically significantly more likely following TEP repair. The findings of the supplementary analysis for the other outcomes were essentially similar to those in the original report. On incorporation of these data into the economic model, it was found that, in terms of incremental cost per quality-adjusted life year (QALY), laparoscopic repair at levels of willingness to pay for an additional QALY accepted by decision-makers in the past is still likely to be considered cost-effective. See Appendix 15.

Chapter 2

Background

Description of underlying health problem

Introduction
An inguinal hernia is a protrusion of the intestine through a weakness in the abdominal wall. It usually presents as a lump, with or without discomfort, which may limit daily activities and the ability to work. Inguinal hernias can occasionally be life-threatening if the bowel strangulates or becomes obstructed and in these cases emergency surgery is indicated. Groin hernia repair is a common surgical procedure but a variety of methods of repair exist.

Epidemiology
In 2001–02, 62,696 primary inguinal hernia repairs were carried out in England. In addition, 4939 repairs of recurrent inguinal hernias were also carried out. There were 2924 (4.7%) primary hernia repairs classed as emergency surgery whereas 427 (8.6%) of the recurrent hernia repairs were emergencies. The mean length of stay in hospital was 2.3 days for primary repair of inguinal hernia and 2.6 days for recurrent hernia repair. A total of 26,527 (42.3%) of primary hernia repairs were carried out as day cases whereas the figure for recurrent hernia repair was 1045 (21.2%). For both primary and recurrent hernia repairs, most patients were male: 92.4% and 96.4%, respectively. The mean age of patients undergoing primary hernia repair was 57 years and the figure for recurrent hernia repair was 63 years. A significant number of patients were aged 60 years or over: 49.4% for primary hernia repair and 68.4% for recurrent hernia repair. The figures have remained relatively stable over the past 4 years and *Tables 1* and *2* and *Figure 1* provide further details.

Significance in terms of ill-health
Since inguinal hernia repair is such a frequently performed surgical procedure, relatively small differences in health or quality of life (QoL) are potentially important. The primary purpose of the procedure is to prevent the hernia recurring; recurrence is likely to lead to further surgery, which may be technically more difficult the second time. The significance of discomfort due to pain or numbness depends on whether it is short-term or persistent; severe chronic pain can occur after hernia repair.[2–4] There are also rare intraoperative risks from the surgical procedure.[5]

TABLE 1 Details of primary inguinal hernia repairs, England, 1998–2001

Year	No. of repairs	Emergency (%)	Male (%)	Day case (%)	Average age (years)	Aged over 60 years (%)	Mean stay (days)
2001–02	62,696	4.7	92.4	42.3	57	49.4	2.3
2000–01	64,745	4.7	92.3	41.2	56	49.2	2.3
1999–2000	63,527	5.0	92.5	38.5	56	49.6	2.3
1998–99	66,346	4.9	92.4	36.1	56	50.0	2.4

TABLE 2 Details of recurrent inguinal hernia repairs, England, 1998–2001

Year	No. of repairs	Emergency (%)	Male (%)	Day case (%)	Average age (years)	Aged over 60 years (%)	Mean stay (days)
2001–02	4939	8.6	96.4	21.2	63	68.4	2.6
2000–01	5147	9.3	96.4	20.8	63	65.3	2.7
1999–2000	5287	8.3	96.4	19.3	63	66.4	2.7
1998–99	5478	7.9	97.0	18.0	63	66.2	2.6

FIGURE 1 *Age distributions for primary and recurrent hernia repair England, 1998–2001. Data taken from HES (Hospital Episode Statistics) database for England, Department of Health.[1]*

Current service provision and variation in service

Surgical treatment is recommended, in the majority of patients, to prevent the bowel from becoming strangulated or obstructed or to alleviate symptoms. Most herniorrhaphies are therefore performed as elective procedures. However, emergency repair of inguinal hernia is necessary if the hernia presents as a serious complication. In such circumstances there is a greater risk of postoperative morbidity and mortality.

Inguinal hernia can be repaired using traditional open methods or using newer laparoscopic techniques. The traditional method of open repair of groin hernias using suturing has changed little in the 100 years following the introduction of Bassini's method in the late nineteenth century. The use of open tension-free methods of inguinal hernia repair using prosthetic mesh has only recently become widely adopted.[6] The most common open technique in use in the UK is that popularised by Lichtenstein and colleagues. This involves the suturing of a mesh deep to the external oblique muscle, thus reinforcing the posterior wall of the inguinal canal and deep

internal ring.[7] Open mesh repairs can be further classified as flat mesh (including, for example, the Lichtenstein method of repair), open preperitoneal mesh (including the Stoppa and Nyhus methods of repair) and the plug and mesh (including the Rutkow and Robbins repair).

In 2001–02, 62,696 primary operations were performed in England using 81,730 bed-days.[1] The majority of these were prosthetic mesh repairs (84.5%). Within the four time periods surveyed, there was a relative increase in the proportion of primary prosthetic mesh repairs (rising from 78 to 80, 82 and 85% of the total operations) and a fall in the proportion of non-mesh repairs (from 9 to 8.1, 6.5 and 5.6%) over the same period. As the data suggest, this was mostly due to an increase in the number of mesh repairs performed at the expense of non-mesh repairs. A similar pattern of operation frequency was seen for repair of recurrent inguinal hernia.

The proportion of patients undergoing day-case procedures in England increased slowly over the same time periods (primary prosthetic mesh repair, rising from 36 to 39, 41 and 42%; recurrent prosthetic mesh repair, rising from 18 to 19, 20 and 21%).

TABLE 3 *Cost of current and recent service provision: use of NHS resources on operations for primary repair of inguinal hernia in England[a]*

Name of operation	Finished episodes		Cost per episode (£)	Cost to the NHS (£)
	No.	%		
2001–02				
Laparoscopic	2,172[b]	4.1	1078[c]	2,341,594
Open flat mesh	50,805[b]	95.9	987[d]	50,141,003
Open non-mesh repair	3,534	100	942[e]	3,328,311
Total				55,810,908 (95% CI 30,609,000 to 98,764,000)[f]

[a] Unit costs in the table are rounded.
[b] Based on the assumption that 4.1% of the 52,977 mesh repairs are laparoscopic repair and the remainder are open flat mesh.
[c] Unit cost procedure for TEP.
[d] Unit cost procedure for open flat mesh.
[e] Unit cost procedure for open non-mesh.
[f] 2.5 and 97.5 percentiles of the Monte Carlo simulation.

Exact figures on the types of repair used in current surgical practice are not easy to obtain. Data taken from Hospital Episode Statistics (HES) for England report the number of primary and recurrent inguinal hernia repairs grouped within broad ranges of main operations. It was not possible to obtain secondary procedure codes for laparoscopic surgery within the project time frame. However, a study published in 2003, describing patterns of surgical repair using HES for England from April 1998 to December 2001, was able to provide this information.[8] This study found that 8960 (4.1% of the total operations) inguinal hernia repairs were carried out using laparoscopic surgery within the period surveyed. The rate of laparoscopic repairs as a proportion of all repairs was found to be increasing slowly and non-significantly by 0.14% [95% confidence interval (CI) 0.02 to 0.25%] per year.

In 2000, an audit of the NHS in Scotland between 1 April 1998 and 31 March 1999 found that 229 (4%) inguinal hernia repairs were carried out using laparoscopic surgery; 4612 (84%) were open mesh surgery, 65 (1%) were open preperitoneal surgery and 600 (11%) were open non-mesh surgery.[9] Most repairs were performed using general anaesthetic on an inpatient basis and there was a significant trend to perform laparoscopic repair or open preperitoneal repair for patients with bilateral and recurrent hernias.

Current service costs
Assuming that 4.1% of all mesh repairs are carried out using laparoscopic techniques and taking the cost of different types of repair as £1078, £987

and £942 for laparoscopic, open mesh repair and non-mesh repair, respectively, then the cost to the health service in England in 2001–02 pounds is £55.81 million (*Table 3*).

Description of new interventions

Intervention
Laparoscopic techniques
The first report of a hernia repair using laparoscopy was made in 1982 using laparoscopic closure of the neck of the sac.[10] The first reported use of prosthetic mesh for laparoscopic inguinal hernia repair was in 1991.[11,12] Laparoscopic approaches allow hernia repair without the need to open the abdominal wall. Instead, small incisions are made for the operating instruments and for a laparoscope. As with open mesh techniques (see below), a piece of mesh is generally used to close the hernia hole and prevent the intestine from protruding again through the abdominal wall. The main variations in laparoscopic approaches depend on whether or not the instruments enter the peritoneal cavity.

Transabdominal preperitoneal repair
Transabdominal preperitoneal (TAPP) repair requires access to the peritoneal cavity with placement of mesh through a peritoneal incision.[13] A large piece of mesh is placed in the preperitoneal space covering all potential hernia sites in the inguinal region. The peritoneum is then closed above the mesh, leaving it between the preperitoneal tissues and the abdominal wall, where it becomes incorporated by fibrous tissue.

Totally extraperitoneal repair

The totally extraperitoneal (TEP) approach is a newer laparoscopic technique and was first reported in 1992.[14] In this method, the peritoneal cavity is not entered and mesh is used to seal the hernia from outside the peritoneum. The TEP approach is considered to be technically more difficult than the TAPP approach but it may lessen the risks of damage to the intra-abdominal organs and of adhesion formation leading to intestinal obstruction, risks which have been linked to the TAPP technique.

Identification of subgroups of patients

Factors that might distinguish subgroups of patients for whom a particular type of repair is more (or less) appropriate include age, sex, whether the hernia is unilateral or bilateral, or primary or recurrent, and the fitness of the patient for anaesthesia.

Although inguinal hernias occur relatively frequently in children, particularly in the first few years of life, they are managed differently from adults; paediatric hernias have not therefore been considered in this report. Although both men and women can develop inguinal hernias, most hernia repairs are carried out on male patients, reflecting anatomical differences that affect the risk of a hernia developing.

When examined at operation, 10–25% of patients are found to have an occult hernia on the contralateral side.[15–19] Both laparoscopic approaches allow assessment and treatment of the contralateral side at the same operation without the need for further surgical incisions (although TEP does require further dissection). Potential advantages of laparoscopic repair are the ability to repair bilateral hernias at the same time and the ability to rule out the possibility of an undetected contralateral hernia during unilateral repair.

A proportion of hernia repairs carried out in the UK are for recurrent hernia.[1] Although repair of recurrent hernia is generally considered less straightforward, the same surgical options as for primary hernias are available.

Inguinal hernia may be repaired under general, local or regional anaesthesia. Laparoscopic repair is usually carried out under general anaesthesia whereas the option of surgery under local anaesthetic is more suitable for open mesh repairs. However, some patients express a strong preference for the type of anaesthesia used and for some patients general anaesthesia may clinically be considered too risky.

Criteria for treatment

An inguinal hernia is not in itself dangerous but it can lead to serious complications due to strangulation or bowel obstruction. However, not all inguinal hernias are brought to the attention of healthcare professionals; some may remain undetected until complications develop. Although the majority of hernia repairs are elective operations, a proportion of repairs, often involving strangulated hernias, are emergencies requiring immediate surgery. Surgical repair is the only method of repairing an irreducible hernia. In the case of reducible hernias, particularly in frail, elderly patients, a decision may be taken not to operate, on the basis that repair may do more harm than managing the hernia non-surgically.

Personnel involved

The number of staff employed in laparoscopic operations is usually similar to the number involved in open repairs. The operating time for laparoscopic repair is believed to be longer. Laparoscopic repair is also technically more difficult and so takes longer to learn and tends to be performed by more experienced surgeons. It is therefore associated with a learning curve.[20]

Setting

Laparoscopic surgery is usually followed by at least one night's stay in hospital, although it can be carried out as a day case. There is a wide variation in the length of postoperative stay for hernia repair, reflecting differences in surgeon and hospital policy, rather than differences in surgical technique.

Equipment required

The main extra material costs of laparoscopic repair are associated with the endoscopy system, video unit, monitor, endoscope and CO_2 insufflator. Laparoscopic equipment costs are strongly influenced by whether disposable or reusable equipment is used. Disposable equipment can include all of the main surgical items required or it may be limited to specific items such as trocars, staplers, diathermy scissors or ports.

Anticipated costs

The anticipated costs of adopting laparoscopic surgery are based on the degree of diffusion of this technique (*Table 4*). The total direct costs to the NHS are based on the cost in 2001–02 prices of £1078, £987 and £942 for laparoscopic, open mesh and open non-mesh repair, respectively (the

TABLE 4 *Costs of hernia repair to the NHS (based on 2001–02 number of patients)[a]*

Percentage of total mesh repairs that are laparoscopic	NHS mesh repair costs (£)	NHS total costs (mesh and non-mesh repairs) (£)
5	52,526,063	55,854,353
10	52,767,411	56,095,722
15	53,008,779	56,337,090
20	53,250,148	56,578,458

[a] Unit costs used to derive table values are rounded to the nearest £.

methods used to derive these estimates are described in Chapter 5). In *Table 4* it has been assumed that laparoscopic repair would displace open mesh repair rather than non-mesh repair.

If the actual percentage of repairs carried out laparoscopically increased to 20% from the current service use of 4.1%, the total cost to the NHS in England would increase by approximately £1 million.

The data presented in *Table 4* have assumed a fixed operation cost and have not considered whether the unit cost of laparoscopic surgery would change as diffusion of laparoscopic techniques increases. Such changes might arise as a result of purchases of new equipment (diseconomies of scale) or equipment costs being spread over a greater number of hernia repair procedures (economies of scale) or the use of laparoscopic equipment for other surgical interventions (economies of scope). A further factor that has not been considered in these figures is the cost of training surgeons to perform laparoscopic repairs. The net impact of these factors on total NHS costs is uncertain.

Chapter 3

Effectiveness

The original Health Technology Assessment (HTA) Report submitted to the National Institute for Clinical Excellence (NICE) summarised the evidence on the effectiveness of laparoscopic compared with open non-mesh and open mesh procedures for the repair of inguinal hernia.[21] There was clear evidence that open mesh repair was more clinically effective and cost-effective than open non-mesh techniques, and open mesh techniques became the standard. Open non-mesh repair is therefore not considered in this report. For this reason, not all the trials included in the original report are eligible for inclusion in this update. Evidence for assessing the clinical effectiveness thus comprises the eligible trials from the original report and additional randomised controlled trials (RCTs) or quasi-RCTs identified from literature searching specific to this review. Any new data to the original review, including individual patient data (IPD) obtained through the European Union (EU) Hernia Trialists Collaboration, were added to the original data in a meta-analysis, where possible.

Methods for reviewing effectiveness

Search strategy
Electronic searches were conducted to identify reports of trials of laparoscopic inguinal hernia repair, including TAPP and TEP procedures. Systematic reviews and other evidence-based reports were also identified. The original HTA Report had searched MEDLINE and EMBASE up to 2000; therefore, these databases were searched only from 2000 onwards using a revised strategy to reflect the scope of the new review. Since the original strategies used had not specifically searched for studies comparing TAPP with TEP procedures, supplementary searching of these databases for all years was also undertaken. The following databases were searched, and full details of the strategies used are documented in Appendix 1:

- MEDLINE (2000 to week 1, June 2003); additional TAPP versus TEP search (1966 to week 1, June 2003)
- MEDLINE Extra (13 June 2003)

- EMBASE (2000 to week 23, 2003); additional TAPP versus TEP search (1980 to week 23, 2003)
- CINAHL (1985 to week 1, June 2003)
- BIOSIS (1985 to 18 June 2003)
- Science Citation Index (1981 to 21 June 2003)
- Web of Science Proceedings (1990 to 21 June 2003)
- Cochrane Controlled Trials Register (Cochrane Library Issue 2, 2003)
- Cochrane Database of Systematic Reviews (Cochrane Library Issue 2, 2003)
- Database of Abstracts of Reviews of Effectiveness (June 2003)
- HTA Database (June 2003)
- Journals@Ovid Full Text (16 July 2003)
- SpringerLink (16 July 2003)
- National Research Register (Issue 2, 2003)
- Clinical Trials (June 2003)
- Current Controlled Trials (June 2003)
- Research Findings Register (June 2003).

In addition, selected conference proceedings were handsearched and websites consulted, details of which can also be found in Appendix 1. Reference lists of all included papers were scanned and experts contacted for other potentially eligible reports.

Inclusion and exclusion criteria
All titles and, where possible, abstracts identified by the search strategies were assessed to identify potentially relevant reports. A total of 1421 citations were identified from electronic searching and a further 23 abstracts from handsearching; 213 reports (180 papers; 33 abstracts) were assessed as potentially relevant, for which full text papers were then obtained where available. These were formally assessed independently by two researchers to check whether they met the inclusion criteria, using a study eligibility form developed for this purpose (Appendix 2). Any disagreements that could not be resolved through discussion were referred to an arbiter. The following inclusion criteria were applied.

Types of studies
All published and unpublished RCTs and quasi-RCTs were eligible for inclusion if they compared (1) laparoscopic inguinal hernia repair with open

mesh inguinal hernia repair or (2) laparoscopic TAPP with laparoscopic TEP methods of inguinal hernia repair. Trials were included irrespective of the language in which they were reported.

Types of participants
The trials included all patients with a clinical diagnosis of inguinal hernia for whom surgical management was judged appropriate. Where possible, analyses based on IPD from randomised patients were included in the meta-analysis, including data obtained for any patients excluded from the original published analyses. Where data allowed, the patient population was split according to whether or not the hernia was recurrent or bilateral and whether or not the patient was fit enough for general anaesthesia. Data from children aged 12 years and older were included where these patients were included in a trial of adults; however, trials specifically relating to children were not included.

Types of interventions
Methods of surgical repair of inguinal hernia:

1. laparoscopic inguinal hernia repair (TAPP and TEP)
2. open mesh inguinal hernia repair (including open flat mesh, open preperitoneal mesh and open plug and mesh).

Types of outcome measures
The following data items were sought for all trials:

Primary outcomes:	*Secondary outcomes*:
Hernia recurrence	Duration of operation
Persisting pain	Opposite method initiated
	Conversion
	Postoperative pain
	Haematoma
	Seroma
	Wound/superficial infection
	Mesh/deep infection
	Port-site hernia
	Vascular injury
	Visceral injury
	Length of hospital stay
	Time to return to usual activities
	Persisting numbness
	QoL

Data extraction strategy
The titles and abstracts of all papers identified by the search strategy were screened. Full text copies of all potentially relevant studies were obtained and two reviewers independently assessed them for inclusion. Reviewers were not blinded to the names of studies' authors, institutions or publications. Any disagreements were resolved by consensus or arbitration.

A data extraction form was developed to record details of trial methods, participants, interventions, patient characteristics and outcomes (Appendix 3). Two reviewers extracted data independently. Any differences that could not be resolved through discussion were referred to an arbiter.

Quality assessment strategy
Two reviewers, working independently, assessed all studies that met the selection criteria for methodological quality. Any disagreements were resolved by consensus or arbitration. The system for classifying methodological quality of controlled trials was based on an assessment of four principal potential sources of bias: selection bias from inadequate concealment of allocation of treatments; attrition bias from losses to follow-up without appropriate intention-to-treat (ITT) analysis, particularly if related to one or other surgical approaches; detection bias from biased ascertainment of outcome where knowledge of the allocation might have influenced the measurement of outcome; and selection bias in analysis (Appendix 3).

Data synthesis
For each outcome the results were derived from the best available source: if IPD reanalysis was not available, information from aggregate data provided by the trialist or data from the trial publications were used. Dichotomous outcome data were combined using the relative risk (RR) method and continuous outcomes were combined using the Mantel–Haenszel weighted mean difference (WMD) method. Time to return to usual activities was described using hazard ratios (HRs) derived from IPD reanalysis. The HR is defined as the ratio of the instantaneous adverse event rates of the groups, i.e. the ratio of the adverse event rate of the treatment group to that of the control group. Unlike the OR, the HR can allow for the fact that some patients were not followed up for the full time period (censored). Even when the instantaneous adverse event rates of the groups both change with time, the ratio of the two is always assumed to be constant (i.e. the HR assumes that the survival curves are proportional and do not cross over). An $HR = 1$ indicates no difference between comparison groups. For undesirable outcomes an $HR < 1$ indicates that the intervention was effective in reducing the risk of

that outcome. In the context of meta-analysis, Peto's formula gives an estimate of the OR and this is also usually a close approximation to the HR. The results are all reported using a fixed-effects model. Chi-squared tests were used to explore statistical heterogeneity across studies and, where a significant result was found, possible reasons were explored using sensitivity analyses.

The review was conducted using the standard Cochrane software RevMan 4.1.

Duration of operation was defined as time from first incision to last suture or, where this was not available, time in theatre. 'Opposite' method initiated was defined as a laparoscopic repair initiated when an open repair was allocated, or vice versa. A conversion was defined as a procedure initiated as a laparoscopic but converted to an open repair, or vice versa. 'Postoperative pain' could include data collected on the second or third day, if no data were reported for the first postoperative day. Haematoma included wound or scrotal haematoma or ecchymosis but not bruising. Seroma included hydrocele. Wound/superficial infection was defined as wound-related infections only and included pus from wound, fistula and sinus formation. Length of postoperative stay was defined as time from admission to discharge. Time to return to usual activities was defined as number of days to resumption of normal social activities or work where this was not available. Persisting pain was defined as groin pain of any severity (including testicular) persisting at 1 year after the operation, or at the closest timepoint to 1 year provided that this was at least 3 months after surgery. Persisting numbness included paraesthesia, dysaesthesia and discomfort persisting at 1 year after the operation, or at the closest time point to 1 year provided that this was at least 3 months after surgery. Hernia recurrence data were based on the methods of ascertainment used in individual trials.

Results

Quantity and quality of research available
A total of 213 reports (180 papers; 33 abstracts) were identified as potentially relevant to the review. The full text of seven of these reports was unobtainable because no copies could be traced in the UK.

Number and type of studies included
Twenty-four trials from the original review compared laparoscopic with open mesh procedures and were included in this updated review. In addition, from the searching conducted for this update, 37 new reports of trials met the criteria for inclusion. These comprised 20 reports relating to the originally included trials and 17 reports relating to 13 new trials. Thus, in total, 37 eligible trials were identified. A list of these studies with their associated references is given in Appendix 4.

Number and type of studies excluded, with reasons for specific exclusions
A total of 169 articles (142 full text papers and 27 abstracts) were obtained but were excluded because they failed to meet one or more of the specified inclusion criteria in terms of study design, participants, interventions or outcomes. Of the 169 articles excluded, 141 were not RCTs. Of the remaining 28 reports, 25 were comparisons of laparoscopic versus open non-mesh,[22–46] one compared two versions of TEP, i.e. had no comparison to an open technique,[47] one report had no usable results[48] and one was an ongoing trial.[49]

Tabulation of quality of studies, characteristics of studies and evidence rating
Appendix 5 contains the detailed quality assessment score for each of the included primary studies. The method of randomisation used was stated explicitly for 29 of 37 trials: central randomisation service in four, sealed envelopes in 18, computer-generated random numbers in three, random number tables in one, by birthdate in one, by alternation in one and random selection by cards in one. In eight trials, the allocation was said to be 'randomised' but the method was not specified. The trials ranged in size from 18 to 928 randomised patients. The mean or median duration of follow-up ranged from 1 week to 5 years, 22 trials confirmed hernia diagnosis by clinical examination and in 18 trials the operation was reported to have been performed by either an 'experienced' surgeon or by one who had performed at least 10 laparoscopic hernia repairs.

Appendix 15 provides a summary of the quality of the trial by Neumayer and colleagues (2004), which forms the basis of the Supplementary Report.

Characteristics of included studies
Appendix 6 provides details of the characteristics of the included studies. There were 39 relevant comparisons in the 37 eligible trials (5560 randomised participants), because two trials had three arms. Of the 37 trials included, 31 were

reported in full papers and six as abstracts only. IPD reanalysis was available for 15 trials (2907 participants), two of which had a published abstract only, and additional aggregated data for a further four (506 participants). Published data only were available for the other 18 (2147 participants). Nineteen trials included both recurrent and primary hernias, 13 were limited to primary hernias only, one included recurrent hernias only and these details were not reported for four. The comparisons in the 37 trials were as follows: TAPP versus open flat mesh (13 trials, 1408 participants);[50–66] TAPP versus open preperitoneal mesh (four trials, 937 participants);[67–71] TAPP versus plug and mesh (one trial, 160 participants);[72–75] TEP versus open flat mesh (seven trials, 664 participants);[76–83] TEP versus open preperitoneal mesh (five trials, 424 participants);[84–92] TEP versus plug and mesh (one trial, 293 participants);[93] TEP versus open flat mesh versus open preperitoneal mesh (one trial, 65 participants);[94] TEP versus open flat mesh versus plug and mesh (one trial, 299 participants);[95] mixed laparoscopic versus mixed open (two trials, 1058 participants);[96–107] mixed laparoscopic versus open flat mesh (one trial, 200 participants);[108] and TAPP versus TEP (one trial, 52 participants).[109,110] Across the trials, where reported, all but two patients allocated to laparoscopic repairs received a general anaesthetic (both had a regional anaesthetic). Patients in the open groups received general, regional or local anaesthesia, determined by the trial protocol or surgeon's choice.

Appendix 15 provides a summary of the characteristics of the trial by Neumayer and colleagues (2004), which forms the basis of the Supplementary Report.

Tabulation of results
The results of the meta-analyses are given in Appendix 7. Appendix 7(1) considers TAPP versus open mesh repair. Within this analysis, the trials were ordered by the method of open mesh repair (open flat mesh, open preperitoneal mesh and open plug and mesh). Appendix 7(2) considers TEP versus open mesh repair and the trials were similarly ordered by the method of open repair (open flat mesh, open pre-peritoneal mesh and open plug and mesh). Appendices 7(4)–7(5), and 7(6)–7(7) repeat this but only include patients with recurrent and bilateral hernias, respectively.

Appendix 15 reports the results of the revised meta-analyses based on the additional data

available from the trial by Neumayer and colleagues, 2004. Those outcomes for which this trial contributed additional data are indicated in the following section.

Assessment of effectiveness
Laparoscopic versus open mesh
Duration of operation
The average length of operation was longer in the laparoscopic groups in all but three trials with data (Comparison 01:01 and 02:01) [Appendix 7(1) and 7(2)]. Overall, the WMD was 13.33 minutes (95% CI 12.08 to 14.57, $p < 0.0001$) for TAPP versus open mesh and 7.89 minutes (95% CI 6.22 to 9.57, $p < 0.0001$) for TEP versus open mesh. There was evidence of statistical heterogeneity, but generally there was consistency in direction of effect in the subcategories, although the size of effect estimates varied (*Table 5*).

'Opposite' method initiated
The 'opposite' method was initiated in 15/440 (3.4%) allocated TAPP repairs versus 1/437 (0.2%) allocated open mesh repairs (Comparison 01:02) and in 26/614 (4.2%) allocated TEP repairs versus 9/590 (1.5%) allocated open mesh repairs (Comparison 02:02). The direction of effect was similar in all subcategories where data were available.

Conversions
In total, 17 (1.4%) TAPP operations were stated to have been converted to an open procedure amongst 1249 allocated TAPP repairs and no open mesh procedures were converted to a laparoscopic repair amongst 1226 allocated to open mesh repairs (Comparison 01:03: RR 5.91, 95% CI 1.91 to 18.27, $p = 0.002$). For TEP operations, 39 (3.6%) were converted to an open procedure amongst 1074 allocated TEP repairs compared with one (0.1%) open mesh procedure amongst 1113 allocated open mesh repairs (Comparison 02:03: RR 10.77, 95% CI 3.91 to 29.68, $p < 0.0001$). Higher rates observed in TEP trials reflected one study in particular.[96–103]

Postoperative pain
Data were not presented in a form sufficiently similar to allow quantitative synthesis; in these cases a qualitative review looking for consistency between studies was performed, principally in the direction of apparent effect using the Sign test.[111] The conservative approach was taken of comparing the number of trials favouring laparoscopic management with all others, which included those where no differences in either direction were detected.

TABLE 5 *Overall WMD for duration of operation (minutes) when comparing TAPP versus open and TEP versus open with subcategories open flat mesh, open preperitoneal mesh, open plug and mesh and open mixed mesh*

Comparison subcategory	WMD	95% CI	*p*-Value
TAPP vs open mesh (16 RCTs)	13.33	12.08 to 14.57	<0.00001
TAPP vs flat mesh (10 RCTs)	10.93	9.38 to 12.48	<0.00001
TAPP vs preperitoneal mesh (4 RCTs)	15.62	12.89 to 18.36	<0.00001
TAPP vs plug and mesh (1 RCT)	25.00	20.96 to 29.04	<0.00001
TAPP vs mixed mesh (1 RCT)	12.68	7.34 to 18.02	<0.00001
TEP vs open mesh (8 RCTs)	7.89	6.22 to 9.57	<0.00001
TEP vs flat mesh (4 RCTs)	4.33	1.31 to 7.34	0.005
TEP vs preperitoneal mesh (2 RCTs)	16.31	9.30 to 23.31	0.00001
TEP vs plug and mesh (1 RCT)	1.30	–1.74 to 4.34	0.4
TEP vs mixed mesh (1 RCT)	15.91	12.98 to 18.84	<0.00001

Twenty relevant comparisons in 19 trials reports included a measure of postoperative pain (one trial had three arms). Sixteen favoured the laparoscopic group, one trial favoured the open group and in three trials there were no differences (Sign test, $p < 0.001$) (*Table 6*).

Haematoma
Overall, there appeared to be fewer haematomas in the TAPP groups (Comparison 01:04: 117/841 versus 152/836: RR 0.76, 95% CI 0.62 to 0.94, $p = 0.009$). However, these results were particularly influenced by the Wellwood 1998 trial[64–66] and the difference was not significant when this trial was removed. When TEP trials were considered, there appeared to be a clear difference with fewer haematomas in the TEP groups (Comparison 02:04: RR 0.44, 95% CI 0.33 to 0.58, $p < 0.0001$). The estimated effect was similar in all subcategories.

Seroma
Overall, there were more seromas in the TAPP groups (Comparison 01:05: 49/836 versus 23/836: RR 1.97, 95% CI 1.27 to 3.07, $p = 0.003$). Although the estimated effect was statistically significant when comparing TAPP with open flat mesh, there were too few data to judge whether or not there was a consistent finding across all the other subcategories. There was no apparent difference when considering the TEP groups (Comparison 02:05: 28/810 versus 39/804: RR 0.73, 95% CI 0.46 to 1.14, $p = 0.17$). Although these results were particularly influenced by the Medical Research Council (MRC) laparoscopic groin hernia trial,[196–103] the difference remained non-significant when this trial was removed.

Wound/superficial infection
Where reported, wound/superficial infection appeared less frequent in the TAPP groups (Comparison 01:06: RR 0.41, 95% CI 0.26 to 0.64,

$p = 0.0001$). However, these results were again influenced by the Wellwood 1998 trial[64–66] and the difference was not significant when this trial was removed. There were also fewer wound/superficial infections when comparing TEP with open mesh (Comparison 02:06: RR 0.62, 95% CI 0.33 to 1.16, $p = 0.14$) but none of these differences were statistically significant.

Appendix 15 reports the results of the revised meta-analysis which include the data from the trial by Neumayer and colleagues (2004).

Mesh/deep infection
There were only two reported cases of mesh/deep infection in all included studies: one case of deep infection in an open preperitoneal mesh group[89] and one case of mesh infection in an open flat mesh group[51] (Comparison 01:07 and 02:07).

Vascular or visceral injuries
Overall, there were 1/764 (0.13%) potentially serious vascular and 5/764 (0.65%) potentially serious visceral injuries in the TAPP groups, no potentially serious vascular and 1/644 (0.16%) potentially serious visceral injuries in the TEP group compared with no potentially serious vascular and 2/1388 (0.14%) potentially serious visceral injuries in the open groups (*Table 7*: Comparison 01:08, 01:09, 02:09, 02:09); note, less strict definitions of injury were used in the meta-analyses. It should be noted that these data are difficult to interpret as it is unclear whether definitions have been used consistently.

Appendix 15 reports the results of the revised meta-analysis which include the data from the trial by Neumayer and colleagues (2004).

Port-site hernia
There were only three cases of port-site hernia

TABLE 6 *Postoperative pain*

Reference	Laparoscopic	Open	Comments
TAPP versus flat mesh			
Filipi, 1996[50]	NR	NR	VAS (favours TAPP)
Gontarz, 1998[51]	NR	NR	NR
Heikkinen, 1997[53]	3.9	5.5	Median (estimated from graph)
Heikkinen, 1998[52]	NR	NR	NR
Jess, 2000[54]	NR	NR	NR
Köninger, 1998[55]	NR	NR	NR
Mahon, 2001[56]	2.4[a]	4.8[a]	VAS
Paganini, 1998[58]	2(2–3)	2(1–3)	VAS (0–10) median (IQR)
Payne, 1994[59]	NR	NR	NR
Picchio, 1999[61]	3.1(0.2)(1–7)	2.7(0.2)(1–5)	VAS (0–10) mean (SEM) (range)
Sarli, 1997[62]	2.3	2.5	VAS mean
Sarli, 2001[63]	1(1–3)	4(2–6)	VAS (1–10) median (IQR)
Wellwood, 1998[64]	NR	NR	Categorical data (favours TAPP)
TAPP versus preperitoneal mesh			
Aitola, 1998[67]	NR	NR	Pain on coughing, movement (favours TAPP)
Beets, 1999[68]	NR	NR	NR
Johansson, 1999[70]	NR	NR	NR
Laporte, 1997[69]	NR	NR	NR
TAPP versus plug and mesh			
Zieren, 1998[72]	3.9	4.1	Mean (estimated from graph)
TEP versus flat mesh			
Andersson, 2003[76]	NR	NR	NR
Bringman, 2003[95]	1(0–3)	2(0–6)	VAS (0–10) median (range)
Colak, 2003[77]	2.73(1.69)	4.61(1.77)	VAS (0–10) mean (SD)
Gholghesaei, 2003[78]	NR	NR	NR
Heikkinen, 1998[80]	NR	NR	NR
Lal, 2003[81]	1.76(1.4)[a]	2.74(1.5)[a]	VAS (favours TEP)
Merello, 1997[82]	NR	NR	NR
Payne, 1996[83]	NR	NR	NR
Vatansev, 2002[94]	NR	NR	NR
TEP versus preperitoneal mesh			
Bostanci, 1998[84]	NR	NR	NR
Champault, 1997[85]	NR	NR	Ratios given (favours TEP)
Ramon, 1998[88]	NR	NR	NR
Simmermacher, 2000[89]	NR	NR	NR
Suter, 2002[90]	3.3(0–9)	3.36(0–8)	VAS maximum (range)
Vatansev, 2002[94]	NR	NR	NR
TEP versus plug and mesh			
Bringman, 2003[95]	1(0–3)	2(0–7)	VAS (0–10) median (range)
Khoury, 1998[93]	3	7	VAS (0–10) 'average'
Mixed laparoscopic versus mixed open			
Barkun, 1995[104]	NR	NR	McGill pain score (favours TEP)
MRC Trial Group[96]	NR	NR	NR
Mixed laparoscopic versus flat mesh			
Snyder, 1998[108]	4.7[a]	5.8[a]	VAS (0–10)

IQR, interquartile range; NR, not reported; SEM, standard error of the mean; VAS, visual analogue score.
Note: three-armed trials entered twice in appropriate comparisons.
[a] Values unclear.

TABLE 7 *Potentially serious complications*

Complication	TAPP	TEP	Open[a]
Intra-operative:			
Vascular:			
Trocar injury to left common iliac artery[96]	1/764	0/744	0/1475
Visceral:			
Bladder injury[67,70,96]	4/764	0/644	0/1388
Small bowel injury[76,96]	0/764	0/644	2/1388
Postoperative:			
Visceral:			
Small bowel obstruction[76,96]	1/764	1/644	0/1388
[a] Data combined for open groups from the RCT, comparing TAPP with open and TEP with open.			

TABLE 8 *Overall HR for time to return to usual activities when comparing TAPP versus open and TEP versus open with subcategories open flat mesh, open preperitoneal mesh, open plug and mesh and open mixed mesh*

Comparison subcategory	HR	95% CI	*p*-Value
TAPP vs open mesh (7 RCTs)	**0.66**	**0.58 to 0.75**	**<0.00001**
TAPP vs flat mesh (4 RCTs)	0.59	0.50 to 0.70	<0.00001
TAPP vs preperitoneal mesh (3 RCTs)	0.70	0.56 to 0.87	0.001
TAPP vs plug and mesh (0 RCTs)	ND	ND	ND
TAPP vs mixed mesh (1 RCT)	0.86	0.62 to 1.19	0.4
TEP vs open mesh (5 RCTs)	**0.49**	**0.42 to 0.56**	**<0.00001**
TEP vs flat mesh (3 RCTs)	0.35	0.25 to 0.50	<0.00001
TEP vs preperitoneal mesh (0 RCTs)	ND	ND	ND
TEP vs plug and mesh (1 RCT)	0.22	0.16 to 0.29	<0.00001
TEP vs mixed mesh (1 RCT)	0.80	0.66 to 0.97	0.02
ND, no data.			

reported.[64,96] All occurred within the TAPP groups (Comparison 01:10).

Appendix 15 reports the results of the revised meta-analysis which include the data from the trial by Neumayer and colleagues (2004).

Length of stay (days)
There was marked heterogeneity in length of hospital stay, with greater differences in mean stay between different hospitals than there were between laparoscopic and open repairs in the same hospital (Comparison 01:11 and 02:11). In respect of between-trial group differences, the trials tended to show either no difference or a clear difference, sometimes in exact days.[73] This suggests that the overall findings reflect different healthcare systems rather than a true effect of the repair.

Time to return to usual activity (days)
In all trials with data, the time to return to usual activity was shorter in both the TAPP groups (Comparison 01:12: HR 0.66, 95% CI 0.58 to 0.75, $p < 0.0001$) and the TEP groups (Comparison 02:12: HR 0.49, 95% CI 0.42 to 0.56, $p < 0.0001$) (*Table 8*). It is difficult to interpret the HRs as absolute differences, but a simple crude aggregation of return to usual activity data from the IPD reanalysis showed that this was about 3 and 4 days shorter, respectively, when compared with open flat mesh. There is no obvious reason why the other open mesh procedures would perform very much differently. These data are consistent in terms of direction of effect with the findings of the HRs. The estimated effect was similar in all subcategories. However, there was evidence of statistical heterogeneity when considering the TEP groups and this is likely to be due to differences between trials in postoperative advice, definition of usual activity (e.g. work, walking, sport), existing co-morbidity and local 'cultures'.

TABLE 9 *Overall RR for persisting numbness when comparing TAPP versus open and TEP versus open with subcategories open flat mesh, open preperitoneal mesh, open plug and mesh, and open mixed mesh*

Comparison subcategory	RR	95% CI	*p*-Value
TAPP vs open mesh (8 RCTs)	**0.26**	**0.17 to 0.40**	**<0.00001**
TAPP vs flat mesh (4 RCTs)	0.10	0.03 to 0.32	0.0001
TAPP vs preperitoneal mesh (2 RCTs)	0.07	0.00 to 1.31	0.08
TAPP vs plug and mesh (1 RCT)	1.00	0.06 to 15.71	1.00
TAPP vs mixed mesh (1 RCT)	0.38	0.24 to 0.59	0.00003
TEP vs open mesh (4 RCTs)	**0.67**	**0.53 to 0.86**	**0.002**
TEP vs flat mesh (2 RCTs)	0.17	0.03 to 1.16	0.07
TEP vs preperitoneal mesh (0 RCTs)	ND	ND	ND
TEP vs plug and mesh (1 RCT)	2.57	0.11 to 62.38	0.6
TEP vs mixed mesh (1 RCT)	0.69	0.54 to 0.89	0.004

ND, no data.

TABLE 10 *Overall RR for persisting pain when comparing TAPP versus open and TEP versus open with subcategories open flat mesh, open preperitoneal mesh, open plug and mesh, and open mixed mesh*

Comparison subcategory	RR	95% CI	*p*-Value
TAPP vs open mesh (8 RCTs)	**0.72**	**0.58 to 0.88**	**0.001**
TAPP vs flat mesh (4 RCTs)	0.68	0.52 to 0.89	0.005
TAPP vs preperitoneal mesh (2 RCTs)	0.46	0.16 to 1.32	0.15
TAPP vs plug and mesh (1 RCT)	2.00	0.19 to 21.62	0.6
TAPP vs mixed mesh (1 RCT)	0.83	0.60 to 1.14	0.2
TEP vs open mesh (4 RCTs)	**0.77**	**0.64 to 0.92**	**0.004**
TEP vs flat mesh (2 RCTs)	0.10	0.01 to 0.66	0.02
TEP vs preperitoneal mesh (0 RCTs)	ND	ND	ND
TEP vs plug and mesh (1 RCT)	0.16	0.04 to 0.69	0.01
TEP vs mixed mesh (1 RCT)	0.86	0.72 to 1.04	0.11

ND, no data.

Persisting numbness

Overall, there were fewer cases of persisting numbness at 1 year after the operation in both the TAPP groups (Comparison 01:13: overall 23/750 versus 82/733; RR 0.26, 95% CI 0.17 to 0.40, $p < 0.0001$) and the TEP groups (Comparison 01:13: overall 76/468 versus 110/438; RR 0.67, 95% CI 0.53 to 0.86, $p = 0.002$) (*Table 9*). The estimated effect size was broadly consistent in all subcategories.

Persisting pain

Overall, there were fewer cases of persisting pain at 1 year after the operation in both the TAPP groups (Comparison 01:14: overall 116/787 versus 154/763; RR 0.72, 95% CI 0.58 to 0.88, $p = 0.001$) and the TEP groups (Comparison 02:14: overall 127/517 versus 159/474; RR 0.77, 95% CI 0.64 to 0.92, $p = 0.004$) (*Table 10*). The direction of effect was similar in all subcategories other than TAPP

versus plug and mesh. Only one trial was available in this comparison, having only three cases of persisting pain and the CIs are therefore very wide and statistically compatible with the overall results.

Forest plots for TAPP and TEP versus open mesh for persisting pain are shown in *Figures 2* and *3*, respectively.

Appendix 15 reports the results of the revised meta-analysis which include the data from the trial by Neumayer and colleagues (2004).

Hernia recurrence

The rates of recurrence were similar in the trial groups. A total of 26 recurrences were reported amongst 1052 allocated to TAPP repairs versus 22 amongst 1062 allocated to open mesh repairs (Comparison 01:15: RR 1.18, 95% CI 0.69 to 2.02, $p = 0.5$) and 23 recurrences amongst 1007

	Treatment	Control	RR	Weight	RR
Study	n/N	n/N	(95% fixed)	%	(95% CI fixed)
01 TAPP versus Flat Mesh					
Koninger, 1998	15/94	22/90		14.2	0.65 (0.36 to 1.18)
Peganini, 1998	6/52	17/56		10.4	0.38 (0.16 to 0.89)
Sarli, 1997	1/52	0/56		0.5	3.23 (0.13 to 77.49)
Welwood, 1988	45/184	58/180		37.8	0.75 (0.54 to 1.04)
Subtotal (95% CI)	67/382	98/382		62.7	0.68 (0.52 to 0.89)
Test for heterogeneity $\chi^2 = 3.05$, df = 3, $p = 0.38$					
Test for overall effect $z = -2.38$, $p = 0.02$					
02 TAPP versus Preperitoneal Mesh					
Beels, 1999	4/42	3/37		2.0	1.17 (0.28 to 4.91)
SCUR, 1999	1/176	7/169		4.5	0.14 (0.02 to 1.10)
Subtotal (95% CI)	5/218	10/206		8.5	0.46 (0.16 to 1.32)
Test for heterogeneity $\chi^2 = 2.95$, df = 0.086					
Test for overall effect $z = -1.45$, $p = 0.15$					
03 TAPP versus Plug and Mesh					
Zheven, 1998	2/80	1/80		0.6	2.00 (0.19 to 21.62)
Subtotal (95% CI)	2/80	1/80		0.6	2.00 (0.19 to 21.62)
Test for heterogeneity $\chi^2 = 0.0$, df = 0					
Test for overall effect $z = 0.57$, $p = 0.6$					
04 TAPP versus Mixed Mesh					
MRC multicentre, 1999	42/107	45/95		30.2	0.83 (0.60 to 1.14)
Subtotal (95% CI)	42/107	45/95		30.2	0.83 (0.60 to 1.14)
Test for heterogeneity $\chi^2 = 0.1$, df = 0					
Test for overall effect $z = -1.16$, $p = 0.2$					
Total (95% CI)	116/787	154/763		100.0	0.72 (0.56 to 0.88)
Test for heterogeneity $\chi^2 = 7.55$, df = 7, $p = 0.37$					
Test for overall effect $z = -3.22$, $p = 0.001$					

Comparison: 01 TAPP versus Open Mesh
Outcome: 14 Persisting pain

0.001 0.002   1   50   1000
Favours treatment   Favours control

FIGURE 2 *TAPP versus open mesh: persisting pain*

allocated to TEP repairs versus 13 amongst 1002 allocated to open mesh repairs (Comparison 02:15: RR 1.61, 95% CI 0.87 to 2.98, $p = 0.13$) (*Table 11*). (The higher rate of recurrence after TEP reflects the MRC multicentre trial. Questions have been raised as to whether this reflects inexperience with TEP and longer term follow-up in a subgroup of surgeons in this trial showed no difference at 5 years.[20,103]) The estimated effect size was broadly consistent in all subcategories. It should be noted, however, that the CIs are all wide, even for the overall comparisons, and so clinically important differences may exist.

Forest plots for TAPP and TEP versus open mesh for hernia recurrence are shown in *Figures 4* and *5*, respectively.

Five-year follow-up
Only one report,[66] an update of Wellwood and colleagues,[64] presented results with 5-year follow-

up comparing laparoscopic TAPP with open flat mesh repair. The main long-term objective of this trial was to compare the complication rates of these procedures. The results are given in *Table 12*.

The follow-up included 65% of those still alive. No data were provided for assessing whether any differential loss to follow-up introduced selection bias. The much smaller numbers of people reporting pain in the report by Douek and colleagues[66] when compared with the IPD provided by Wellwood and colleagues[64] (Comparison 01:14) is probably due to differing definitions of pain.

TAPP versus TEP
Only one RCT[109] was available and reported outcomes on operation time, intraoperative and postoperative complications, length of hospital stay, time to return to work, time to return to usual activities and hernia recurrence. These results are given in *Table 13* [Appendix 7(3)].

17

FIGURE 3 *TEP versus open mesh: persisting pain*

TABLE 11 *Overall RR for hernia recurrence when comparing TAPP versus open and TEP versus open with subcategories open flat mesh, open preperitoneal mesh, open plug and mesh and open mixed mesh*

Comparison subcategory	RR	95% CI	*p*-Value
TAPP vs open mesh (15 RCTs)	**1.18**	**0.69 to 2.02**	**0.5**
TAPP vs flat mesh (10 RCTs)	1.68	0.73 to 3.88	0.69
TAPP vs preperitoneal mesh (3 RCTs)	0.90	0.44 to 1.85	0.0049
TAPP vs plug and mesh (1 RCT)	Not estimable	Not estimable	Not estimable
TAPP vs mixed mesh (1 RCT)	Not estimable	Not estimable	Not estimable
TEP vs open mesh (13 RCTs)	**1.61**	**0.87 to 2.98**	**0.13**
TEP vs flat mesh (7 RCTs)	1.61	0.57 to 4.60	0.4
TEP vs preperitoneal mesh (3 RCTs)	2.97	0.48 to 18.28	0.2
TEP vs plug and mesh (2 RCT)	0.58	0.20 to 1.73	0.3
TEP vs mixed mesh (1 RCT)	14.27	0.82 to 248.59	0.07

Duration of operation

The operating time was slightly longer in TEP than TAPP; however, the difference was not statistically significant (Comparison 03:01: WMD –6.30, 95% CI –12.82 to 0.22, $p = 0.06$).

Haematoma

There was only one haematoma recorded in the study and this was in the TAPP group (Comparison 03:04: RR 2.59, 95% CI 0.11 to 60.69, $p = 0.6$).

```
Comparison:  01 TAPP versus Open Mesh
Outcome:     15 Hernia recurrence
```

Study	Treatment n/N	Control n/N	RR (95% fixed)	Weight %	RR (95% CI fixed)
01 TAPP versus Flat Mesh					
Filipi, 1996	0/24	2/29		9.5	0.24 (0.01 to 4.77)
Gontarz, 1998	2/62	1/73		3.9	2.35 (0.22 to 25.36)
x Heikkinen, 1997	0/20	0/18		0.0	Not estimable
Koninger, 1998	1/94	1/90		4.3	0.96 (0.06 to 15.08)
Mahon, 2001	4/45	0/45		2.1	9.00 (0.50 to 162.44)
Paganini, 1998	2/52	0/56		2.0	5.38 (0.26 to 109.45)
x Payne, 1994	0/51	0/49		0.0	Not estimable
Sarli, 1997	2/52	1/56		4.0	2.15 (0.20 to 23.06)
Sarli, 2001	0/20	1/23		5.9	0.36 (0.02 to 8.86)
Wellwood, 1998	1/200	1/200		4.2	1.00 (0.06 to 15.88)
Subtotal (95% CI)	12/620	7/639		35.9	1.68 (0.73 to 3.88)

Test for heterogeneity $\chi^2 = 4.76$, df = 7, $p = 0.69$
Test for overall effect $z = 1.22$, $p = 0.2$

02 TAPP versus Preperitoneal Mesh					
Aitola, 1998	5/28	1/31		4.0	5.54 (0.69 to 44.55)
Beets, 1999	6/42	1/37		4.5	5.39 (0.67 to 41.91)
SCUR, 1999	3/207	13/199		55.6	0.22 (0.06 to 0.77)
Subtotal (95% CI)	14/277	15/267		64.1	0.90 (0.44 to 1.85)

Test for heterogeneity $\chi^2 = 10.63$, df = 0.0049
Test for overall effect $z = -0.27$, $p = 0.8$

03 TAPP versus Plug and Mesh					
x Zieren, 1996	0/80	0/80		0.0	Not estimable
Subtotal (95% CI)	0/80	0/80		0.0	Not estimable

Test for heterogeneity $\chi^2 = 0.0$, df = 0
Test for overall effect $z = 0.00$, $p = 1$

04 TAPP versus Mixed Mesh					
x MRC multicentre, 1999	0/75	0/76		0.0	Not estimable
Subtotal (95% CI)	0/75	0/76		0.0	Not estimable

Test for heterogeneity $\chi^2 = 0.1$, df = 0
Test for overall effect $z = 0.0$, $p = 1$

Total (95% CI)	26/1052	22/1062		100.0	1.18 (0.69 to 2.02)

Test for heterogeneity $\chi^2 = 16.17$, df = 10, $p = 0.095$
Test for overall effect $z = 0.62$, $p = 0.5$

```
        0.01   0.1     1    10   100
        Favours treatment  Favours control
```

FIGURE 4 *TAPP versus open mesh: hernia recurrence*

Length of stay (days)
Length of stay was shorter in the TAPP group (Comparison 03:11: WMD –0.70, 95% CI –1.33 to –0.07, $p = 0.03$).

Time to return to usual activity (days)
An overall figure for time to return to usual activities was not given in the paper, but several separate activities were listed. Of all of those listed there were no statistically significant differences between TAPP and TEP.

Hernia recurrence
Hernia recurrence was only assessed up to 3 months. Within this time there was one recurrence

in the TAPP group (Comparison 03:15: RR 2.59, 95% CI 0.11 to 60.69, $p = 0.6$).

Complications/adverse events from non-randomised studies and observational studies
There were no reported complications or adverse events in the trial. For this reason, studies using other designs were identified in order to provide further comparative evidence of complications and adverse events. This was not formally part of the protocol for the review. Attention was focused on vascular injuries, visceral injuries, deep/mesh infections, port-site hernia and conversions as these were deemed to be the more serious complications. In order to achieve this, any studies

19

Comparison: 02 TEP versus Open Mesh
Outcome: 15 Hernia recurrence

Study	Treatment *n/N*	Control *n/N*	RR (95% fixed)	Weight %	RR (95% CI fixed)
01 TEP versus Flat Mesh					
Andersson, 2003	2/76	0/85		3.0	5.58 (0.27 to 114.52)
Bringman, 2003	2/92	0/103		3.0	5.59 (0.27 to 114.98)
Colak, 2003	2/67	4/67		25.3	0.50 (0.09 to 2.64)
x Heikkinen (2), 1998	0/22	0/23		0.0	Not estimable
x Lal, 2003	0/25	0/25		0.0	Not estimable
x Merello, 1997	0/59	0/57		0.0	Not estimable
Payne, 1996	1/50	0/50		3.2	3.00 (0.13 to 71.93)
Subtotal (95% CI)	7/391	4/410		34.4	1.61 (0.57 to 4.60)
Test for heterogeneity $\chi^2 = 3.35$, df = 3, $p = 0.34$					
Test for overall effect $z = 0.89$, $p = 0.4$					
02 TEP versus Preperitoneal Mesh					
x Bostanci, 1998	0/32	0/32		0.0	Not estimable
Champault, 1997	3/51	1/49		6.4	2.88 (0.31 to 26.78)
Suter, 2002	1/19	0/20		3.1	3.15 (0.14 to 72.89)
Subtotal (95% CI)	4/102	1/101		9.5	2.97 (0.48 to 18.28)
Test for heterogeneity $\chi^2 = 0.00$, df = 1, $p = 0.96$					
Test for overall effect $z = 1.17$, $p = 0.2$					
03 TEP versus Plug and Mesh					
Bringmen, 2003	2/92	2/104		11.9	1.13 (0.16 to 7.87)
Khoury, 1998	3/137	6/116		41.0	0.42 (0.11 to 1.66)
Subtotal (95% CI)	5/229	8/220		52.9	0.58 (0.20 to 1.73)
Test for heterogeneity $\chi^2 = 0.66$, df = 1, $p = 0.42$					
Test for overall effect $z = -0.98$, $p = 3$					
04 TEP versus Mixed Mesh					
x MRC multicentre, 1999	7/285	0/271		3.2	14.27 (0.82 to 248.59)
Subtotal (95% CI)	7/285	0/271		3.2	14.27 (0.82 to 248.59)
Test for heterogeneity $\chi^2 = 0.0$, df = 0					
Test for overall effect $z = 1.82$, $p = 0.07$					
Total (95% CI)	23/1007	13/1002		100.0	1.61 (0.87 to 2.96)
Test for heterogeneity $\chi^2 = 9.83$, df = 8, $p = 0.28$					
Test for overall effect $z = 1$, $p = 0.13$					

0.01 0.1 1 10 100
Favours treatment   Favours control

FIGURE 5 *TEP versus open mesh: hernia recurrence*

TABLE 12 *Long-term complications in patients at least 5 years after undergoing inguinal hernia repair*[a]

Complication	TAPP (*n* = 122) *n* (%)	Open flat mesh (*n* = 120) *n* (%)
Mesh infection	0	1 (1)
Groin pain	2 (2)	12 (10)[b]
Numbness	3 (3)	27 (23)[b]
Hernia recurrence	2 (2)	3 (3)

[a] IPD provided by Wellwood and colleagues[64] contributed to the meta-analyses (Appendix 7) and not the 5-year data for this trial.
[b] Statistically significant.

TABLE 13 *Results from study comparing effectiveness of TAPP with TEPP[109]*

Outcome	TAPP (*n* = 28)	TEP (*n* = 24)
Operation time: mean (SD)	46.0 (9.2)	52.3 (13.9)
Intraoperative complications	None	None
Haematoma	1/28	0/24
Time to return to usual activities (days): mean (SEM):		
Walking	8.6 (1.4)	8.5 (1.3)
Driving a car	10.1 (1.4)	12.4 (1.7)
Sexual Intercourse	17.7 (2.7)	18.9 (2.6)
Sports	35.5 (4.9)	35.2 (4.6)
Time to return to work (weeks): mean (SEM)	4.9 (0.7)	4.6 (0.6)
Length of hospital stay (days): mean (SD)	3.7 (1.4)	4.4 (0.9)[a]
Recurrence at 3 months	1/28	0/24

SD, standard deviation; SEM, standard error of the mean.
[a] Statistically significant result.

which met the following inclusion criteria were used:

- any study with TAPP and TEP as concurrent comparators where results of complications were given separately
- any non-concurrent comparative study of TAPP and TEP with >1000 hernia repairs where results of complications were given separately
- any TAPP or TEP case series with >1000 hernia repairs with results for complications.

On application of these criteria, nine studies were identified:[112–120] five studies with concurrent comparators were included;[113–115,117,119] one with a non-concurrent comparator;[120] and three studies[112,116,118] were case series (TEP,[118] 5203 hernia repairs; and TAPP,[112,116] 2500[112] and 5203[116] hernia repairs). Details of these studies can be found in Appendix 8 and results of potentially serious complications are detailed in *Table 14*.

Vascular injury
Seven studies reported vascular injuries,[112,114–119] including three large case series.[112,116,118] In the comparative studies, three reported no vascular injuries[114,117,119] and one reported a higher rate (3% versus 0%) in TEP; however this was only a small study of 120 patients.[115] In the three case series, one reported no vascular injuries in TAPP[112] whereas the rates from the other two case series showed similar rates for TAPP (0.5%, based on 5707 cases)[116] and TEP (0.47%, based on 5203 cases).[118]

Visceral injury
Seven studies reported visceral injuries[112–116,118,119] including the three large case series.[112,116,118] In the comparative studies, two reported no visceral injuries[115,119] and two reported a higher rate (0.9% versus 0% and 0.4% versus 0%) in TAPP than in TEP.[113,114] In the three case series, the two TAPP series[112,116] reported similar rates of 0.64% and 0.6% with a combined case number of 8207,[112,116] whereas the one TEP series reported a lower rate of 0.23% based on 5203 cases.[118]

Deep infection
Deep infections, primarily mesh infections, are potentially more serious than superficial infections and can result in removal of the mesh. These were reported in seven studies.[112,114–116,118–120] In the comparative studies, three reported no deep infections[114,115,119] and one reported rates of 0.2% and 0% for TAPP and TEP, respectively.[120] Rates for TAPP were low in the two case series:[112,116] 0% and 0.1%. The rate in TEP was again low, 0.02%,[118] and did not indicate a difference between TAPP and TEP.

Port-site hernia
Eight of the nine studies reported port-site hernia.[112–116,118–120] The comparative studies showed rates of 0–3.7%.[113–115,119,120] In all four studies where cases of port-site hernia were observed, TAPP was associated with a higher rate than TEP.[113–115,120] In three studies there were no cases of port-site hernia reported in the TEP groups compared with 3.7%,[113] 0.8%[114] and 1.7%[115] in the TAPP groups. This trend was also confirmed in the case series where there were no reported cases of port-site hernia amongst 5203 TEP repairs,[118] compared with 0.24%[112] and 0.35%[116] amongst 8207 TAPP repairs.

TABLE 14 Results of potentially serious adverse events from non-randomised studies of TAPP and TEP

Study ID	Vascular injury		Visceral injury		Deep/mesh infection		Port-site hernia		Conversions	
	TAPP (%) (n/N)	TEP (%) (n/N)	TAPP (%) (n/N)	TEP (%) (n/N)	TAPP (%) (n/N)	TEP (%) (n/N)	TAPP (%) (n/N)	TEP (%) (n/N)	TAPP (%) (n/N)	TEP (%) (n/N)
Comparative studies:										
Cohen, 1998[113]	NR	NR	0.9 (1/108)	0 (0/100)	NR	NR	3.7 (4/108)	0 (0/100)	0 (0/108)	4 (4/100)
Felix, 1995[114]	0 (0/733)	0 (0/382)	0.4 (3/733)	0 (0/382)	0 (0/733)	0 (0/382)	0.8 (6/733)	0 (0/733)	0 (0/382)	1.8 (7/382)
Khoury, 1995[115]	0 (0/60)	3 (2/60)	0 (0/60)	0 (0/60)	0 (0/60)	0 (0/60)	1.7 (1/60)	0 (0/60)	0 (0/60)	0 (0/60)
Lepere, 2000[117]	0 (0/1290)	0 (0/682)	NR	NR	NR	NR	NR	NR	NR	NR
Van Hee, 1998[119]	0 (0/33)	0 (0/58)	0 (0/33)	0 (0/58)	0 (0/33)	0 (0/58)	0 (0/33)	0 (0/58)	5 (2/33)	7 (4/58)
Weiser, 2000[120]	NR	NR	NR	NR	0.2 (2/1216)	0 (0/1547)	0.3 (4/1216)	0.1 (2/1547)	NR	NR
Case series:										
Baca, 2000[112]	0 (0/2500)	NA	0.64 (16/2500)	NA	0 (0/2500)	NA	0.24 (6/2500)	NA	0.24 (6/2500)	NA
Leibl, 2000[116]	0.5 (29/5707)	NA	0.6 (34/5707)	NA	0.1 (6/5707)	NA	0.35 (20/5707)	NA	NR	NA
Tamme, 2003[118]	NA	0.47 (24/5203)	NA	0.23 (12/5203)	NA	0.02 (1/5203)	NA	0 (0/5203)	NA	0.23 (12/5203)

NA, not applicable; NR, not reported.

Conversions

The conversion rate was reported in six of the studies.[112–115,118,119] In three of the four comparative studies the rate was higher in the TEP group, with rates of 0% versus 4%,[113] 0% versus 1.8%[114] and 5% versus 7%.[119] The fourth comparative study was small with only 120 procedures and had no conversions.[115] However, in the large case series the conversion rates between TAPP and TEP were very similar at 0.24%[112] and 0.23%,[118] respectively.

Important subgroup differences for laparoscopic versus open techniques

Laparoscopic repair might be most useful in specified subgroups of patients, such as those with recurrent or bilateral hernias. Subgroup analyses were performed for these groups of patients from the data provided in the included RCTs. Data were available from six trials for recurrent hernias when considering TAPP versus open mesh and five trials when considering TEP versus open mesh [Appendices 7(4) and 7(5)]. When considering bilateral hernias, data were available for seven RCTs comparing TAPP with open mesh trials and six comparing TEP with open mesh trials [Appendices 7(6) and 7(7)]. All subgroup analyses were not clearly different from those in less selected populations, but these estimates were based on small numbers and so should be interpreted with caution.

Recurrent hernias: TAPP versus open mesh

Duration of operation was reported for recurrent hernias separately in six trials.[59,64,67,68,70,96] Overall there was a statistically significant difference between TAPP and open mesh repair in favour of open mesh repair (Comparison 04:01: WMD 13.3, 95% CI 8.14 to 18.46, $p < 0.00001$). For opposite method initiated, four trials[59,67,68,96] reported results with no apparent difference between the groups (Comparison 04:02: RR 3.92, 95% CI 0.49 to 31.68, $p = 0.2$). Five trials provided data about conversions.[59,64,67,70,96] Overall, 2/65 (3.1%) allocated TAPP repairs were converted compared with 0/56 (0%) allocated open mesh repairs (Comparison: 04:03 RR 2.28, 95% CI 0.25 to 20.47, $p = 0.5$). The incidence of haematomas and seromas appeared to be similar between the groups (Comparison 04:04: RR 1.07, 95% CI 0.51 to 2.21, $p = 0.9$, Comparison 04:05: RR 1.45 95% CI 0.75 to 2.82, $p = 0.3$).[64,67,68,96] Results for wound/superficial infection were available for five trials with no apparent difference between the groups (Comparison 04:06: RR 0.6, 95% CI 0.24 to 1.54, $p = 0.3$).[64,67,68,70,96] Although some trials had collected data for mesh/deep infection,

vascular injury and port-site hernia, no cases were reported and therefore the RRs could not be estimated. Overall, there was 1/59(2%)[67] potentially serious visceral injury in the TAPP group compared with 0/54 in the open mesh group (Comparison 04:09: RR 2.18, 95% CI 0.1 to 46.92, $p = 0.6$).[64,67,96] Length of stay was compared in six trials with an overall WMD of 0.02 (95% CI –0.13 to 0.17, $p = 0.8$) (Comparison 04:11).[59,64,67,68,70,96] In all trials except one reporting this outcome, the time to return to usual activities was shorter in the TAPP groups (Comparison 04:12: HR 0.6, 95% CI 0.41 to 0.87, $p = 0.008$).[59,64,67,68,70,96] There appeared to be fewer cases of persisting numbness in the TAPP groups, although this was not statistically significant (Comparison 04:13: RR 0.33, 95% CI 0.1 to 1.14, $p = 0.08$).[59,64,68,70,96] When considering persisting pain and hernia recurrence, there appeared to be no difference between the groups (Comparison 04:14: RR 1.0, 95% CI 0.54 to 1.85, $p = 1$);[64,68,96] (Comparison 04:15: RR 1.32, 95% CI 0.53 to 3.31, $p = 0.5$).[59,64,67,68,70,96]

Recurrent hernias: TEP versus open mesh

Duration of operation was reported for recurrent hernias separately in five trials.[77,83,85,93,96] The overall WMD was 6.31 (95% CI 1.58 to 11.05, $p = 0.009$) and favoured open mesh repair (Comparison 05:01). For opposite method initiated, three trials reported results with no apparent differences between the groups;[83,93,96] the RR was only estimable for one trial (Comparison 05:02: RR 1.16, 95% CI 0.2 to 6.62, $p = 0.9$).[96] Three trials provided data about conversions.[83,93,96] Overall, 8/63 (12.7%) allocated to TEP repairs were converted compared with 1/62 (1.6%) allocated to open mesh repairs (Comparison 05:03: RR 6.61, 95% CI 0.86 to 50.52, $p = 0.07$). There appeared to be fewer haematomas in the TEP groups (Comparison 05:04: RR 0.29, 95% CI 0.13 to 0.66, $p = 0.003$).[93,96] Similar rates of seromas were reported between the groups (Comparison 05:05: RR was only estimable in one, 0.6, 95% CI 0.14 to 2.51, $p = 0.5$).[93,96] RRs were not estimable for wound/superficial and mesh/deep infection, visceral and vascular injury and port-site hernia as no events were recorded. Length of hospital stay was compared in one trial with a WMD of 0.24 (95% CI –0.45 to 0.93, $p = 0.5$) (Comparison 05:11).[96] The time to return to usual activities appeared to be shorter in the TEP groups (Comparison 05:12: HR 0.55, 95% CI 0.35 to 0.89, $p = 0.01$).[83,93,96] There appeared to be no difference in the reported number of cases of persisting numbness, persisting pain and hernia

recurrence (Comparison 05:13: RR 1.22, 95% CI 0.63 to 2.35, $p = 0.6$; Comparison 05:14: RR 0.9, 95% CI 0.59 to 1.38, $p = 0.6$; Comparison 05:15: RR 1.08, 95% CI 0.57 to 2.05, $p = 0.8$).[93,96]

Bilateral hernias: TAPP versus open mesh
Duration of operation was reported for bilateral hernias separately in seven trials.[53,59,63,64,67,68,96] Overall there was no difference between TAPP and open mesh repair (Comparison 06:01: WMD –0.28, 95% CI –5.67 to 5.12, $p = 0.9$). For opposite method initiated, five trials reported results with no apparent differences between the groups (Comparison 06:02: RR 1.98, 95% CI 0.23 to 16.83, $p = 0.74$).[53,59,67,68,96] One trial provided data about conversions.[96] Overall, there was only one (1.6%) conversion reported amongst 63 allocated to TAPP repair compared with zero in the open mesh group (Comparison 06:03: RR 3.5, 95% CI 0.17 to 70.95, $p = 0.4$). The incidence of haematomas was similar between the two groups (Comparison 06:04: RR 0.76, 95% CI 0.35 to 1.65, $p = 0.5$).[53,59,63,64,67,96] There appeared to be fewer cases of seromas in the open mesh groups, although this was not statistically significant (Comparison 06:05: RR 2.62, 95% CI 0.92 to 7.48, $p = 0.07$).[53,63,64,67,68,96] Data about wound/superficial infection were provided for six trials.[53,59,63,64,67,96] This suggested fewer cases following TAPP repair (Comparison 06:06: RR 0.26, 95% CI 0.09 to 0.72, $p = 0.009$). RRs were not estimable for mesh/deep infection, visceral and vascular injury and port-site hernia as no events were recorded. There was no difference between the groups for the length of hospital stay (Comparison 06:11: WMD –0.18, 95% CI –0.38 to 0.02, $p = 0.07$).[53,59,64,67,68,96] The time to return to usual activities was shorter in the TAPP groups (Comparison 06:12: HR 0.51, 95% CI 0.32 to 0.81, $p = 0.005$).[53,59,64,67,68,96] There appeared to be fewer cases of persisting numbness in the TAPP groups (Comparison 06:13: RR 0.23, 95% CI 0.06 to 0.94, $p = 0.04$).[59,64,68,96] However, there appeared to be no difference between the groups when comparing persisting pain and hernia recurrence (Comparison 06:14: RR 0.8, 95% CI 0.45 to 1.45, $p = 0.5$;[64,68,96] Comparison 06:15: RR 2.02, 95% CI 0.52 to 7.83, $p = 0.3$).[53,59,63,64,67,68,96]

Bilateral hernias: TEP versus open mesh
The duration of operation was reported for bilateral hernias separately in five trials.[77,83,85,93,96] The overall WMD was 6.16 (95% CI 0.35 to 11.97, $p = 0.04$) favouring open mesh repair (Comparison 07:01). For opposite method initiated, three trials reported results with no apparent difference between the groups [Comparison 07:02: estimable for one trial (3):

RR 3.10, 95% CI 0.13 to 73.13; $p = 0.5$].[83,93,96] Two trials provided data about conversions.[93,96] Overall, there were three (5.8%) conversions reported amongst 51 allocated TAPP repairs compared with zero in the open mesh group (Comparison 07:03: RR 2.48, 95% CI 0.35 to 17.44, $p = 0.4$). The incidences of haematomas, seromas and wound/superficial infection were similar between the groups (Comparison 07:04: RR 2.17, 95% CI 0.57 to 8.24, $p = 0.3$; Comparison 07:05: RR 0.58, 95% CI 0.12 to 2.91, $p = 0.5$; Comparison 07:06: RR 0.39, 95% CI 0.02 to 9.07, $p = 0.6$).[93,96] RRs were not estimable for mesh/deep infection, visceral and vascular injury and port-site hernia as no events were recorded. Length of hospital stay was compared in one trial (Comparison 07:11: WMD –0.15, 95% CI –0.62 to 0.32, $p = 0.5$).[96] The time to return to usual activities was shorter in the TEP groups, although this was not statistically significant (Comparison 07:12: HR 0.79, 95% CI 0.49 to 2.22, $p = 0.4$).[83,93,96] There appeared to be no difference in the reported number of cases of persisting numbness, persisting pain and hernia recurrence (Comparison 07:13: RR 1.05, 95% CI 0.49 to 2.22, $p = 0.9$;[93,96] Comparison 07:14: RR 0.97, 95% CI 0.62 to 1.52, $p = 0.9$;[93,96] Comparison 07:15: RR 4.44, 95% CI 0.52 to 38.01, $p = 0.17$).[92,93,96]

No separate data were available from the included trials to compare symptomatic and occult hernias, although it is accepted that there may be an important implication of detecting occult bilateral hernias and therefore preventing further surgery.

Older versus younger patients
No separate data were provided in the included trials to compare older and younger patients.

Men versus women
No separate data were provided in the included trials to compare male and female patients.

Fitness for anaesthesia
No separate data were provided in the included trials to compare results in groups for different levels of fitness for anaesthesia. However, for those patients for whom general anaesthesia is not appropriate, open repair would be preferable, and for those patients who would choose not to undergo surgery under local anaesthesia, either approach could be used.

Learning effects
Limited data were available in the included trials describing the effects of learning of laparoscopic techniques on the relevant outcomes, although it

is widely accepted that a learning effect exists for laparoscopic repair and particularly for the more complex TEP repair. It was concluded that this was an important consideration and therefore a separate search was carried out on MEDLINE, EMBASE and Science Citation Index databases to identify any papers reporting learning curves for TAPP and TEP [see Appendix 1, 'Search strategies for learning curves' (p. 85) for full details].

Searches identified an additional 175 reports, 37 of which were considered potentially relevant. Full text papers were obtained, where available, and formally assessed independently by two researchers to check whether they met the inclusion criteria, using a study eligibility form developed for this purpose (Appendix 9). Any disagreements that could not be resolved through discussion were referred to an arbiter. The following inclusion criteria were applied:

- data reported for an individual operator rather than an institution
- data reported for at least three points on the learning curve
- consecutive procedures
- data reported for at least one of the relevant learning outcomes.

The relevant outcomes were duration of operation, complications, length of stay, return to usual activities, hernia recurrence, persisting pain and persisting numbness. Seven studies were included,[20,120–127] although two provided the same data[123,126] and so results from the study with most detail are shown in the tables.[126]

Data were abstracted using a predesigned and piloted data extraction form (Appendix 10). Two reviewers extracted data independently. Any differences that could not be resolved through discussion were referred to an arbiter. Appendix 11 provides details of the characteristics of the included studies. Two studies were prospective audits,[121,125] two were retrospective analyses,[20,122,127] one was a report of two RCTs[126] and one was a systematic review.[124] Two studies[122,125] considered the TAPP repair, three studies considered the TEP repair[20,121,126,127] and one considered a combination of both.[124] The number of laparoscopic procedures performed prior to the study varied; however, for the majority of surgeons TAPP and/or TEP were relatively new techniques. The characteristics of patients, where given, did not vary significantly between the studies. Studies ranged in size from 120 repairs for one surgeon to 1605 repairs for 29 surgeons.

Although data were collected for several outcomes, it was considered inappropriate (owing to study heterogeneity and scarcity of data) to report on any outcome other than duration of operation. This data indicates that it takes between 30 and 100 procedures to become 'expert' in performing laparoscopic hernia repair; however, in the majority of the studies the figure was more likely to be closer to 50 or more procedures. However, this could be misleading since surgeons performing TEP may already be experienced in TAPP. Crude interpretation of these data provide estimates for duration of operation for inexperienced operators (up to 20 procedures) to be 70 minutes for TAPP and 95 minutes for TEP. For experienced operators (between 30 and 100 procedures), the estimated duration of operation are 40 minutes for TAPP and 55 minutes for TEP.

Results of operation time from the studies are given in *Table 15*.

Appendix 15 reports additional data relating to learning effects based on the data from the trial by Neumayer and colleagues (2004).

Summary and conclusions of the evidence for and against the intervention

Since the last assessment of laparoscopic inguinal hernia repair for NICE, the results of the IPD meta-analyses conducted by the EU Hernia Trialists Collaboration have been published. IPD allowed the generation of necessary statistics not provided in the trial publications. This enhanced the information available for all outcomes and was particularly important for the analyses of persisting pain where usable data were only available in a small minority of published reports. The availability of IPD also helped to increase the data quality through detailed data checking, avoiding the need to estimate numerators and denominators (as was necessary for some published reports) and ensured randomisation integrity. The framework of this collaboration also meant that it is unlikely that important trials were missed, although two large trials with long-term follow-up are known to be currently unreported. However, IPD were not available for all trials considered by the Collaboration; for four, trialists checked aggregated data and supplied additional information when available; published data only were available for five trials (two of these trials were identified too late to approach the authors

TABLE 15 *Operation time (minutes) over the learning curve of TAPP and TEP*

	Details	Interval 1	Interval 2	Interval 3	Interval 4	Interval 5	Interval 6	Interval 7
Aeberhard, 1999[121]	TEP 29 operators Mean (SD)	Series (cases): < 16 Unilateral 105 (38) Bilateral 147 (55)	Series (cases): 16–50 Unilateral 102 (41) Bilateral 144 (46)	Series (cases): 51–100 Unilateral 85 (28) Bilateral 128 (36)	Series (cases): >100 Unilateral 53 (26) Bilateral 78 (32)	None	None	None
Lau, 2002[20,127]	TEP 1 operator Mean	Series (cases): 1–20 92	Series (cases): 21–40 76	Series (cases): 41–60 74	Series (cases): 61–80 70	Series (cases): 81–100 58	Series (cases): 101–120 56	None
Leibl, 2000[122]	TAPP 1 operator Mean	Series (cases): 1–5 Learner 72 Expert 55	Series (cases): 16–20 Learner 62 Expert 62	Series (cases): 31–35 Learner 58 Expert 50	Series (cases): 46–50 Learner 50 Expert 45	Series (cases): 61–65 Learner 54 Expert 40	Series (cases): 76–80 Learner 50 Expert 50	Series (cases): 91–95 Learner 52 Expert 52
Ramsay, 2001[124]	TAPP and TEP 27 operators Mean	Series (case): 1 70.5	Series (case): 25 56.6	Series (case): 50 54	Series (case): 100 51.5	Series (case): 200 49.1	None	None
Voitk, 1998[125]	TAPP 1 operator Mean	Series (cases): 1–25 Unilateral 59 Bilateral 67	Series (cases): 26–50 Unilateral 45 Bilateral 67	Series (cases): 51–75 Unilateral 38 Bilateral 58	Series (cases): 76–100 Unilateral 37 Bilateral 52	None	None	None
Wright, 1998[126]	TEP 7 operators Mean (range)	Series (cases): 1–10 COALA 75 (32–155) MRC 75 (50–175)	Series (cases): 11–20 COALA 68 (38–140) MRC 75 (45–120)	Series (cases): 21–30 COALA 55 (25–120) MRC 60 (42–100)	None	None	None	None

SD, standard deviation.

for individual patient data); and a further 13 trials have been identified for this update.

This update considered data for over 5000 randomised participants. These data indicate that after a laparoscopic repair, return to usual activity is faster and persisting pain and numbness are less than with open repair. There appears to be fewer cases of wound/superficial infection and haematomas occur less frequently (TEP repair has a lower incidence than the TAPP repair). However, operation times are longer and there appears to be a higher rate of serious complications in respect of visceral (especially bladder) injuries, especially after TAPP. Seroma is more common, again mainly after TAPP repair. Mesh infection is very uncommon and not different between the groups. Our findings relating to hernia recurrence are consistent with those in the original HTA Report that there is no evidence of a difference in the rate of hernia recurrence when comparing laparoscopic methods (which use mesh) with open mesh methods of hernia repair. There appeared to be no differences in analyses stratified by whether the open mesh method used was flat mesh, preperitoneal or plug and mesh.

When considering the comparison of TAPP with TEP, only one small randomised trial[109] met the inclusion criteria. There appeared to be no differences between TAPP and TEP in terms of length of operation, haematomas, time to return to usual activities and hernia recurrence, but the CIs were all wide.

The data about complications from the additional non-RCT studies[112–120] of TAPP and TEP indicate that an increased number of port-site hernias and visceral injuries are associated with TAPP rather than TEP whereas there appear to be more conversions with TEP. These results appear to be broadly consistent regardless of the evidence source. Vascular injuries and deep/mesh infections were very rare and there was no obvious difference between the groups, the numbers being too small to draw any conclusions.

The results for many of the outcomes in this review displayed significant heterogeneity. However, there was generally consistency in direction of effect, even when size estimates varied. Much of the variation was explained by differences in the methods of open mesh repair (flat mesh, preperitoneal mesh or plug and mesh). Other likely sources of heterogeneity, however, are differences in the way in which the outcomes were defined or measured, in operator experience, in

the types of people studied and in length of follow-up.

Laparoscopic repair is, therefore, associated with short-term benefits in terms of more rapid recovery and long-term benefits in terms of less persisting pain and numbness. However, the findings relating to persisting pain should be interpreted with caution. This is based largely on the work of the EU Hernia Trialists Collaboration. It adopted a broad definition and included any pain in the groin region (including testicular pain), regardless of severity or impact, reported around 1 year after the operation. As a consequence, prevalence rates differed widely. There are currently few published data and most of those reported here came from IPD analysis. Laparoscopic repair is also associated with an estimated 4.6 serious adverse events per 1000 procedures and recurrence rates appear to be similar to those for open mesh repair.

A key issue for laparoscopic inguinal hernia repair is learning effects; studies show that it takes ~50 or more procedures to become experienced in the technique. There did not seem to be any differences between TAPP and TEP in this respect, although this is clouded by the fact that some surgeons performing TEP were likely to be experienced in performing TAPP already.

Appendix 15 provides a summary of the finding of the review following the addition of the trial by Neumayer and colleagues (2004). Additional outcome data were available for wound/superficial infection, vascular injury, visceral injury, port-site hernia, persisting pain and hernia recurrence. The main change from the main HTA Report is that recurrence is now statistically significantly more likely following TEP repair. One suggested explanation of this was the inexperience of some surgeons. A further finding is the increased risk of serious complications following laparoscopic repair, although these data are difficult to assess. The findings of the supplementary analysis for the other outcomes were essentially similar to those reported in this section.

Important subgroup differences

Only small amounts of data were available for all outcomes when comparing TAPP and TEP with open mesh for recurrent hernias and therefore true differences (if they exist) were unlikely to be detected. However, there was statistically significant evidence that the length of operation is longer in both TAPP and TEP when compared with open

TABLE 16 *Summary of the clinical effect size*

Outcome	TAPP vs open mesh[a]	TEP vs open mesh[a]	TAPP vs TEP[a]
Duration of operation (WMD)	13.33 (12.08 to 14.57)	7.89 (6.22 to 9.57)	–6.30 (–12.82 to 0.22)
Opposite method initiated (RR)	6.46 (1.74 to 24.02)	2.87 (1.37 to 6.04)	ND
Conversion (RR)	5.91 (1.91 to 18.27)	10.77 (3.91 to 29.68)	Not estimable
Haematoma (RR)	0.76 (0.62 to 0.94)	0.44 (0.33 to 0.58)	2.59 (0.11 to 60.69)
Seroma (RR)	1.97 (1.27 to 3.07)	0.73 (0.46 to 1.14)	ND
Wound/superficial infection (RR)[b]	0.41 (0.26 to 0.64)	0.62 (0.33 to 1.16)	ND
Mesh/deep infection (RR)	0.39 (0.02 to 9.44)	0.34 (0.01 to 8.26)	ND
Vascular injury (RR)[b]	2.83 (0.12 to 68.58)	1.05 (0.27 to 4.12)	ND
Visceral injury (RR)[b]	4.26 (0.73 to 25.02)	0.62 (0.08 to 4.62)	ND
Port-site hernia (RR)[b]	4.03 (0.45 to 35.70)	Not estimable	ND
Length of hospital stay (WMD)	0.15 (0.09 to 0.21)	–0.12 (–0.18 to –0.06)	–0.70 (–1.33 to –0.07)
Return to usual activities (HR)	0.66 (0.58 to 0.75)	0.49 (0.42 to 0.56)	ND
Persisting numbness (RR)	0.26 (0.17 to 0.40)	0.67 (0.53 to 0.86)	ND
Persisting pain (RR)[b]	0.72 (0.58 to 0.88)	0.77 (0.64 to 0.92)	ND
Hernia recurrence (RR)[b]	1.18 (0.69 to 2.02)	1.61 (0.87 to 2.98)	2.59 (0.11 to 60.69)

ND, no data; WMD, weight mean difference; RR, relative risk; HR, hazard ratio.

[a] Values in parentheses are 95% CIs.

[b] Revised estimates of clinical effect size obtained once the data of Neumayer and colleagues (2004) are included are provided in Appendix 15.

mesh repair and that the return to usual activities is shorter.

When comparing TAPP and TEP with open mesh for bilateral hernias, there was again a scarcity of data. When considering the TEP groups, the duration of operation is again longer than the open mesh groups ($p = 0.04$). However, when considering the TAPP method of repair for bilateral hernias, the duration of operation appears to be similar to that of the open mesh groups ($p = 0.9$). There is also statistically significant evidence to suggest that following a TAPP repair there are fewer cases of wound/superficial infection and persisting numbness and that time to return to usual activities is shorter.

Clinical effect size

A summary of the clinical effect size for all outcomes where data were available is given in *Table 16*.

Chapter 4
Systematic review of economic evidence

This section is an update of the technology assessment review considered by NICE in 2001.[21] The aim of this part of the study was to identify, summarise and quality assess economic evaluations reported since the searches for the original HTA review were conducted. In order to set these studies in context, the findings of the original report are also briefly summarised.

Methods for the review of economic evidence

Search strategy
The literature search for this review updated what had been undertaken for the original HTA review. Consequently, MEDLINE and EMBASE were searched only from 2000 onwards. Additional databases were also searched to identify relevant economic evaluations. Furthermore, all reports related to the RCTs included in the review of effectiveness and the submissions from industry were also considered for inclusion. Listed below are the databases searched:

- MEDLINE (2000 to week 2, July 2003)
- MEDLINE Extra (17 July 2003)
- EMBASE (2000 to week 28, 2003)
- NHS EED Database (July 2003)
- HMIC – Health Management Information Consortium (July 2003)
- Journals @ Ovid Full Text (17 July 2003).

Full details of the search strategies used are documented in Appendix 1.

Inclusion and exclusion criteria
To be included, studies had to involve the comparison of alternative methods of hernia repair in terms of their costs and effectiveness. Studies were not excluded on the basis of language. It should be noted that in the original technology assessment review, studies published prior to 1990 were not included.

An economist assessed the abstracts of all reports identified by the supplementary searching for economic evaluations. All additional RCTs included in the update of the systematic review of effectiveness were also assessed for inclusion. The full published papers were obtained for those studies that appeared potentially relevant and were formally assessed for relevance.

Data extraction
The following data were extracted for each included study:

1. The study characteristics.
   The research question.
   The study design.
   The comparison.
   The setting.
   The basis of costing.
2. Characteristics of the study population.
   Numbers receiving or randomised to each intervention.
   Other systematic differences in clinical management (e.g. type of anaesthesia used, use of day-case or inpatient care).
   Inclusion/exclusion criteria.
   Dates to which data on effectiveness and costs related.
3. Duration of follow-up for both effectiveness and costs.
4. Results.
   Summary of effectiveness and costs (point estimate and if reported range or standard deviation).
   Summary of cost-effectiveness/utility (point estimate and if reported range or standard deviation).
   Sensitivity analysis [including changes to single variable (univariant), two or more variables (multivariate) and stochastic (e.g. bootstrapping). In the first two cases this also includes when one or more variables are altered in order to identify when costs or benefits are equivalent (threshold analysis).]
5. Conclusions as reported by the authors of the study.

Quality assessment
Included studies were assessed against the *BMJ* checklist for referees of economic analyses.[128] Where possible, costs and cost-effectiveness were assessed from the perspective of the NHS and personal social services.

Data synthesis

No attempt was made to synthesise quantitatively the studies that were identified. Data from the included studies were summarised in order to identify common results and variations between studies. These data were then interpreted alongside the results of the systematic review of effectiveness to aid assessment of the relative efficiency of laparoscopic compared with open inguinal hernia repair.

The data reported in the studies conducted alongside RCTs were extracted and used to assess two outcomes: recurrences and time taken to return to usual activities/work. Recurrence was chosen because it has been reported that it is the single most important outcome to patients.[129] Time taken to usual activities was chosen as a proxy for short-term benefits that may be provided by laparoscopic repair in comparison with open repair. Several studies considered the effect of earlier return to work on productivity costs. The inclusion and measurement of productivity costs (indirect costs) in economic evaluations are a contentious issue.[130] However, the implied value of earlier return to work or to usual activities was considered by determining what direct costs are incurred in order to provide an additional day at work or of usual activity. This recognised that a judgement still has to be made about whether the benefits from an additional day at work or usual activity and in any other outcomes are worth this sum.

Systematic review of published economic evaluation – results

Quality and quantity of data available

A total of 286 potentially relevant reports were selected for full text assessment: 31 related to the RCTs included in the review of effectiveness and 255 reports of other studies were identified from the searches. From these, a total of seven new studies met the inclusion criteria (Appendix 12). In addition, seven studies had been identified as part of the previous technology assessment review and are summarised later in this chapter. One of the seven newly identified included studies (Ethicon Endo-Surgery Industry Submission, 2003) was based on a reanalysis of the MRC Laparoscopic Groin Hernia Trial economic evaluation, which is also summarised later.[131] Three were based on models (two of which were based on systematic reviews) and four primary studies (one based on an RCT and three on non-randomised comparisons).

Two of the modelling exercises used the same body of RCT evidence to estimate effects. In neither study was it immediately obvious how the parameter estimates were derived. In one it was based on the application of relative effect differences to baseline effect data for one of the comparators (Vale and colleagues, University of Aberdeen, 2003). In the other[132] it was unclear, although it was likely to be similar to Vale and colleagues. Costs in one study were based on Medicare charges[132] whereas the other used data from bottom-up costing exercises from three economic evaluations conducted alongside RCTs (two from the UK and one from The Netherlands). One study was a cost–utility analysis with utility estimates based on the Quality of Wellbeing Index[132] and the other presented the results in terms of a cost–consequence analysis (in a balance sheet format) and incremental costs per recurrence avoided and per additional day at usual activities. Both studies discounted where appropriate and both reported sensitivity analysis, although only one attempted to formally incorporate parameter uncertainty (Vale and colleagues, University of Aberdeen, 2003). In this latter case the choice of distribution form was not clearly explained.

Bard, as part of their submission, conducted a further model (Bard Industry Submission, 2003). The model compared Bard's 'Perfix Plug' for open mesh repair with laparoscopic repair. The recurrence rate for a Perfix Plug is based on a crude aggregation of available data rather than consideration of the relative risk when compared with laparoscopic repair. It was assumed that the cost of the laparoscopic repair would be the same as the Perfix Plug apart from the cost of the materials required. This assumption is likely to be conservative as the national reference costs used are probably more appropriate to open mesh procedures. Therefore, they would tend to underestimate the cost of laparoscopic repair. One-way sensitivity analysis was conducted to investigate the effects of differences in recurrence rates and the proportion of patients managed as inpatients.

One of the primary studies was a reanalysis of the published results of the MRC Laparoscopic Groin Hernia Trial[131] by Ethicon Endo-Surgery as part of their industry submission. The data used came from the MRC Laparoscopic Groin Hernia Trial, which was, in general, well conducted and reported economic evaluation which took the perspective of the UK NHS. The main limitations of the trial data were the shortness of follow-up

(3 months) and the limited handling of the statistical uncertainty surrounding the results. The industry submission expanded on the results of this evaluation to explore how the cost-effectiveness of laparoscopic repair would change if allowance was made for the management of occult bilateral hernias. No sensitivity analysis was reported and the validity of the estimate of 30% for the rate of occult bilateral hernias which laparoscopic repair could identify and treat was unclear.

Apart from the study by Papachristou,[133] the costing component was poor. None of the other three primary studies were conducted in the UK. Follow-up was short (maximum 17 months) and all relied on observational data with little or no attempts made to control for potential biases. In no study were the major outcomes of effectiveness aggregated into a single measure of effectiveness or utility. In each of the studies, some or all of the following outcome measures were available: pain and analgesic use; return to work/usual activities; recurrences and complications. None of the studies reported any sensitivity analysis.

Comparison of laparoscopic and open mesh repair
Modelling exercises
Comparators
Table 17 details the comparators considered in the three included studies.

Summary of results
Two studies reported that over the time horizons considered (5 years and lifetime) open non-mesh was the most costly and least effective of the open procedures[132] (Vale and colleagues, University of Aberdeen, 2003). Vale and colleagues reported that over 5 years, open flat mesh was less costly [vs TEP mean saving £101; 95% CI £63 to £177 (CIs are the 2.5 and 97.5 percentile points from the range of values produced by the Monte Carlo simulation); vs TAPP mean saving £161; 95% CI £138 to £203]; a similar rate of recurrence [TEP: two fewer recurrences per 1000 patients over 5 years (95% CI – 49.5 to 109.0); TAPP: one

additional recurrence per 1000 patients over 5 years (95% CI –30.8 to 56.4)]. However, laparoscopic repair was associated with more time spent at usual activities [TEP: 4.3 (95% CI 0.4 to 8.2) more days; TAPP: 3.2 (95% CI 1.8 to 4.5) more days] and fewer people with long-term pain [TEP: 67 (95% CI 41 to 107) fewer people per 1000; TAPP: 32 (95% CI 12 to 57) fewer people per 1000]. The incremental cost per additional day at usual activities was also estimated with a probability of >90% that the incremental cost per additional day at usual activities was <£63 for TEP versus open flat mesh (data for TAPP not presented).

Stylopoulos and colleagues reported that laparoscopic repair was the dominant option.[132] The mean cost (in 2002 US dollars) for laparoscopic was $4086 and for open mesh $4290. The lower cost of laparoscopic repair is explained by the inclusion of a patient opportunity cost of between $26 and $113 per day. Laparoscopic repair was also associated with more QALYs than open mesh (9.04 vs 8.975).

The default analysis provided by Bard concluded that the Perfix Plug would be less costly and more effective than laparoscopic repair (Bard Industry Submission, 2003). In the analysis it was assumed that almost all patients receiving the Perfix Plug approach could be managed as day cases whereas for laparoscopic repair only two-thirds would be managed as day cases. The hypothesised cost-saving disappears should the proportions of patients managed as day cases be equal for both laparoscopic and open repair. The data from the RCTs and also the submission from the Association of Endoscopic Surgeons of Great Britain and Ireland suggest that the proportions could be equal. The lower recurrence rates reported for the Perfix Plug approach is of questionable validity and potentially biased (rates of recurrence depend on the method of follow-up, the method of diagnosis and the length of follow-up and these differed between the studies on which the estimates were based).

TABLE 17 *List of comparators used*

Vale (unpublished)	Stylopoulos, 2003[132]	Bard Industry Submission, 2003
TAPP	Laparoscopic	Laparoscopic
TEP	Open mesh	Perfix Plug
Open flat mesh	Open non-mesh	
Open non-mesh	Expectant management	

Patient-level analysis

One of the four patient-level analyses focused on occult bilateral repairs and this study is considered separately below (Ethicon Endo-Surgery Industry Submission, 2003). The remaining three studies compared laparoscopic with open repair and are summarised and critiqued next.

Comparisons made

TAPP and TEP were compared with the open mesh procedure in one of the studies.[133] TAPP was compared with open mesh in the second study.[134] The third study[135] did not report separately TAPP and TEP and it was unclear what type of open procedure was performed.

Results

As already indicated, none of the studies were conducted in the UK and it is unclear how applicable the data are to the UK. Furthermore, their observational nature makes their effectiveness results prone to bias and hence unreliable. For these reasons, only a brief description of the most salient results is presented here.

All of the studies reported that direct costs were, on average, higher for patients who received laparoscopic compared with open repair. The extra cost of laparoscopic ranged from 18% to 140% more. The data on effectiveness were more mixed. In terms of time before usual activities/work were resumed, the data were broadly consistent with the results reported in the review of effectiveness (see the section 'Results', p. 11). None of the studies attempted to incorporate productivity gains (indirect costs) into their analysis but they suggested that these would compensate for the increased hospital costs. The data on recurrences and complications tended to favour open repair, in all but one of the studies.[135] However, the reliability of the effectiveness data is questionable owing to the non-randomised nature of the studies.

Summary of findings from the original HTA report

In the earlier HTA review seven studies performed alongside RCTs comparing laparoscopic to open mesh techniques were identified.[53,58,59,64,68,83,131] At least four of these were of reasonable quality.[53,64,68,131]

In all but one of these studies,[68] the direct costs of laparoscopic repair were greater than those for open repair. In those based on UK RCTs the additional cost per operation was 41%[131] and 122%[64] greater, although the absolute cost differences were very similar (around £300). In the

studies conducted alongside non-UK trials, the additional cost varied between –2% (but probably equal to open mesh) and 65%. The study by Beets and colleagues was unusual in that only patients with recurrent hernias were included.[68]

The higher costs of laparoscopic repair principally reflected two factors. The first is the extra cost of the equipment. This is influenced by whether disposable or reusable equipment is used. If a policy of only using reusable equipment is followed, the extra cost per laparoscopic operation was reduced to about £100–150. The second factor is extra theatre costs due to the longer operation time for laparoscopic repair (typically about an extra 15 minutes per procedure).

In terms of incremental cost per recurrence avoided, open mesh repair was judged dominant as it was less costly and equally or more effective (except for Beets and colleagues,[68] where open mesh was as costly but more effective). It should be noted that although the cost differences may exist, the systematic review of effectiveness found no evidence of a difference in recurrence rates.

Some of the studies reviewed included productivity costs and where this was done it tended to reduce significantly or eliminate the cost differential between laparoscopic and open repair.

Repair of bilateral hernias

Although none of the identified economic evaluations considered the use of laparoscopic techniques to repair bilateral hernias, it can be argued that an advantage of laparoscopic techniques is that bilateral hernias can be repaired within a single incision whereas two separate open incisions would be required for an open bilateral hernia repair. Hence laparoscopic repair could, in principle, prevent significant morbidity and cost. Tentative extrapolation of this within the MRC Laparoscopic Groin Hernia Trial suggested that laparoscopic repair might be more efficient than open repair in these circumstances.[131]

The role of laparoscopic techniques in repairing occult hernia

The only economic evaluation that explicitly addressed the issue of repair of occult hernia was the submission by Ethicon Endo-surgery. This submission presented a revised version of the economic evaluation performed alongside an RCT.[131] The submission also presents a budget impact assessment considering the implications for the NHS of expanding the use of laparoscopic repair.

Summary of results and critique
The MRC Laparoscopic Groin Hernia Trial reported an incremental cost per QALY of £55,549 for a time horizon of 3 months.[131] However, by assuming that 30% of all individuals would develop a contralateral hernia that would require further surgery which could be detected at the time of the initial operation, it was estimated that the adoption of laparoscopic repair would reduce costs and improve the cost-effectiveness of laparoscopic repair to £15,000 per QALY even without taking into account any health gains associated with avoiding an additional open operation.

This analysis does not make any allowance for occult hernias that would not go on to develop into a clinically significant hernia. An RCT reported that 29% (six out of 21 patients), only three of whom developed clinically overt hernias and were referred back by the GP, of those found to have incidental defects on the contralateral side progress to clinically apparent hernias in 12 months. None of those randomised to have their incidental defects repaired at the time of the initial operation subsequently developed a hernia ($n = 16$).[19] Therefore, although the evidence is limited it appears between 10% and 25% of all patients have incidental finding on the contralateral side but within a 12-month period only a proportion will go on to develop a clinically demonstrable hernia.

Comparison of TAPP with TEP
Only one evaluation explicitly considered the relative cost-effectiveness of TAPP and TEP although the data were derived using indirect comparisons (Vale and colleagues, University of Aberdeen, 2003). There was a trend favouring TEP in terms of time to return to usual activities, pain and cost but none of these were definite. Probabilistic sensitivity analysis suggests that in terms of cost per recurrence avoided there is nearly 40% chance that TEP was dominant or is associated with an incremental cost per recurrence avoided of <€1000. In contrast, the probability that TAPP is dominant or is associated with a cost per recurrence avoided of <€1000 is <0.1%.

TEP repair appeared less costly because the evidence available for this study suggests that TEP repair takes less time, but this indirect comparison might be biased despite patients' groups appearing to be comparable. This is not certain and it is possible that the surgeons involved in the trials comparing TEP with open mesh were more experienced, and therefore quicker, than those involved in the trials of TAPP with open mesh. For surgeons with the same experience the operation time and hence cost of TAPP and TEP may be similar.

Summary and implications of studies reporting costs and outcomes

Estimates of laparoscopic costs were greater than those for open mesh in four of the five studies following the trend of the previous review.[21] In terms of cost per recurrence avoided, almost all studies indicated that open mesh was the dominant option. However, it is possible that other health effects may make laparoscopic repair cost-effective.

Results from the previous review reported a cost per additional day at work between £86 and £130 based on UK studies;[21] unpublished data from Vale and colleagues were similar. Where productivity costs were included they eliminated the cost differential between laparoscopic and open mesh (regardless of whether productivity costs were assessed using a human capital or friction cost approach).

Overall, many of the studies considered were only partial analyses with incomplete descriptions of costs and effects. Several, including the two industry submissions, presented very simple analyses. Owing to the simplicity of the analyses and the choice of data used, the results are of limited validity. In all but two of the studies[132] (Vale and colleagues, University of Aberdeen, 2003), the time horizon over which costs and benefits were considered was short. Even in these two studies costs and/or outcomes used are of limited use to priority setting within the UK NHS. Furthermore, their handling of uncertainty was also limited.

Chapter 5
Economic analysis

Introduction

As described in Chapter 4, existing attempts to investigate the relative efficiency of laparoscopic compared with open mesh methods of inguinal hernia repair are of limited value to decision-makers within the UK. First, the identified studies are, in all but two cases, based on the results of a single study and their results may be imprecise and of limited transferability. Second, in all but two studies the time horizon considered was relatively short and the long-term implications for measures of clinical effectiveness and cost would not have been measured. Third, only one study (with only a 3-month time horizon) reported QALYs based on a preference-based measure and using UK population valuations. A final limitation is that none of the available economic evaluations compare all the relevant alternatives. As a result of these limitations it was necessary to develop an economic model to compare the cost-effectiveness of the different surgical interventions.

Methods

A Markov model was used to assess the cost-effectiveness of the various laparoscopic and open mesh procedures for the surgical repair of inguinal hernias. The model was designed to estimate costs, from the perspective of the UK NHS, and outcomes, principally in terms of QALYs, for up to 25 years for the different management strategies (*Figure 6*). The model attempts to incorporate uncertainty in probabilities, costs and utilities by incorporating the input parameters of the model as probability distributions. These distributions were used in a Monte Carlo simulation so that the uncertainty in the results of the model could be presented. The model was developed in Microsoft Excel using Crystal Ball to conduct the Monte Carlo simulation. Data from the model are presented for two time horizons: 5 and 25 years. The first time horizon was chosen as the reliable data from the RCTs and case series relate to no more than this time horizon. The second time horizon investigates the impact of extrapolating the available data over a longer period. All costs are presented in 2001–02 UK pounds and costs

and benefits are discounted at 6% and 1.5%, respectively.

Description of the model

The model was composed of a series of defined health states between which a patient could move over specified periods. On entry into the model all patients had an inguinal hernia that was surgically treated with either a laparoscopic or an open mesh procedure. Provided that the patient survived the operative procedure, they would then enter a period of convalescence followed by return to full health. Patients could at this stage move into one of the following states:

- No recurrence but potentially with persisting long-term pain or numbness.
- Recurrent hernia and proceeding straight to a reoperation.
- Recurrent hernia and choosing not to seek a reoperation. While in this state patients face the risk of undergoing an emergency operation for complications associated with the recurrent hernia.
- Death (included as all-cause mortality and also the operative mortality following both elective and emergency procedures).

Figure 6 provides a simplified summary of the model. Operative complications are assumed to be reflected in terms of longer operating times and length of stay. The rationale behind this assumption is that the weighted mean differences in operation length and length of stay which are reported in Chapter 3 were derived using data from those who suffered complications in addition to those who did not.

The time spent in any of the states before a transition could be made to another state was 1 year (i.e. the cycle length was 1 year). In the years following the initial surgery a patient would either remain without a recurrence (no recurrence) or eventually move to a state of recurrence. Should they suffer a recurrence then they either received a reoperation or remained with an inguinal hernia. Hence transitions between states are governed by four parameters: annual risk of recurrence; proportion of patients who experience

FIGURE 6 *Markov model for the comparison of alternative methods of hernia repair*

a recurrence but do not get a reoperation; risk of emergency surgery for those with an untreated recurrent hernia; and mortality.

The model described in *Figure 6* was used to compare five alternative surgical treatments for inguinal hernia:

1. initial surgery: TAPP, surgery for recurrence: TAPP
2. initial surgery: TEP, surgery for recurrence: TEP
3. initial surgery: open flat mesh, surgery for recurrence: open flat mesh
4. initial surgery: open plug and mesh, surgery for recurrence: open plug and mesh
5. initial surgery: open preperitoneal mesh, surgery for recurrence: open preperitoneal mesh.

The assumption that recurrent hernias would be repaired using the same procedure is uncertain. Therefore, as part of the sensitivity analysis, a second set of interventions were considered which assumed that the recurrent hernias would be repaired using the open flat mesh procedure. The model did not allow anyone to receive more than a total of three surgical treatments (the initial surgery and two subsequent treatments). Provided that the patient survived the third treatment, it was assumed that a further recurrence would not occur.

The parameters required for the model included the recurrence rates following the different procedures; probabilities of reoperation;

probabilities of specific events used to estimate the cost of the health states; rates of long-term pain and numbness; time away from usual activities (used for the presentation of additional days at usual activities); and health status utilities.

Estimation of model parameters
Baseline parameters
The outputs of the systematic reviews derived in Chapter 3 were primarily presented in terms of relative effect sizes (RRs and WMDs). In order to incorporate these data within the model, they needed to be combined with estimates of baseline rates for one of the interventions. Furthermore, while it might be argued that such relative effect sizes are transferable between settings, it is important to ensure that they are applied to baseline rates that are applicable to the UK, so that the resultant absolute differences between interventions are also more likely to be applicable. One of the problems faced in this study was that baseline rates were not always available for the same intervention. Therefore, the best available data were used. Computationally this does not cause problems as the appropriate relative effect sizes can still be used to estimate the required absolute rates for the other interventions under consideration. As outlined below, open flat mesh repair was used for all baseline effect sizes except for recurrence, where superior data were available for TAPP. A further problem is that only very limited data were available for recurrent hernias. Therefore, except where stated otherwise, the values used for recurrent hernias are the same as those used for primary hernias.

Where possible, data on clinical outcomes (recurrences, operative mortality, long-term persisting pain and numbness) were sought from large case series and from recent pragmatic RCTs conducted within the UK. Both the Swedish and Danish Hernia Registries were contacted and additional data were obtained from the Swedish Registry. Further data were also obtained from the MRC Laparoscopic Groin Hernia Trial Group.

Baseline event rates for the risk of recurrence came from the Swedish Registry with cumulative rates for both TAPP and TEP for up to 10 years (Nilsson E, Swedish Registry: personal communication, 2003). For the purposes of this study, the data for TAPP ($n = 2805$) were chosen as the baseline event rates. From the available data, annual rates were estimated for a 5-year follow-up as few patients had been followed up for a longer period. Data are therefore likely to be unreliable. On the basis of the available data, it was assumed that the recurrence rates for the baseline comparator were constant after 5 years.

Data on operative mortality were also sought from the Swedish Registry. Rates of 0.2% (55 out of 27,386 patients) and 0.1% (two out of 2805 patients) for open and laparascopic procedures were reported, respectively. Unfortunately, these data aggregated mortality rates for relatively low-risk elective and high-risk emergency procedures. Emergency procedures were more likely to be performed as an open procedure: 6% ($N = 74,741$) of all open procedures performed as emergencies versus only 0.8% ($N = 7849$) laparoscopic procedures. Therefore, data reported in a UK surgical training website which reported mortality rates for both elective and emergency surgery separately were used in preference (www.surgical-tutor.org.uk/syste/abdomen/hernia.htm). It was assumed in the baseline analysis that the mortality rates for both laparoscopic and open procedures were the same.

Data on the risk of long-term pain and numbness applicable to the UK were obtained from a recent pragmatic multicentre RCT, the MRC Laparoscopic Groin Hernia Trial. Unpublished data from this trial are available for both persisting long-term pain and numbness. Both the outcomes were measured on a five-point scale. For this analysis, the proportion of patients with the two most severe categories of persisting long-term pain and numbness were obtained for the open mesh arm of the trial (Scott N, University of Aberdeen: personal communication, 2003). These data were collected at 12, 24, 36 and 60 months

and are based on between 362 (12 months) and 269 (60 months) trial participants for persisting pain and 362 (12 months) and 271 (60 months) for numbness.

Baseline estimates of operation length, length of hospital stay for day-case procedures and time before return to usual activities were based on the aggregation of data from the open flat mesh arms of the trials included in the systematic review reported in Chapter 3. The length of stay for inpatients was based on data reported in HES for inguinal hernia repair procedures of primary (T20) and recurrent (T21) hernias (http://www.doh.gov.uk/hes/free_data/index.html). These data do not make a distinction between open and laparoscopic procedures. Nonetheless, as reported in Chapter 2, the proportion of laparoscopic procedures performed in the UK is low and it has been assumed that these data are applicable to the open flat mesh procedure.

The baseline point estimates used in the model are detailed in *Table 18*. Also included are notes summarising the method used to characterise the uncertainty in these estimates. Where β distributions have been used, the α parameter is the number of patients who experienced the event of interest and the β parameter is the total number of patients.

Two other parameters included in the model were the risk of recurrence but no reoperation and the risk of emergency operations amongst those who do not have a recurrent hernia repaired. For both parameters data were obtained from the HES (http://www.doh.gov.uk/hes/free_data/index.html). For the former, a rate of 4.8% was used based on 3874 of the 80,414 people presenting with a diagnosis of inguinal hernia not receiving surgical repair. For the latter, a rate of 11.0% was used based on the risk of the number of emergency reoperations (427) divided by the number of people who do not seek an operation for their inguinal hernia (3874). Uncertainty was characterised by β distributions for both of these parameters.

Relative effect sizes
Chapter 3 reports the relative effects from a series of meta-analyses comparing TAPP with open mesh, TEP with open mesh and TAPP with TEP. For some of the comparisons only very limited data were available. Furthermore, relative effect sizes were not available for all relevant comparisons. Therefore, choices were made about which relative effect sizes were to be used in the

TABLE 18 *Baseline parameter values used in the model*

Parameter	Value	Baseline Intervention	Distribution	Values used to define the distribution
Operation length (primary)	54 minutes	Open flat mesh	Normal	SD 16.4
Operation length (subsequent)	56 minutes	Open flat mesh	Normal	SD 16.4
Length of stay (inpatient) (primary)	2.3 days	Open flat mesh	Log-normal	Median 2 days
Length of stay (day case) (primary and subsequent)	4.2 hours	Open flat mesh	Log-normal	SD 6.4
Length of stay (inpatient) (subsequent)	2.6 days	Open flat mesh	Log-normal	Median 2 days
Operative mortality (elective)	0.1%	All		
Operative mortality (emergency)	10%	All		
Return to usual activities (primary and subsequent)	11 days	Open flat mesh	Normal	SD 0.45
Annual risk of recurrence (primary and subsequent)	1.6–0.3%	TAPP		
Annual risk of pain (primary and subsequent)	2.2–1.5%	Open flat mesh	Beta	α 8 to 4; β 362 to 269
Annual risk of numbness (primary and subsequent)	5.5–2.2%	Open flat mesh	Beta	α 20 to 6; β 362 to 269
SD, standard deviation.				

model. These choices were based on the quantity of data available.

In order to reflect differences in the costs and outcomes between primary and subsequent procedures, data on relative effect sizes were sought for both the primary and subsequent procedures. Unfortunately, as detailed in Chapter 3, only very limited data were available on secondary procedures and such data are likely to be unreliable. Therefore, except where detailed otherwise, the same relative effect sizes estimated for the primary procedure were used for both primary and subsequent procedures. It has also been assumed that the RRs of recurrence, long-term pain and numbness do not change over time. The relative effect size for time to return to usual activities was reported in terms of an HR. Such data are not readily interpretable in terms of differences in days at usual activities without information on the hazard rate for return to usual activities. Unfortunately, such data were not available. As a compromise, information was requested from the EU Trialists Collaboration on the mean [and standard deviation (SD)] of the number of days before return to usual activities for each of the interventions based on a crude aggregation of data from the different arms of the trials included in the reviews conducted by this collaboration (Scott N, University of Aberdeen, on behalf of the EU Trialists Collaboration: personal communication, 2003). These data were consistent with the direction of effect indicated by hazard ratios although may not accurately reflect the true difference between interventions.

Table 19 details the point estimate of the relative effect sizes used in the model. Also included are the 95% CIs surrounding the point estimates and estimates for the time to return to usual activities for each intervention. This uncertainty was characterised by log-normal distributions for RRs and time to return to usual activities. Normal distributions were used for WMDs.

Absolute parameter values for each intervention were derived by applying the relative rates obtained from the meta-analyses to estimates of the absolute rate for a baseline comparator. On testing the model it was found that for open plug and mesh and open preperitoneal mesh, estimates of length of stay were implausible for some simulations. Therefore, a decision was made to impose a lower bound on length of stay of 0.4 days as a plausible extreme minimum value. The choice of 0.4 days as a minimum value was informed by consideration of the total period of hospital stay that might be experienced by a day-case patient.

Resource use and costs
The main cost components of the model were the costs of the operative period (i.e. initial operation and hospitalisation) and the costs of any

TABLE 19 *Relative effect sizes used in the model*

Parameter	Point estimate	Limits of 95% CI		Distribution
		Low	**High**	
RR for long-term pain (primary and subsequent)				
TAPP vs OFM	0.68	0.52	0.89	Log-normal
TEP vs OFM	0.10	0.01	0.66	Log-normal
TAPP vs OPM	2.00	0.19	21.62	Log-normal
TAPP vs OPPM	0.46	0.16	1.32	Log-normal
RR for numbness (primary and subsequent)				
TAPP vs OFM	0.10	0.03	0.32	Log-normal
TEP vs OFM	0.17	0.33	1.16	Log-normal
TAPP vs OPM	1.00	0.06	15.71	Log-normal
TAPP vs OPPM	0.07	0.00	1.31	Log-normal
RR for recurrences (primary)				
TAPP vs OFM	1.68	0.73	3.88	Log-normal
TEP vs OFM	1.61	0.57	4.6	Log-normal
TEP vs OPM	0.58	0.2	1.73	Log-normal
TAPP vs OPPM	0.90	0.44	1.85	Log-normal
RR for recurrences (subsequent)				
TAPP vs OFM	0.41	0.02	9.61	Log-normal
TEP vs mixed mesh	1.22	0.63	2.35	Log-normal
TEP vs OPM	0.31	0.02	5.95	Log-normal
TAPP vs OPPM	0.13	0.01	2.25	Log-normal
WMD for operation time (primary) (minutes)				
TAPP vs OFM	10.9	9.4	12.5	Normal
TEP vs OFM	4.3	1.3	7.3	Normal
TAPP vs OPM	25.0	21.0	29.0	Normal
TAPP vs OPPM	15.6	12.9	18.6	Normal
WMD for operation time (subsequent) (minutes)				
TAPP vs OFM	0.40	−8.5	9.3	Normal
TEP vs OFM	−26.0	−36.6	−15.4	Normal
TAPP vs OPM	25.0	21.0	29.0	Normal
TAPP vs OPPM	20.4	13.0	27.8	Normal
WMD for length of stay (inpatients) (primary) (days)				
TAPP vs OFM	0.10	0.04	0.17	Normal
TEP vs OFM	−0.04	−0.11	0.02	Normal
TAPP vs OPM	1.00	0.51	1.49	Normal
TAPP vs OPPM	0.27	0.14	0.39	Normal
WMD for length of stay (inpatients) (secondary) (days)				
TAPP vs OFM	0.07	−0.13	0.27	Normal
TEP vs OFM	0.24	−0.45	0.93	Normal
TAPP vs OPM	1.00	0.51	1.49	Normal
TAPP vs OPPM	−0.05	−0.3	0.19	Normal
Return to usual activities) (primary and secondary) (days)				
OFM	11	10	11	Log-normal
OPM	14	14	14	Log-normal
OPPM	19	15	23	Log-normal
TAPP	8	7	9	Log-normal
TEP	7	7	7	Log-normal

OFM, open flat mesh; OPM, open plug and mesh; OPPM, open preperitoneal mesh.

39

subsequent reoperation. It was assumed that if a recurrence occurred then it would be repaired using the same procedure. This assumption was made as there was no evidence to suggest which method of repair would be used in routine practice to repair recurrent hernias. The impact of relaxing this assumption and assuming recurrent hernias were all repaired with the open flat mesh procedure was assessed as part of the sensitivity analysis. Costs of operative and postoperative complications were not explicitly modelled in the base-case analysis, as their effect would be captured through longer operating times and hospitalisation. Nonetheless, the extreme assumption that all serious complications resulted in immediate death was assessed as part of the sensitivity analysis. The costs of management in the community were also excluded as a recent systematic review of economic evaluations and cost analyses has shown that these are typically a small proportion of total costs in this context.[21]

Data on costs and resources used were obtained from the costing exercises conducted as part of recently conducted pragmatic RCTs conducted in the UK.[64,131] Information on resource use and cost was requested from the investigators involved in these RCTs. Very similar costing methodology was used in the two studies but, as would be expected, the actual resources used to provide the different interventions did vary. From these studies, estimates of resource use were derived under three headings:

- cost per minute for operation staff and theatre time
- cost per day in hospital
- reusable and disposable equipment/consumables costs.

The cost of either a primary or subsequent procedure was estimated by:

1. Multiplying the cost per minute of operation staff and theatre time by the estimated operation length. The estimated operation length was in turn based on the baseline operation length and WMDs between procedures.
2. Multiplying the cost per day by the estimated length of stay. The estimated length of stay was calculated in the same way as described above.

To the summation of (1) and (2), the cost of reusable and disposable equipment/consumables was added and thus the cost of the surgical procedure estimated. For the baseline analysis, data from the MRC Laparoscopic Groin Hernia Trial Group were used, although the use of alternative cost estimates was explored in the sensitivity analysis. Capital costs were obtained by annuitising unit costs over the lifetime of the capital at a 6% discount rate and dividing this figure by expected annual throughput. Appendix 13 provides details of the resource use and unit costs that form the basis of the procedure costs. The cost parameters used for each intervention are detailed in *Table 20*.

TABLE 20 *Cost parameters used for each intervention*[131]

Cost element	Value (£)	Unit
Operation staff + theatre costs		
TAPP	6.40	Cost per minute
TEP	6.40	Cost per minute
Open flat mesh	6.34	Cost per minute
Open plug and mesh	6.34	Cost per minute
Open preperitoneal mesh	6.34	Cost per minute
Operation equipment costs – general anaesthetic, reusables		
TAPP	166.58	Cost per procedure
TEP	166.58	Cost per procedure
Open flat mesh	97.60	Cost per procedure
Open plug and mesh	97.60	Cost per procedure
Open preperitoneal mesh	97.60	Cost per procedure
Operation equipment costs – general anaesthetic, disposables		
TAPP	788.02	Cost per procedure
TEP	788.02	Cost per procedure
Hospitalisation		
Cost per hospital day	236.57	Cost per day

TABLE 21 *Utilities used in the estimation of QALYs for the 3-month postoperative period[131]*

Type of repair	1 week (SD)	1 month (SD)	3 months (SD)
Laparoscopic	0.74 (0.24) (n = 308)	0.82 (0.23) (n = 249)	0.85 (0.22) (n = 261)
Open mesh	0.68 (0.24) (n = 302)	0.79 (0.22) (n = 246)	0.86 (0.2) (n = 236)
Average		0.805	0.855

TABLE 22 *Utility values used to estimate utility weights for each Markov state*

Health state	Value	Distribution	Source	N	SD
Healthy	0.952	Normal	MRC 3-month data	215	0.011
Persisting long-term pain	0.836	Normal	MRC 3-month data	77	0.021
Persisting long-term numbness	0.919	Normal	MRC 3-month data	14	0.023
Persisting pain and numbness	0.739	Normal	MRC 3-month data	88	0.021
Recurrence	0.836	Normal	Assumed equal to score for long-term pain		

Cumulative QALYs score at 3 months postoperation			
Operation	**QALYs (3 months)**	**Source**	**Notes**
TAPP	0.212	MRC 3-month data	Based on *Table 21*
TEP	0.213	MRC 3-month data	Based on *Table 21*
Open flat mesh	0.209	MRC 3-month data	Based on *Table 21*
Open plug and mesh	0.208	MRC 3-month data	Based on *Table 21*
Open preperitoneal mesh	0.209	MRC 3-month data	Based on *Table 21*

Estimation of QALYs

Data used to estimate utilities were available from two studies.[131,132] As outlined in Chapter 4, the data reported by Stylopoulos and colleagues (2003)[132] was based on the Quality of Wellbeing index and potentially not relevant to the UK. Utilities in the MRC Laparoscopic Groin Hernia Trial Group[131] were based upon responses to the EQ-5D questionnaire and valued using UK population tariffs (*Table 21*). Furthermore, the individual patient data from this trial were available. Therefore, these data were used as the basis of utility estimates.

The utility weight for the operation state (cycle length 1 year) was based on the utility for the 3-month convalescence period following the initial operation plus the utility for the remaining 9 months. During the remaining 9 months, an individual might have reduced utility because of the presence of long-term pain and numbness. In order to reflect this, data from the MRC Laparoscopic Groin Hernia Trial were reanalysed to provide utility estimates for (1) persisting long-term pain; (2) persisting long-term numbness; (3) persisting long-term pain and numbness and (4) neither persisting long-term pain or numbness

(*Table 22*). The proportions of patients who would fall into these four categories were estimated using data from the MRC Laparoscopic Groin Hernia Trial. These data showed that for open procedures, 53% (76 out of 143) of patients who experienced numbness also experienced long-term pain. For laparoscopic procedures, the corresponding figure was 38% (27 out of 71). Beta distributions were used to reflect the uncertainty surrounding these estimates using the methods outlined earlier.

The utility weight for the 'No recurrence' state also reflected the risk that a patient might suffer long-term pain and/or numbness. The methods used to estimate this utility weight were the same as those outlined for the estimation of the utility weight for the operation state.

For patients in the state of recurrence and reoperation the utility weight depended on the proportion of the year spent (1) with a recurrence; (2) in convalescence following a reoperation; and (3) no recurrence but possibly with persisting long-term pain or numbness. The proportion of time spent with a recurrence was based on the waiting time for the repair of a recurrent hernia (mean

0.47 years, median 0.31 years). The time spent in convalescence was assumed to be 0.25 years and the time spent with no recurrence (but potentially with persisting long-term pain or numbness) was the remainder of the year. In order to reflect the uncertainty surrounding the period in recurrence, a triangular distribution with a minimum value of 0.22 years (an assumed lower limit), a likeliest value of 0.31 years (equal to the median waiting time) and a maximum of 0.75 years (as the period in convalescence is 0.25 years and the total duration of the state is 1 year). The utility scores for the period spent in convalescence and time spent with no recurrence (but potentially with persisting long-term pain or numbness) were estimated using the same methods as described above. No data were available for the utility weight associated with an untreated recurrence. Stylopoulos and colleagues assumed that a person with an untreated recurrence would have the same utility as a patient who was otherwise healthy.[132] In this analysis, it was assumed that the presence of a hernia reduces utility to the level equal to that of long-term pain.

The utility values for each of the states were estimated using the methods outlined above and using the data reported in *Tables 21* and *22* and estimates of pain and numbness derived from the data reported in *Tables 18* and *19*. As the rates of pain and numbness change over time, the utility scores for cycles spent in states without a recurrence also change over time. *Table 23* provides an example of the utility weights attached to each state of the model for the first year of the model.

Assessment of cost-effectiveness

The results of the base-case analysis are based on the costs and outcomes faced by a cohort of 57-year-old males (the mean age of patients receiving a primary repair of inguinal hernia in England and Wales). The central outcomes of the analysis and the systematic review are first presented in terms of a balance sheet. In the balance sheet, the incremental differences between the alternative interventions are presented in their natural units,

such as days away from usual activities, recurrences avoided. The purpose of the balance sheet is to illustrate the trade-offs that would exist when choosing between interventions. Within the economic model, the different outcomes are combined into a single measure of relative efficiency measured in terms of the incremental cost per QALY. Data on the incremental cost per QALY are presented in two ways. First, mean costs and QALYs for the alternative interventions are presented and incremental cost per QALYs calculated where appropriate. These data are presented for two time horizons: 5 and 25 years. The second way in which the cost-effectiveness of the alternative interventions is presented is in terms of cost-effectiveness acceptability curves (CEACs). CEACs were used to illustrate the uncertainty caused by the combined statistical variability in the model's parameter estimates. These curves illustrate the likelihood that a strategy is cost-effective at various threshold values for society's willingness to pay for an additional QALY.

Sensitivity analysis and sub-group analysis
Sensitivity analysis
Sensitivity analysis focused on varying assumptions or parameters in the base-case model. These sensitivity analyses are split into changes to the relative effect sizes, costs, structure of the model and utilities. Justification and details are provided below.

Relative effect sizes
Changes to the length of stay and operation length. The results of the baseline analysis are influenced by the scarcity of data available. In particular, the rates of operation time and length of stay for both open plug and mesh and TEP are suspect. For open plug and mesh, estimates for both operation length and length of stay are very much less than for open flat mesh. A further issue is that for TEP the data on length of stay and operation length are based on indirect comparisons and suggest that length of stay and operation length are

TABLE 23 *Utility values attached to each state of the model in the first year*

Procedure	Initial operation	No recurrence	Reoperation	Recurrence, no reoperation	Death
TAPP	0.924	0.950	0.871	0.837	0.000
TEP	0.926	0.951	0.872	0.837	0.000
Open flat mesh	0.918	0.946	0.867	0.836	0.000
Open preperitoneal mesh	0.916	0.943	0.866	0.836	0.000
Open plug and mesh	0.922	0.950	0.868	0.836	0.000

shorter for TEP than TAPP, whereas data from direct comparisons suggest that length of stay and operation length are the same or indeed longer for TEP. In the sensitivity analysis, the analysis was repeated for the comparison of all five procedures assuming that open flat mesh and open plug and mesh had the same operation times and lengths of stay. A second sensitivity analysis was performed for the comparison of TAPP, TEP and open flat mesh that assumed that TAPP and TEP had the same operation length.

Adoption of day-case procedure. It has been reported that the open mesh procedures can be performed as day-case procedures whereas the laparoscopic procedures are performed on an inpatient basis. However, it can be seen from the consideration of the trials included in Chapter 3 that discharge policies differ widely between settings and that, although differences may exist between procedures, it is clear that it is hospital policy rather than need which determines length of stay for many cases. Therefore, a sensitivity analysis was conducted that assumed the same length of stay for all procedures.

Effect of learning on cost-effectiveness of TAPP and TEP. As Chapter 3 reported, both TAPP and TEP are associated with a degree of learning. Unfortunately, limited data describing learning were available only on operation length. Crude interpretation of these data provides estimates of operation time for inexperienced operators (up to 20 procedures) of 70 minutes for TAPP and 95 minutes for TEP. For experienced operators (between 30 and 100 procedures), the operation times are 40 minutes for TAPP and 55 minutes for TEP. These data were substituted into the model comparing TAPP, TEP and open flat mesh.

Extrapolation of the relative effect sizes to a 25-year time horizon. In the baseline model, it was assumed that between 5 and 25 years there is a constant annual risk of recurrences, numbness and long-term pain. The limited data available from the review and from the MRC Laparoscopic Groin Hernia Trial Group suggest that this might not be unrealistic for recurrences and numbness, respectively. However, data from the MRC Laparoscopic Groin Hernia Trial Group suggest that rates of pain for all interventions may not differ after 5 years. Therefore, in one sensitivity analysis it was assumed that rates of pain after 5 years are the same for all interventions and in another it was assumed that the relative effects for recurrences, persisting long-term numbness and persisting long-term pain do not persist beyond 5 years.

Incorporation of additional data. The additional data provided by Neumayer and colleagues (2004) were incorporated into the economic model. Appendix 15 provides a summary of the methods and findings of the model following the addition of these trial data.

Source of unit cost data
Data for costs of procedures are available from different sources. In this sensitivity analysis, the impact of different cost estimates on cost-effectiveness were explored. In the first sensitivity analysis, the costs for disposable laparoscopic equipment reported in *Table 20* were used. In the second sensitivity analysis, alternative unit cost data derived from the original costing work performed by the MRC Laparoscopic Groin Hernia Trial Group[131] and Wellwood and colleagues[64] were used. The data used in these sensitivity analyses are reported in *Table 24*.

Structural changes to the economic model
Type of secondary repair. One area of structural uncertainty in the model is which of the available methods of surgical repair would be adopted for a recurrence. In the base-case analysis, it was assumed that all recurrences will be repaired using the same procedure as the initial procedure. In this sensitivity analysis, an alternative assumption was adopted in which all recurrent hernias are repaired using an open flat mesh repair.

Effect of serious complications. The base-case of the model assumed that the serious complications would be captured in terms of longer operation time and length of stay. The extreme assumption that all serious complications result in immediate death was used to test the extent to which this sufficiently captures the effect on outcomes. Using the data reported in *Table 8*, the risk of visceral and vascular complications are 0.79% (6/764) for TAPP, 0.16% (1/644) for TEP and 0.14% (2/1388) for open mesh.

Utilities
Uncertainty surrounding utility estimates. No data were available to determine the utility associated with time spent with a recurrence. In the base-case analysis, it was assumed that the utility associated with a recurrence is the same as that associated with long-term pain. However, the analysis by Stylopoulos and colleagues[132] assumed that the utility associated with a recurrence was the same as that for cured. No justification was provided for this assumption but it may represent a plausible value. Within this sensitivity analysis, the same assumption was made.

43

TABLE 24 *Unit costs used in cost sensitivity analysis*

Cost element	Value (£)		Source	
	1	2	1	2[a]
Operation staff + theatre costs				
TAPP	2.32	6.67	Wellwood	MRC
TEP	2.32	6.67	Wellwood	MRC
Open flat mesh	2.22	6.93	Wellwood	MRC
Open plug and mesh	2.22	6.93	Wellwood	MRC
Open pre-peritoneal mesh	2.22	6.93	Wellwood	MRC
Operation equipment costs – general anaesthetic, reusables				
TAPP	457.80	236.26	Wellwood	MRC[b]
TEP	457.80	236.26	Wellwood	MRC[b]
Open flat mesh	104.65	92.38	Wellwood	MRC[c]
Open plug and mesh	104.65	92.38	Wellwood	Stonehouse MRC[c]
Open pre-peritoneal mesh	104.65	92.38	Wellwood	Stonehouse MRC[c]
Hospitalisation				
Cost per hospital day	226.20	476.44	Wellwood	MRC

[a] Within the MRC trial, six centres contributed data towards costs. One centre formed the basis of the analysis for reuseable equipment and another formed the basis of the sensitivity analysis on disposable equipment.
[b] Consumables Edinburgh West.
[c] Local anaesthetics, prophylactic antibiotics, medium basic tray and self-retaining extractors.

Utility estimates used for long-term pain and numbness. As has been stated previously, the utility estimates used within the model come from one trial.[131] The data from this trial were reanalysed to provide utility estimates for long-term persisting pain and numbness. These data are likely to be key determinants of QALYs but they may not be more generally applicable. In order to explore the importance of utility values for those with long-term persisting pain and numbness, a series of sensitivity analyses were conducted. In these sensitivity analyses, it was assumed that there is no disutility associated with long-term pain, numbness either alone or in combination.

Alternative source of utilities. The base-case analysis adopted the perspective of the NHS for costs and the general population for utilities. The utility data used were based on patient responses to the EQ 5D questionnaire weighted using UK population tariffs. The extent to which these valuations match those based on preferences of patients is unclear. The results of a recent discrete choice experiment[136] were, therefore, integrated into the economic model in order to provide estimates of the net benefit of the different procedures.

Owing to the complex nature of this work, a description of the methodology used by the discrete choice experiment is provided in Appendix 14. *Table 25* reports the coefficients and welfare results of the ordered probit model for the strength of preference format used in the discrete choice experiment.

The data reported in *Table 25* were combined with estimates of recurrence at 4 years, pain at 1 year and cost derived from the economic model and also estimates of risk of serious complications derived from the systematic review of effectiveness reported in Chapter 3. The number of days following surgery were based on data from the MRC Laparoscopic Groin Hernia Trial. These data were consistent with the data reported in Chapter 3 on short-term pain.

Incorporating the data on outcomes for each intervention into the regression equation allows the net benefits for each intervention to be estimated. *Table 26* details the additional parameter values and distributions used in this analysis. The risk of serious complication is assigned with a beta distribution using the same methods as outlined previously. Number of days in long-term pain was assigned a log-normal distribution and all coefficients were assigned normal distributions, as this is the assumption underpinning random effects probit models.

TABLE 25 Random effects ordered probit model – all responders[a]

Variable	Attribute unit	Coefficient (95% CI)	SE	*p*-Value	WTP (£) per unit (95% CI)
Type of anaesthetic (0 = general, 1 = local)	Categorical	–0.1660 (–0.12541 to –0.1801)	0.02345	0.000	327.65 (247.52 to 355.44)
Risk of serious complications (%)	0.01%	–0.3386 (–0.3786 to –0.2232)	0.04825	0.000	668.33 (440.52 to 747.26)
Time in pain following surgery (days)	1 day	–0.0609 (–0.0652 to –0.05124)	0.00342	0.000	120.20 (101.13 to 128.66)
Cost (£)	£	–0.0005 (–0.00057 to –0.00044)	0.000032	0.000	NA
Chance of long-term pain up to 1 year (%)	1%	–0.0432 (–0.043247 to –0.0645)	0.00502	0.000	85.35 (78.87 to 127.37)
Chance of recurrence (%)	%	–0.0516 (–0.05877 to –0.04653)	0.00221	0.000	101.88 (91.84 to 116.00)
Constant	–	1.62143 (1.546 to 1.711)	0.08834	0.000	NA

NA, not applicable; SE, standard error.

[a] Number of observations, 3104; Unbalanced panel, 246 individuals; Log-likelihood function, –3369.97; Restricted log-likelihood, –3714.41; χ^2, 599; Significance level, 0.000; McFadden's R^2 0.09; Correct predictions, 40%.

TABLE 26 Additional parameters used in the assessment of net benefits using the discrete choice experiment

Parameters in DCE	Parameter value		Source	Attribute unit	Coefficient	SE of coefficient	Monetary valuation	Distribution of coefficient
Type of anaesthetic (1 = local, 0 = general)								
TAPP	0		Ass	1	–0.166	0.02345	£332.00	Normal
TEP	0		Ass	1	–0.166	0.02345	£332.00	Normal
OFM	0		Ass	1	–0.166	0.02345	£332.00	Normal
Risk of serious complications								
	Events	*Sample*						
TAPP	0.79% 6	764	Review	0.1%	–0.3386	0.04825	£677.20	Normal
TEP	0.16% 1	644	Review	0.1%	–0.3386	0.04825	£677.20	Normal
OFM	0.14% 2	1388	Review	0.1%	–0.3386	0.04825	£677.20	Normal
Days in pain following surgery								
	SE							
TAPP	3.56 0.241		MRC	1	–0.0609	0.00342	£121.80	Normal
TEP	3.56 0.241		MRC	1	–0.0609	0.00342	£121.80	Normal
OFM	4.2 0.256		MRC	1	–0.0609	0.00342	£121.80	Normal
Cost at 4 years								
TAPP	£1272		Model		–0.0005	0.000032	£1.00	Normal
TEP	£1303		Model		–0.0005	0.000032	£1.00	Normal
OFM	£1020		Model		–0.0005	0.000032	£1.00	Normal
Chance of long-term pain at 1 year								
TAPP	1.59%		Model	1%	–0.0432	0.00502	£86.40	Normal
TEP	1.70%		Model	1%	–0.0432	0.00502	£86.40	Normal
OFM	2.21%		Model	1%	–0.0432	0.00502	£86.40	Normal
Chance of recurrence at 4 years								
TAPP	3.70%		Model	1%	–0.0516	0.00221	£103.20	Normal
TEP	4.41%		Model	1%	–0.0516	0.00221	£103.20	Normal
OFM	3.13%		Model	1%	–0.0516	0.00221	£103.20	Normal

Ass, assumption; DCE, discrete choice experiment; OFM, open flat mesh; SE, standard error.

TABLE 27 *Details of the parameters used to assess the cost-effectiveness of laparoscopic compared with open repair for the surgical treatment of occult hernias*

Parameter	Value	Distribution
Risk of occult hernia	10 or 25%	
Risk of progression	29%	Beta; α 6; β 21[19]
Duration of effect	NA	1 year[a]
Relative risk of recurrences	NA	Subsequent procedures the same as primary
Operation time TAPP	76.1 minutes	
Operation time TEP	94.2 minutes	
Operation time open mesh	NA	Same as base-case analysis

NA, not applicable.
[a] Available data relate to rate of progression at 1 year. This assumes that if an occult hernia develops into symptomatic hernia, it will do so in 1 year.

As described above the using the framework provided by the discrete choice experiment, the parameters were combined using the similar methods to those adopted by McIntosh and colleagues[136] to provide an estimate of willingness to pay for each comparator. The principal differences between the two approaches are that in McIntosh and colleagues' work, the focus was on an incremental analysis between comparators. In this study, the focus was initially on the net benefits (benefits – costs) for each comparator presented in terms of net benefit curves. This was an arithmetic convenience that when coupled with the assumption that the choice faced by decision-makers was between mutually exclusive comparators (an assumption underlying the estimation of the probability that an intervention was cost-effective) allowed a calculation of the likelihood that each comparator is cost-effective. A second, incremental analysis was also performed. With this analysis both TAPP and TEP were compared with open flat mesh. TAPP and TEP were also compared. The results of this analysis were presented in terms of incremental net benefit curves.

Subgroup analysis
The model parameters were adjusted in order to estimate relative cost-effectiveness for a number of prespecified subgroups. The first subgroup of interest was the surgical management of recurrent hernias. In this analysis, the initial operation was given the same parameter values as subsequent procedures. In most cases, owing to the limited evidence available, this did not result in a change in parameter value when compared with the assessment of cost-effectiveness for a primary inguinal hernia.

A final subgroup of interest was the management of bilateral hernias. Two specific scenarios were defined for this subgroup; the first relates to the management of symptomatic bilateral hernias and the second to the management of occult second hernias. For the former scenario, reasonably clear evidence is provided from the existing economic evaluations on relative cost-effectiveness. Therefore, the focus of the subgroup analysis is on the management of occult bilateral hernias. The available evidence suggests that the laparoscopic techniques can both be used to detect occult hernias but only a proportion of these will develop into symptomatic hernias. These data were incorporated into the model by increasing the risk of recurrence for the open mesh procedure by the risk that there is an occult hernia that goes on to develop into a symptomatic hernia. The risk of recurrence following laparoscopic repair was also increased to reflect the probability that a repaired occult hernia might recur. However, it was assumed that only repaired occult hernias that might otherwise have progressed could recur. To reflect the extra procedure cost of repairing a contralateral hernia, the operation time for both TAPP and TEP was based on that reported for the repair of a bilateral hernia. These data were based on the times reported in the systematic review of effectiveness. Details of the additional parameter values used and their distributions are reported in *Table 27*.

The risk of progression has been reduced to 14% (three out of 21 patients presented to their GP with a recurrent hernia)[19] and 5% (one out of 21 patients with progression) to explore the impact of progression on cost-effectiveness.

Further subgroups of interest were gender and age. Little information was available split by gender and for this reason it was assumed that the results are equally applicable to females and males. In terms of age, few age-dependent data

TABLE 28 *Balance sheet for the comparison of laparoscopic repair with open flat mesh for 5-year time horizon*

Favours TAPP and TEP[a]	**Favours open flat mesh**[a]
More time at usual activities after five years TAPP: 2.88 (95% CI 1.65 to 4.16) more days TEP: 3.91 (95% CI 2.78 to 4.90) more days	**Lower costs over five years** TAPP: mean saving £181; 95% CI £150 to £208) TEP: mean saving £105; 95% CI £67 to £234)
Fewer people with numbness TAPP: 20.1(95% CI 6.2 to 36.7) fewer patients per 1000 TEP: 18.5 (95% CI –2.9 to 34.1) fewer patients per 1000	**Potentially more serious complications** TAPP: 7.9 more serious complications per 1000 patients TEP: 0.2 more serious complications per 1000 patients
Fewer people have long-term pain TAPP: 4.8 (95%CI 1.0 to 11.2) fewer people per 1000 TEP: 13.4 (95%CI 2.3 to 29.7) fewer people per 1000	
Similar risk of recurrence for TAPP and TEP compared with OFM over 5 years TAPP: 2 more recurrences per 100 patients (95% CI –2 to 3) TEP: 1 more recurrence per 100 patients (95% CI –1 to 9)	

[a] Ranges are the 2.5 and 97.5 percentile points from the range of values produced by the Monte Carlo simulations.

TABLE 29 *Balance sheet for the comparison of laparoscopic repair with open flat mesh for a 25-year time horizon*

Favours TAPP and TEP[a]	**Favours open flat mesh**[a]
More time at usual activities TAPP: 2.87 (95% CI 1.57 to 4.37) more days TEP: 3.92 (95% CI 2.69 to 5.03) more days	**Potentially lower costs** TAPP: mean saving £188 (95% CI 137 to £226) TEP: mean saving £133 (95% CI £64 to £308)
Fewer people with numbness TAPP 20.1 (95% CI 6.2 to 36.7) fewer patients per 1000 TEP 18.5 (95% CI –2.9 to 34.1) fewer patients per 1000	**Potentially more serious complications** TAPP: 7.9 more serious complications per 1000 patients TEP: 0.2 more serious complications per 1000 patients
Fewer people have long-term pain TAPP: 4.8 (95% CI 1.0 to 11.2) fewer people per 1000 TEP: 13.4 (95% CI 2.3 to 29.7) fewer people per 1000	
Similar risk of recurrence for TAPP and TEP compared with OFM over 25 years TAPP: 3 more recurrences per 100 patients over 25 years (95% CI –4 to 6) TEP: 3 more recurrences per 100 patients over 25 years (95% CI –2 to 19)	

[a] Ranges are the 2.5 and 97.5 percentile points from the range of values produced by the Monte Carlo simulations.

are available; however, the lower and higher ages were modelled to illustrate the impact that changes in mortality rates have on cumulative risk of recurrence, long-term pain, numbness and hence QALYs.

Results

Management of primary inguinal hernias
Tables 28 and *29* present the balance sheets for the comparison of both TAPP and TEP with open flat mesh for 5- and 25-year time horizons. Laparoscopic repair is associated with more time at usual activities and fewer people with long-term

pain, but this is achieved at higher cost and an increased risk of rare but serious complications. The costs presented in *Tables 28* and *29* are based on reusable laparoscopic equipment.

The data presented in *Tables 28* and *29* allow implicit valuations about how the alternative outcomes can be traded off. These implicit valuations, which inform decisions about whether the use of laparoscopic repair should be increased, depend on whether the benefits of laparoscopic repair (reduced persisting long-term pain and numbness and earlier return to usual activities) are worth the extra cost, the increased risk of serious complication and the uncertainty of differences in rates of recurrence.

TABLE 30 *Results of the deterministic model for a 5- and a 25-year time horizon*

Time horizon (years)	Procedure	Cost (£)	QALYs	Incremental cost (£)	Incremental QALYs	Incremental cost per QALY
5	TAPP	1190	4.44			Dominated
	TEP	1113	4.45	384 vs OPM	0.01 vs OPM	46,443 vs OPM
	OFM	1009	4.42			Dominated
	OPPM	926	4.41			Dominated
	OPM	730	4.44			
25	TAPP	1211	16.23	75		Dominated
	TEP	1135	16.24	373	0.02	20,014 vs OPM
	OFM	1022	16.19			Dominated
	OPPM	944	16.16			Dominated
	OPM	763	16.23			

OFM, open flat mesh; OPM, open plug and mesh; OPPM, open preperitoneal mesh.

The different outcomes reported in *Tables 28* and *29* are explicitly combined within the estimates of incremental cost per QALY. Nonetheless, the data from these tables are still useful as they allow discrepancies between implicit and explicit valuations to be identified and explored. The results of a deterministic analysis of incremental cost per QALY are reported in *Table 30,* which compares all five surgical interventions.

TAPP repair is dominated by TEP over the time horizons considered. Furthermore, open preperitoneal mesh and open flat mesh are dominated by open plug and mesh. The point estimates of incremental cost-effectiveness provided in *Tables 30* do not provide any indication of the uncertainty that exists. The uncertainty surrounding the precision of many of the parameter estimates is reflected in the likelihood that the interventions are cost-effective at different threshold values for society's willingness to pay for a QALY (*Table 31*).

The data presented in *Table 31* indicate that the likelihood that the laparoscopic procedures will be considered as cost-effective increases as the maximum amount that society is willing to pay for an additional QALY and the time horizon increase. The data also illustrate some of the limitations of the data available for the model. In particular, the results for open plug and mesh and open preperitoneal mesh are based on the results of only one or two relatively small trials. Therefore, some of the estimates derived from these trials are very imprecise in addition to being potentially unreliable. For example, the relatively low cost of the open plug and mesh procedure is driven by the estimates of length of stay and operation time used in the model. These estimates are based on the available data but it is possible

that in reality there is no meaningful difference between open flat mesh and open plug and mesh in these outcomes. As *Table 31* shows, should the length of stay and operation length for open plug and mesh be the same then open flat mesh becomes the least costly option. It should be noted that the same reservations that can be raised about the cumulative costs of open plug and mesh and open preperitoneal mesh could also be raised for estimates of QALYs for these procedures.

Owing to the unreliability of data for open plug and mesh and open preperitoneal mesh, the remainder of the analysis is presented for the comparison of TAPP and TEP with open flat mesh. This makes the realistic assumption that open plug and mesh and open preperitoneal mesh have the same effectiveness as open flat mesh (*Figures 7* and *8*). As these figures show, TEP is more likely to be considered cost-effective than TAPP at all threshold values for society's willingness to pay for an additional QALY. Furthermore, it appears that once society is willing to pay more than £10,000 per QALY, the likelihood that open flat mesh is cost-effective is very low.

Sensitivity analysis
Changes to relative effect sizes
Table 32 shows that if the length of stay and operation lengths for TAPP and TEP are the same then TAPP becomes very slightly less costly than TEP, although TEP has extended dominance over TAPP. Overall, TEP remains the most likely to be cost-effective. Similarly, assuming that there are no meaningful differences in length of stay between procedures, TEP is marginally less cost-effective than the other interventions, although there was little difference compared with the base-case model.

TABLE 31 *Comparison of the five interventions together with incremental analysis*

Sensitivity analysis	Procedure	Cost (£)	QALYs	Incremental cost per QALY (£)	Probability cost-effectiveness for different threshold values for society's willingness to pay for a QALY (%)				
					£10,000	£20,000	£30,000	£50,000	
Baseline model for a 5-year time horizon	TAPP	1190	4.44	Dominated	1.1	4.0	5.2	7.4	
	TEP	1113	4.45	46,443 vs OPM	6.6	21.2	34.8	54.2	
	OFM	1009	4.42	Dominated	2.2	0.9	0.0	0.0	
	OPPM	926	4.41	Dominated	5.1	5.1	4.9	4.2	
	OPM	730	4.44		85.0	69.7	55.1	34.2	
Baseline model for a 25-year time horizon	TAPP	1211	16.23	Dominated	6.4	8.8	9.9	11.3	
	TEP	1135	16.24	20,014 vs OPM	28.5	49.4	57.9	66.0	
	OFM	1022	16.19	Dominated	0.1	0.0	0.0	0.0	
	OPPM	944	16.16	Dominated	3.8	3.4	3.2	3.0	
	OPM	763	16.23		61.2	38.4	29.0	19.7	
Open flat mesh and open plug and mesh have the same operation length and length of stay (25-year time horizon)	TAPP	1211	16.23	Dominated	10.3	11.7	12.5	12.6	
	TEP	1135	16.24	2094 (2093 vs OPM)	66.8	72.1	73.6	74.8	
	OPM	1096	16.23	ED (2095 vs OFM)	18.7	12.9	10.8	9.5	
	OPPM	1037	16.16	Dominated	4.0	3.3	3.1	3.1	
	OFM	1022	16.19		0.2	0.0	0.0	0.0	

ED, extended dominance; OFM, open flat mesh; OPM, open plug and mesh; OPPM, open preperitoneal mesh.

FIGURE 7 *CEACs for the comparison of TAPP, TEP and open flat mesh for a 5-year time horizon*

FIGURE 8 *CEACs for the comparison of TAPP, TEP and open flat mesh for a 25-year time horizon*

Changes to the duration over which the relative effect size differs had relatively little effect on cost owing to the relatively low rate of recurrences but relatively more on estimates of QALY. Should differences in long term pain, numbness and recurrence not persist into the long term, then open flat mesh becomes more likely to be considered cost-effective. Nonetheless, it would appear that TEP dominates TAPP and is associated with a relatively low incremental cost per QALY (*Table 32*).

Costs

Table 33 shows the effect of changing the cost estimates of the model. In the first sensitivity analysis it was assumed that laparoscopic procedures are conducted using disposable equipment. This has the effect of greatly increasing the cumulative costs of both TAPP and TEP. As a result, at lower incremental cost per QALY thresholds (e.g. £10,000) it is unlikely that either laparoscopic procedures are cost-effective. However, at higher thresholds TEP becomes increasingly more likely to be cost-effective as it is more likely to provide additional QALYs over open flat mesh.

Also shown in *Table 33* is the effect on relative cost-effectiveness of using different cost estimates available from one of the other centres included in the MRC Laparoscopic Groin Hernia Trial Group and the estimates from Wellwood and colleagues.[64,131] As these analyses show, although the mean incremental cost per QALY of TEP compared with open flat mesh is increased, the overall likelihood that TEP is the most cost-effective option at the threshold values for society's willingness to pay for a QALY reported is virtually unchanged.

Changes to the structure of the model

The impact of experience (as a proxy for the effect on learning) is shown in *Figure 9*. The plots show that TAPP becomes more likely to be cost-effective. Nonetheless, even for inexperienced surgeons, at threshold values >£10,000 per QALY TEP is more likely to be efficient than the other interventions. What these analyses do not reflect is any change in effectiveness or safety and they do not reflect any other impact on cost other than that mitigated through operation time.

Changing the structure of the model so that all subsequent procedures are open flat mesh slightly reduces the likelihood that TEP is cost-effective. The reason the impact of this change is small is the relatively low risk that a recurrence will occur

(*Table 34*). Also shown in *Table 34* is the effect of including all serious complications such as operative mortality. As reported in the section 'Methods' (p. 35), the estimated rate of serious complications is higher for TAPP than either TEP or open flat mesh. As a consequence, the overall cost-effectiveness of TEP is not greatly changed but TAPP is less likely to be cost-effective and open flat mesh is more likely to be cost-effective.

Changes to utilities

Table 35 provides details of the effect of changing the utility associated with a recurrence. In this sensitivity analysis it was assumed that a recurrence is associated with the same utility as being healthy. This is the same assumption as used by Stylopoulos and colleagues in their analysis.[132] As the data show, the results do not change greatly. The reason for this is that there is a relatively low risk of recurrence and hence a relatively small risk of a patient suffering the associated disutility.

Also shown in *Table 35* is the effect of removing the disutility associated with long-term persisting pain and numbness. As the results of these sensitivity analyses show, the utility values assumed for people with long-term persisting pain and numbness greatly influence cost-effectiveness. Assuming that there is no disutility associated with long-term persisting pain reduced the cost-effectiveness of TEP and led to a reduction in difference between TAPP and TEP. Indeed, in this sensitivity analysis TAPP is associated with a slightly higher estimate of mean QALYs than TEP. An assumption that there is no disutility associated with long-term numbness has less impact, although the mean cost-effectiveness of TEP is again reduced. Nonetheless, at higher threshold values, such as £20,000, for a cost per QALY TEP is highly likely to be considered cost-effective.

The greatest impact on cost-effectiveness occurs when there is no disutility from either long-term pain or numbness. This sensitivity analysis is essentially the same as assuming that the only differences in QALYs between interventions are caused by differences in the risk of recurrence and the speed of recovery from a procedure. In this analysis, it is unlikely that either TAPP or TEP will be considered cost-effective at threshold values for a cost per QALY deemed affordable by society.

Although the utilities used in the model were derived using the EQ-5D, they relate to a single study. Furthermore, these valuations may not match those of patients. In an attempt to explore

TABLE 32 Results of sensitivity analysis for variations in length of operation time and length of stay

Sensitivity analysis	Procedure	Cost (£)	QALYs	Incremental cost per QALY (£)	Probability cost-effectiveness for different threshold values for society's willingness to pay for a QALY (%)			
					£10,000	£20,000	£30,000	£50,000
Base-case model for a 25-year time horizon	TAPP	1211	16.23	Dominated	14.1	14.8	15.2	15.1
	TEP	1135	16.24	2093	85.5	85.2	84.8	84.9
	OFM	1022	16.19		0.4	0.0	0.0	0.0
TAPP and TEP have the same operation length and length of stay	TEP	1121	16.24	3240 vs OFM (8 vs TAPP)	77.7	80.9	81.9	82.8
	TAPP	1121	16.23	ED (5218 vs OFM)	20.7	19.1	18.1	17.2
	OFM	1022	16.19		0.3	0.0	0.0	0.0
Assumption that the length of stay for each procedure is the same	TAPP	1186	16.23	Dominated	17.1	16.9	16.1	16.1
	TEP	1144	16.24	2252	82.6	83.1	83.9	83.9
	OFM	1022	16.19		0.3	0.0	0.0	0.0
Assumption that the duration of effect for pain is 5 years	TAPP	1211	16.22	Dominated	23.6	31.3	34.2	36.1
	TEP	1135	16.22	3302	71.5	68.4	65.7	63.9
	OFM	1022	16.19		4.9	0.3	0.1	0.0
Assumption that the duration of effect for pain, recurrences and numbness is 5 years	TAPP	1211	16.20	Dominated	3.2	11.3	14.1	16.6
	TEP	1134	16.21	5471	79.6	86.3	85.1	83.3
	OFM	1030	16.19		17.25	2.4	0.8	0.1

ED, extended dominance; OFM, open flat mesh.

TABLE 33 Results of sensitivity analysis for variations in costs

Sensitivity analysis	Procedure	Cost (£)	QALYs	Incremental cost per QALY (£)	Probability cost-effectiveness for different threshold values for society's willingness to pay for a QALY (%)			
					£10,000	£20,000	£30,000	£50,000
Baseline model for a 25-year time horizon	TAPP	1211	16.23	Dominated	14.1	14.8	15.2	15.1
	TEP	1135	16.24	2093	85.5	85.2	84.8	84.9
	OFM	1022	16.19		0.4	0.0	0.0	0.0
TAPP and TEP use disposable equipment	TAPP	1832	16.23	Dominated	0.2	5.8	12.6	15.1
	TEP	1757	16.24	13,616	6.3	65.6	81.4	84.6
	OFM	1022	16.19		93.5	28.6	6.0	0.3
Alternative unit costs (1) (see *Table 24*)	TAPP	1110	16.23	Dominated	9.2	15.4	15.6	15.6
	TEP	1064	16.24	5538	75.7	84.2	84.4	84.4
	OFM	765	16.19		15.1	0.4	0.0	0.0
Alternative unit costs (2) (see *Table 24*)	TEP	1838	16.23	Dominated	13.0	14.5	15.0	15.2
	TAPP	1724	16.24	2107	85.6	85.5	85.0	84.8
	OFM	1614	16.19		1.4	0.0	0.0	0.0

OFM, open flat mesh.

TABLE 34 Results of sensitivity analysis for variations in the structure of the model

Sensitivity analysis	Procedure	Cost (£)	QALYs	Incremental cost per QALY (£)	Probability cost-effectiveness for different threshold values for society's willingness to pay for a QALY (%)			
					£10,000	£20,000	£30,000	£50,000
Baseline model for a 25-year time horizon	TAPP	1211	16.23	Dominated	14.1	14.8	15.2	15.1
	TEP	1135	16.24	2093	85.5	85.2	84.8	84.9
	OFM	1022	16.19		0.4	0.0	0.0	0.0
Subsequent procedures are all open flat mesh	TAPP	1213	16.22	Dominated	13.4	15.1	15.7	16.3
	TEP	1135	16.24	2180	87.5	84.9	84.3	83.7
	OFM	1022	16.19		1.1	0.0	0.0	0.0
Inclusion of serious complications as operative mortality	TAPP	1210	16.09	Dominated	0.6	0.7	0.8	0.9
	TEP	1135	16.22	2190	81.9	86.4	87.2	88.0
	OFM	1022	16.17		17.5	12.9	12.0	11.1

OFM, open flat mesh.

FIGURE 9 *CEACs for the comparison of TAPP, TEP and open flat mesh for laparoscopic surgeons at different levels of experience: (a) experienced and (b) inexperienced*

TABLE 35 *Results of sensitivity analysis for changes in the utility values*

Sensitivity analysis	Procedure	Cost (£)	QALYs	Incremental cost per QALY (£)	Probability cost-effectiveness for different threshold values for society's willingness to pay for a QALY (%)			
					£10,000	£20,000	£30,000	£50,000
Baseline model for a 25-year time horizon	TAPP	1211	16.23	Dominated	14.1	14.8	15.2	15.1
	TEP	1135	16.24	2,093	85.5	85.2	84.8	84.9
	OFM	1022	16.19		0.4	0.0	0.0	0.0
Assuming that the utility associated with recurrent hernias is the same as healthy	TAPP	1211	16.23	Dominated	9.1	9.1	8.2	8.0
	TEP	1135	16.25	2,004	90.8	90.9	91.8	92.0
	OFM	1022	16.19		0.1	0.0	0.0	0.0
Assuming that there is no disutility associated with pain	TAPP	1211	16.26	72,671	13.6	28.8	37.7	47.2
	TEP	1135	16.26	8,262	42.1	50.0	47.1	41.9
	OFM	1022	16.24		44.3	21.2	15.2	10.9
Assuming that there is no disutility associated with numbness	TAPP	1211	16.23	Dominated	0.2	5.8	7.8	9.0
	TEP	1135	16.25	4008	81.3	89.4	91.0	90.7
	OFM	1022	16.22		16.7	4.8	1.2	0.3
Assuming that there is no disutility associated with pain or numbness	TAPP	1211	16.26	2,173,247	0.0	0.2	1.7	8.6
	TEP	1135	16.26	98,584	0.3	3.6	13.4	30.8
	OFM	1022	16.26		99.7	96.2	84.9	60.6

OFM, open flat mesh.

TABLE 36 *Estimated costs and benefits for each treatment option*

Procedure	Cost (£)	Benefits (£)					
		Constant[a]	Complications	Short-term pain	Long-term pain	Recurrences	Total benefits
TAPP	1188	3243	−5318	−434	−130	−381	−3020
TEP	1111	3243	−1052	−434	−19	−323	1416
OFM	1008	3243	−976	−512	−191	−230	1335

OFM, open flat mesh.
[a] Benefits of repair that do not differ between procedures.

TABLE 37 *Incremental analysis comparing the alternative interventions*

	Cost (£)	Total benefits (£)	Incremental cost (£)	Incremental benefit (£)	Net benefit[a]
TAPP	1192	−3020	77	−4436	Dominated
TEP	1115	1416	96	81	Dominated
OFM	1020	1335			

OFM, open flat mesh.
[a] Incremental benefits − incremental cost.

the importance of this, the analysis was repeated using the findings of a discrete choice experiment. It should be noted that the discrete choice approach essentially assumes that there are no meaningful differences between interventions other than in the attributes chosen.

Tables 36 and *37* report the deterministic results of the analysis. *Table 36* reports the estimated cost and benefits for each procedure and also the relative contribution to benefits of each attribute of the discrete choice experiment (DCE). [The relevance of a negative net benefit to decision-making is unclear as this is not the same as a comparison with no treatment. Even if it was decided that a hernia should not be treated, some costs (e.g. the cost of emergency operations to treat strangulated hernias) and effects (e.g. risk of long-term pain) would be incurred.]

The incremental costs and benefits and incremental net benefit are shown in *Table 37*. As this table shows, TAPP is associated with the highest costs and the lowest benefits and hence is dominated. TEP provides more benefits than open flat mesh but at considerably more cost. As a result TEP is dominated by open flat mesh.

The methods used to derive these results are similar to those presented by McIntosh and

colleagues[136] with the main exception being that they are based on the more precise and generalisable data provided by the systematic reviews of the available literature.

The results presented in *Tables 36* and *37* do not, however, reflect the statistical imprecision surrounding parameter estimates. Monte Carlo simulation, conducted in the same manner as described for the cost per QALY comparisons, was used to reflect this uncertainty. *Figure 10* presents the incremental net benefits for the three pairwise comparisons. The vertical axis shows the incremental net benefit when comparing two interventions. If for the comparison of TEP with open flat mesh there is a positive incremental net benefit, then TEP provides more benefits than OFM. The horizontal access shows the likelihood that the incremental net benefit is equal to or less than a specified value.

As *Figure 10* shows, there is very little likelihood that TAPP is associated with an incremental net benefit greater than TEP or OFM. In terms of the comparison between TEP and OFM, there is approximately a 53% chance that TEP is associated with positive net benefits. However, as the slope of the curve is close to £0 for most of its range, this indicates that there is little difference between these two treatments.

FIGURE 10 *Incremental net benefits for pairwise comparisons between procedures*

TABLE 38 *Incremental and probabilistic analysis comparing the alternative interventions*

Procedure	Cost (£)	Total benefits (£)	Net benefit[a]	Probability cost-effectiveness (%)
TAPP	1188	−3233	Dominated	0.0
TEP	1111	1363	Dominated	53.1
OFM	1008	1301		46.9

OFM, open flat mesh.
[a] Incremental benefits − incremental cost.

The pairwise comparisons presented in *Figure 10* are difficult to interpret when faced with the decision between three mutually exclusive interventions. A more useful guide would be information about which of the three methods is associated with the greatest net benefits. This information can be derived using the same methodology that underpinned the multiple incremental CEACs presented in *Figures 7* and *8*. In this situation the estimation is aided by the removal of the uncertainty surrounding the amount society is willing to pay for a QALY and because of this the results can be presented as a simple probability that each intervention would be associated with the greatest benefit (*Table 38*).

Management of recurrent hernias

The limited data available suggest that the TEP approach may be associated with a mean lower cost and higher mean QALYs than either TAPP or open flat mesh. The results of the probabilistic analysis indicate that at threshold values for a cost per QALY of ≥£10,000 there is a very small

chance that open flat mesh might be considered cost-effective (*Table 39*). However, the data available to assess the management of recurrent hernias are very limited. For example, for comparisons of TAPP with the individual open mesh procedures, the data relate to <100 patients per randomised group, and for TEP the data are considerably more limited. Therefore, the results presented require very cautious interpretation and a judgement about whether the best estimate for the treatment of recurrent hernias is provided by these data or the base-case analysis.

Different age groups

Age-specific relative risks were not available from the literature and as a result the effect on costs and QALYs arose solely through changes in the risk of mortality. For the younger age group (age 40 years), operative mortality was the same as baseline but all-cause mortality was reduced. For older age groups (age 75 years), operative mortality increased from 0.1% to 1.6% with the mortality for emergency procedures increasing

TABLE 39 Results of subgroup analysis for recurrent hernias and different age groups

Sensitivity analysis	Procedure	Cost (£)	QALYs	Incremental cost per QALY (£)	Probability cost-effectiveness for different threshold values for society's willingness to pay for a QALY (%)				
					£10,000	£20,000	£30,000	£50,000	
Primary unilateral inguinal hernia [age at first procedure 57 years (base case)]	TAPP	1211	16.23	Dominated	14.1	14.8	15.2	15.1	
	TEP	1135	16.24	2093	85.5	85.2	84.8	84.9	
	OFM	1022	16.19		0.4	0.0	0.0	0.0	
Management of recurrent hernia	TAPP	1131	16.19	Dominated	30	28.6	27.7	26.6	
	OFM	1126	16.17	Dominated	0.0	0.0	0.0	0.0	
	TEP	1103	16.23		70.0	71.4	72.8	73.4	
Age at first procedure 75 years	TAPP	1195	8.71	Dominated	13.7	19.8	20.1	21.3	
	TEP	1119	8.72	3489	79.7	79.9	79.9	78.7	
	OFM	1012	8.69		6.6	0.3	0.0	0.0	
Age at first procedure 40 years	TAPP	1215	18.92	Dominated	12.6	13.4	13.5	14.4	
	TEP	1140	18.94	1869	87.1	86.6	86.5	85.6	
	OFM	1026	18.88		0.3	0.0	0.0	0.0	

OFM, open flat mesh.

from 1% to 2.5%. Furthermore, for older age groups all-cause mortality also increased. The effect of these changes on cost-effectiveness was minimal (*Table 39*).

Management of occult bilateral hernias

Relatively few data were available to model the cost-effectiveness of the alternative procedures. For the comparison of TAPP, TEP and open flat mesh procedures, the limited data available suggest that there is nearly a 90% chance that TEP is cost-effective if society is willing to pay £20,000 per additional QALY. These results are driven by the likelihood of an occult hernia and the likelihood that it will progress. Nonetheless, even if prevalence falls to 10% (the lower end of rates reported in the literature) and the rate of progression falls to 5% (lower than rates reported in the one small study available), there is still over an 83% chance that TEP will be considered cost-effective at a threshold of £20,000 per QALY (*Table 40*). It should be noted that this analysis does not take into account any adverse events caused by the additional dissection required when TEP is used for this subgroup.

Summary of evidence on cost-effectiveness

For the comparison of all five interventions, the results indicate that judgements about relative cost-effectiveness are sensitive to the time horizon chosen. The longer the time horizon, the more likely it is that laparoscopic procedures will be considered cost-effective. The data used to model the costs and QALYs for open plug and mesh and open preperitoneal mesh are limited and may not be applicable to the UK NHS. As a result, in subsequent analyses it was assumed that both open plug and mesh and open preperitoneal mesh have costs and effects similar to those of open flat mesh.

For the comparison of TAPP, TEP and open flat mesh, the results were less sensitive to the time horizon. In this analysis, open flat mesh was the least costly option but provided less QALYs. The analysis suggests that TEP is the most cost-effective intervention when the amount society is willing to pay for an additional QALY is >£10,000.

The results of the analysis were sensitive to whether the laparoscopic procedures were performed using disposable laparoscopic equipment. The use of disposable equipment greatly increases the cost of laparoscopic procedures but does not change estimates of

QALYs. As a result, at lower thresholds for society's willingness to pay for an additional QALY (<£10,000), open flat mesh is more likely to be cost-effective when compared with the base-case analysis. Above this threshold level, TEP is more likely to be cost-effective.

The results of the analysis are most sensitive to assumptions about the disutility attached to either long-term pain or numbness. The utility data came from only one trial and were extrapolated. They may therefore not represent the true disutility associated with long-term pain and numbness. If there is no disutility associated with long-term pain or numbness or the disutility is reduced, then it is highly likely that neither TAPP nor TEP is cost-effective.

Overall, based on the data used in the model, TEP appears to dominate TAPP. This analysis was based on indirect comparisons as directly comparative data were sparse. Nonetheless, it is possible that the length of stay with TAPP and TEP would be the same in practice and operation time would either be equal or slightly longer for TEP. In such a situation, the cost advantage enjoyed by TEP over TAPP would disappear and TEP may be the more costly procedure. Should there be no meaningful difference in numbness, pain and recurrences (and hence QALYs), then the choice between TAPP and TEP procedures would be determined by the risk of complications and their importance to patients.

The estimation of QALYs may not fully capture the preferences of patients to avoid serious complications. Using data on the strength of patients' preference for the different outcomes from surgery showed that both TAPP and TEP were most likely to be dominated by open flat mesh. This finding is driven principally by the preferences of patients to avoid serious complications.

The base-case results were based on the extrapolation of the relative effect sizes over the whole 25-year time horizon. Limiting the duration of effects for pain numbness and recurrence to 5 years did not greatly alter the results. The results were also not greatly influenced when the analysis was based on alternative unit costs, all subsequent procedures being flat mesh, utility associated with a recurrent hernia or the inclusion of the risk of serious complications as operative mortality. In the last analysis, however, TAPP was much less likely and open flat mesh was more likely to be considered cost-effective.

TABLE 40 Results of subgroup analysis for occult bilateral hernias

Sensitivity analysis	Procedure	Cost (£)	QALYs	Incremental cost per QALY (£)	Probability cost-effectiveness for different threshold values for society's willingness to pay for a QALY (%)			
					£10,000	£20,000	£30,000	£50,000
Base-case analysis at 5 years for comparison of TAPP, TEP and open mesh	TAPP	1190	4.44	Dominated	3.7	10.8	11.3	12.1
	TEP	1113	4.45	4928	85.0	88.9	88.7	87.9
	OFM	1009	4.42		11.3	0.3	0.0	0.0
Management of occult hernias Results of 5-year model Prevalence of bilateral hernias 25%	TAPP	1377	4.44	Dominated	0.7	2.9	5.2	6.7
	TEP	1227	4.44	5294	69.3	94.6	94.6	93.3
	OFM	1080	4.42		30.0	2.5	0.2	0.0
Management of occult hernias Results of 5-year model Prevalence of bilateral hernias 10%	TAPP	1375	4.44	Dominated	0.7	3.8	7.0	8.9
	TEP	1225	4.45	7887	49.2	88.6	92.0	90.8
	OFM	1037	4.42		50.1	7.6	1.0	0.3
Management of occult hernias Results of 5-year model Prevalence of bilateral hernias 10% and a 14% progression rate	TAPP	1375	4.44	Dominated	0.3	1.8	5.4	8.2
	TEP	1225	4.45	8952	44.0	87.3	93.0	91.7
	OFM	1023	4.42		55.7	10.9	1.6	0.1
Management of occult hernias Results of 5-year model Prevalence of bilateral hernias 10% and a 5% progression rate	TAPP	1374	4.44	Dominated	0.1	1.9	5.3	8.5
	TEP	1224	4.45	9732	37.0	83.3	91.7	91.3
	OFM	1014	4.42		62.9	14.8	3.0	0.2

OFM, open flat mesh.

Few data were available to assess cost-effectiveness for the different subgroups. Based on the very limited data available, the analyses suggest that TEP is highly likely to be cost-effective should the threshold value of society's willingness to pay for an additional QALY be >£10,000. With respect to age of the patient it was assumed that relative effects would be the same as in the base-case analysis but operative and all-cause mortality would change. There was, however, relatively little impact on estimates of cost-effectiveness.

For the management of occult hernias, the limited data available suggest that TEP has a >80% chance of being cost-effective at a threshold value of society's willingness to pay for an additional QALY >£20,000 irrespective of plausible variations in the prevalence and rate of progression of occult hernias. Below threshold values of society's willingness to pay for an additional QALY of <£20,000, open flat mesh is increasingly likely to be considered cost-effective.

61

Chapter 6

Implications for other parties

Quality of life for family and carers

The use of a laparoscopic approach to repair inguinal hernia appears to be associated with faster recovery and less pain. Any reduction in the time required to recover after a hernia repair may also reduce the time and effort that a patient's family or other carers devote to care following discharge from hospital. However, open mesh repair also has advantages for patients and carers. There are concerns about rare serious complications associated with laparoscopic repair and it is usually performed under general anaesthesia.

Financial impact for the patient and others

Less pain after operation is associated with a more rapid return to usual activities, including work. For this reason, laparoscopic surgery may sometimes be the preferred technique. Where there are compelling reasons for wanting as rapid a recovery as possible, these benefits may offset the additional costs associated with this method. In particular, those who experience financial hardship as a result of time away from employment may prefer laparoscopic repair. In addition, some employers may welcome an earlier return to work of their employees.

Impact on other sectors of the community

The adoption of laparoscopic repair has been argued to reduce the net costs to society. Such estimates are based on a range of assumptions which may not be realised, wholly or in part, in practice. However, although the precise magnitude of benefit is uncertain, employers may find that the reduction in a patient's absence reduces the disruption to productivity.

63

Chapter 7
Implications for the NHS

Training

Serious complications can occur during laparoscopic hernia repair and, as for other minimal access techniques, the risk of these is likely to be related to operator experience and skill. The largest European series, published by Bittner, in which 12 of the 15 surgeons were trainees, reported that there were 9/8050 (0.11%) bowel injuries and 8/8050 (0.10%) bladder injuries.[137] These complications could be minimised by adequate training. It is difficult to determine the true clinical value of laparoscopic herniorrhaphy when surgeons, in general, are more technically proficient with open techniques.

It can be argued that the skills obtained in laparoscopic hernia surgery can be transferred to other more complex laparoscopic operations and hence help to maintain these laparoscopic skills. The high incidence of inguinal hernia has the potential to provide training potential for surgeons since the skills learnt are transferable to other types of minimally invasive surgery. The counter argument is that the number of other applications of laparoscopic techniques (e.g. laparoscopic cholecystectomy) is more than sufficient to provide adequate training. The UK training facilities for laparoscopic surgery are currently being enhanced with the development of the National Training Programme for Laparoscopic Surgery with the support of the Royal College of Surgeons of England, the Association of Surgeons of Great Britain and Ireland, the Association of Endoscopic Surgeons of Great Britain and Ireland and the Department of Health (AESGBI submission).

Although the nature of the procedure would appear to preclude its use outside specialist centres, if its use is to be extended, appropriate training and supervision would be needed for additional surgeons.

Fair access and equity issues

Currently only 4% of patients receive laparoscopic repair (RCS submission). Access to this type of surgery must be limited, as expertise and equipment are concentrated in a limited number of specialist centres. It may be difficult for patients to obtain access to hospitals, where laparoscopic repair is performed, owing to the limited availability of this type of surgery and to the cost of travelling to those centres that can provide it.

Seymour and Garthwaite conducted a study to examine patterns of inpatient inguinal hernia surgery in men using a mixture of routine hospital data, demographic data and the Carstairs deprivation category.[138] Comparison of data describing men undergoing inguinal hernia surgery in Scotland in 1982–84, 1987–89 and 1992–94 revealed that the inequality of access to inguinal hernia surgery because of age had decreased, but inequity, on the basis of deprivation category, persisted. The effect of time off work/usual activities for those who suffer the most deprivation and who have an inguinal hernia may be reduced if laparoscopic hernia repair was introduced.

Chapter 8

Discussion

Main results

Laparoscopic repair is consistently more costly than open repair. The magnitude of the extra cost from studies conducted in the UK appears to be about £300–£350 per patient. The point estimates of cost provided by the economic model presented in Chapter 5 also suggest that the laparoscopic techniques are more costly (approximately £100–£200 more per patient after 5 years). The costs of laparoscopic surgery are sensitive to factors relating to surgeon and hospital preference, such as the use of disposable or reusable equipment or whether patients are treated as inpatients or day cases. In addition to the costs of equipment, the other 'cost driver' is the extra theatre costs associated with the longer operating time.

These cost estimates are similar to those in the HTA report considered by NICE in 2001. That report concluded that laparoscopic repair was unlikely to be cost-effective compared with open mesh repair on the basis that the extra costs were unlikely to be offset by the benefits then identified – short-term advantages, such as in the time to return to usual activities.

This new report is based on a considerably enhanced evidence base, particularly because of new data available through the EU Hernia Trialists Collaboration. This group conducted meta-analyses based on reanalysis of the raw data (including previously unpublished data) from the majority of relevant trials. This was the basis for a more complete meta-analysis for this report, providing estimates of effectiveness which are more precise and arguably more generalisable.

The results of the meta-analyses of data for short-term outcomes have not fundamentally changed the overall picture: convalescence is more rapid after laparoscopic repair.

The main difference between the HTA report conducted in 2001 and the present update is in the availability of data describing longer term persisting pain and persisting numbness. Meta-analysis of these data suggests that the risk of both is reduced by laparoscopic repair. These findings are also supported by the 5-year follow-up data from one large UK trial.[66]

The results of the updated meta-analyses (including consideration of persisting pain and numbness) were incorporated into the economic model outlined in Chapter 5. The base-case analysis and much of the sensitivity analysis suggest that the mean incremental cost per QALY for TEP compared with open flat mesh repair is <£10,000 and that there is an ~80% chance that TEP is the most cost-effective intervention, should society's maximum willingness to pay for an additional QALY be £20,000. The results were most sensitive to assumptions about the disutility associated with long-term persisting pain and persisting numbness. When long-term persisting pain and persisting numbness are excluded from the model, the results are similar to those that formed the basis of the 2001 assessment, that is, that it is unlikely that laparoscopic repair would be associated with an incremental cost per QALY of <£50,000.

A concern with laparoscopic repair is the possible increased risk of rare but serious intraoperative complications. The evidence suggests that the risk of these may be greater during TAPP than TEP.

New evidence has also become available on the strengths of patients' preferences for the various outcomes, based on a discrete choice experiment.[136] This showed that people facing surgical hernia repair wish to avoid, in particular, the risk of serious complications. When the discrete choice experiment preference weights (rather than the utility estimates derived from the MRC Laparoscopic Groin Hernia Trial Group[131]) are incorporated in the model, neither TAPP nor TEP was associated with a mean net benefit compared with open flat mesh. The results of a probabilistic analysis showed that there was a 53% chance that TEP would be considered the most cost-effective (47% chance that open flat mesh was cost-effective and 0% that TAPP was cost-effective).

The evidence comparing TAPP with TEP directly was sparse. For this reason, the economic modelling depended on indirect comparisons.

The economic model tended to favour TEP but minor changes in the assumptions would change the balance. For example, assuming that duration of operation and length of hospital stay were the same for the two procedures removed the cost advantage of TEP.

For the open procedures, most of the data related to comparisons of laparoscopic repair with open flat mesh. Estimates for open preperitoneal mesh repair and open plug and mesh repair were based on very limited data and, therefore, unlikely to be reliable. There is no clear evidence that the various open approaches differ in respect to comparative performance with laparoscopic repair. For this reason, the report has concentrated on the comparison of laparoscopic repair with open flat mesh repair (currently the most commonly used open procedure).

Appendix 15 reports the findings of a supplementary analysis including the results of a large, recently conducted trial. The main change from the data currently available is that recurrence is now statistically significantly more likely following TEP repair. The findings of the supplementary analysis for the other outcomes were essentially similar to those in the main body of this report. If recurrence is the only measure of effectiveness of importance, then in the supplementary analyses TEP and TAPP repair are dominated by open flat mesh. In terms of cost per QALY, the probability that TEP repair is cost-effective is still relatively high. This principally reflects the lower risk of persisting pain after laparoscopic repair. In the supplementary analysis TEP is less likely to be considered cost-effective and the principal beneficiary of this is TAPP, rather than open flat mesh.

There were some new data for the repair of recurrent hernias. However, these data were still sparse. On the basis of what was available, TEP was the dominant intervention. However, the results are unreliable, and in these circumstances extrapolation from the base case for primary hernia repair may provide the best available evidence base.

It is plausible that, for management of symptomatic bilateral hernias, laparoscopic repair would become relatively more cost-effective as differences in operation time (a key cost driver) may be reduced and the difference in convalescence time may become more marked (hence QALYs will increase). For occult contralateral hernias, the analysis was conducted for a 5-year time horizon only. This analysis showed that on average TEP dominated TAPP but was more costly and more effective than open flat mesh. The mean incremental cost per QALY of TEP compared with open flat mesh was <£10,000 in sensitivity analyses conducted over a range of plausible estimates of prevalence and progression of occult hernias. Overall, TEP repair is most likely to be considered cost-effective at threshold values for the cost per additional QALY above £20,000. Nonetheless, the results are based on estimates of prevalence and risk of progression of occult hernias for which data are limited.

Few data were available for subgroup analysis by gender or age. There was no specific relative effect size data for age or gender. There is no reason to believe that costs of the procedures will vary by gender, and cost estimates for younger (age 40 years) and older (age 75 years) were close to the base-case results (age 57 years).

Assumptions, limitations and uncertainties

The systematic review of effectiveness was based on meta-analyses using a fixed-effects model. This approach assumed that there was little heterogeneity between the study populations and that each study was attempting to assess the same true differences between the trial arms. A sensitivity analysis using a random effects model was conducted and showed that there was little effect on estimated differential effects, although the CIs were widened. The meta-analyses also did not attempt to adjust for variation in study methodological quality as it was concluded that the validity of the results was not seriously threatened.

As mentioned above, the data available were very limited for some of the outcomes and for some of the subgroups and insufficient to draw firm conclusions about the relative effectiveness of the techniques being compared. Further work could use sources of data other than RCTs to try to address these issues.

In respect of persisting pain and numbness, the findings were based on predominantly unpublished data using differing definitions of severity of pain and numbness. Furthermore, few data are available beyond a 1-year follow-up. Only one report of 5-year follow-up was available and these results were consistent with the meta-analyses.[66] It is anticipated that another large

multi-centre trial will be reporting these data shortly.[96] A non-randomised study carried out in Scotland using a postal questionnaire to patients who had undergone hernia repair with either TEP or open mesh repair supports the findings of less persisting pain after laparoscopic repair.[139] As was noted above in the section 'Main results' (p. 67), long-term outcomes such as these are particularly important in terms of cost-effectiveness where patients may be living for many years with such morbidity. Longer follow-up data are required to confirm these findings and provide more reliable estimates of prevalence.

Data describing hernia recurrence were available from the majority of trials. Although this showed no evidence of a statistically significant difference between the laparoscopic and open repair, the CI did not rule out a clinically important difference. Furthermore, the data mostly relate to only a 1-year time horizon. More long-term follow-up data are therefore required before it is certain that there is no difference in this respect (Appendix 15 reports the results of a supplementary analysis in which the addition of data from a large RCT to the meta-analysis now provides evidence of a higher rate of recurrences for laparoscopic repair which is now statistically significant).

Very meagre data were available for the direct comparison of TAPP and TEP. Although attempts were made to identify non-randomised evidence for the comparison of TAPP and TEP, the data identified were heterogeneous and their ability to control selection biases was limited. The paucity of data highlights the need for more studies for these comparisons.

Laparoscopic repair is technically more difficult than open repair and there is evidence of a 'learning curve' in its performance. The cost-effectiveness (and also almost certainly the safety) of laparoscopic repair is influenced by where operators are on their learning curves. The literature on operator learning of laparoscopic methods was reviewed and the effect, for example in terms of length of operation, incorporated into the model in a sensitivity analysis. This showed that for a less experienced surgeon there was a >70% chance that TEP (and a >20% chance that TAPP) would be considered cost-effective if society were willing to pay >£30,000 for an additional QALY.

Determining which open mesh repair method is superior was not within the remit of this review. Most of the trial data came from comparison of laparoscopic repair with open flat mesh repair, and data for the other open mesh techniques were too few to be reliable. Access to trial data directly comparing the alternative open mesh techniques might have improved this.

As with any economic evaluation, a number of assumptions were made with respect to both the structure of the model and the data used. One of the main structural assumptions was that an individual would experience a maximum of three operations and that the third operation would not fail. For the rates of recurrence used in this model, this did not appear to cause a problem. A further structural assumption related to the omission of serious complications. However, sensitivity analysis showed that even extreme assumptions about the effect of these had a minimal impact on the incremental cost per QALY.

One concern about the economic model is the quantity and quality of data available. As mentioned above, the data available for some of the subgroups and for open plug and mesh and also open preperitoneal mesh were imprecise and unreliable. Although the imprecision was incorporated into the model, the issue of reliability remains. It is for this reason that it was felt most appropriate to limit the economic evaluation to comparisons of open flat mesh with TAPP and TEP. Ideally, more studies are required that compare open plug and mesh and open preperitoneal mesh with TAPP and TEP.

The nature of the data available also had an impact on the economic evaluation. In the base case analysis, it was assumed that baseline event rates could be extrapolated for up to 25 years. Although these assumptions appeared to be in accordance with the limited data available, these were all extrapolated. For this reason, the base-case results were also presented for a 5-year time horizon, which is consistent with the time period for which data are available. Further assumptions were made about the duration over which relative effects would persist. These assumptions were tested in a series of sensitivity analyses and it was found that varying them did not substantially alter the results.

There is also concern about the data chosen for baseline event rates. Ideally, baseline event data should have related to the same intervention for all events of interest and have come from the same source. Such data were not available and as a result data were identified from the best available source. For all events, apart from recurrences, the

baseline event data related to open flat mesh. For recurrences, superior data were available from the Swedish registry. However, these data related to TAPP. Computationally this does not cause problems as the appropriate relative effect sizes can still be used to estimate the required absolute rates for the other interventions under consideration.

A further concern about baseline rates used in the model relates to rates used for long-term persisting pain and long-term numbness. The baseline rates for these parameters were derived from a single source and were measured on a crude five-point scale. For pain this included (1) none, (2) very mild, (3) mild, (4) severe, (5) very severe and for numbness the scale covered (1) not at all, (2) slightly, (3) moderately, (4) quite a lot, (5) extremely. Estimates of the risk of pain for the baseline comparator were based on points (4) and (5). Had a less strict definition of long-term pain and long-term numbness been used (e.g. any versus none), then the laparoscopic procedures would have appeared more cost-effective.

The base-case analysis used data on costs and utility weights from a single study. This naturally raises concerns about whether such data are typical after hernia repair. Furthermore, sensitivity analysis showed that the values assumed for the utility weights for long-term persisting pain and numbness were key determinants of cost-effectiveness. The utility weights were extrapolated from data describing patients with pain and numbness at 3 months postoperatively. Direct measurements of utility at 1 year (or later) would have strengthened the model. Data from a discrete choice experiment provided information on the strength of patients' preferences for a range of parameters. This showed that risk of serious complication, which had limited effect on QALY estimates, was highly important and was the key determinant of net benefit when these data were incorporated into the economic model. This work raises two questions: (1) are the utilities used to estimate QALYs generalisable to the UK? and (2) given the potential increased risk of rare serious complications from TAPP and TEP, are the laparoscopic techniques acceptable to informed patients?

Chapter 9
Conclusions

Implications for the NHS

Clearly the use of laparoscopic inguinal hernia repair within the NHS will depend on judgements about the balance of costs, benefits and risks. Laparoscopic repair costs more than mesh repair (the current standard), principally because it takes longer to perform. Using disposable equipment and keeping patients overnight increases this difference. This cost difference may be reduced if experienced surgeons perform laparoscopic surgery.

Both laparoscopic and open mesh methods utilise mesh to reinforce the repair; the chances of hernia recurrence appear to be similar after each type of procedure.

Laparoscopic repair is associated with short-term benefits, in terms of the postoperative pain and more rapid return to usual activities.

Data newly available since the preparation of the HTA report considered by NICE in 2001 show that laparoscopic repair also has longer term benefits in terms of a lower risk of persisting groin pain and persisting numbness. Appendix 15 suggests that laparoscopic repair (specifically TEP) is associated with greater recurrences. The risk of some potentially serious intraoperative complications appears to be higher during laparoscopic repair, particularly TAPP (overall estimates 7.9 per 1000 versus 1.4 per 1000).

There is a scarcity of data comparing laparoscopic TAPP and TEP and the choice between laparoscopic approaches would therefore be based on clinical decisions. Most data describe open flat mesh repair, but there appear to be no differences in analyses in this report stratified by method of open repair.

An economic model relating benefits to costs suggested that it was likely that an additional QALY would cost >£10,000; this is sensitive to whether or not persisting pain and numbness are considered. When they are not, the model suggests that an additional QALY would cost >£50,000.

There are clinical arguments for the selective use of laparoscopic repair. This may apply to recurrent hernias but the data were too sparse to address this reliably. The use of laparoscopic repair for bilateral hernias avoids two incisions and the recovery advantages may be more marked. Routine identification and repair of 'occult' contralateral hernias during laparoscopic repair are controversial and the estimates of cost-effectiveness are subject to the assumptions made about prevalence and likely progress to clinical symptoms.

Increased adoption of laparoscopic hernia repair would require more surgeons to be proficient in the technique. It is likely that some of the higher rates of potentially serious complications, such as bladder injuries, reported for laparoscopic repair are associated with a 'learning curve'. Appropriate and supervised training will therefore be needed for surgeons new to the operation, in respect of both the technical aspects of the procedure and the choice of patients suitable for the operation. The training of surgeons in techniques for laparoscopic hernia repair might also provide useful skills and experience which are transferable to other laparoscopic procedures.

Implications for patients and carers

Laparoscopic hernia repair has the advantage that it is less invasive than open mesh hernia repair but is usually performed under general anaesthesia. Any reduction in the time required to recover after a hernia repair may reduce the time and effort that a patient's family or other carers devote to care, following discharge from hospital.

The use of a laparoscopic approach to repair inguinal hernia is associated with an easier convalescence, less pain and a more rapid return to usual activities but an increased risk of recurrences (based on data reported in Appendix 15) and possibly an increased risk of serious complications. Those who experience financial hardship as a result of time away from

employment may prefer laparoscopic repair. In addition, employers may welcome an earlier return to work of their employees.

Implications for research

- Direct measurements of utilities at 1 year and later are required to confirm the study findings.
- The issue of chronic pain after inguinal hernia repair should be addressed prospectively using standard definitions and allow for the assessment of the degree of pain.
- Rare, serious complications are an important consideration in the context of minor surgery. Even consideration of RCTs involving >5000 participants gives imprecise estimates; prospective population-based registries of new surgical procedures may be the best way to address this general issue.
- More data from methodologically sound RCTs comparing laparoscopic TAPP with laparoscopic TEP techniques would be valuable.

- Further research is required relating to whether the balance of advantages and disadvantages of alternative surgical approaches changes when hernias are recurrent or bilateral.
- Laparoscopic groin hernia repair, like most other surgical procedures, is technically challenging and performance is likely to improve with experience. This issue is important in its evaluation, and further methodological research related to this is warranted in the context of both trials and meta-analyses of trials.
- Unlike most surgical procedures, laparoscopic inguinal hernia repair has been tested in a large number of RCTs. These provide a reliable evidence base which demonstrates the feasibility and value of RCTs for assessing the effectiveness of surgical interventions.

◆

Acknowledgements

References

1. UK Department of Health. *Hospital episode statistics*. URL: http://www.dh.gov.uk/PublicationsAndStatistics/Statistics/HospitalEpisodeStatistics/fs/en

2. Bay Nielsen M, Perkins F. Pain and functional impairment 1 year after inguinal herniorrhaphy: a nationwide questionnaire study. *Ann Surg* 2001; **233**:1–7.

3. Callesen T, Bech K, Kehlet H. Prospective study of chronic pain after groin hernia repair. *Br J Surg* 1999;**86**:1528–31.

4. Courtney CA. Outcome of patients with severe chronic pain following repair of groin. *Br J Surg* 2002;**89**:1310–14.

5. Felix EL, Harbertson N, Vartanian S. Laparoscopic hernioplasty: significant complications. *Surg Endosc* 1999;**13**:328–31.

6. O'Riordan DC, Morgan M, Kingsnorth AN, Black NA, Clements L, Brady H, *et al*. *Current surgical practice in the management of groin hernias in the United Kingdom*. Report to the Department of Health. London: Department of Health; 1996.

7. Lichtenstein IL, Shulman AG, Amid PK, Montllor MM. The tension-free hernioplasty. *Am J Surg* 1989;**157**:188–93.

8. Bloor K, Freemantle N, Khadjesari Z, Maynard A. Impact of NICE guidance on laparoscopic surgery for inguinal hernias: analysis of interrupted time series. *BMJ* 2003;**326**:578.

9. Hair A, Duffy K, McLean J, Taylor S, Smith H, Walker A, *et al*. Groin hernia repair in Scotland. *Br J Surg* 2000;**87**:1722–6.

10. Ger R. The management of certain abdominal hernia by intra-abdominal closure of the neck of the sac. Preliminary communication. *Ann R Coll Surg Engl* 1982;**64**:342–4.

11. Schultz LS, Graber J, Pietrafitta JJ. Laser laparoscopic herniorrhaphy – a clinical trial. Preliminary results. *J Laparoendosc Surg* 1991; **1**:41–5.

12. Corbitt JD Jr. Laparoscopic herniorrhaphy. *Surg Laparosc Endosc* 1991;**1**:23–5.

13. Arregui ME, Davis CJ, Yucel O, Nagan RF. Laparoscopic mesh repair of inguinal hernia using a preperitoneal approach: a preliminary report. *Surg Laparosc Endosc* 1992;**2**:53–8.

14. Ferzli G, Massaad A, Ambert P, Worth MH. Endoscopic extraperitoneal herniorrhaphy versus conventional hernia repair: a comparative study. *Curr Surg* 1993;**50**:291–4.

15. Crawford DL, Hiatt JR, Phillips EH. Laparoscopy identifies unexpected groin hernias. *Am Surg* 1998;**64**:976–8.

16. Evans DS, Ghanesh P, Khan IM. Day-case laparoscopic hernia repair. *Br J Surg* 1996; **83**:1361–3.

17. Panton ON, Panton RJ. Laparoscopic hernia repair. *Am J Surg* 1994;**167**:535–7.

18. Quilici PJ, Greaney EM, Jr., Quilici J, Anderson S. Laparoscopic inguinal hernia repair: optimal technical variations and results in 1700 cases. *Am Surg* 2000;**66**:848–52.

19. Thumbe VK, Evans DS. To repair or not to repair incidental defects found on laparoscopic repair of groin hernia: early results of a randomized control trial. *Surg Endosc* 2001;**15**:47–9.

20. Lau H. Learning curve for unilateral endoscopic totally extraperitoneal (TEP) inguinal hernioplasty. *Surg Endosc* 2002;**16**:1724–8.

21. Vale L, McCormack K, Scott N, Grant A. *Systematic review of the effectiveness and cost-effectiveness of laparoscopic versus open repair of inguinal hernia*. Technology Assessment Review submitted to the National Institute for Clinical Excellence. London: NICE; 2000.

22. Kald A, Anderberg B, Carlsson P, Park PO, Smedh K. Surgical outcome and cost-minimisation-analyses of laparoscopic and open hernia repair: a randomised prospective trial with one year follow up. *Eur J Surg* 1997;**163**:505–10.

23. Akhtar K. Metabolic and inflammatory responses after laparoscopic and open inguinal hernia repair. *Ann R Coll Surg Engl* 1998;**80**:125–30.

24. Berndsen F, Arvidsson D, Enander LK, Leijonmarck CE, Wingren U, Rudberg C, *et al*. Postoperative convalescence after inguinal hernia surgery: prospective randomized multicenter study of laparoscopic versus shouldice inguinal hernia repair in 1042 patients. *Hernia* 2002;**6**:56–61.

25. Bhandarkar DS. Randomized clinical trial of laparoscopic versus open inguinal hernia repair. *Br J Surg* 1999;**86**:1226–7.

26. Champault G, Benoit J, Lauroy J, Rizk N, Boutelier P. Inguinal hernia in adults. Laparoscopic surgery versus Shouldice's operation. Controlled randomised study in 181 patients. Preliminary results. *Ann Chir* 1994;**48**:1003–8.

27. Dirksen CD, Beets GL, Go PM, Geisler FE, Baeten CG, Kootstra G. Bassini repair compared with laparoscopic repair for primary inguinal hernia: a randomised controlled trial. *Eur J Surg* 1998;**164**:439–47.

28. Hauters P, Meunier D, Urgyan S, Jouret JC, Janssen P, Nys JM. Prospective controlled study comparing laparoscopy and the Shouldice technique in the treatment of unilateral inguinal hernia. *Ann Chir* 1996;**50**:776–81.

29. Juul P, Christensen K. Randomized clinical trial of laparoscopic versus open inguinal hernia repair. *Br J Surg* 1999;**86**:316–19.

30. Kark AE. Randomized clinical trial of laparoscopic versus open inguinal hernia repair. *Br J Surg* 1999;**86**:1227.

31. Kozol R, Lange PM, Kosir M, Beleski K, Mason K, Tennenberg S, *et al*. A prospective, randomized study of open vs. laparoscopic inguinal hernia repair. An assessment of postoperative pain. *Arch Surg* 1997;**132**:292–5.

32. Kunz R, Schwarz A, Beger HG. Laparoscopic transperitoneal hernia repair vs. Shouldice herniorrhaphy – preliminary results of a prospective randomised trial. *Chirurgie Endoscopique, Numero Hors Serie* 1993;**7**:12–13.

33. Leibl B, Daubler P, Schwarz J, Ulrich M, Bittner R. Standardized laparoscopic hernioplasty vs. Shouldice repair. Results of a randomized comparative study. *Chirurg* 1995;**66**:895–8.

34. Liem MS. A randomized comparison of physical performance following laparoscopic and open inguinal hernia repair. *Br J Surg* 1997;**84**:64–7.

35. Liem MS, van der GY, van Steensel CJ, Boelhouwer RU, Clevers GJ, Meijer WS, *et al*. Comparison of conventional anterior surgery and laparoscopic surgery for inguinal-hernia repair. *N Engl J Med* 1997;**336**:1541–7.

36. Liem MS, van Duyn EB, van der GY, van Vroonhoven TJ, Coala Trial Group. Recurrences after conventional anterior and laparoscopic inguinal hernia repair: a randomized comparison. *Ann Surg* 2003;**237**:136–41.

37. Maddern GJ, Rudkin G, Bessell JR, Devitt P, Ponte L. A comparison of laparoscopic and open hernia repair as a day surgical procedure. *Surg Endosc* 1994;**8**:1404–8.

38. Murata N, Ishida H, Makita Y, Odaka A, Shimomura K, Takahashi K, *et al*. Muscle strength and walking ability after laparoscopic hernioplasty versus conventional repair. *Surgery Today* 2003;**33**:259–63.

39. Nathanson L, Adib R, Branild F. Randomised trial of open and laparoscopic inguinal hernia repair. In *Proceedings of the Society of American Gastrointestinal Surgeons (SAGES)*, 1996, Philadelphia, PA. New York: Springer, 1996. p. 28.

40. Nathanson L. Five-year follow-up of a randomized trial of open versus laparoscopic inguinal hernia repair. *Aust N Z J Surg* 1997;**67** (Suppl 1):A27.

41. Negro P. Prospective randomized trial comparing. *Br J Surg* 1997;**84**:728–9.

42. Tanphiphat C, Tanprayoon T, Sangsubhan C, Chatamra K. Laparoscopic vs. open inguinal hernia repair. A randomized, controlled trial. *Surg Endosc* 1998;**12**:846–51.

43. Tschudi J, Wagner M, Klaiber C, Brugger J, Frei E, Krahenbuhl L, *et al*. Controlled multicenter trial of laparoscopic transabdominal preperitoneal hernioplasty vs. Shouldice herniorrhaphy. Early results. *Surg Endosc* 1996;**10**:845–7.

44. Vogt DM. Preliminary results of a prospective randomized trial of laparoscopic only versus conventional inguinal herniorrhaphy. *Am J Surg* 1995;**169**:84–90.

45. Vrijland W. Randomized clinical trial of non-mesh versus mesh repair of primary inguinal hernia. *Br J Surg* 2002;**89**:293–7.

46. Werthmann K. Laparoscopic or traditional repair of inguinal hernia? Preliminary results of a prospective randomized trial. *Prog Surg* 1995;**21**:161–4.

47. Bringman S, Ek A, Haglind E, Heikkinen T, Kald A, Kylberg F, *et al*. Is a dissection balloon beneficial in totally extraperitoneal endoscopic hernioplasty (TEP)? A randomized prospective multicenter study. *Surg Endosc* 2001;**15**:266–70.

48. Sarli L, Villa F, Marchesi F. Hernioplasty and simultaneous laparoscopic cholecystectomy: a prospective randomized study of open tension-free versus laparoscopic inguinal hernia repair. *Surgery* 2001;**129**:530–6.

49. Neumayer L, Jonasson O, Fitzgibbons R, Henderson W, Gibbs J, Carrico CJ, *et al*. Tension-free inguinal hernia repair: the design of a trial to compare open and laparoscopic surgical techniques. *J Am Coll Surg* 2003;**196**:743–52.

50. Filipi CJ, Gaston-Johansson F, McBride PJ, Murayama K, Gerhardt J, Cornet DA, *et al*. An assessment of pain and return to normal activity. Laparoscopic herniorrhaphy vs. open tension-free Lichtenstein repair. *Surg Endosc* 1996;**10**:983–6.

51. Gontarz W, Wolanski L, Leksowski K. A comparison of two 'tension free' inguinal hernia repair methods. *Br J Surg* 1998;**85** (Suppl II):18.

52. Heikkinen TJ, Haukipuro K, Hulkko A. A cost and outcome comparison between laparoscopic and Lichtenstein hernia operations in a day-case unit. A randomized prospective study. *Surg Endosc* 1998;**12**:1199–203.

53. Heikkinen T, Haukipuro K, Leppala J, Hulkko A. Total costs of laparoscopic and Lichtenstein inguinal hernia repairs: a randomized prospective study. *Surg Laparosc Endosc* 1997;**7**:1–5.

54. Jess P, Schultz K, Bendtzen K, Nielsen OH. Systemic inflammatory responses during laparoscopic and open inguinal hernia repair: a randomised prospective study. *Eur J Surg* 2000; **166**:540–4.

55. Köninger JS, Oster M, Butters M. Management of inguinal hernia – a comparison of current methods. *Chirurg* 1998;**69**:1340–4.

56. Mahon D, Decadt B, Cheadle T, Clarke JM, Speakman C, Stebbings SW, *et al*. Prospective randomised trial of laparoscopic (transabdominal preperitoneal – TAPP) versus open (mesh) repair for bilateral and recurrent inguinal hernia. *Surg Endosc* 2001;**15** (Suppl 1):S102.

57. Mahon D, Decadt B, Cheadle T, Clarke JM, Speakman C, Stebbings SW, *et al*. Prospective randomized trial of laparoscopic (trans-abdominal preperitoneal TAPP) versus open (Lichtenstein) inguinal hernia repair for bilateral and recurrent inguinal hernia. *Br J Surg* 2000;**87** (Suppl 1):35.

58. Paganini AM, Lezoche E, Carle F, Carlei F, Favretti F, Feliciotti F, *et al*. A randomized, controlled, clinical study of laparoscopic vs. open tension-free inguinal hernia repair. *Surg Endosc* 1998;**12**:979–86.

59. Payne JH Jr, Grininger LM, Izawa MT, Podoll EF, Lindahl PJ, Balfour J. Laparoscopic or open inguinal herniorrhaphy? A randomized prospective trial. *Arch Surg* 1994;**129**:973–9.

60. Payne J, Grininger L, Izawa M, Lindahl PJ, Podoll EF. A randomised prospective comparison between a laparoscopic, preperitoneal and anterior tension-free repair of inguinal hernia. *Surg Laparosc Endosc* 1994;**4**:471–2.

61. Picchio M, Lombardi A, Zolovkins A, Mihelsons M, La Torre G. Tension-free laparoscopic and open hernia repair: randomized controlled trial of early results. *World J Surg* 1999;**23**:1004–7.

62. Sarli L, Pietra N, Choua O, Costi R, Thenasseril B, Giunta A. Prospective randomized comparative study of laparoscopic hernioplasty and Lichtenstein tension-free hernioplasty. *Acta Biomed Ateneo Parmense* 1997;**68**:5–10.

63. Sarli L, Iusco DR, Sansebastiano G, Costi R. Simultaneous repair of bilateral inguinal hernias: a prospective, randomized study of open, tension-free versus laparoscopic approach. *Surg Laparosc Endosc Percutan Tech* 2001;**11**:262–7.

64. Wellwood J, Sculpher MJ, Stoker D, Nicholls GJ, Geddes C, Whitehead A, *et al*. Randomised controlled trial of laparoscopic versus open mesh repair for inguinal hernia: outcome and cost. *BMJ* 1998;**317**:103–10.

65. Douek M, Smith G, Oshowo A, Stoker DL, Wellwood JM. Prospective randomized controlled trial of laparoscopic versus open hernia mesh repair: 5-year follow-up. *Br J Surg* 2002;**89** (Suppl 1):37.

66. Douek M, Smith G, Oshowo A, Stoker DL, Wellwood JM. Prospective randomised controlled trial of laparoscopic versus open inguinal hernia mesh repair: five year follow up. *BMJ* 2003; **326**:1012–13.

67. Aitola P, Airo I, Matikainen M. Laparoscopic versus open preperitoneal inguinal hernia repair: a prospective randomised trial. *Ann Chir Gynaecol* 1998;**87**:22–5.

68. Beets GL, Dirksen CD, Go PM, Geisler FE, Baeten CG, Kootstra G. Open or laparoscopic preperitoneal mesh repair for recurrent inguinal hernia? A randomized controlled trial. *Surg Endosc* 1999;**13**:323–7.

69. Laporte E, Miras M, Ramirez JM, Segura J, Semeraro C, Vicens C. Comparison of the anterior approach versus transabdominal laparoscopy in inguinal hernia repair using preperitoneal polypropylene prostheses. *Cir Esp* 1997;**61**:325–8.

70. Johansson B, Hallerback B, Glise H, Anesten B, Smedberg S, Roman J. Laparoscopic mesh versus open preperitoneal mesh versus conventional technique for inguinal hernia repair: a randomized multicenter trial (SCUR Hernia Repair Study). *Ann Surg* 1999;**230**:225–31.

71. Johansson B, Hallerback B, Glise H, Anesten B, Melen K, Holm J, *et al*. Laparoscopic mesh repair vs. open repair w/wo mesh graft for inguinal hernia (SCUR groin hernia repair study) – preliminary results. *Surg Endosc* 1997;**11**:170.

72. Zieren J, Zieren HU, Jacobi CA, Wenger FA, Muller JM. Prospective randomized study comparing laparoscopic and open tension-free inguinal hernia repair with Shouldice's operation. *Am J Surg* 1998;**175**:330–3.

73. Zieren J, Zieren HU, Wenger FA, Muller JM. Laparoscopic or conventional inguinal hernia repair with mesh? *Langenbecks Arch Chir* 1996; **381**:289–94.

74. Zieren J, Zieren HU, Said S, Muller JM. Laparoscopic or conventional inguinal hernia repair with or without implant. *Langenbecks Arch Chir* 1996;**113** (Suppl 2):609–10.

75. Zieren J, Zieren HU, Muller JM. Is there a reason for a laparoscopic tension-free groin hernia repair? *Zentralbl Chir* 1999;**124**:A20.

76. Andersson B, Hall AC, Leveau P, Bergenfelz A, Westerdahl J. Laparoscopic extraperitoneal inguinal hernia repair versus open mesh repair: a prospective randomized controlled trial. *Surgery* 2003;**133**:464–72.

77

77. Colak T, Akca T, Kanik A, Aydin S. Randomized clinical trial comparing laparoscopic totally extraperitoneal approach with open mesh repair in inguinal hernia. *Surg Laparosc Endosc Percutan Tech* 2003;**13**:191–5.

78. Gholghesaei M, Essink-Bot ML, van't Riet M, Veldkamp R, Jeekel J, Bonjer HJ. Lichtenstein versus endoscopic inguinal hernia repair: differences in quality of life. *Surg Endosc* 2003; **17** (Suppl 1):S81.

79. Gholghesaei M, Essink-Bot ML, van't Riet M, Veldkamp R, Jeekel J, Bonjer HJ. Lichtenstein versus endoscopic inguinal hernia repair: differences in quality of life. *Surg Endosc* 2002; **16** (Suppl 1):S308.

80. Heikkinen TJ, Haukipuro K, Koivukangas P, Hulkko A. A prospective randomized outcome and cost comparison of totally extraperitoneal endoscopic hernioplasty versus Lichtenstein hernia operation among employed patients. *Surg Laparosc Endosc* 1998;**8**:338–44.

81. Lal P, Kajla RK, Chander J, Saha R, Ramteke VK. Randomized controlled study of laparoscopic total extraperitoneal vs. open Lichtenstein inguinal hernia repair. *Surg Endosc* 2003;**17**:850–6.

82. Merello J, Guerra AG, Madriz J, Guerra GG. Laparoscopic TEP versus open Lichtenstein hernia repair. *Surg Endosc* 1997;**11**:545.

83. Payne J, Izawa M, Glen P, Grininger L, Podoll E, Balfour J. Laparoscopic or tension-free inguinal hernia repair. In *Proceedings of the Society of American Gastrointestinal Surgeons (SAGES)*, 1996, Philadelphia, PA. New York: Springer, 1996.

84. Bostanci BE, Tetik C, Ozer S, Ozden A. Posterior approaches in groin hernia repair with prosthesis: open or closed. *Acta Chir Belg* 1998;**98**:241–4.

85. Champault GG, Rizk N, Catheline JM, Turner R, Boutelier P. Inguinal hernia repair: totally preperitoneal laparoscopic approach versus Stoppa operation: randomized trial of 100 cases. *Surg Laparosc Endosc* 1997;**7**:445–50.

86. Champault G, Rizk N, Catheline JM, Riskalla H, Boutelier P. Groin hernia: pre-peritoneal laparoscopic surgery versus open (Stoppa) procedure. *J Chir (Paris)* 1996;**133**:274–80.

87. Champault G, Barrat C, Catheline JM, Rizk N. Groin hernias: four-year follow-up of two randomised trials comparing laparoscopic totally preperitoneal approach to Shouldice and Stoppa procedures: 361 cases. *Ann Chir* 1998;**52**:132–6.

88. Ramon JM, Carulla X, Serrano A, Roura J, Castillo J, Solsona J, *et al*. The endoscopic preperitoneal inguinal hernia repair (TEP). *Br J Surg* 1998;**85** (Suppl 2):48.

89. Simmermacher RKJ, Van Duyn EB, Clevers GJ, de Vries LS, van Vroonhoven TJ. Preperitoneal mesh in groin hernia surgery. A randomized clinical trial emphasizing the surgical aspects of preperitoneal placement via a laparoscopic (TEP) or Grid-iron (Ugahary) approach. *Hernia* 2000;**4**:296–8.

90. Suter M, Martinet O, Spertin F. Reduced acute inflammatory response after bilateral hernia repair with TEPP compared to Stoppa; a prospective randomised study. *Surg Endosc* 2002; **16** (Suppl 1):S10.

91. Suter M, Martinet O, Spertin F. Reduced acute phase response after laparoscopic total extraperitoneal bilateral hernia repair compared to open repair with the Stoppa procedure. *Surg Endosc* 2002;**16**:1214–19.

92. Suter M, Martinet O. Postoperative pulmonary dysfunction after bilateral inguinal hernia repair: a prospective randomized study comparing the Stoppa procedure with laparoscopic total extraperitoneal repair (TEPP). *Surg Laparosc Endosc Percutan Tech* 2002;**12**:420–5.

93. Khoury N. A randomized prospective controlled trial of laparoscopic extraperitoneal hernia repair and mesh-plug hernioplasty: a study of 315 cases. *J Laparoendosc Adv Surg Tech A* 1998;**8**:367–72.

94. Vatansev C, Belviranli M, Aksoy F, Tuncer S, Sahin M, Karahan O. The effects of different hernia repair methods on postoperative pain medication and CRP levels. *Surg Laparosc Endosc Percutan Tech* 2002;**12**:243–6.

95. Bringman S, Ramel S, Heikkinen TJ, Englund T, Westman B, Anderberg B. Tension-free inguinal hernia repair: TEP versus mesh-plug versus Lichtenstein: a prospective randomized controlled trial. *Ann Surg* 2003;**237**:142–7.

96. Laparoscopic versus open repair of groin hernia: a randomised comparison. The MRC Laparoscopic Groin Hernia Trial Group. *Lancet* 1999;**354**:185–90.

97. Wright DM, Kennedy A, Baxter JN, Fullarton GM, Fife LM, Sunderland GT, *et al*. Early outcome after open versus extraperitoneal endoscopic tension-free hernioplasty. *Surgery* 1996;**119**:552–7.

98. Wright D, Paterson CR, O'Dwyer PJ. Early outcome following open and laparoscopic tension-free hernioplasty – a randomised clinical trial. *Gastroenterology* 1997;**112** (4 Suppl):A49.

99. Wright D, Hall MG, Paterson C, O'Dwyer PJ. A randomized comparison of driver reaction time after open and endoscopic tension-free inguinal hernia repair. *Surg Endosc* 1999;**13**:332–4.

100. Kumar S, Nixon SJ, Macintyre IM. Laparoscopic or Lichtenstein repair for recurrent inguinal hernia: one unit's experience. *J R Coll Surg Edinb* 1999;**44**:301–2.

101. Scott NW, Grant AM, Ross SJ, Smith A, Macintyre IMC, O'Dwyer PJ. Patient-assessed

outcome up to three months in a randomised controlled trial comparing laparoscopic with open groin hernia repair. *Hernia* 2000;**4**:73–9.

102. Hair A, Taylor S, Wright D, Paterson C, O'Dwyer PJ. Five year outcome following laparoscopic and open hernia repair. *Surg Endosc* 2001;**15** (Suppl 1):S79.

103. Wright D, Paterson C, Scott N, Hair A, O'Dwyer PJ. Five-year follow-up of patients undergoing laparoscopic or open groin hernia repair: a randomized controlled trial. *Ann Surg* 2002;**235**:333–7.

104. Barkun JS, Wexler MJ, Hinchey EJ, Thibeault D, Meakins JL. Laparoscopic versus open inguinal herniorrhaphy: preliminary results of a randomized controlled trial. *Surgery* 1995; **118**:703–9.

105. Barkun JS, Wexler MJ, Fernandez M, Meakins JL. Laparoscopic vs. open inguinal herniorrhaphy, a randomized controlled trial. *Gastroenterology* 1998; **114** (4 Part 2):A1378.

106. Barkun JS, Keyser EJ, Wexler MJ, Fried GM, Hinchey EJ, Fernandez M, *et al*. Short-term outcomes in open vs. laparoscopic herniorrhaphy: confounding impact of worker's compensation on convalescence. *J Gastrointest Surg* 1999;**3**:575–82.

107. Barkun JS, Mederios LE, Wexler MJ, Fried GM. Convalescence after inguinal hernia repair. *Surg Endosc* 2001;**15** (Suppl 1):S30.

108. Snyder S, Frazee R, Smith R, Symmonds R, Hendricks J, Roberts J, *et al*. A prospective randomised comparison and long-term follow-up of open and laparoscopic mesh inguinal hernia repair. In Montori A, Lirici MM, Montori J, editors. *Proceedings of the 6th World Congress of Endoscopic Surgery, Parts 1 and 2*. Bologna: Monduzzi Editore, 1998. pp. A979–82.

109. Schrenk P, Woisetschlager R, Rieger R, Wayand W. Prospective randomized trial comparing postoperative pain and return to physical activity after transabdominal preperitoneal, total preperitoneal or Shouldice technique for inguinal hernia repair. *Br J Surg* 1996;**83**:1563–6.

110. Schrenk P, Bettelheim P, Woisetschlager R, Rieger R, Wayand WU. Metabolic responses after laparoscopic or open hernia repair. *Surg Endosc* 1996;**10**:628–32.

111. Sutton AJ, Abrams KR, Jones DR, Sheldon TA, Song F. Systematic reviews of trials and other studies. *Health Technol Assess* 1998;**2**(19).

112. Baca I, Schultz C, Gotzen V, Jazek G. Laparoscopic inguinal hernia repair. A review of 2500 cases. In Lomanto D, Kum CK, So JBY, Goh PMY, editors. *Proceedings of the 7th World Congress of Endoscopic Surgery*. Bologna: Monduzzi Editore, 2000. pp. 425–30.

113. Cohen RV, Alvarez G, Roll S, Garcia ME, Kawahara N, Schiavon CA, *et al*. Transabdominal or totally extraperitoneal laparoscopic hernia repair? *Surg Laparosc Endosc* 1998;**8**:264–8.

114. Felix EL, Michas CA, Gonzalez MH Jr. Laparoscopic hernioplasty. TAPP vs. TEP. *Surg Endosc* 1995;**9**:984–9.

115. Khoury N. A comparative study of laparoscopic extraperitoneal and transabdominal preperitoneal herniorrhaphy. *J Laparoendosc Surg* 1995;**5**:349–55.

116. Leibl BJ, Schmedt CG, Kraft K, Bittner R. Laparoscopic transperitoneal hernioplasty (TAPP) – efficiency and dangers. *Chir Gastroenterol* 2000; **16**:106–9.

117. Lepere M, Benchetrit S, Debaert M, Detruit B, Dufilho A, Gaujoux D, *et al*. A multicentric comparison of transabdominal versus totally extraperitoneal laparoscopic hernia repair using PARIETEX meshes. *J Soc Laparoendosc Surg* 2000;**4**:147–53.

118. Tamme C, Scheidbach H, Hampe C, Schneider C, Kockerling F. Totally extraperitoneal endoscopic inguinal hernia repair (TEP). *Surg Endosc* 2003; **17**:190–5.

119. Van Hee R, Goverde P, Hendrick L, Van der SG, Totte E. Laparoscopic transperitoneal versus extraperitoneal inguinal hernia repair: a prospective clinical trial. *Acta Chir Belg* 1998; **98**:132–5.

120. Weiser HF, Klinge B. Endoscopic hernia repair – experiences and characteristic features. *Viszeralchirurgie* 2000;**35**:316–20.

121. Aeberhard P, Klaiber C, Meyenberg A, Osterwalder A, Tschudi J. Prospective audit of laparoscopic totally extraperitoneal inguinal hernia repair: a multicenter study of the Swiss Association for Laparoscopic and Thoracoscopic Surgery (SALTC). *Surg Endosc* 1999;**13**:1115–20.

122. Leibl BJ, Schmedt CG, Ulrich M, Kraft K, Bittner R. Laparoscopic hernia therapy (TAPP) as a teaching operation. *Chirurg* 2000;**71**:939–42.

123. Liem MS, van Steensel CJ, Boelhouwer RU, Weidema WF, Clevers GJ, Meijer WS, *et al*. The learning curve for totally extraperitoneal laparoscopic inguinal hernia repair. *Am J Surg* 1996;**171**:281–5.

124. Ramsay CR, Grant AM, Wallace SA, Garthwaite PH, Monk AF, Russell IT. Statistical assessment of the learning curves of health technologies. *Health Technol Assess* 2001;**5**(12).

125. Voitk AJ. The learning curve in laparoscopic inguinal hernia repair for the community general surgeon. *Can J Surg* 1998;**41**:446–50.

126. Wright D, O'Dwyer PJ. The learning curve for laparoscopic hernia repair. *Semin Laparosc Surg* 1998;**5**:227–32.

79

127. Lau H, Yeung E, Patil N-G, Yuen W-K, Lee F. Learning curves for unilateral endoscopic totally extraperitoneal inguinal hernioplasty. *Surg Endosc* 2002;**16** (Suppl 1):S311.

128. Drummond MF, Jefferson TO. Guidelines for authors and peer reviewers of economic submissions to the *BMJ*. The *BMJ* Economic Evaluation Working Party. *BMJ* 1996;**313**:275–83.

129. Lawrence K, McWhinnie D, Goodwin A, Gray A, Gordon J, Storie J, *et al*. An economic evaluation of laparoscopic versus open inguinal hernia repair. *J Public Health Med* 1996;**18**:41–8.

130. McIntosh E, Donaldson C, Ryan M. Recent advances in the methods of cost–benefit analysis in healthcare. Matching the art to the science. *Pharmacoeconomics* 1999;**15**:357–67.

131. MRC Laparoscopic Groin Hernia Trial Group. Cost–utility analysis of open versus laparoscopic groin hernia repair: results from a multicentre randomized clinical trial. *Br J Surg* 2001;**88**:653–61.

132. Stylopoulos N, Gazelle GS, Rattner DW. A cost–utility analysis of treatment options for inguinal hernia in 1,513,008 adult patients. *Surg Endosc* 2003;**17**:180–9.

133. Papachristou EA. Surgical outcome and hospital cost analyses of laparoscopic and open tension-free hernia repair. *Hernia* 2002;**6**:68–72.

134. Pikoulis E. Laparoscopic preperitoneal mesh repair or tension-free mesh plug technique? *Eur J Surg* 2002;**168**:587–91.

135. Eno LM, Spigelman AD. An audit of open and laparoscopic inguinal hernia repair. *J Qual Clin Pract* 2000;**20**:56–9.

136. McIntosh E. Using discrete choice experiments to value the benefits of health. PhD thesis. University of Aberdeen; 2003.

137. Bittner R. Laparoscopic transperitoneal procedure for routine repair of groin hernia. *Br J Surg* 2002; **89**:1062–6.

138. Seymour DG, Garthwaite PH. Age, deprivation and rates of inguinal hernia surgery in men. Is there inequity of access to healthcare? *Age Ageing* 1999;**28**:485–90.

139. Kumar S, Wilson RG, Nixon SJ, Macintyre IM. Chronic pain after laparoscopic and open mesh repair of groin hernia. *Br J Surg* 2002;**89**: 1476–9.

Appendix 1

Literature search strategies

Search strategies for clinical effectiveness

MEDLINE (2000–June week 1, 2003), EMBASE (2000–week 23, 2003)
Ovid Multifile Search
URL: http://gateway.ovid.com/athens

1   hernia,inguinal/su
2   (inguinal or groin).tw.
3   hernioplasty/ use emez
4   herniorrhaphy/ use emez
5   hernioplasty.tw.
6   herniorrhaphy.tw.
7   (hernia adj3 repair).tw.
8   2 and (3 or 4 or 5 or 6 or 7)
9   1 or 8
10 (tapp or transabdominal or preperitoneal or transperitoneal).tw.
11 (tep or totally extraperitoneal).tw.
12 2 and (10 or 11)
13 laparoscopy/
14 laparoscopic surgery/ use emez
15 endoscopy/
16 endoscopic surgery/ use emez
17 Video-Assisted Surgery/
18 (laparoscop$ or endoscop$ or video$).tw.
19 13 or 14 or 15 or 16 or 17 or 18
20 9 and 19
21 12 or 20
22 randomized controlled trial.pt. use mesz
23 controlled clinical trial.pt. use mesz
24 randomized controlled trials/
25 random allocation/
26 double blind method/
27 single-blind method/
28 clinical trial.pt. use mesz
29 22 or 23
30 exp clinical trials/
31 exp controlled study/ use emez
32 (clin$ adj25 trial$).tw.
33 ((singl$ or doubl$ or trebl$ or tripl$) adj25 (blind$ or mask$)).tw.
34 random$.tw.
35 research design/ use mesz
36 comparative study/
37 exp evaluation studies/
38 follow up studies/
39 (control$ or prospectiv$ or volunteer$).tw.

40 or/22-39
41 animal/ not human/ use mesz
42 (animal/ or nonhuman/) not human/ use emez
43 40 not (41 or 42)
44 21 and 43
45 remove duplicates from 44

Supplementary search for TAPP versus TEP comparison
1 (tapp or transabdominal or preperitoneal or transperitoneal).tw.
2 (tep or totally extraperitoneal).tw.
3 (inguinal or groin).tw
4 1 and 2 and 3

MEDLINE Extra (13 June 2003)
Ovid URL: http://gateway.ovid.com/athens

1   (inguinal or groin).tw.
2   hernioplasty.tw.
3   herniorrhaphy.tw.
4   (hernia adj3 repair).tw.
5   tapp or transabdominal or preperitoneal or transperitoneal).tw.
6   (tep or totally extraperitoneal).tw.
7   1 and (2 or 3 or 4)
8   1 and (5 or 6)
9   (laparoscop$ or endoscop$ or video$).tw.
10 7 and 9
11 8 or 10

CINAHL (1982–June week 1, 2003)
Ovid URL: http://gateway.ovid.com/athens

1   hernia,inguinal/su
2   (inguinal or groin).tw.
3   hernioplasty.tw.
4   herniorrhaphy.tw.
5   (hernia adj3 repair).tw.
6   2 and (3 or 4 or 5)
7   1 or 6
8   (tapp or transabdominal or preperitoneal or transperitoneal).tw.
9   (tep or total$ extraperitoneal).tw.
10 2 and (8 or 9)
11 laparoscopy/
12 surgery,laparoscopic/
13 endoscopy/

14 (laparoscop$ or endoscop$ or video$).tw.
15 11 or 12 or 13 or 14
16 7 and 15
17 10 or 16

BIOSIS (1985–18 June 2003)
Edina URL: http://edina.ac.uk/biosis/

(((((((((al: transperitoneal) or (al: tapp or al:
transabdominal or al: preperitoneal))) and
(al: tep or al: extraperitoneal))) and (al: inguinal
or al: groin))
or
(((al: random* or al: control* or al: trial*) and
(((((((((al: transperitoneal) or (al: tapp or al:
transabdominal or al: preperitoneal))) or (al: tep
or al: extraperitoneal)))and (al: inguinal or al:
groin)))or
((((((al: repair) or (al: hernia* or al: hernioplasty
or al: herniorrhaphy))) and
(al: laparoscop* or al: endoscop* or al:
video*))and(al: inguinal or al: groin))))))))

Science Citation Index (1981–21 June 2003)
Web of Science Proceedings (1990–19 June 2003)
Web of Knowledge URL: http://wok.mimas.ac.uk/

(((inguinal or groin) and (hernioplasty or
herniorrhaphy or repair)) and (laparoscop* or
endoscop* or video*)) and (random* or trial* or
control*)
or
((tapp or transabdominal or preperitoneal or
transperitoneal) and (tep or extraperitoneal)) and
hernia

Cochrane Library (Issue 2, 2003)
URL: http://www.update-software.com/clibng/
cliblogon.htm

#1   HERNIA INGUINAL [su] single term
     (MeSH)
#2   (inguinal or groin)
#3   (hernioplasty or herniorrhaphy)
#4   (hernia near repair)
#5   (#1 or (#2 and (#3 or #4)))
#6   LAPAROSCOPY single mesh (MeSH)
#7   ENDOSCOPY single mesh (MeSH)
#8   VIDEO-ASSISTED SURGERY single term
     (MeSH)
#9   (laparoscop* or endoscop* or video*)
#10 (#5 and (#6 or #7 or #8 or #9))
#11 (tapp or transabdominal or preperitoneal or
     transperitoneal)
#12 (total* next extraperitoneal)
#13 tep

#14 #2 and (#11 or #12 or #13)
#15 #10 or #14
#16 (#11 and (#12 or #13))
#17 (#1 or #2 or #3 or #4)
#18 #16 and #17
#19 #15 or #18

DARE and HTA Database (June 2003)
NHS Centre for Reviews and Dissemination
URL: http://nhscrd.york.ac.uk/welcome.htm

Hernia-inguinal
Or
(inguinal or groin) and herni*

National Research Register (Issue 2, 2003)
URL: http://www.update-software.com/National/

#1   HERNIA INGUINAL [su] single term
     (MeSH)
#2   (inguinal or groin)
#3   (hernioplasty or herniorrhaphy)
#4   (hernia near repair)
#5   (#1 or (#2 and (#3 or #4)))
#6   LAPAROSCOPY single mesh (MeSH)
#7   ENDOSCOPY single mesh (MeSH)
#8   VIDEO-ASSISTED SURGERY single term
     (MeSH)
#9   (laparoscop* or endoscop* or video*)
#10 (#5 and (#6 or #7 or #8 or #9))
#11 (tapp or transabdominal or preperitoneal or
     transperitoneal)
#12 (total* next extraperitoneal)
#13 tep
#14 #2 and (#11 or #12 or #13)
#15 #10 or #14
#16 (#11 and (#12 or #13))
#17 (#1 or #2 or #3 or #4)
#18 #16 and #17
#19 #15 or #18

Clinical Trials (May 2003)
URL: http://clinicaltrials.gov/ct/gui/c/r

Current Controlled Trials (May 2003)
URL: http://www.controlled-trials.com/

Research Findings Register (May 2003)
URL: http://tap.ukwebhost.eds.com/doh/
refr_web.nsf/Home?OpenForm

Inguinal or groin or herni*

Journals@Ovid Full Text (15 July 2003)

Ovid URL: http://gateway.ovid.com/athens

Journals searched:
Annals of Surgery 1996–July 2003
Archives of Surgery 1995–June 2003
British Journal of Surgery + Supplements
1995–June 2003
Surgical Laparoscopy 1996–June 2003

1 (inguinal or groin).tw.
2 hernioplasty.tw.
3 herniorrhaphy.tw.
4 (hernia adj3 repair).tw.
5 tapp or transabdominal or preperitoneal or transperitoneal).tw.
6 (tep or totally extraperitoneal).tw.
7 1 and (2 or 3 or 4)
8 1 and (5 or 6)
9 (laparoscop$ or endoscop$ or video$).tw.
10 (random$ or control$ or trial$).tw
11 7 and 9 and 10
12 8 or 11

SpringerLink (16 July 2003)

URL: http://www.springerlink.com/

Journal searched:
Surgical Endoscopy 1996–June 2003
Hernia* or hernio*

Handsearching

The following conference proceedings were handsearched:

Association of Endoscopic Surgeons of
  Great Britain and Ireland (AESGBI):
Autumn Meeting, Bath, UK, 1999
Spring Meeting, Cardiff, UK, 2000
Spring Meeting, Birmingham, UK, 2001
Autumn Meeting, Guilford, UK, 2001
Annual Meeting, Dublin, UK, 2002
Annual Meeting, Edinburgh,UK, 2003
International Congress of the European
  Association for Endoscopic Surgery (EAES):
8th Annual Meeting, Nice, 2000
9th Annual Meeting, Maastricht, 2001
10th Annual Meeting, Lisbon, 2002
Scientific Session of the Society of American
  Gastrointestinal and Endoscopic Surgeons
  (SAGES):
Annual Meeting, St Louis, 2001
Annual Meeting, New York, 2002
Annual Meeting, Los Angeles, 2003
Italian Society of Endosopic Surgery:
7th Annual Congress, Urbio, 2001

Search strategies for economic evaluations

MEDLINE (2000–July week 2, 2003), EMBASE (2000–Week 28, 2003)

Ovid Multifile Search
URL: http://gateway.ovid.com/athens

1 hernia,inguinal/su
2 (inguinal or groin).tw.
3 hernioplasty/ use emez
4 herniorrhaphy/ use emez
5 hernioplasty.tw.
6 herniorrhaphy.tw.
7 (hernia adj3 repair).tw.
8 2 and (3 or 4 or 5 or 6 or 7)
9 1 or 8
10 (tapp or transabdominal or preperitoneal or transperitoneal).tw.
11 (tep or total$ extraperitoneal).tw.
12 2 and (10 or 11)
13 laparoscopy/
14 laparoscopic surgery/ use emez
15 endoscopy/
16 endoscopic surgery/ use emez
17 Video-Assisted Surgery/
18 (laparoscop$ or endoscop$ or video$).tw.
19 13 or 14 or 15 or 16 or 17 or 18
20 9 and 19
21 12 or 20
22 economics/
23 exp "costs and cost analysis"/ use mesz
24 exp economics,hospital/ use mesz
25 exp budgets/
26 exp economic evaluation/ use emez
27 exp hospital cost/ use emez
28 ec.fs. use mesz
29 exp models,economic/ use mesz
30 monte carlo method/
31 markov chains/
32 exp quality of life/
33 value of life/ use mesz
34 health status/
35 health status indicators/ use mesz
36 cost of illness/
37 (cost? adj3 (analys?s or evaluat$ or effective$ or utilit$ or benefit$ or minimi$)).tw.
38 cost$.ti.
39 (price or pricing$).tw.
40 (financial or finance or finances or financed).tw.
41 (fee or fees).tw.
42 (value adj2 (money or monetary)).tw.
43 (economic adj3 (analys?s or evaluat$ or effectiveness)).tw.
44 (decision$ adj2 (tree$ or analy$ or model$)).tw.

83

46 (quality adj2 life).tw.
47 (qol or qaly? or qald? or qale? or qtime?).tw.
48 (euroqol or hql or hqol).tw.
49 (health adj3 (indicator? or status or utilit$)).tw.
50 qwb.tw.
51 or/22-50
52 21 and 51
53 remove duplicates from 52

MEDLINE Extra (17 July 2003)

Ovid URL: http://gateway.ovid.com/athens

1   (inguinal or groin).tw.
2   hernioplasty.tw.
3   herniorrhaphy.tw.
4   (hernia adj3 repair).tw.
5   tapp or transabdominal or preperitoneal or transperitoneal).tw.
6   (tep or totally extraperitoneal).tw.
7   1 and (2 or 3 or 4)
8   1 and (5 or 6)
9   (laparoscop$ or endoscop$ or video$).tw.
10 7 and 9
11 8 or 10
12 (cost? adj3 (analys?s or evaluat$ or effective$ or utilit$ or benefit$ or minimi$)).tw.
13 cost$.ti.
14 (price or pricing$).tw.
15 (financial or finance or finances or financed).tw.
16 (fee or fees).tw.
17 (value adj2 (money or monetary)).tw.
18 (economic adj3 (analys?s or evaluat$ or effectiveness)).tw.
19 (decision$ adj2 (tree$ or analy$ or model$)).tw.
20 (quality adj2 life).tw.
21 (qol or qaly? or qald? or qale? or qtime?).tw.
22 (euroqol or hql or hqol).tw.
23 (health adj3 (indicator? or status or utilit$)).tw.
24 qwb.tw.
25 or/12-24
26 11 and 25

NHS EED (July 2003)

NHS Centre for Reviews and Dissemination
URL:http://nhscrd.york.ac.uk/welcome.htm

Hernia-inguinal
Or
(inguinal or groin) and herni*

Health Management Information Consortium (July 2003)

Ovid URL: http://gateway.ovid.com/athens

1 Hernia/
2 ((inguinal or groin) and hernia).tw
3 (hernioplasty or herniorrhaphy or hernia adj2 repair$).tw
4 or/1-3

Journals@Ovid Full Text (17 July 2003)

Ovid URL: http://gateway.ovid.com/athens

Journals searched:
Annals of Surgery 1996–July 2003
Archives of Surgery 1995–June 2003
British Journal of Surgery + Supplements 1995–June 2003
Surgical Laparoscopy 1996–June 2003

1   (inguinal or groin).tw.
2   hernioplasty.tw.
3   herniorrhaphy.tw.
4   (hernia adj3 repair).tw.
5   tapp or transabdominal or preperitoneal or transperitoneal).tw.
6   (tep or totally extraperitoneal).tw.
7   1 and (2 or 3 or 4)
8   1 and (5 or 6)
9   (laparoscop$ or endoscop$ or video$).tw.
10 7 and 9
11 8 or 10
12 (cost? adj3 (analys?s or evaluat$ or effective$ or utilit$ or benefit$ or minimi$)).tw.
13 cost$.ti.
14 (price or pricing$).tw.
15 (financial or finance or finances or financed).tw.
16 (fee or fees).tw.
17 (value adj2 (money or monetary)).tw.
18 (economic adj3 (analys?s or evaluat$ or effectiveness)).tw.
19 (decision$ adj2 (tree$ or analy$ or model$)).tw.
20 (quality adj2 life).tw.
21 (qol or qaly? or qald? or qale? or qtime?).tw.
22 (euroqol or hql or hqol).tw.
23 (health adj3 (indicator? or status or utilit$)).tw.
24 qwb.tw.
25 or/12-24
26 11 and 25

Search strategies for learning curves

MEDLINE (1966–July week 2, 2003), EMBASE (1980–Week 29, 2003)

Ovid Multifile Search
URL: http://gateway.ovid.com/athens

1   hernia,inguinal/su
2   (inguinal or groin).tw.
3   hernioplasty/ use emez
4   herniorrhaphy/ use emez
5   hernioplasty.tw.
6   herniorrhaphy.tw.
7   (hernia adj3 repair).tw.
8   2 and (3 or 4 or 5 or 6 or 7)
9   1 or 8
10 (tapp or transabdominal or preperitoneal or transperitoneal).tw.
11 (tep or total$ extraperitoneal).tw.
12 2 and (10 or 11)
13 laparoscopy/
14 laparoscopic surgery/ use emez
15 endoscopy/
16 endoscopic surgery/ use emez
17 Video-Assisted Surgery/
18 (laparoscop$ or endoscop$ or video$).tw.
19 13 or 14 or 15 or 16 or 17 or 18
20 9 and 19
21 12 or 20
22 clinical competence/
23 surgical training/ use emez
24 surgery/ed use mesz
25 (learn$ adj3 curve$).tw.
26 (learn$ adj3 (effect$ or rate? or method?)).tw.
27 (skill? adj3 (acquir$ or acquisit$ or develop$)).tw.
28 (competence adj3 (acquir$ or acquisit$ or develop$)).tw.
29 (expertise adj3 (acquir$ or acquisit$ or develop$)).tw.
30 (error? or mistake?).tw.
31 (surgeon? adj3 (experience? or expertise or skill? or competence)).tw.
32 training.tw.
33 or/22-32
34 21 and 33
35 remove duplicates from 34

Science Citation Index (1981–21 June 2003)

Web of Knowledge URL: http://wok.mimas.ac.uk/

(((tapp or transabdominal or preperitoneal or transperitoneal or tep or extraperitoneal) and hernia*) or ((hernia* or hernio*)
and (laparoscop* or endoscop* or video*)))
 and
((learning same (curve* or effect* or rate* or method*) or
(skill* or expertise or competence) same (acquir* or acquisit* or develop*)
or (surgeon* same (experience or expertise or skill* or competence*))
or (error* or mistake* or training))

The following Websites were searched for evidence-based reports (accessed June 2003):

Alberta Heritage Foundation for Medical Research URL: http://www.ahfmr.ca/
ASERNIP-S URL: http://www.surgeons.org/asernip-s/
Association of Endoscopic Surgeons of Great Britain and Ireland URL:http://www.aesgbi.org/
Blue Cross Blue Shield Technology Evaluation Center URL:
http://www.bcbs.com/tec/tecassessments.html
CCOHTA URL: http://www.ccohta.ca/
Centers for Medicare and Medicaid Services URL: http://cms.hhs.gov/mcd/index_list.asp?list_type=tech
ECRI URL: http://www.ecri.org/
Ethicon URL:http://www.ethicon.com/
European Association of Endoscopic Surgeons URL:http://www.eaes-eur.org/
Society of American Gastrointestinal Endoscopic Surgeons URL:http://www.sages.org/
SUMSEARCH URL: http://sumsearch.uthscsa.edu
TRIP database URL: http://www.update-software.com/scripts/clibng/usauth.exe?Server=TRIPUSER&Product=TRIP&Guest=YES

Appendix 2

Study eligibility form

NICE review of the effectiveness and cost-effectiveness of laparoscopic surgery for inguinal hernia repair

Study ID: _____   **Refman ID:** _____

Type of study
Q1. Is the study a randomised controlled trial or a quasi-randomised controlled trial?

      Yes   Unclear   No

           Go to   **Exclude**
       Next question

Participants in the study
Q2. Were the participants in the study adults with a clinical diagnosis of inguinal hernia for whom surgical management is judged appropriate?

      Yes   Unclear   No

           Go to   **Exclude**
       Next question

Interventions in the study
Q3. Did one group receive a laparoscopic repair?

      Yes   Unclear   No

           Go to   **Exclude**
       Next question

Q4. Did another group receive an open mesh repair or a different type of laparoscopic repair?

      Yes   Unclear   No

           Go to   **Exclude**
       Next question

Outcomes in the study
Q5. Did the study report duration of operation, conversions, intra-operative or post-operative complications, post-operative pain, length of hospital stay, return to usual activities, persisting pain or numbness or hernia recurrence

      Yes   Unclear   No

      Include, subject   **Exclude**
       clarification of
       'unclear' points

Final decision: Included ☐   Unclear ☐   Excluded ☐

If included:
What are the comparisons?   Lap vs. Open Mesh ☐   TAPP vs. TEP ☐
Is the study included in original review?   Yes ☐   No ☐

If yes, please indicate data source: IPD ☐ Additional data ☐ Published data ☐

87

Appendix 3

Data abstraction and quality assessment form

NICE review of the effectiveness and cost-effectiveness of laparoscopic surgery for inguinal hernia repair

Reviewer ID: _____

Study Details

Study ID: Abstract ☐ Full text ☐ Unpublished ☐

Authors:

Title:

Publication year or date of interim data collection:

Language:

Study Design

RCT ☐ Quasi-RCT ☐ Observational study ☐

Other: _____

Study Methods

Allocation concealment:

Central ☐ Sealed envelopes ☐ Computer generated Nos ☐ Random Nos table ☐

Birthdate ☐ Alternation ☐ Coin toss ☐ Not reported ☐

Other (please give details): _____

Outcome assessor-blinded, where possible: YES ☐ NO ☐ Unclear ☐

Participants lost to follow-up: YES ☐ NO ☐ Unclear ☐

If yes, please give details: _____

Analysis by intention to treat: YES ☐ NO ☐ Unclear ☐

Comments

Participants			
Number of participants randomised or included in study:			
Criteria for inclusion:		Criteria for exclusion:	

Setting and Timing
Setting of study: _____
The number of laparoscopic procedures performed prior to trial entry: _____
Recruitment period: _____
Follow-up period: _____

Intervention

	Surgical technique	Type of anaesthesia	No of patients
Intervention 1			
Intervention 2			
Intervention 3			

Patient Characteristics

	Intervention 1	Intervention 2	Intervention 3	Overall
Age (years)				
Sex (M/F)				
Unilateral (No)				
Bilateral (No)				
Indirect (No)				
Direct (No)				
Femoral (No)				
Recurrent (No)				

Outcomes				
	Time Recorded	**Intervention 1**	**Intervention 2**	**Intervention 3**
Short term outcomes:				
Duration of operation (min)				
Opposite method initiated (No & specify)				
Conversions (No & specify)				
Visceral injuries (No & specify)				
Vascular injuries (No & specify)				
Post-operative pain				
Haematoma				
Seroma				
Wound/superficial infection				
Mesh/deep infection				
Port site hernia				
Length of hospital stay (days)				
Return to usual activity (days)				
Return to work (days)				

Long-term outcomes				
Hernia recurrence				
Persisting pain				
Persisting numbness				
Quality of life				

Comments

Contact with author

Date: _____   Signature: _____

Appendix 4

List of included studies: laparoscopic versus open mesh

Aitola, 1998
Primary reference:
Aitola P, Airo I, Matikainen M. Laparoscopic versus open preperitoneal inguinal hernia repair: a prospective randomised trial. *Ann Chir Gynaecol* 1998;**87**:22–5.

Andersson, 2003
Primary reference:
Andersson B, Hall AC, Leveau P, Bergenfelz A, Westerdahl J. Laparoscopic extraperitoneal inguinal hernia repair versus open mesh repair: A prospective randomized controlled trial. *Surgery* 2003;**133**:464–72.

Barkun, 1995
Primary reference:
Barkun JS, Wexler MJ, Hinchey EJ, Thibeault D, Meakins JL. Laparoscopic versus open inguinal herniorrhaphy: preliminary results of a randomized controlled trial. *Surgery* 1995; **118**:703–9.

Related references:
Barkun JS, Wexler MJ, Fernandez M, Meakins JL. Laparoscopic vs. open inguinal herniorraphy, a randomized controlled trial. *Gastroenterology* 1998; **114** (4 Part 2):A1378.

Barkun JS, Keyser EJ, Wexler MJ, Fried GM, Hinchey EJ, Fernandez M, *et al*. Short-term outcomes in open vs. laparoscopic herniorrhaphy: confounding impact of worker's compensation on convalescence. *J Gastrointest Surg* 1999;**3**:575–82.

Barkun JS, Mederios LE, Wexler MJ, Fried GM. Convalescence after inguinal hernia repair. *Surg Endosc* 2001;**15** (Suppl 1):S30.

Beets, 1999
Primary reference:
Beets GL, Dirksen CD, Go PM, Geisler FE, Baeten CG, Kootstra G. Open or laparoscopic preperitoneal mesh repair for recurrent inguinal hernia? A randomized controlled trial. *Surg Endosc* 1999;**13**:323–7.

Bostanci, 1998
Primary reference:
Bostanci BE, Tetik C, Ozer S, Ozden A. Posterior approaches in groin hernia repair with prosthesis: open or closed. *Acta Chir Belg* 1998;**98**:241–4.

Bringman, 2003
Primary reference:
Bringman S, Ramel S, Heikkinen TJ, Englund T, Westman B, Anderberg B. Tension-free inguinal hernia repair: TEP versus mesh-plug versus Lichtenstein: a prospective randomized controlled trial. *Ann Surg* 2003;**237**:142–7.

Champault, 1997
Primary reference:
Champault GG, Rizk N, Catheline JM, Turner R, Boutelier P. Inguinal hernia repair: totally preperitoneal laparoscopic approach versus Stoppa operation: randomized trial of 100 cases. *Surg Laparosc Endosc* 1997;**7**:445–50.

Related references:
Champault G, Rizk N, Catheline JM, Riskalla H, Boutelier P. Groin hernia: pre-peritoneal laparoscopic surgery versus open (Stoppa) procedure. *J Chir (Paris)* 1996;**133**:274–80.

Champault G, Barrat C, Catheline JM, Rizk N. Groin hernias: four-year follow-up of two randomised trials comparing laparoscopic totally preperitoneal approach to Shouldice and Stoppa procedures: 361 cases. *Ann Chir* 1998;**52**:132–6.

Colak, 2003
Primary reference:
Colak T, Akca T, Kanik A, Aydin S. Randomized clinical trial comparing laparoscopic totally extraperitoneal approach with open mesh repair in inguinal hernia. *Surg Laparosc Endosc Percutan Tech* 2003;**13**:191–5.

Filipi, 1996
Primary reference:
Filipi CJ, Gaston-Johansson F, McBride PJ, Murayama K, Gerhardt J, Cornet DA, *et al*.

93

An assessment of pain and return to normal activity. Laparoscopic herniorrhaphy vs. open tension-free Lichtenstein repair. *Surg Endosc* 1996; **10**:983–6.

Gholghesaei, 2003
Primary reference:
Gholghesaei M, Essink-Bot ML, van't Riet M, Veldkamp R, Jeekel J, Bonjer HJ. Lichtenstein versus endoscopic inguinal hernia repair: differences in quality of life. *Surg Endosc* 2003; **17** (Suppl 1):S81.

Related reference:
Gholghesaei M, Essink-Bot ML, van't Riet M, Veldkamp R, Jeekel J, Bonjer HJ. Lichtenstein versus endoscopic inguinal hernia repair: differences in quality of life. *Surg Endosc* 2002; **16** (Suppl 1):S308.

Gontarz, 1998
Primary reference:
Gontarz W, Wolanski L, Leksowski K.
A comparison of two 'tension free' inguinal hernia repair methods. *Br J Surg* 1998;**85** (Suppl II):18.

Heikkinen (1), 1998
Primary reference:
Heikkinen TJ, Haukipuro K, Hulkko A. A cost and outcome comparison between laparoscopic and Lichtenstein hernia operations in a day-case unit. A randomized prospective study. *Surg Endosc* 1998; **12**:1199–203.

Heikkinen (2), 1998
Primary reference:
Heikkinen TJ, Haukipuro K, Koivukangas P, Hulkko A. A prospective randomized outcome and cost comparison of totally extraperitoneal endoscopic hernioplasty versus Lichtenstein hernia operation among employed patients. *Surg Laparosc Endosc* 1998;**8**:338–44.

Heikkinen, 1997
Primary reference:
Heikkinen T, Haukipuro K, Leppala J, Hulkko A. Total costs of laparoscopic and Lichtenstein inguinal hernia repairs: a randomized prospective study. *Surg Laparosc Endosc* 1997;**7**:1–5.

Jess, 2000
Primary reference:
Jess P, Schultz K, Bendtzen K, Nielsen OH. Systemic inflammatory responses during laparoscopic and open inguinal hernia repair: a randomised prospective study. *Eur J Surg* 2000; **166**:540–4.

Khoury, 1998
Primary reference:
Khoury N. A randomized prospective controlled trial of laparoscopic extraperitoneal hernia repair and mesh-plug hernioplasty: a study of 315 cases. *J Laparoendosc Adv Surg Tech A* 1998;**8**:367–72.

Koninger, 1998
Primary reference:
Koninger JS, Oster M, Butters M. Management of inguinal hernia – a comparison of current methods. *Chirurg* 1998;**69**:1340–4.

Lal, 2003
Primary reference:
Lal P, Kajla RK, Chander J, Saha R, Ramteke VK. Randomized controlled study of laparoscopic total extraperitoneal vs. open Lichtenstein inguinal hernia repair. *Surg Endosc* 2003;**17**:850–6.

Laporte, 1997
Primary reference:
Laporte E, Miras M, Ramirez JM, Segura J, Semeraro C, Vicens C. Comparison of the anterior approach versus transabdominal laparoscopy in inguinal hernia repair using preperitoneal polypropylene prostheses. *Cir Esp* 1997;**61**:325–8.

Mahon, 2001
Primary reference:
Mahon D, Decadt B, Cheadle T, Clarke JM, Speakman C, Stebbings SW, *et al*. Prospective randomised trial of laparoscopic (transabdominal preperitoneal – TAPP) versus open (mesh) repair for bilateral and recurrent inguinal hernia. *Surg Endosc* 2001;**15** (Suppl 1):S102.

Related reference:
Mahon D, Decadt B, Cheadle T, Clarke JM, Speakman C, Stebbings SW, *et al*. Prospective randomized trial of laparoscopic (trans-abdominal preperitoneal TAPP) versus open (Lichtenstein) inguinal hernia repair for bilateral and recurrent inguinal hernia. *Br J Surg* 2000;**87** (Suppl 1):35.

Merello, 1997
Primary reference:
Merello J, Guerra AG, Madriz J, Guerra GG. Laparoscopic TEP versus open Lichtenstein hernia repair. *Surg Endosc* 1997;**11**:545.

MRC Multicentre, 1999
Primary reference:
Laparoscopic versus open repair of groin hernia: a randomised comparison. The MRC Laparoscopic Groin Hernia Trial Group. *Lancet* 1999;**354**:185–90.

Related references:
Wright DM, Kennedy A, Baxter JN, Fullarton GM, Fife LM, Sunderland GT, *et al*. Early outcome after open versus extraperitoneal endoscopic tension-free hernioplasty. *Surgery* 1996;**119**:552–7.

Wright DM, Paterson CR, O'Dwyer PJ. Early outcome following open and laparoscopic tension-free hernioplasty – a randomised clinical trial. *Gastroenterology* 1997;**112** (4 Suppl):A49.

Kumar S, Nixon SJ, MacIntyre IM. Laparoscopic or Lichtenstein repair for recurrent inguinal hernia: one unit's experience. *J R Coll Surg Edinb* 1999;**44**:301–2.

Wright D, Hall MG, Paterson C, O'Dwyer PJ. A randomized comparison of driver reaction time after open and endoscopic tension-free inguinal hernia repair. *Surg Endosc* 1999;**13**:332–4.

Scott NW, Grant AM, Ross SJ, Smith A, Macintyre IMC, O'Dwyer PJ. Patient-assessed outcome up to three months in a randomised controlled trial comparing laparoscopic with open groin hernia repair. *Hernia* 2000;**4**:73–9.

Hair A, Taylor S, Wright D, Paterson C, O'Dwyer PJ. Five-year outcome following laparoscopic and open hernia repair. *Surg Endosc* 2001;**15** (Suppl 1):S79.

Wright D, Paterson C, Scott N, Hair A, O'Dwyer PJ. Five-year follow-up of patients undergoing laparoscopic or open groin hernia repair: a randomized controlled trial. *Ann Surg* 2002;**235**:333–7.

Paganini, 1998
Primary reference:
Paganini AM, Lezoche E, Carle F, Carlei F, Favretti F, Feliciotti F, *et al*. A randomized, controlled, clinical study of laparoscopic vs. open tension-free inguinal hernia repair. *Surg Endosc* 1998;**12**:979–86.

Payne, 1994
Primary reference:
Payne JH Jr, Grininger LM, Izawa MT, Podoll EF, Lindahl PJ, Balfour J. Laparoscopic or open inguinal herniorrhaphy? A randomized prospective trial. *Arch Surg* 1994;**129**:973–9.

Related reference:
Payne J, Grininger L, Izawa M, Lindahl PJ, Podoll EF. A randomised prospective comparison between a laparoscopic, preperitoneal and anterior tension-free repair of inguinal hernia. *Surg Laparosc Endosc* 1994;**4**:471–2.

Payne, 1996
Primary reference:
Payne J, Izawa M, Glen P, Grininger L, Podoll E, Balfour J. Laparoscopic or tension-free inguinal hernia repair. In *Proceedings of the Society of American Gastrointestinal Surgeons (SAGES)*, 1996, Philadelphia, PA. New York: Springer, 1996.

Picchio, 1999
Primary reference:
Picchio M, Lombardi A, Zolovkins A, Mihelsons M, La Torre G. Tension-free laparoscopic and open hernia repair: randomized controlled trial of early results. *World J Surg* 1999; **23**:1004–7.

Ramon, 1998
Primary reference:
Ramon JM, Carulla X, Serrano A, Roura J, Castillo J, Solsona, J., *et al*. The endoscopic preperitoneal inguinal hernia repair (TEP). *Br J Surg* 1998;**85** (Suppl 2):48.

Sarli, 1997
Primary reference:
Sarli L, Pietra N, Choua O, Costi R, Thenasseril B, Giunta A. Prospective randomized comparative study of laparoscopic hernioplasty and Lichtenstein tension-free hernioplasty. *Acta Biomed Ateneo Parmense* 1997;**68**:5–10.

Sarli, 2001
Primary reference:
Sarli L, Iusco DR, Sansebastiano G, Costi R. Simultaneous repair of bilateral inguinal hernias: a prospective, randomized study of open, tension-free versus laparoscopic approach. *Surg Laparosc Endosc Percutan Tech* 2001;**11**:262–7.

Schrenk, 1996
Primary reference:
Schrenk P, Woisetschlager R, Rieger R, Wayand W. Prospective randomized trial comparing postoperative pain and return to physical activity after transabdominal preperitoneal, total preperitoneal or Shouldice technique for inguinal hernia repair. *Br J Surg* 1996;**83**:1563–6.

Related reference:
Schrenk P, Bettelheim P, Woisetschlager R, Rieger R, Wayand WU. Metabolic responses after laparoscopic or open hernia repair. *Surg Endosc* 1996;**10**:628–32.

SCUR, 1999
Primary reference:
Johansson B, Hallerback B, Glise H, Anesten B, Smedberg S, Roman J. Laparoscopic mesh versus open preperitoneal mesh versus conventional technique for inguinal hernia repair: a randomized multicenter trial (SCUR Hernia Repair Study). *Ann Surg* 1999;**230**:225–31.

Related reference:
Johansson B, Hallerback B, Glise H, Anesten B, Melen K, Holm J, *et al*. Laparoscopic mesh repair vs. open repair w/wo mesh graft for inguinal hernia (SCUR groin hernia repair study) – preliminary results. *Surg Endosc* 1997;**11**:170.

Simmermacher, 2000
Primary reference:
Simmermacher RKJ, Van Duyn EB, Clevers GJ, de Vries LS, van Vroonhoven TJ. Preperitoneal mesh in groin hernia surgery. A randomized clinical trial emphasizing the surgical aspects of preperitoneal placement via a laparoscopic (TEP) or Grid-iron (Ugahary) approach. *Hernia* 2000; **4**:296–8.

Snyder, 1998
Primary reference:
Snyder S, Frazee R, Smith R, Symmonds R, Hendricks J, Roberts J, *et al*. A prospective randomised comparison and long-term follow-up of open and laparoscopic mesh inguinal hernia repair. In Montori A, Lirici MM, Montori J, editors. *Proceedings of the 6th World Congress of Endoscopic Surgery, Part 1 and 2*. Bologna: Monduzzi Editore, 1998. pp. A979–82.

Suter, 2002
Primary reference:
Suter M, Martinet O, Spertin F. Reduced acute inflammatory response after bilateral hernia repair with TEPP compared to Stoppa; a prospective randomised study. *Surg Endosc* 2002; **16** (Suppl1):S10.

Related references:
Suter M, Martinet O, Spertin F. Reduced acute phase response after laparoscopic total extraperitoneal bilateral hernia repair compared to open repair with the Stoppa procedure. *Surg Endosc* 2002;**16**:1214–19.

Suter M, Martinet O. Postoperative pulmonary dysfunction after bilateral inguinal hernia repair: a prospective randomized study comparing the Stoppa procedure with laparoscopic total extraperitoneal repair (TEPP). *Surg Laparosc Endosc Percutan Tech* 2002;**12**:420–5.

Vatansev, 2002
Primary reference:
Vatansev C, Belviranli M, Aksoy F, Tuncer S, Sahin M, Karahan O. The effects of different hernia repair methods on postoperative pain medication and CRP levels. *Surg Laparosc Percutan Tech* 2002;**12**:243–6.

Wellwood, 1998
Primary reference:
Wellwood J, Sculpher MJ, Stoker D, Nicholls GJ, Geddes C, Whitehead A, *et al*. Randomised controlled trial of laparoscopic versus open mesh repair for inguinal hernia: outcome and cost. *BMJ* 1998;**317**:103–10.

Related references:
Douek M, Smith G, Oshowo A, Stoker DL, Wellwood JM. Prospective randomized controlled trial of laparoscopic versus open hernia mesh repair: 5-year follow-up. *Br J Surg* 2002; **89** (Suppl 1):37.

Douek M, Smith G, Oshowo A, Stoker DL, Wellwood JM. Prospective randomised controlled trial of laparoscopic versus open inguinal hernia mesh repair: five-year follow up. *BMJ* 2003; **326**:1012–13.

Zieren, 1998
Primary reference:
Zieren J, Zieren HU, Jacobi CA, Wenger FA, Muller JM. Prospective randomized study comparing laparoscopic and open tension-free inguinal hernia repair with Shouldice's operation. *Am J Surg* 1998;**175**:330–3.

Related references:
Zieren J, Zieren HU, Wenger FA, Muller JM. Laparoscopic or conventional inguinal hernia repair with mesh? *Langenbecks Arch Chir* 1996; **381**:289–94.

Zieren J, Zieren HU, Said S, Muller JM. Laparoscopic or conventional inguinal hernia repair with or without implant. *Langenbecks Arch Chir* 1996;**113** (Suppl 2):609–10.

Zieren J, Zieren HU, Muller JM. Is there a reason for a laparoscopic tension-free groin hernia repair? *Zentralbl Chir* 1999;**124**:A20.

Appendix 5

Detailed quality assessment results for included primary studies

Study	Method of randomisation	Concealment of allocation	Blinding of outcome assessor	Loss to follow-up	Analysis by ITT
Aitola, 1998[67]	Alternation	Inadequate	Unclear	Yes	No
Andersson, 2003[76]	Sealed envelopes	Adequate	Unclear	Yes	Yes
Barkun, 1995[104]	Sealed envelopes	Adequate	Unclear	Unclear	Yes
Beets, 1999[68]	Sealed envelopes	Adequate	Unclear	Yes	Yes
Bostanci, 1998[84]	Not reported	Unclear	Unclear	Unclear	Unclear
Bringman, 2003[95]	Sealed envelopes	Adequate	Unclear	Yes	Unclear
Champault, 1997[85]	Random number tables	Inadequate	Unclear	Yes	Unclear
Colak, 2003[77]	Computer-generated numbers	Adequate	Unclear	Unclear	Unclear
Filipi, 1996[50]	Computer-generated numbers	Inadequate	Unclear	Yes	Unclear
Gholghessaei, 2003[78]	Not reported	Unclear	Unclear	Unclear	Unclear
Gontarz, 1998[51]	Not reported	Unclear	Unclear	Unclear	Unclear
Heikkinen (1), 1998[52]	Sealed envelopes	Adequate	Unclear	Unclear	No
Heikkinen (2), 1998[80]	Sealed envelopes	Adequate	Unclear	Unclear	Unclear
Heikkinen, 1997[53]	Not reported	Unclear	Unclear	Unclear	Unclear
Jess, 2000[54]	Sealed envelopes	Adequate	Unclear	Unclear	Unclear
Khoury, 1998[93]	Cards	Inadequate	Unclear	Unclear	No
Koninger, 1998[55]	Not reported	Unclear	Unclear	Yes	No
Lal, 2003[81]	Sealed envelopes	Adequate	Unclear	Unclear	No
Laporte, 1997[69]	Birthdate	Inadequate	Unclear	Unclear	Unclear
Mahon, 2001[56]	Not reported	Unclear	Unclear	Unclear	Unclear
Merello, 1997[82]	Not reported	Unclear	Unclear	Unclear	Unclear
MRC multicentre, 1999[96]	Central computer randomisation	Adequate	Unclear	Yes	Yes
Paganini, 1998[58]	Central computer randomisation	Adequate	Unclear	No	Unclear
Payne, 1994[59]	Sealed envelopes	Adequate	Unclear	Unclear	Unclear
Payne, 1996[83]	Sealed envelopes	Adequate	Unclear	Yes	Unclear
Picchio, 1999[61]	Sealed envelopes	Adequate	Unclear	Yes	Unclear
Ramon, 1998[88]	Sealed envelopes	Adequate	Unclear	Unclear	Unclear
Sarli, 1997[62]	Sealed envelopes	Adequate	Unclear	Yes	No
Sarli, 2001[63]	Sealed envelopes	Adequate	Unclear	Yes	Unclear
Schrenk, 1996[109]	Sealed envelopes	Adequate	Unclear	Unclear	Unclear
SCUR, 1999[70]	Central computer randomisation	Adequate	Unclear	Yes	Yes
Simmermacher, 2000[89]	Not reported	Unclear	Unclear	Unclear	Unclear
Snyder, 1998[108]	Central computer randomisation	Adequate	Unclear	Yes	Yes
Suter, 2002[90]	Sealed envelopes	Adequate	Unclear	Unclear	Unclear
Vatansev, 2002[94]	Sealed envelopes	Adequate	Unclear	Unclear	No
Wellwood, 1998[64]	Sealed envelopes	Adequate	Unclear	Yes	Yes
Zieren, 1998[72]	Computer-generated numbers	Adequate	Unclear	Unclear	Unclear

Appendix 6

Characteristics of included studies for effectiveness

Study	Study details	Intervention/comparator	Intervention population characteristics	Comparator population characteristics	Outcomes
Aitola, 1998[67]	Single-centre RCT 60 participants Follow-up = median 18 months Full text IPD available	TAPP (*n* = 29) versus open preperitoneal mesh (*n* = 31)	29/29 general anaesthetic 10/29 bilateral 10/29 recurrent Direct – unknown Indirect – unknown Age mean (SD) 54.52 (16.37) years 26 male/3 female	16/31 general anaesthetic 14/31 regional anaesthetic (1 not known) 4/31 bilateral 7/31 recurrent Direct – unknown Indirect – unknown Age mean (SD) 54.39 (18.06) years 26 male/5 female	Duration of operation Conversions Intraoperative complications Postoperative complications Length of hospital stay Return to usual activities Hernia recurrence
Andersson, 2003[76]	Single-centre RCT 168 participants Follow-up = 1 year Full text	TEP (*n* = 87) versus open flat mesh (*n* = 81)	87/87 general anaesthetic 3/87 bilateral 15/87 recurrent Direct – unknown Indirect – unknown Age mean (SD) 49 (9) years 81 male/0 female	General and regional anaesthetic 7/81 bilateral 13/81 recurrent Direct – unknown Indirect – unknown Age mean (SD) 50 (9) years 87 male/0 female	Duration of operation Conversions Intraoperative complications Postoperative complications Length of hospital stay Return to work/normal activity Hernia recurrence
Barkun, 1995[104–107]	Multi-centre RCT 92 participants Follow-up = median 54 months Full text IPD available	Mixed laparoscopic (*n* = 43) versus mixed open (*n* = 49) (choice left to surgeon)	43/43 general anaesthetic Bilateral – unknown Recurrent – unknown 23/43 direct 19/43 indirect 1/43 other Age mean (SD) 49.1 (14.7) years 42 male/1 female	18/49 general anaesthetic, 31/49 local/regional anaesthetic 49 bilateral – unknown 49 recurrent – unknown 23/49 direct 25/49 indirect 1/49 other Age mean (SD) 51.4 (17) years 47 male/2 female	Duration of operation Conversions Postoperative pain (day 1) Postoperative complications Length of hospital stay Convalescence Hernia recurrence QoL Patient satisfaction
Beets, 1999[68]	Single-centre RCT 79 participants Follow-up = mean (range) 21 (8–36) months Full text IPD available	TAPP (*n* = 42) versus open preperitoneal mesh (*n* = 37)	42/42 general anaesthetic 14/42 bilateral 42/42 recurrent Direct – unknown Indirect – unknown Age mean (SD) 58.10 (12.26) years 41 male/1 female	37/37 general anaesthetic 13/37 bilateral 37/37 recurrent Direct – unknown Indirect – unknown Age mean (SD) 57.86 (12.34) years 36 male/1 female	Duration of operation Postoperative pain (days 1–7) Postoperative complications Length of hospital stay Return to usual activities Persisting pain Persisting numbness Hernia recurrence Return to physical activities Mortality

Study	Study details	Intervention/comparator	Intervention population characteristics	Comparator population characteristics	Outcomes
Bostanci, 1998[84]	RCT 64 participants Follow-up = mean (range) 15 (4–24) months Full text	TEP (*n* = 32) versus open preperitoneal mesh (*n* = 32)	32/32 general anaesthetic 3/32 bilateral 1/35 recurrent (hernias) Direct 3/34 (primary hernias) Indirect 30/34 (primary hernias) Other 1/34 (primary hernias) Age median (range) 25 (20–59) years 31 male/1 female	General anaesthetic – unknown 3/32 bilateral 5/35 recurrent (hernias) Direct 2/30 (primary hernias) Indirect 27/30 (primary hernias) Other 1/30 (primary hernias) Age median (range) 31 (20–71) years 32 male/0 female	Duration of operation Conversions Intraoperative complications Postoperative complications Hernia recurrence Mortality
Bringman, 2003[95]	Multi-centre RCT 299 participants Follow-up = mean (SD) 19.8 (8.6) months Full text	TEP (*n* = 92) versus open plug and mesh (*n* = 104) versus open flat mesh (*n* = 103)	92/92 general anaesthetic 0/92 bilateral 13/92 recurrent 34/92 direct 49/92 indirect 1/92 other Age mean (SD) 55 (12) years 92 male/0 female	*Open plug and mesh* 98/104 general anaesthetic 6/104 regional anaesthetic 0/104 bilateral 17/104 recurrent 45/104 direct 54/104 indirect 1/104 other Age mean (SD) 55 (12) years 104 male/0 female *Open flat mesh* 100/103 general anaesthetic 3/103 regional anaesthesia 0/103 bilateral 11/103 recurrent 44/103 direct 56/103 indirect 0/103 other Age mean (SD) 54 (11) years 103 male/0 female	Duration of operation Conversions Postoperative complications Length of hospital stay Return to work/normal activity Hernia recurrence Persisting pain Persisting numbness
Champault, 1997[85–87]	RCT 100 participants Follow-up = TEP mean 570 days, open 610 days Full text	TEP (*n* = 51) versus open preperitoneal mesh (*n* = 49)	51/51 general anaesthetic 21/51 bilateral 20/51 recurrent 36/51 direct 15/51 indirect Age mean (SD) 57.2 (40.74) years 51 male/0 female	49/49 general anaesthetic 24/49 bilateral 23/49 recurrent 39/49 direct 10/49 indirect Age mean (SD) 61.3 (43.77) years 49 male/0 female	Duration of operation Conversions Intraoperative complications Postoperative complications Length of hospital stay Return to work Hernia recurrence

102

Study	Study details	Intervention/comparator	Intervention population characteristics	Comparator population characteristics	Outcomes
Colak, 2003[77]	Single-centre RCT 134 participants Follow-up = TEP mean (SD) 12.04 (2.84) months, open 11.1 (2.67) months Full text	TEP (*n* = 67) versus open flat mesh (*n* = 67)	67/67 general anaesthetic 21/67 bilateral 7/67 recurrent Direct – unknown Indirect – unknown Age mean (range) 49.4 (21–78) years 57 male/10 female	67/67 general anaesthetic 6/67 bilateral 5/67 recurrent Direct – unknown Indirect – unknown Age mean (range) 51.6 (16–77) years 62 male/5 female	Duration of operation Conversions Intraoperative complications Postoperative complications Length of hospital stay Return to usual activities Hernia recurrence Persisting pain Persisting numbness
Filipi, 1996[50]	Multi-centre RCT 53 participants Follow-up = mean (range) 11 (1–24) months Full text IPD available	TAPP (*n* = 24) versus open flat mesh (*n* = 29)	24/24 general anaesthetic 0/24 bilateral Recurrent – unknown Direct – unknown Indirect – unknown Age (mean) 58 years 24 male/0 female	General, regional or local anaesthetic 0/29 bilateral Recurrent – unknown Direct – unknown Indirect – unknown Age (mean) 57 years 29 male/0 female	Duration of operation Postoperative complications Length of hospital stay Hernia recurrence
Gholghessaei, 2003[78,79]	RCT 30 participants Follow-up = unclear Abstract	TEP (*n* = 13) versus open flat mesh (*n* = 17)	No data reported	No data reported	QoL
Gontarz, 1998[51]	RCT 112 participants Follow-up = median (range) 6 (3–11) months Abstract	TAPP (*n* = 62 hernia repairs) versus open flat mesh (*n* = 73 hernia repairs)	No data reported	No data reported	Postoperative complications Hernia recurrence
Heikkinen (1), 1998[52]	Single-centre RCT 42 participants Follow-up = median 17 months Full text IPD available	TAPP (*n* = 20) versus open flat mesh (*n* = 20)	20/20 general anaesthetic 0/20 bilateral 0/20 recurrent Direct – unknown Indirect – unknown Age mean (SD) 49.2 (11.0) years 19 male/1 female	20/20 local anaesthetic 0/20 bilateral 0/20 recurrent Direct – unknown Indirect – unknown Age mean (SD) 52.7 (13.0) years 20 male/0 female	Duration of operation Conversions Intraoperative complications Postoperative complications Length of hospital stay Return to usual activities Hernia recurrence

Study	Study details	Intervention/comparator	Intervention population characteristics	Comparator population characteristics	Outcomes
Heikkinen (2), 1998[80]	Single-centre RCT 45 participants Follow-up = median 10 months Full text IPD available	TEP (*n* = 22) versus open flat mesh (*n* = 23)	22/22 general anaesthetic 0/22 bilateral 0/22 recurrent Direct – unknown Indirect – unknown Age median (range) 41.55 (11.90) years 22 male/0 female	2/23 general anaesthetic 9/23 regional anaesthetic 12/23 local anaesthetic 0/23 bilateral 0/23 recurrent Direct – unknown Indirect – unknown Age median (range) 43.61 (12.30) years 23 male/0 female	Duration of operation Conversions Intraoperative complications Postoperative complications Length of hospital stay Return to normal activities Persisting pain Persisting numbness Hernia recurrence
Heikkinen, 1997[53]	Single-centre RCT 38 participants Follow-up = median 10 months Full text IPD available	TAPP (*n* = 20) versus open flat mesh (*n* = 18)	20/20 general anaesthetic 2/20 bilateral 0/20 recurrent Direct – unknown Indirect – unknown Age median (range) 46.50 (13.13) years 19 male/1 female	18/18 general anaesthetic 0/18 bilateral 0/18 recurrent Direct – unknown Indirect – unknown Age median (range) 48.94 (13.89) years 17 male/1 female	Duration of operation Conversions Intraoperative complications Postoperative complications Length of hospital stay Return to work Hernia recurrence
Jess, 2000[54]	Single-centre RCT 18 participants Follow-up = 4 weeks Full text	TAPP (*n* = 10) versus open flat mesh (*n* = 8)	10/10 general anaesthetic 0/10 bilateral 4/10 recurrent 6/10 direct 4/10 indirect Age median (range) 61 (25–77) years 10 male/0 female	8/8 general anaesthetic 0/8 bilateral 0/8 recurrent 6/8 direct 2/8 indirect Age median (range) 62 (41–72) years 8 male/0 female	Duration of operation Return to usual activities
Khoury, 1998[93]	Single-centre RCT 292 participants Follow-up = 36 months Full text IPD available	TEP (*n* = 150) versus open plug and mesh (*n* = 142)	150/150 general anaesthetic 19/150 bilateral 13/150 recurrent 41/150 direct 118/150 indirect 6/150 other Age median (range) 48 (19–76) years 140 male/10 female	7/142 general anaesthetic 4/142 bilateral 17/142 recurrent 34/142 direct 103/142 indirect 4/142 other Age median (range) 54 (18–80) years 132 male/10 female	Duration of operation Return to work Postoperative complications Persisting pain Persisting numbness Hernia recurrence

Study	Study details	Intervention/comparator	Intervention population characteristics	Comparator population characteristics	Outcomes
Koninger, 1998[55]	Single-centre RCT 186 participants included (280 in total) Follow-up = median 18 months Full text (German) Additional aggregated data available	TAPP (*n* = 93) versus open flat mesh (*n* = 93) (The third arm of the trial is not relevant to this review)	94/93 general anaesthetic Bilateral – unknown 0/93 recurrent Direct – unknown Indirect – unknown Age median (range) 53 (30–74) years 94 male/0 female	93/93 general anaesthetic Bilateral – unknown 0/93 recurrent Direct – unknown Indirect – unknown Age median (range) 53 (26–74) years 93 male/0 female	Duration of operation Postoperative complications Return to work Persisting pain Hernia recurrence
Lal, 2003[81]	Single-centre RCT 50 participants Follow-up = mean (range) 13 (9–18) months Full text	TEP (*n* = 25) versus open flat mesh (*n* = 25)	24/25 general anaesthetic 0/25 bilateral 0/25 recurrent Direct – unknown Indirect – unknown Age mean (SD) 36.72 (12.08) years 25 male/0 female	3/25 general anaesthetic 0/25 bilateral 0/25 recurrent Direct – unknown Indirect – unknown Age mean (SD) 37.8 (12.43) years 25 male/0 female	Duration of operation Postoperative complications Length of hospital stay Return to usual activities Return to work Hernia recurrence
Laporte, 1997[69]	Multi-centre RCT 402 participants Follow-up = 1 month Full text (Spanish)	TAPP (*n* = 209) versus open preperitoneal mesh (*n* = 183)	General anaesthetic – unknown 54/209 bilateral 49/209 recurrent 128/209 direct 77/209 indirect Age mean (SD) 52 (14) years 195 male/14 female	General anaesthetic – unknown 35/183 bilateral 37/183 recurrent 94/183 direct 85/183 indirect Age mean (SD) 54 (15) years 168 male/15 female	Duration of operation Return to usual activities
Mahon, 2001[56,57]	Single-centre RCT 90 participants Follow-up = unclear Abstract	TAPP (*n* = 45) versus open flat mesh (*n* = 45)	No data reported	No data reported	Duration of operation Length of hospital stay Return to usual activities Return to work QoL
Merello, 1997[82]	Single-centre RCT 120 participants Follow-up = 'short' Abstract IPD available	TEP (*n* = 60) versus open flat mesh (*n* = 60)	60/60 general anaesthetic 0/60 bilateral 0/60 recurrent Direct – unknown Indirect – unknown Age mean (SD) 52.08 (12.58) years 60 male/0 female	60/60 general anaesthetic 0/60 bilateral 0/60 recurrent Direct – unknown Indirect – unknown Age mean (SD) 52.70 (12.23) years 60 male/0 female	Duration of operation Conversions Intraoperative complications Postoperative complications Length of hospital stay Return to usual activities Persisting pain Persisting numbness Hernia recurrence

Study	Study details	Intervention/comparator	Intervention population characteristics	Comparator population characteristics	Outcomes
MRC multicentre 1999[96–103]	Multi-centre RCT 928 participants Follow-up = 60 months Full text IPD available	Mixed laparoscopic (n = 468) versus mixed open repair (n = 460) (93/468 TAPP, 295/468 TEP; 93% of mixed open repairs were open mesh repairs)	447/468 general anaesthetic 2/468 regional anaesthetic 4/468 local anaesthetic (7 not known) 33/468 bilateral (8 not known) 56/468 recurrent (9 not known) Direct – unknown Indirect – unknown 9/468 other Age mean (SD) 55.3 (16.1) years 441 male/27 female	399/460 general anaesthetic 16/460 regional anaesthetic 30/460 local anaesthetic (15 not known) 37/460 bilateral (10 not known) 42/460 recurrent (12 not known) Direct – unknown Indirect – unknown 4/460 other Age mean (SD) 55.7 (16.8) years 445 male/15 female	Duration of operation Conversions Intraoperative complications Postoperative complications Length of hospital stay Return to usual activities Persisting pain Persisting numbness Hernia recurrence
Paganini, 1998[58]	Multi-centre RCT 108 participants Follow-up = mean 28 months Full text IPD available	TAPP (n = 52) versus open flat mesh (n = 56)	48/52 general anaesthetic 1/52 regional anaesthetic 2/52 local anaesthetic (1 not known) 13/52 bilateral 11/52 recurrent 33/77 direct (hernias) 30/77 indirect (hernias) 14/77 other (hernias) Age mean (SD) 54 (15.3) years 48 male/4 female	10/56 general anaesthetic 10/56 regional anaesthetic 35/56 local anaesthetic (1 not known) 16/56 bilateral (2 not known) 5/56 recurrent 33/72 direct (hernias) 37/72 indirect (hernias) 2/72 other (hernias) Age mean (SD) 55.6 (15.2) years 51 male/5 female	Duration of operation Conversions Intraoperative complications Postoperative complications Postoperative pain Length of hospital stay Return to usual activities Persisting pain Persisting numbness Hernia recurrence
Payne, 1994[59,60]	Single-centre RCT 100 participants Follow-up = median (range) 10 (7–18) months Full text IPD available	TAPP (n = 48) versus open flat mesh (n = 52)	48/48 general anaesthetic 4/48 bilateral 6/48 recurrent Direct – unknown Indirect – unknown Age (mean) 46 years 47 male/1 female	3/52 general anaesthetic 6/52 bilateral 2/52 recurrent Direct – unknown Indirect – unknown Age (mean) 45 years 50 male/2 female	Duration of operation Conversions Length of hospital stay Complications Time to return to work Persisting numbness Hernia recurrence

105

Study	Study details	Intervention/comparator	Intervention population characteristics	Comparator population characteristics	Outcomes
Payne, 1996[83]	RCT 100 participants Follow-up = median (range) 20 (4–40) months Abstract IPD available	TEP (*n* = 51) versus open flat mesh (*n* = 49)	Anaesthetic – unknown 9/51 bilateral 4/51 recurrent Direct – unknown Indirect – unknown Age mean (SD) 46.4 (13.6) years Sex – unknown	Anaesthetic – unknown 6/49 bilateral 1/49 recurrent Direct – unknown Indirect – unknown Age mean (SD) 46.5 (14.9) years Sex – unknown	Duration of operation Length of hospital stay Complications Time to return to work Hernia recurrence
Picchio, 1999[61]	Single-centre RCT 105 participants Follow-up = 4 weeks Full text	TAPP (*n* = 52) versus open flat mesh (*n* = 52)	52/52 general anaesthetic Bilateral – unknown 0/52 recurrent 40/52 direct 12/52 indirect Age mean (SD) 57.5 (11.0) years 37 male/15 female	52/52 general anaesthetic Bilateral – unknown 0/52 recurrent 37/52 direct 15/52 indirect Age mean (SD) 55.2 (12.4) years 40 male/12 female	Duration of operation Conversions Intraoperative complications Postoperative complications Length of hospital stay
Ramon, 1998[88]	RCT 59 participants Follow-up = 30 days Abstract	TEP (*n* = 31) versus open preperitoneal mesh (*n* = 28)	No data reported	No data reported	Return to work
Sarli, 1997[62]	Single-centre RCT 108 participants Follow-up = unclear Full text (Italian) Additional aggregated data available	TAPP (*n* = 52) versus open flat mesh (*n* = 56)	52/52 general anaesthetic Bilateral – unknown Recurrent – unknown Direct – unknown Indirect – unknown Age mean (range) 46.3 (7–88) years 42 male/10 female	Local or regional anaesthetic Bilateral – unknown Recurrent – unknown Direct – unknown Indirect – unknown Age mean (range) 45.3 (22–83) years 45 male/11 female	Duration of operation Postoperative complications Length of hospital stay Return to normal activities Persisting pain Persisting numbness
Sarli, 2001[63]	Single-centre RCT 43 participants Follow-up = 36 months Full text	TAPP (*n* = 20) versus open flat mesh (*n* = 23)	20/20 general anaesthetic 20/20 bilateral 0/20 recurrent 11/40 direct (hernias) 25/40 indirect (hernias) 3/40 other (hernias) Age mean (SD) 48.7 (14.8) years 20 male/0 female	8/23 general anaesthetic 23/23 bilateral 0/23 recurrent 15/46 direct (hernias) 29/46 indirect (hernias) 2/46 other (hernias) Age mean (SD) 49.4 (15.1) years 23 male/0 female	Duration of operation Conversions Intraoperative complications Postoperative complications Length of hospital stay Return to work Hernia recurrence

Study	Study details	Intervention/comparator	Intervention population characteristics	Comparator population characteristics	Outcomes
Schrenk, 1996[109,110] (TAPP versus TEP only)	Single-centre RCT; 52 participants included (86 in total); Follow-up = 3 months; Full text; Additional aggregated data available	TAPP (n = 28) versus TEP (n = 24)	TAPP; 28/28 general anaesthetic; 0/28 bilateral; 0/28 recurrent; 9/28 direct; 19/28 indirect; Age mean (SD) 39.1 (14.3) years; 24 male/4 female	TEP; 24/24 general anaesthetic; 0/24 bilateral; 0/24 recurrent; 6/24 direct; 18/24 indirect; Age mean (SD) 42.3 (11.9) years; 22 male/2 female	Duration of operation; Conversions; Intraoperative complications; Postoperative complications; Length of hospital stay; Return to work; Hernia recurrence
SCUR, 1999[70,71]	Multi-centre RCT; 406 participants included (613 in total); Follow-up = 12 months; Full text; IPD available	TAPP (n = 207) versus preperitoneal mesh (n = 200) (The third arm of the trial is not relevant to this review)	206/207 general anaesthetic; 1/207 regional anaesthetic; 0/207 bilateral; 23/207 recurrent; Direct – unknown; Indirect – unknown; Age mean (SD) 55.93 (9.68) years; 207 male/0 female	49/200 general anaesthetic; 150/200 regional anaesthetic; (1 not known); 0/200 bilateral; 18/200 recurrent; Direct – unknown; Indirect – unknown; Age mean (SD) 56.83 (9.37) years; (n = 199); 200 male/0 female	Duration of operation; Conversions; Intraoperative complications; Postoperative complications; Length of hospital stay; Return to work; Persisting pain; Persisting numbness; Hernia recurrence
Simmermacher, 2000[89]	RCT; 162 participants; Follow-up = unclear; Full text	TEP (n = 80) versus open preperitoneal mesh (n = 82)	80/80 general anaesthetic; 0/80 bilateral; 0/80 recurrent; 50/80 direct; 30/80 indirect; Age – unknown; 80 male/0 female	82/82 general anaesthetic; 0/82 bilateral; 0/82 recurrent; 65/82 direct; 17/82 indirect; Age – unknown; 82 male/0 female	Duration of operation; Conversions; Intraoperative complications; Postoperative complications
Snyder, 1998[108]	Single-centre RCT; 200 participants; Follow-up = median 1 year; Full text	Mixed laparoscopic (n = 100) versus open flat mesh (n = 100)	100/100 general anaesthetic; 23/100 bilateral; Recurrent – unknown; Direct – unknown; Indirect – unknown; Age – unknown; Sex – unknown	'Generally' general anaesthetic; 16/100 bilateral; Recurrent – unknown; Direct – unknown; Indirect – unknown; Age – unknown; Sex – unknown	Postoperative pain; Return to usual activities; Hernia recurrence

continued

Study	Study details	Intervention/comparator	Intervention population characteristics	Comparator population characteristics	Outcomes
Suter, 2002[90–92]	Single-centre RCT 39 participants Follow-up = unclear Full text	TEP (*n* = 19) versus open preperitoneal mesh (*n* = 20)	19/19 general anaesthetic 19/19 bilateral Recurrent – unknown Direct – unknown Indirect – unknown Age mean (range) 63 (36–82) years 18 male/1 female	20/20 general anaesthetic 20/20 bilateral Recurrent – unknown Direct – unknown Indirect – unknown Age mean (range) 57 (36–91) years 20 male/0 female	Duration of operation Length of hospital stay Return to usual activities Hernia recurrence
Vatansev, 2002[94]	Single-centre RCT 65 participants Follow-up = 1 week Full text	TEP (*n* = 20) versus open flat mesh (*n* = 24) versus open preperitoneal mesh (*n* = 21)	20/20 general anaesthetic 0/20 bilateral 0/20 recurrent 6/20 direct 13/20 indirect 1/20 other Age mean (SD) 54.6 (12.8) years 18 male/2 female	*Open flat mesh* 24/24 general anaesthetic 0/24 bilateral 0/24 recurrent 5/24 direct 17/24 indirect 2/24 other Age mean (SD) 53.2 (12.6) years 22 male/2 female *Open preperitoneal mesh* 21/21 general anaesthetic 0/21 bilateral 0/21 recurrent 4/21 direct 16/21 indirect 1/21 other Age mean (SD) 56.7 (15.3) years 18 male/3 female	Duration of operation
Wellwood, 1998[64–66]	Multi-centre RCT 400 participants Follow-up = 60 months Full text IPD available	TAPP (*n* = 201) versus open flat mesh (*n* = 202)	201/201 general anaesthetic 23/201 bilateral 20/201 recurrent Direct – unknown Indirect – unknown Age mean (SD) 52.11 (15.76) years 193 male/8 female	202/202 local anaesthetic 24/202 bilateral 25/202 recurrent Direct – unknown Indirect – unknown Age mean (SD) 49.26 (16.02) years 190 male/12 female	Duration of operation Conversions Intraoperative complications Postoperative complications Length of hospital stay Return to usual activities Persistent pain Persistent numbness Hernia recurrence

Study	Study details	Intervention/comparator	Intervention population characteristics	Comparator population characteristics	Outcomes
Zieren, 1998[72-75]	Single-centre RCT 160 participants included (240 in total) Follow-up = mean (SD) 25 (7) months Full text (German) Additional aggregated data available	TAPP (*n* = 80) versus open plug and mesh (*n* = 80) (The third arm of the trial is not relevant to this review)	80/80 general anaesthetic Bilateral – unknown Recurrent – 0/80 Direct – 28/80 Indirect – 52/80 Age mean (SD) 43 (12) years 72 male/8 female	9/80 general anaesthetic Bilateral – unknown Recurrent – 0/80 Direct – 24/80 Indirect – 56/80 Age mean (SD) 47 (14) years 74 male/6 female	Duration of operation Intraoperative complications Postoperative pain Postoperative complications Length of hospital stay Limitation of daily activities Persisting pain Persisting numbness Hernia recurrence

Appendix 7(1)

Results of meta-analyses:
laparoscopic TAPP versus open mesh repair

Comparison: 01 TAPP versus Open Mesh
Outcome: 01 Duration of operation (minutes)

Study	Treatment n	Mean (SD)	Control n	Mean (SD)	WMD (95% CI fixed)	Weight %	WMD (95% CI fixed)
01 TAPP versus Flat Mesh							
Filipi, 1996	24	109.00 (23.79)	29	87.00 (17.27)		1.2	22.00 (10.60 to 33.40)
Heikkinen (1), 1998	20	73.5 (26.93)	20	65.05 (11.55)		0.9	8.60 (−4.24 to 21.44)
Heikkinen, 1997	20	78.90 (25.65)	18	48.00 (17.20)		0.8	30.90 (17.13 to 44.67)
Koninger, 1998	94	52.00 (23.78)	93	48.00 (17.27)		4.4	4.00 (−1.95 to 9.95)
Paganini, 1998	52	73.75 (28.37)	56	55.63 (31.97)		1.2	18.12 (6.74 to 29.50)
Payne, 1994	51	73.10 (20.12)	49	59.86 (15.39)		3.1	13.24 (6.24 to 20.24)
Picchio, 1999	52	49.60 (5.40)	52	33.90 (6.20)		30.9	15.70 (13.47 to 17.93)
Sarli, 1997	52	73.00 (15.00)	56	59.00 (11.00)		6.2	14.00 (9.01 to 18.99)
Sarli, 2001	20	95.00 (32.30)	21	99.00 (28.30)		0.4	−4.00 (−22.63 to 14.63)
Wellwood, 1998	201	46.42 (16.92)	201	46.86 (15.67)		15.2	−0.44 (−3.63 to 2.75)
Subtotal (95% CI)	586		595			64.4	10.93 (9.38 to 12.48)
Test for heterogeneity $\chi^2 = 89.27$, df = 9, $p < 0.00001$							
Test for overall effect $z = 13.83$, $p < 0.00001$							
02 TAPP versus Preperitoneal Mesh							
Aitola, 1998	27	46.26 (15.78)	29	38.48 (12.126)		2.8	7.78 (0.36 to 15.20)
Beets, 1999	42	79.38 (31.67)	37	55.70 (16.468)		1.3	23.68 (12.73 too 34.63)
Laporte, 1997	209	58.00 (25.00)	183	57.00 (23.00)		6.8	1.00 (−3.75 to 5.75)
SCUR, 1999	07	65.10 (25.47)	199	38.01 (14.09)		9.7	27.09 (23.11 to 31.07)
Subtotal (95% CI)	485		448			20.7	15.62 (12.89 to 18.36)
Test for heterogeneity $\chi^2 = 74.56$, df = 3, $p < 0.0001$							
Test for overall effect $z = 11.20$, $p < 0.0001$							
03 TAPP versus Plug and Mesh							
Zieren, 1998	80	61.00 (12.00)	80	36.00 (14.00)		9.5	25.00 (0.96 to 29.04)
Subtotal (95% CI)	80		80			9.5	25.00 (20.96 to 29.04)
Test for heterogeneity $\chi^2 = 0.00$, df = 0, $p < 1$							
Test for overall effect $z = 12.13$, $p < 0.00001$							
04 TAPP versus Mixed Mesh							
MRC multicentre 1999	101	54.60 (23.42)	98	41.92 (13.96)		5.4	12.68 (7.34 to 18.02)
Subtotal (95% CI)	101					5.4	12.68 (7.34 to 18.02)
Test for heterogeneity $\chi^2 = 0.0$, df = 0							
Test for overall effect $z = 4.66$, $p < 0.00001$							
Total (95% CI)	1252		1221			100.0	13.33 (12.08 to 14.57)
Test for heterogeneity $\chi^2 = 207.86$, df = 15, $p < 0.00001$							
Test for overall effect $z = 21.01$, $p < 0.00001$							

```
        −100     −50      0      50     100
              Favours treatment   Favours control
```

Comparison: 01 TAPP versus Open Mesh
Outcome: 02 "Opposite" method initiated

Study	Treatment n/N	Control n/N	RR (95% CI fixed)	Weight %	RR (95% CI fixed)
01 TAPP versus Flat Mesh					
Gontarz, 1998	3/62	0/73		18.2	8.22 (0.43 to 156.17)
x Heikkinen, 1997	0/20	0/18		0.0	Not estimable
x Paganini, 1998	0/52	0/56		0.0	No estimaable
x Payne, 1994	0/51	0/49		0.0	Not estimaable
Subtotal (95% CI)	3/185	0/196		18.2	8.22 (0.43 to 156.17)
Test for heterogeneity $\chi^2 = 0.0$, df = 0					
Test for overall effect z = 1, p = 0.16					
02 TAPP versus Preperitoneal Mesh					
Aitola, 1998	3/29	0/31		19.1	7.47 (0.40 to 138.59)
Beets, 1999	1/42	0/37		21.0	2.65 (0.1 to 63.17)
Subtotal (95% CI)	4/71	0/68		40.1	4.95 (0.61 to 40.33)
Test for heterogeneity $\chi^2 = 0.22$, df = 1, p < 0.64					
Test for overall effect z = 1.49, p = 0.14					
03 TAPP versus Plug and Mesh					
x Zieren, 1998	0/80	0/80		0.0	Not estimable
Subtotal (95% CI)	0/80	0/80		0.0	Not estimable
Test for heterogeneity $\chi^2 = 0.0$, df = 0					
Test for overall effect z = 0.0, p = 1					
04 TAPP versus Mixed Mesh					
MRC multicentre, 1999	8/104	1/93		41.7	7.15 (0.91 to 56.13)
Subtotal (95% CI)	8/104	1/93		41.7	7.15 (0.91 to 56.13)
Test for heterogeneity $\chi^2 = 0.0$, df = 0					
Test for overall effect z = 1.87, p = 0.06					
Total (95% CI)	15/440	1/437		100.0	6.46 (1.74 to 24.02)
Test for heterogeneity $\chi^2 = 0.35$, df = 3, p = 0.95					
Test for overall effect z = 2.79, p = 0.005					

0.001 0.01 0.1 1 10 100 1000
Favours treatment   Favours control

Comparison: 01 TAPP versus Open Mesh
Outcome: 03 Conversion

Study	Treatment n/N	Control n/N	RR (95% CI fixed)	Weight %	RR (95% CI fixed)
01 TAPP versus Flat Mesh					
Gontarz, 1998	3/62	0/73		13.2	8.22 (0.43 to 156.17)
x Heikkinen (1), 1998	0/20	0/20		0.0	Not estimable
x Heikkinen, 1997	0/20	0/18		0.0	Not estimable
x Koninger, 1998	0/94	0/93		0.0	Not estimable
x Paganini, 1998	0/52	0/56		0.0	Not estimable
Payne, 1994	0/51	0/49		14.7	4.81 (0.24 to 97.68)
Picchio, 1999	1/53	0/52		14.5	2.94 (0.12 to 70.67)
x Sarli, 1997	0/52	0/56		0.0	Not estimable
x Sarli, 2001	0/23	0/23		0.0	Not estimable
Wellwood, 1998	1/200	0/200		14.4	3.00 (0.12 to 73.21)
Subtotal (95% CI)	7/627	0/640		56.8	4.67 (1.03 to 21.19)
Test for heterogeneity $\chi^2 = 0.30$, df = 0, p = 0.96					
Test for overall effect z = 2.00, p = 0.05					
02 TAPP versus Preperitoneal Mesh					
Aitola, 1998	1/29	0/31		13.9	3.20 (0.14 to 75.55)
x Laporte, 1997	0/209	0/163		0.0	Not estimable
SCUR, 1999	3/207	0/199		14.7	6.73 (0.35 to 129.94)
Subtotal (95% CI)	4/445	0/413		28.6	5.01 (0.59 to 42.84)
Test for heterogeneity $\chi^2 = 0.12$, df = 1, p = 0.73					
Test for overall effect z = 1, p = 0.14					
03 TAPP versus Plug and Mesh					
x Zieren, 1998	0/80	0/80		0.0	Not estimable
Subtotal (95% CI)	0/80	0/80		0.0	Not estimable
Test for heterogeneity $\chi^2 = 0.0$, df = 0					
Test for overall effect z = 0.0, p = 1					
04 TAPP versus Mixed Mesh					
MRC multicentre, 1999	6/97	0/93		14.7	12.47 (0.71 to 218.29)
Subtotal (95% CI)	6/97	0/93		14.7	12.47 (0.71 to 218.29)
Test for heterogeneity $\chi^2 = 0.0$, df = 0					
Test for overall effect z = 1, p = 0.08					
Total (95% CI)	17/1249	0/1226		100.0	5.91 (1.91 to 18.27)
Test for heterogeneity $\chi^2 = 0.84$, df = 6, p = 0.99					
Test for overall effect z = 3.09, p = 0.002					

0.001 0.01 0.1 1 10 100 1000
Favours treatment   Favours control

Comparison: 01 TAPP versus Open Mesh
Outcome: 04 Haematoma

Study	Treatment n/N	Control n/N	RR (95% CI fixed)	Weight %	RR (95% CI fixed)
01 TAPP versus Flat Mesh					
Heikkinen (1), 1988	2/20	3/20		2.0	0.67 (0.12 to 3.57)
Heikkinen, 1997	2/20	10/18		6.9	0.18 (0.05 to 0.71)
Paganini, 1998	4/52	8/56		5.1	0.54 (0.17 to 1.68)
Picchio, 1999	1/52	2/52		1.3	0.50 (0.05 to 5.35)
Sarli, 1997	6/52	3/56		1.9	2.15 (0.57 to 8.17)
Sarli, 2001	1/20	4/23		2.4	0.29 (0.03 to 2.37)
Wellwood, 1998	72/200	96/200		63.0	0.75 (0.59 to 0.95)
Subtotal (95% CI)	88/416	126/425		82.6	0.70 (0.56 to 0.87)`
Test for heterogeneity $\chi^2 = 7.75$, df = 6, $p = 0.26$					
Test for overall effect $z = -3.16$, $p = 0.002$					
02 TAPP versus Preperitoneal Mesh					
Aitola, 1998	1/29	2/31		1.3	0.53 (0.05 to 5.58)
Beets, 1999	10/42	5/37		3.5	1.76 (0.66 to 4.69)
SCUR	5/207	6/199		4.0	0.80 (0.25 to 2.58)
Subtotal (95% CI)	16/278	13/267		8.8	1.14 (0.57 to 2.30)
Test for heterogeneity $\chi^2 = 1.51$, df = 2, $p = 0.47$					
Test for overall effect $z = 0.38$, $p = 0.7$					
03 TAPP versus Plug and Mesh					
Zieren, 1998	6/80	5/80		3.3	1.20 (0.38 to 3.77)
Subtotal (95% CI)	6/80	5/80		3.3	1.20 (0.38 to 3.77)
Test for heterogeneity $\chi^2 = 0.0$, df = 0					
Test for overall effect $z = 0.31$, $p = 0.8$					
04 TAPP versus Mixed Mesh					
MRC multicentre, 1999	7/67	8/64		5.4	0.84 (0.32 to 2.17)
Subtotal (95% CI)	7/67	8/64		5.4	0.84 (0.32 to 2.17)
Test for heterogeneity $\chi^2 = 0.0$, df = 0					
Test for overall effect $z = -0.37$, $p = 0.7$					
Total (95% CI)	117/841	152/836		100.0	0.76 (0.62 to 0.94)
Test for heterogeneity $\chi^2 = 11.44$, df = 11, $p = 0.41$					
Test for overall effect $z = -2.60$, $p = 0.009$					

0.001   0.01   0.1   1   10   100   1000

Favours treatment   Favours control

Comparison: 01 TAPP versus Open Mesh
Outcome: 05 Seroma

Study	Treatment n/N	Control n/N	RR (95% CI fixed)	Weight %	RR (95% CI fixed)
01 TAPP versus Flat Mesh					
Heikkinen (1), 1998	1/20	0/20		1.9	3.00 (0.13 to 69.52)
Heikkinen, 1997	1/20	0/18		2.0	2.71 (0.12 to 62.71)
Paganini, 1998	4/52	0/56		1.8	9.68 (0.53 to 175.52)
Picchio, 1999	3/52	0/52		1.9	7.00 (0.37 to 132.24)
Sarli, 1997	3/52	0/56		1.8	7.53 (0.40 to 142.34)
Sarli, 2001	2/20	0/23		1.7	5.71 (0.29 to 112.43)
Wellwood, 1998	8/200	6/200		22.5	1.33 (0.47 to 3.77)
Subtotal (95% CI)	22/416	6/425		33.6	2.83 (1.34 to 5.98)
Test for heterogeneity $\chi^2 = 3.71$, df = 6, $p = 0.72$					
Test for overall effect $z = 2.73$, $p = 0.006$					
02 TAPP versus Preperitoneal Mesh					
Aitola, 1998	2/29	0/31		1.8	5.33 (0.27 to 106.62)
Beets, 1999	15/38	7/37		26.6	2.09 (0.96 to 4.53)
SCUR, 1999	1/207	3/199		11.5	0.32 (0.03 to 3.06)
Subtotal (95% CI)	18/274	10/257		39.9	1.73 (0.88 to 3.40)
Test for heterogeneity $\chi^2 = 2.92$, df = 2, $p = 0.23$					
Test for overall effect $z = 1.58$, $p = 0.11$					
03 TAPP versus Plug and Mesh					
Zieren, 1998	4/80	2/80		7.5	2.00 (0.38 to 10.61)
Subtotal (95% CI)	4/80	2/80		7.5	2.00 (0.38 to 10.61)
Test for heterogeneity $\chi^2 = 0.0$, df = 0					
Test for overall effect $z = 0.81$, $p = 0.4$					
04 TAPP versus Mixed Mesh					
MRC multicentre, 1999	5/66	5/64		19.0	0.97 (0.29 to 3.19)
Subtotal (95% CI)	5/66	5/64		19.0	0.97 (0.29 to 3.19)
Test for heterogeneity $\chi^2 = 0.0$, df = 0					
Test for overall effect $z = -0.05$, $p = 1$					
Total (95% CI)	49/836	23/836		100.0	1.97 (1.27 to 3.07)
Test for heterogeneity $\chi^2 = 8.12$, df = 11, $p = 0.7$					
Test for overall effect $z = 3.02$, $p = 0.003$					

0.001   0.01   0.1   1   10   100   1000

Favours treatment   Favours control

113

Comparison: 01 TAPP versus Open Mesh
Outcome: 06 Wound/superficial infection

Study	Treatment n/N	Control n/N	RR (95% CI fixed)	Weight %	RR (95% CI fixed)
01 TAPP versus Flat Mesh					
x Heikkinen (1), 1998	0/20	0/20		0.0	Not estimable
x Heikkinen, 1997	0/20	0/18		0.0	Not estimable
x Koninger, 1998	0/94	0/90		0.0	Not estimable
Paganini, 1998	4/52	2/56		3.2	2.15 (0.41 to 11.27)
Sarli, 1997	0/52	6/56		10.4	0.08 (0.00 to 1.43)
Sarli, 2001	0/20	3/23		5.4	0.16 (0.01 to 2.98)
Wellwood, 1998	13/200	37/200		61.4	0.35 (0.19 to 0.64)
Subtotal (95% CI)	17/458	48/463		80.4	0.38 (0.22 to 0.63)
Test for heterogeneity $\chi^2 = 5.72$, df = 3, $p = 0.13$					
Test for overall effect $z = -3.71$, $p = 0.0002$					
02 TAPP versus Preperitoneal Mesh					
Aitola, 1998	2/29	0/31		0.8	5.33 (0.27 to 106.62)
Beets, 1999	0/42	4/37		7.9	0.10 (0.01 to 1.77)
SCUR, 1999	1/207	3/199		5.1	0.32 (0.03 to 3.06)
Subtotal (95% CI)	3/278	7/267		13.8	0.48 (0.15 to 1.55)
Test for heterogeneity $\chi^2 = 3.77$, df = 2, $p = 0.15$					
Test for overall effect $z = -1.22$, $p = 0.2$					
03 TAPP versus Plug and Mesh					
Zieren, 1998	0/80	2/80		4.1	0.20 (0.01 to 4.10)
Subtotal (95% CI)	0/80	2/80		4.1	0.20 (0.01 to 4.10)
Test for heterogeneity $\chi^2 = 0.0$, df = 0					
Test for overall effect $z = -1.04$, $p = 0.3$					
04 TAPP versus Mixed Mesh					
MRC multicentre, 1999	2/66	1/64		1.7	1.94 (0.18 to 20.87)
Subtotal (95% CI)	2/66	1/64		1.7	1.94 (0.18 to 20.87)
Test for heterogeneity $\chi^2 = 0.0$, df = 0					
Test for overall effect $z = 0.05$, $p = 0.6$					
Total (95% CI)	22/882	58/874		100.0	0.41 (0.26 to 0.64)
Test for heterogeneity $\chi^2 = 11.38$, df = 8, $p = 0.18$					
Test for overall effect $z = -3.87$, $p = 0.0001$					

0.001 0.01 0.1 1 10 100 1000

Favours treatment   Favours control

Comparison: 01 TAPP versus Open Mesh
Outcome: 07 Mesh/deep infection

Study	Treatment n/N	Control n/N	RR (95% CI fixed)	Weight %	RR (95% CI fixed)
01 TAPP versus Flat Mesh					
Gonterz, 1998	0/62	1/73		100.0	0.39 (0.02 to 9.44)
x Heikkinen (1), 1998	0/20	0/20		0.0	Not estimable
x Heikkinen, 1997	0/20	0/18		0.0	Not estimable
x Panganini, 1998	0/52	0/56		0.0	Not estimable
x Saril, 1997	0/52	0/56		0.0	Not estimable
x Wellwood, 1998	0/201	0/202		0.0	Not estimable
Subtotal (95% CI)	0/407	1/425		100.0	0.39 (0.02 to 9.44)
Test for heterogeneity $\chi^2 = 0.0$, df = 0					
Test for overall effect $z = -0.58$, $p = 0.6$					
02 TAPP versus Preperitoneal Mesh					
x Aitola, 1998	0/29	0/31		0.0	Not estimable
x Beets, 1999	0/42	0/37		0.0	Not estimable
x SCUR, 1999	0/207	0/199		0.0	Not estimable
Subtotal (95% CI)	0/278	0/267		0.0	Not estimable
Test for heterogeneity $\chi^2 = 0.0$, df = 0					
Test for overall effect $z = 0.0$, $p = 1$					
03 TAPP versus Plug and Mesh					
x Zieren, 1998	0/80	0/80		0.0	Not estimable
Subtotal (95% CI)	0/80	0/80		0.0	Not estimable
Test for heterogeneity $\chi^2 = 0.0$, df = 0					
Test for overall effect $z = 0.0$, $p = 1$					
04 TAPP versus Mixed Mesh					
x MRC multicentre, 1999	0/66	0/64		0.0	Not estimable
Subtotal (95% CI)	0/66	0/64		0.0	Not estimable
Test for heterogeneity $\chi^2 = 0.0$, df = 0					
Test for overall effect $z = 0.1$, $p = 1$					
Total (95% CI)	0/831	1/836		100.0	0.39 (0.02 to 9.44)
Test for heterogeneity $\chi^2 = 0.0$, df = 0					
Test for overall effect $z = -0.58$, $p = 0.6$					

0.001 0.01 0.1 1 10 100 1000

Favours treatment   Favours control

Comparison: 01 TAPP versus Open Mesh
Outcome: 08 Vascular injury

Study	Treatment n/N	Control n/N	RR (95% CI fixed)	Weight %	RR (95% CI fixed)
01 TAPP versus Flat Mesh					
x Heikkinen (1), 1998	0/20	0/20		0.0	Not estimable
x Heikkinen, 1997	0/20	0/18		0.0	Not estimable
x Paganini, 1998	0/52	0/56		0.0	Not estimable
x Saril, 1997	0/52	0/56		0.0	Not estimable
x Wellwood, 1998	0/201	0/201		0.0	Not estimable
Subtotal (95% CI)	0/345	0/351		0.0	Not estimable
Test for heterogeneity $\chi^2 = 0.0$, df $= 0$				0.0	Not estimable
Test for overall effect $z = 0.00$, $p = 1$					
02 TAPP versus Preperitoneal Mesh					
x Aitola, 1998	0/29	0/31		0.0	Not estimable
x SCUR, 1999	0/207	0/199		0.0	Not estimable
Subtotal (95% CI)	0/236	0/230		0.0	Not estimable
Test for heterogeneity $\chi^2 = 0.0$, df $= 0$					
Test for overall effect $z = 0.0$, $p = 1$					
03 TAPP versus Plug and Mesh					
x Zieren, 1998	0/80	0/80		0.0	Not estimable
Subtotal (95% CI)	0/80	0/80		0.0	Not estimable
Test for heterogeneity $\chi^2 = 0.0$, df $= 0$					
Test for overall effect $z = 0.0$, $p = 1$					
04 TAPP versus Mixed Mesh					
MRC multicentre, 1999	1/103	0/97		100.0	2.83 (0.12 to 68.58)
Subtotal (95% CI)	1/103	0/97		100.0	2.83 (0.12 to 68.58)
Test for heterogeneity $\chi^2 = 0.0$, df $= 0$					
Test for overall effect $z = 0.64$, $p = 0.5$					
Total (95% CI)	1/764	0/758		100.0	2.83 (0.12 to 68.58)
Test for heterogeneity $\chi^2 = 0.0$, df $= 0$					
Test for overall effect $z = 0.64$, $p = 0.5$					

0.001   0.01   0.1   1   10   100   1000

Favours treatment   Favours control

Comparison: 01 TAPP versus Open Mesh
Outcome: 09 Visceral injury

Study	Treatment n/N	Control n/N	RR (95% CI fixed)	Weight %	RR (95% CI fixed)
01 TAPP versus Flat Mesh					
x Heikkinen (1), 1998	0/20	0/20		0.0	Not estimable
x Heikkinen, 1997	0/20	0/18		0.0	Not estimable
x Paganini, 1998	0/52	0/56		0.0	Not estimable
x Saril, 1997	0/52	0/56		0.0	Not estimable
x Wellwood, 1998	0/201	0/201		0.0	Not estimable
Subtotal (95% CI)	0/345	0/351		0.0	Not estimable
Test for heterogeneity $\chi^2 = 0.0$, df $= 0$				0.0	Not estimable
Test for overall effect $z = 0.00$, $p = 1$					
02 TAPP versus Preperitoneal Mesh					
Aitola, 1998	1/29	0/31		32.1	3.20 (0.14 to 75.55)
SCUR, 1999	2/207	0/199		33.8	4.81 (0.23 to 99.53)
Subtotal (95% CI)	3/236	0/230		65.9	4.02 (0.45 to 35.76)
Test for heterogeneity $\chi^2 = 0.03$, df $= 0.85$					
Test for overall effect $z = 1.25$, $p = 0.2$					
03 TAPP versus Plug and Mesh					
x Zieren, 1998	0/80	0/80		0.0	Not estimable
Subtotal (95% CI)	0/80	0/80		0.0	Not estimable
Test for heterogeneity $\chi^2 = 0.0$, df $= 0$					
Test for overall effect $z = 0.0$, $p = 1$					
04 TAPP versus Mixed Mesh					
MRC multicentre, 1999	2/103	0/97		34.1	4.71 (0.23 to 96.92)
Subtotal (95% CI)	2/103	0/97		34.1	4.71 (0.23 to 96.92)
Test for heterogeneity $\chi^2 = 0.0$, df $= 0$					
Test for overall effect $z = 1.00$, $p = 0.3$					
Total (95% CI)	5/764	0/758		100.0	4.26 (0.73 to 35.02)
Test for heterogeneity $\chi^2 = 0.04$, df $= 2$, $p = 0.98$					
Test for overall effect $z = 1.64$, $p = 0.11$					

0.001   0.01   0.1   1   10   100   1000

Favours treatment   Favours control

115

Comparison: 01 TAPP versus Open Mesh
Outcome: 10 Port site hernia

Study	Treatment n/N	Control n/N	RR (95% CI fixed)	Weight %	RR (95% CI fixed)
01 TAPP versus Flat Mesh					
x Heikkinen (1), 1998	0/20	0/20		0.0	Not estimable
x Heikkinen, 1997	0/20	0/18		0.0	Not estimable
x Paganini, 1998	0/52	0/56		0.0	Not estimable
x Sarli, 1997	0/52	0/56		0.0	Not estimable
Wellwood, 1998	1/200	0/200		50.2	3.00 (0.12 to 73.21)
Subtotal (95% CI)	1/344	0/350		50.2	3.00 (0.12 to 73.21)
Test for heterogeneity $\chi^2 = 0.0$, df = 0					
Test for overall effect z = 0.67, p = 0.5					
02 TAPP versus Preperitoneal Mesh					
x Beets, 1998	0/42	0/37		0.0	Not estimable
x SCUR, 1999	0/27	0/199		0.0	Not estimable
Subtotal (95% CI)	0/249	0/236		0.0	Not estimable
Test for heterogeneity $\chi^2 = 0.0$, df = 0					
Test for overall effect z = 0.00, p = 1					
03 TAPP versus Plug and Mesh					
x Zieren, 1998	0/80	0/80		0.0	Not estimable
Subtotal (95% CI)	0/80	0/80		0.0	Not estimable
Test for heterogeneity $\chi^2 = 0.0$, df = 0					
Test for overall effect z = 0.0, p = 1					
04 TAPP versus Mixed Mesh					
MRC multicentre, 1999	2/75	0/76		49.8	5.07 (0.25 to 103.97)
Subtotal (95% CI)	2/75	0/76		49.8	5.07 (0.25 to 103.97)
Test for heterogeneity $\chi^2 = 0.0$, df = 0					
Test for overall effect z = 1.05, p = 0.3					
Total (95% CI)	3/748	0/742		100.0	4.03 (0.45 to 37.70)
Test for heterogeneity $\chi^2 = 0.05$, df = 2, p = 0.81					
Test for overall effect z = 1.25, p = 0.2					

0.001 0.01 0.1 1 10 100 1000

Favours treatment   Favours control

Comparison: 01 TAPP versus Open Mesh
Outcome: 11 Length of stay (days)

Study	Treatment n	Mean (SD)	Control n	Mean (SD)	WMD (95% CI fixed)	Weight %	WMD (95% CI fixed)
01 TAPP versus Flat Mesh							
Filipi, 1996	24	1.70 (1.16)	29	1.80 (1.29)		0.7	−0.10 (−0.76 to 0.56)
Heikkinen (1), 1998	20	1.07 (2.09)	20	0.23 (0.27)		0.4	0.84 (−0.08 to 1.76)
Heikkinen, 1997	20	1.85 (0.65)	18	1.72 (0.55)		2.2	0.13 (−0.25 to 0.51)
Paganini, 1998	52	2.90 (1.30)	56	3.01 (1.70)		1.0	−0.11 (−0.68 to 0.46)
Payne, 1994	51	0.14 (0.49)	49	0.08 (0.45)		9.6	0.06 (−0.12 to 0.24)
Picchio, 1999	52	2.30 (0.72)	52	2.20 (0.72)		4.3	0.10 (−0.18 to 0.38)
Sarli, 1997	52	2.40 (1.16)	56	1.90 (1.29)		1.5	0.50 (0.04 to 0.96)
Wellwood, 1998	200	0.14 (0.52)	201	0.04 (0.21)		54.1	0.10 (0.02 to 0.18)
Subtotal (95% CI)	471		481			73.9	0.10 (0.04 to 0.17)
Test for heterogeneity $\chi^2 = 6.42$, df = 7, p = 0.49							
Test for overall effect z = 3.03, p = 0.002							
02 TAPP versus Preperitoneal Mesh							
Aitola, 1998	29	1.62 (2.24)	31	1.32 (0.48)		0.5	0.30 (−0.53 to 1.13)
Beets, 1999	42	1.10 (0.48)	37	1.38 (0.72)		4.4	−0.28 (−0.55 to −0.01)
SCUR, 1999	207	0.92 (0.86)	199	0.50 (0.61)		15.6	0.42 (0.28 to 0.56)
Subtotal (95% CI)	278		267			20.5	0.27 (0.14 to 0.39)
Test for heterogeneity $\chi^2 = 19.665$, df = 2, p = 0.0001							
Test for overall effect z = 4.16, p = 0.00003							
03 TAPP versus Plug and Mesh							
Zieren, 1998	80	3.00 (2.00)	80	2.00 (1.00)		1.4	1.00 (0.51 to 1.49)
Subtotal (95% CI)	80		80			1.4	1.00 (0.51 to 1.49)
Test for heterogeneity $\chi^2 = 0.00$, df = 0							
Test for overall effect z = 4.00, p = 0.00006							
04 TAPP versus Mixed Mesh							
MRC multicentre 1999	70	1.30 (0.95)	68	1.16 (0.70)		4.2	0.14 (−0.14 to 0.42)
Subtotal (95% CI)	70		68			4.2	0.14 (−0.14 to 0.42)
Test for heterogeneity $\chi^2 = 0.0$, df = 0							
Test for overall effect z = 0.99, p = 0.3							
Total (95% CI)	899		898			100.0	0.15 (0.09 to 0.21)
Test for heterogeneity $\chi^2 = 42.91$, df = 12, p < 0.00001							
Test for overall effect z = 5.16, p < 0.00001							

−1 −0.5 0 0.5 1

Favours treatment   Favours control

Comparison: 01 TAPP versus Open Mesh
Outcome: 12 Time to return to usual activities (days)

Study	Treatment n/N	Control n/N	HR (95% CI fixed)	Weight %	HR (95% CI fixed)
01 TAPP versus Flat Mesh					
Heikkinen (1), 1998	20/20	19/19		3.7	0.57 (0.30 to 1.09)
Heikkinen, 1997	17/17	13/13		2.8	0.39 (0.18 to 0.82)
Payne, 1994	51/51	49/49		9.1	0.48 (0.31 to 0.72)
Wellwood, 1998	193/193	189/189		37.3	0.65 (0.53 to 0.79)
Subtotal (95% CI)	281/281	270/270		52.9	0.59 (0.50 to 0.70)
Test for heterogeneity $\chi^2 = 3.02$, df = 3, $p = 0.39$					
Test for overall effect $z = -6.00$, $p < 0.00001$					
02 TAPP versus Preperitoneal Mesh					
Aitola, 1998	21/21	19/19		4.1	0.97 (0.52 to 1.80)
Beets, 1999	16/16	16/16		3.1	0.63 (0.31 to 1.28)
SCUR, 1999	137/137	116/116		25.3	0.67 (0.52 to 0.86)
Subtotal (95% CI)	174/174	151/151		32.5	0.70 (0.56 to 0.87)
Test for heterogeneity $\chi^2 = 1.28$, df = 2, $p = 0.53$					
Test for overall effect $z = -3.25$, $p = 0.001$					
03 TAPP versus Plug and Mesh					
Subtotal (95% CI)	0/0	0/0		0.0	Not estimable
Test for heterogeneity $\chi^2 = 0.0$, df = 0					
Test for overall effect $z = 0.0$, $p = 1$					
04 TAPP versus Mixed Mesh					
MRC multicentre, 1999	75/79	69/70		14.6	0.86 (0.62 to 1.19)
Subtotal (95% CI)	75/79	69/70		14.6	0.86 (0.62 to 1.19)
Test for heterogeneity $\chi^2 = 0.0$, df = 0					
Test for overall effect $z = -0.89$, $p = 0.4$					
Total (95% CI)	530/534	490/491		100.0	0.66 (0.58 to 0.75)
Test for heterogeneity $\chi^2 = 8.63$, df = 7, $p = 0.28$					
Test for overall effect $z = -6.56$, $p < 0.00001$					

0.001 0.01 0.1 1 10 100 1000

Favours treatment   Favours control

n/N refers to the number who have returned to activities within the follow-up period. The remaining few people are censored, i.e. they have not yet returned to activities at the time of follow-up.

Comparison: 01 TAPP versus Open Mesh
Outcome: 13 Persisting numbness

Study	Treatment n/N	Control n/N	RR (95% CI fixed)	Weight %	RR (95% CI fixed)
01 TAPP versus Flat Mesh					
x Paganini, 1998	0/52	0/56		0.0	Not estimable
x Payne, 1994	0/51	0/49		0.0	Not estimable
Sarli, 1997	1/52	1/56		1.1	1.08 (0.07 to 17.78)
Wellwood, 1998	2/201	30/202		35.0	0.07 (0.02 to 0.28)
Subtotal (95% CI)	3/356	31/363		36.1	0.10 (0.03 to 0.32)
Test for heterogeneity $\chi^2 = 3.20$, df = 1, $p = 0.074$					
Test for overall effect $z = -3.89$, $p = 0.00010$					
02 TAPP versus Preperitoneal Mesh					
x Beets, 1999	0/42	0/37		0.0	Not estimable
SCUR, 1999	0/170	6/164		7.7	0.07 (0.00 to 1.31)
Subtotal (95% CI)	0/212	6/201		7.7	0.07 (0.00 to 1.31)
Test for heterogeneity $\chi^2 = 0.0$, df = 0					
Test for overall effect $z = -1.78$, $p = 0.08$					
03 TAPP versus Plug and Mesh					
Zieren, 1998	1/80	1/80		1.2	1.00 (0.06 to 15.71)
Subtotal (95% CI)	1/80	1/80		1.2	1.00 (0.06 to 15.71)
Test for heterogeneity $\chi^2 = 0.0$, df = 0					
Test for overall effect $z = 0.0$, $p = 1$					
04 TAPP versus Mixed Mesh					
MRC multicentre, 1999	19/102	44/89		55.0	0.38 (0.24 to 0.59)
Subtotal (95% CI)	19/102	44/89		55.0	0.38 (0.24 to 0.59)
Test for heterogeneity $\chi^2 = 0.0$, df = 0					
Test for overall effect $z = -4.19$, $p = 0.00003$					
Total (95% CI)	23/750	82/733		100.0	0.26 (0.17 to 0.40)
Test for heterogeneity $\chi^2 = 8.72$, df = 4, $p = 0.068$					
Test for overall effect $z = -6.28$, $p < 0.00001$					

0.001 0.01 0.1 1 10 100 1000

Favours treatment   Favours control

117

Comparison: 01 TAPP versus Open Mesh
Outcome: 14 Persisting pain

Study	Treatment n/N	Control n/N	RR (95% CI fixed)	Weight %	RR (95% CI fixed)
01 TAPP versus Flat Mesh					
Koninger, 1998	15/94	22/90		14.2	0.65 (0.36 to 1.18)
Paganini, 1998	6/52	17/56		10.4	0.38 (0.16 to 0.89)
Sarli, 1997	1/52	0/56		0.3	3.23 (0.13 to 77.49)
Wellwood, 1998	45/184	59/180		37.8	0.75 (0.54 to 1.04)
Subtotal (95% CI)	67/382	98/382		62.7	0.68 (0.52 to 0.89)
Test for heterogeneity $\chi^2 = 3.05$, df = 3, $p = 0.38$					
Test for overall effect $z = -2.84$, $p = 0.005$					
02 TAPP versus Preperitoneal Mesh					
Beets, 1999	4/42	3/37		2.0	1.17 (0.28 to 4.91)
SCUR, 1999	1/176	7/169		4.5	0.14 (0.02 to 1.10)
Subtotal (95% CI)	5/218	10/206		6.5	0.46 (0.16 to 1.32)
Test for heterogeneity $\chi^2 = 2.95$, df = 1, $p = 0.086$					
Test for overall effect $z = -1.45$, $p = 0.15$					
03 TAPP versus Plug and Mesh					
Zieren, 1998	2/80	1/80		0.6	2.00 (0.19 to 21.62)
Subtotal (95% CI)	2/80	1/80		0.6	2.00 (0.19 to 21.62)
Test for heterogeneity $\chi^2 = 0.0$, df = 0					
Test for overall effect $z = 0.57$, $p = 0.6$					
04 TAPP versus Mixed Mesh					
MRC multicentre, 1999	42/107	45/95		30.2	0.83 (0.60 to 1.14)
Subtotal (95% CI)	42/107	45/95		30.2	0.83 (0.60 to 1.14)
Test for heterogeneity $\chi^2 = 0.0$, df = 0					
Test for overall effect $z = -1.16$, $p = 0.2$					
Total (95% CI)	116/787	154/763		100.0	0.72 (0.56 to 0.88)
Test for heterogeneity $\chi^2 = 7.55$, df = 7, $p = 0.37$					
Test for overall effect $z = -3.22$, $p = 0.001$					

0.001　0.01　0.1　1　10　100　1000

Favours treatment　　　Favours control

Comparison: 01 TAPP versus Open Mesh
Outcome: 15 Hernia recurrence

Study	Treatment n/N	Control n/N	RR (95% CI fixed)	Weight %	RR (95% CI fixed)
01 TAPP versus Flat Mesh					
Filipi, 1996	0/24	2/29		9.5	0.24 (0.01 to 4.77)
Gontarz, 1998	2/62	1/73		3.9	2.35 (0.22 to 25.36)
x Heikkinen, 1997	0/20	0/18		0.0	Not estimable
Koninger, 1998	1/94	1/90		4.3	0.96 (0.06 to 15.08)
Mahon, 2000	4/45	0/45		2.1	9.00 (0.50 to 162.44)
Paganini, 1998	2/52	0/56		2.0	5.38 (0.26 to 109.45)
x Payne, 1994	0/51	0/49		0.0	Not estimable
Sarli, 1997	2/52	1/56		4.0	2.15 (0.20 to 23.06)
Sarli, 2001	0/20	1/23		5.9	0.38 (0.02 to 8.86)
Wellwood, 1998	1/200	1/200		4.2	1.00 (0.06 to 15.88)
Subtotal (95% CI)	12/620	7/639		35.9	1.68 (0.73 to 3.88)
Test for heterogeneity $\chi^2 = 4.76$, df = 7, $p = 0.69$					
Test for overall effect $z = 1.22$, $p = 0.2$					
02 TAPP versus Preperitoneal Mesh					
Aitola, 1998	5/28	1/31		4.0	5.54 (0.69 to 44.55)
Beets, 1999	6/42	1/37		4.5	5.29 (0.67 to 41.91)
SCUR, 1999	3/207	13/129		55.6	0.22 (0.06 to 0.77)
Subtotal (95% CI)	14/277	15/267		64.1	0.90 (0.44 to 1.85)
Test for heterogeneity $\chi^2 = 10.63$, df = 2, $p = 0.0049$					
Test for overall effect $z = -0.27$, $p = 0.8$					
03 TAPP versus Plug and Mesh					
Zieren, 1998	0/80	0/80		0.0	Not estimable
Subtotal (95% CI)	0/80	0/80		0.0	Not estimable
Test for heterogeneity $\chi^2 = 0.0$, df = 0					
Test for overall effect $z = 0.0$, $p = 1$					
04 TAPP versus Mixed Mesh					
x MRC multicentre, 1999	0/75	0/76		0.0	Not estimable
Subtotal (95% CI)	0/75	0/76		0.0	Not estimable
Test for heterogeneity $\chi^2 = 0.0$, df = 0					
Test for overall effect $z = 0.0$, $p = 1$					
Total (95% CI)	26/1052	22/1062		100.0	1.18 (0.69 to 2.02)
Test for heterogeneity $\chi^2 = 16.17$, df = 10, $p = 0.095$					
Test for overall effect $z = 0.62$, $p = 0.5$					

0.01　0.1　1　10　100

Favours treatment　　　Favours control

Appendix 7(2)

Results of meta-analyses:
laparoscopic TEP versus open mesh repair

Comparison: 02 TEP versus Open Mesh
Outcome: 01 Duration of operation (minutes)

Study	Treatment n	Mean (SD)	Control n	Mean (SD)	WMD (95% CI fixed)	Weight %	WMD (95% CI fixed)
01 TEP versus Flat Mesh							
Andersson, 2003	87	81.00 (27.00)	81	59.00 (20.00)		5.5	22.00 (14.85 to 29.15)
Colak, 2003	67	49.67 (14.11)	67	56.67 (11.67)		14.6	−7.00 (−11.38 to −2.62)
Heikkinen (2), 1998	22	68.14 (13.80)	23	55.87 (8.96)		6.0	12.27 (5.44 to 19.10)
Payne, 1996	51	65.20 (20.69)	49	56.59 (18.26)		4.8	8.61 (0.97 to 16.25)
Subtotal (95% CI)	227		220			31.0	4.33 (1.31 to 7.34)
Test for heterogeneity $\chi^2 = 55.49$, df = 3, $p < 0.00001$							
Test for overall effect $z = 2.81$, $p < 0.005$							
02 TEP versus Preperitoneal Mesh							
Bostanci, 1998	32	58.00 (23.78)	32	35.00 (17.27)		2.7	23.00 (12.82 to 33.18)
Champault, 1997	51	80.60 (31.30)	49	70.30 (15.70)		3.0	10.30 (0.65 to 19.95)
Subtotal (95% CI)	83		81			5.7	16.31 (9.30 to 23.31)
Test for heterogeneity $\chi^2 = 3.15$, df = 1, $p < 0.076$							
Test for overall effect $z = 4.56$, $p = 0.00001$							
03 TEP versus Plug and Mesh							
Khoury, 1998	138	32.64 (14.32)	119	31.34 (10.47)		30.4	1.30 (−1.74 to 4.34)
Subtotal (95% CI)	138		119			30.4	1.30 (−1.74 to 4.34)
Test for heterogeneity $\chi^2 = 0.0$, df = 0							
Test for overall effect $z = 0.84$, $p = 0.4$							
04 TEP versus Mixed Mesh							
MRC multicentre 1999	332	59.44 (21.86)	330	43.53 (16.19)		32.8	15.91 (12.98 to 18.84)
Subtotal (95% CI)	332		330			32.8	15.91 (12.98 to 18.84)
Test for heterogeneity $\chi^2 = 0.0$, df = 0							
Test for overall effect $z = 10.65$, $p < 0.00001$							
Total (95% CI)	780		750			100.0	7.89 (6.22 to 9.57)
Test for heterogeneity $\chi^2 = 116.40$, df = 7, $p < 0.00001$							
Test for overall effect $z = 9.22$, $p < 0.00001$							

−100 −50 0 50 100

Favours treatment Favours control

Comparison: 02 TEP versus Open Mesh
Outcome: 02 "Opposite" method initiated

Study	Treatment n/N	Control n/N	RR (95% CI fixed)	Weight %	RR (95% CI fixed)
01 TEP versus Flat Mesh					
x Heikkinen (2), 1998	0/22	0/23		0.0	Not estimable
x Merello, 1997	0/60	0/60		0.0	Not estimable
x Payne, 1996	0/51	0/49		0.0	Not estimable
Subtotal (95% CI)	0/133	0/132		0.0	Not estimable
Test for heterogeneity $\chi^2 = 0.0$, df = 0					
Test for overall effect $z = 0.0$, $p = 1$					
02 TEP versus Preperitoneal Mesh					
Subtotal (95% CI)	0/0	0/0		0.0	Not estimable
Test for heterogeneity $\chi^2 = 0.0$, df = 0					
Test for overall effect $z = 0.0$, $p = 1$					
03 TEP versus Plug and Mesh					
x Khoury, 1998	0/141	0/120		0.0	Not estimable
Subtotal (95% CI)	0/141	0/120		0.0	Not estimable
Test for heterogeneity $\chi^2 = 0.0$, df = 0					
Test for overall effect $z = 0.0$, $p = 1$					
04 TEP versus Mixed Mesh					
MRC multicentre, 1999	26/340	9/338		100.0	2.87 (1.37 to 6.04)
Subtotal (95% CI)	26/340	9/338		100.0	2.87 (1.37 to 6.04)
Test for heterogeneity $\chi^2 = 0.0$, df = 0					
Test for overall effect $z = 2.78$, $p = 0.005$					
Total (95% CI)	26/614	9/590		100.0	2.87 (1.37 to 6.04)
Test for heterogeneity $\chi^2 = 0.0$, df = 0					
Test for overall effect $z = 2.78$, $p = 0.005$					

0.001 0.01 0.1 1 10 100 1000

Favours treatment   Favours control

Comparison: 02 TEP versus Open Mesh
Outcome: 03 Conversion

Study	Treatment n/N	Control n/N	RR (95% CI fixed)	Weight %	RR (95% CI fixed)
01 TEP versus Flat Mesh					
Andersson, 2003	1/81	0/87		12.1	3.22 (0.13 to 77.92)
x Bringman, 2003	0/92	0/103		0.0	Not estimable
Colak, 2003	3/67	0/67		12.6	7.00 (0.37 to 132.96)
x Heikkinen (2), 1998	0/22	0/23		0.0	Not estimable
x Merello, 1997	0/60	0/60		0.0	Not estimable
x Payne, 1996	0/51	0/49		0.0	Not estimable
Subtotal (95% CI)	4/373	0/389		24.7	5.14 (0.60 to 43.81)
Test for heterogeneity $\chi^2 = 0.13$, df = 1, $p = 0.72$					
Test for overall effect $z = 1.50$, $p = 0.13$					
02 TEP versus Preperitoneal Mesh					
Bostanci, 1998	2/32	0/32		12.6	5.00 (0.25 to 100.21)
Champault, 1997	3/51	0/49		12.8	6.73 (0.36 to 127.03)
Simmermacher, 2000	6/80	0/82		12.4	13.32 (0.76 to 232.64)
Subtotal (95% CI)	11/163	0/163		37.8	8.32 (1.56 to 44.51)
Test for heterogeneity $\chi^2 = 0.23$, df = 2, $p = 0.89$					
Test for overall effect $z = 2.48$, $p = 0.01$					
03 TEP versus Plug and Mesh					
x Bringman, 2003	0/92	0/104		0.0	Not estimable
Khoury, 1998	1/132	0/120		13.2	2.73 (0.11 to 66.37)
Subtotal (95% CI)	1/224	0/224		13.2	2.73 (0.11 to 66.37)
Test for heterogeneity $\chi^2 = 0.0$, df = 0					
Test for overall effect $z = 0.62$, $p = 0.5$					
04 TEP versus Mixed Mesh					
MRC multicentre, 1999	23/314	1/337		24.3	24.68 (3.35 to 181.71)
Subtotal (95% CI)	23/314	1/337		24.3	24.68 (3.35 to 181.71)
Test for heterogeneity $\chi^2 = 0.0$, df = 0					
Test for overall effect $z = 3.15$, $p = 0.002$					
Total (95% CI)	39/1074	1/1113		100.0	10.77 (3.91 to 29.68)
Test for heterogeneity $\chi^2 = 2.38$, df = 6, $p = 0.88$					
Test for overall effect $z = 4.68$, $p = 0.00001$					

0.001 0.01 0.1 1 10 100 1000

Favours treatment   Favours control

Comparison: 02 TEP versus Open Mesh
Outcome: 04 Haematoma

Study	Treatment n/N	Control n/N	RR (95% CI fixed)	Weight %	RR (95% CI fixed)
01 TEP versus Flat Mesh					
Andersson, 2003	7/74	18/68		14.1	0.36 (0.16 to 0.80)
Bringman, 2003	3/92	8/103		5.7	0.42 (0.11 to 1.54)
Heikkinen (2), 1998	4/22	6/23		4.4	0.70 (0.23 to 2.14)
Lal, 2003	0/25	2/25		1.9	0.20 (0.01 to 3.97)
Merello, 1997	2/39	3/25		2.8	0.43 (0.08 to 2.83)
Subtotal (95% CI)	16/252	37/244		28.9	0.42 (0.24 to 0.72)
Test for heterogeneity $\chi^2 = 1.18$, df = 4, $p = 0.88$					
Test for overall effect $z = -3.15$, $p = 0.002$					
02 TEP versus Preperitoneal Mesh					
Bostanci, 1998	0/32	1/32		1.1	0.33 (0.01 to 7.89)
Subtotal (95% CI)	0/32	1/32		1.1	0.33 (0.01 to 7.89)
Test for heterogeneity $\chi^2 = 0.0$, df = 0					
Test for overall effect $z = -0.68$, $p = 0.5$					
03 TEP versus Plug and Mesh					
Bringman, 2003	3/92	7/104		5.0	0.48 (0.13 to 1.82)
Khoury, 1998	6/136	27/117		21.9	0.19 (0.08, to 0.45)
Subtotal (95% CI)	9/228	34/221		26.8	0.25 (0.12 to 0.49)
Test for heterogeneity $\chi^2 = 1.35$, df = 1, $p = 0.25$					
Test for overall effect $z = -3.93$, $p = 0.00009$					
04 TEP versus Mixed Mesh					
MRC multicentre, 1999	33/293	57/291		43.1	0.57 (0.39 to 0.86)
Subtotal (95% CI)	33/293	57/291		43.1	0.57 (0.39 to 0.86)
Test for heterogeneity $\chi^2 = 0.0$, df = 0					
Test for overall effect $z = -2.73$, $p = 0.006$					
Total (95% CI)	58/805	129/788		100.0	0.44 (0.33 to 0.58)
Test for heterogeneity $\chi^2 = 6.68$, df = 8, $p = 0.57$					
Test for overall effect $z = -5.62$, $p < 0.00001$					

0.001 0.01 0.1 1 10 100 1000

Favours treatment   Favours control

Comparison: 02 TEP versus Open Mesh
Outcome: 05 Seroma

Study	Treatment n/N	Control n/N	RR (95% CI fixed)	Weight %	RR (95% CI fixed)
01 TEP versus Flat Mesh					
Andersson, 2003	0/81	2/84		5.9	0.21 (0.01 to 4.25)
Bringman, 2003	1/92	0/103		1.1	3.35 (0.14 to 81.36)
Heikkinen (2), 1998	1/22	0/23		1.2	3.13 (0.13 to 72.99)
Lal, 2003	3/25	0/25		1.2	7.00 (0.38 to 128.88)
Merello, 1997	1/39	2/25		5.9	0.32 (0.03 to 3.35)
Subtotal (95% CI)	6/259	4/260		15.4	1.24 (0.45 to 3.43)
Test for heterogeneity $\chi^2 = 4.69$, df = 4, $p = 0.32$					
Test for overall effect $z = 0.42$, $p = 0.7$					
02 TEP versus Preperitoneal Mesh					
Bostanci, 1998	2/32	1/32		2.4	2.00 (0.19 to 20.97)
Subtotal (95% CI)	2/32	1/32		2.4	2.00 (0.19 to 20.97)
Test for heterogeneity $\chi^2 = 0.0$, df = 0					
Test for overall effect $z = 0.58$, $p = 0.6$					
03 TEP versus Plug and Mesh					
Bringman, 2003	1/92	1/104		2.3	1.13 (0.07 to 17.82)
x Khoury, 1998	0/136	0/117		0.0	Not estimable
Subtotal (95% CI)	1/228	1/221		2.3	1.13 (0.07 to 17.82)
Test for heterogeneity $\chi^2 = 0.0$, df = 0					
Test for overall effect $z = 0.09$, $p = 0.9$					
04 TEP versus Mixed Mesh					
MRC multicentre, 1999	19/291	33/291		79.9	0.58 (0.34 to 0.99)
Subtotal (95% CI)	19/291	33/291		79.9	0.58 (0.34 to 0.99)
Test for heterogeneity $\chi^2 = 0.0$, df = 0					
Test for overall effect $z = -2.00$, $p = 0.05$					
Total (95% CI)	28/805	39/804		100.0	0.73 (0.46 to 1.14)
Test for heterogeneity $\chi^2 = 6.68$, df = 7, $p = 0.46$					
Test for overall effect $z = -1.39$, $p = 0.17$					

0.001 0.01 0.1 1 10 100 1000

Favours treatment   Favours control

121

Comparison: 02 TEP versus Open Mesh
Outcome: 06 Wound/superficial infection

Study	Treatment n/N	Control n/N	RR (95% CI fixed)	Weight %	RR (95% CI fixed)
01 TEP versus Flat Mesh					
Andersson, 2003	0/81	2/84		10.0	0.21 (0.01 to 4.25)
Bringman, 2003	1/92	4/103		15.4	0.28 (0.03 to 2.46)
Colak, 2003	0/67	6/27		10.2	0.20 (0.01 to 4.09)
Heikkinen (2), 1998	2/22	0/23		2.0	5.22 (0.26 to 102.93)
Lal, 2003	1/25	1/25		4.1	1.00 (0.07 to 15.12)
x Merello, 1997	0/39	0/25		0.0	Not estimable
Subtotal (95% CI)	4/326	9/327		41.6	0.55 (0.20 to 1.53)
Test for heterogeneity $\chi^2 = 3.58$, df = 4, $p = 0.47$					
Test for overall effect $z = -1.15$, $p = 0.3$					
02 TEP versus Preperitoneal Mesh					
Bostanci, 1998	0/32	1/32		6.1	0.30 (0.01 to 7.89)
Subtotal (95% CI)	0/32	1/32		6.1	0.33 (0.01 to 7.89)
Test for heterogeneity $\chi^2 = 0.0$, df = 0					
Test for overall effect $z = -0.68$, $p = 0.5$					
03 TEP versus Plug and Mesh					
Bringman, 2003	1/92	3/104		11.5	0.38 (0.04 to 3.56)
x Khoury, 1998	0/136	0/117		0.0	Not estimable
Subtotal (95% CI)	1/228	3/221		11.5	0.38 (0.04 to 3.56)
Test for heterogeneity $\chi^2 = 0.0$, df = 0					
Test for overall effect $z = -0.85$, $p = 0.4$					
04 TEP versus Mixed Mesh					
MRC multicentre, 1999	8/292	10/291		40.8	0.80 (0.32 to 1.99)
Subtotal (95% CI)	8/292	10/291		40.8	0.80 (0.32 to 1.99)
Test for heterogeneity $\chi^2 = 0.0$, df = 0					
Test for overall effect $z = -0.49$, $p = 0.6$					
Total (95% CI)	13/878	23/871		100.00	0.62 (0.33 to 1.16)
Test for heterogeneity $\chi^2 = 4.27$, df = 7, $p = 0.46$					
Test for overall effect $z = -1.49$, $p = 0.14$					

0.001 0.01 0.1 1 10 100 1000

Favours treatment   Favours control

Comparison: 02 TEP versus Open Mesh
Outcome: 07 Mesh/deep infection

Study	Treatment n/N	Control n/N	RR (95% CI fixed)	Weight %	RR (95% CI fixed)
01 TEP versus Flat Mesh					
x Heikkinen (2), 1998	0/22	0/23		0.0	Not estimable
x Merello, 1997	0/7	0/26		0.0	Not estimable
Subtotal (95% CI)	0/29	0/29		0.0	Not estimable
Test for heterogeneity $\chi^2 = 0.0$, df = 0					
Test for overall effect $z = 0.0$, $p = 1$					
02 TEP versus Preperitoneal Mesh					
Simmermacher, 2000	0/80	1/82		100.0	0.34 (0.01 to 8.26)
Subtotal (95% CI)	0/80	1/82		100.0	0.34 (0.01 to 8.26)
Test for heterogeneity $\chi^2 = 0.0$, df = 0					
Test for overall effect $z = -0.66$, $p = 0.5$					
03 TEP versus Plug and Mesh					
x Khoury, 1998	0/136	0/117		0.0	Not estimable
Subtotal (95% CI)	0/136	0/117		0.0	Not estimable
Test for heterogeneity $\chi^2 = 0.0$, df = 0					
Test for overall effect $z = 0.0$, $p = 1$					
04 TEP versus Mixed Mesh					
x MRC multicentre, 1999	0/292	0/291		0.0	Not estimable
Subtotal (95% CI)	0/292	0/291		0.0	Not estimable
Test for heterogeneity $\chi^2 = 0.0$, df = 0					
Test for overall effect $z = 0.0$, $p = 1$					
Total (95% CI)	0/537	1/519		100.0	0.34 (0.01 to 8.26)
Test for heterogeneity $\chi^2 = 0.0$ df = 0					
Test for overall effect $z = -0.66$, $p = 0.5$					

0.001 0.01 0.1 1 10 100 1000

Favours treatment   Favours control

Comparison: 02 TEP versus Open Mesh
Outcome: 08 Vascular injury

Study	Treatment n/N	Control n/N	RR (95% CI fixed)	Weight %	RR (95% CI fixed)
01 TEP versus Flat Mesh					
Andersson, 2003	2/81	2/87		49.4	1.07 (0.157 to 7.45)
x Colak, 2003	0/67	0/67		0.0	Not estimable
x Heikkinen (2), 1998	0/22	0/23		0.0	Not estimable
x Merello, 1997	0/20	0/5		0.0	Not estimable
Subtotal (95% CI)	2/190	2/182		49.4	1.07 (0.15 to 7.45)
Test for heterogeneity $\chi^2 = 0.0$, df = 0					
Test for overall effect $z = 0.07$, $p = 0.9$					
02 TEP versus Preperitoneal Mesh					
Simmermacher, 2000	2/80	2/82		50.6	1.03 (0.157 to 7.10)
Subtotal (95% CI)	2/80	2/82		50.6	1.03 (0.157 to 7.10)
Test for heterogeneity $\chi^2 = 0.0$, df = 0					
Test for overall effect $z = 0.03$, $p = 1$					
03 TEP versus Plug and Mesh					
x Khoury, 1998	0/136	0/117		0.0	Not estimable
Subtotal (95% CI)	0/136	0/117		0.0	Not estimable
Test for heterogeneity $\chi^2 = 0.0$, df = 0					
Test for overall effect $z = 0.0$, $p = 1$					
04 TEP versus Mixed Mesh					
x MRC multicentre, 1999	0/338	0/336		0.0	Not estimable
Subtotal (95% CI)	0/338	0/336		0.0	Not estimable
Test for heterogeneity $\chi^2 = 0.0$, df = 0					
Test for overall effect $z = 0.0$, $p = 1$					
Total (95% CI)	4/744	4/717		100.0	1.05 (0.27 to 4.12)
Test for heterogeneity $\chi^2 = 0.0$ df = 1, $p = 0.97$					
Test for overall effect $z = 0.07$, $p = 0.9$					

0.001 0.01 0.1 1 10 100 1000
Favours treatment   Favours control

Comparison: 02 TEP versus Open Mesh
Outcome: 09 Visceral injury

Study	Treatment n/N	Control n/N	RR (95% CI fixed)	Weight %	RR (95% CI fixed)
01 TEP versus Flat Mesh					
Andersson, 2003	1/81	1/87		39.1	1.07 (0.07 to 16.89)
x Colak, 2003	0/67	0/67		0.0	Not estimable
x Heikkinen (2), 1998	0/22	0/23		0.0	Not estimable
Subtotal (95% CI)	1/170	1/177		39.1	1.07 (0.07 to 16.89)
Test for heterogeneity $\chi^2 = 0.0$, df = 0					
Test for overall effect $z = 0.05$, $p = 1$					
02 TEP versus Preperitoneal Mesh					
Subtotal (95% CI)	0/0	0/0		0.0	Not estimable
Test for heterogeneity $\chi^2 = 0.0$, df = 0					
Test for overall effect $z = 0.0$, $p = 1$					
03 TEP versus Plug and Mesh					
x Khoury, 1998	0/136	0/117		0.0	Not estimable
Subtotal (95% CI)	0/136	0/117		0.0	Not estimable
Test for heterogeneity $\chi^2 = 0.0$, df = 0					
Test for overall effect $z = 0.0$, $p = 1$					
04 TEP versus Mixed Mesh					
MRC multicentre, 1999	0/338	1/336		60.9	0.33 (0.01 to 8.11)
Subtotal (95% CI)	0/338	1/336		60.9	0.33 (0.01 to 8.11)
Test for heterogeneity $\chi^2 = 0.0$, df = 0					
Test for overall effect $z = -0.68$, $p = 0.5$					
Total (95% CI)	1/644	2/630		100.0	0.62 (0.08 to 4.62)
Test for heterogeneity $\chi^2 = 0.30$ df = 1, $p = 0.58$					
Test for overall effect $z = -0.46$, $p = 0.6$					

0.001 0.01 0.1 1 10 100 1000
Favours treatment   Favours control

123

Comparison: 02 TEP versus Open Mesh
Outcome: 11 Length of stay (days)

Study	Treatment n	Mean (SD)	Control n	Mean (SD)	WMD (95% CI fixed)	Weight %	WMD (95% CI fixed)
01 TEP versus Flat Mesh							
Andersson, 2003	81	0.57 (0.29)	87	0.52 (0.26)		58.3	0.05 (–0.03 to 0.13)
Colak, 2003	67	1.80 (0.65)	67	2.73 (1.62)		2.3	–0.93 (–1.35 to –0.51)
Heikkinen (2), 1998	22	0.42 (0.29)	22	0.30 (0.40)		9.5	0.12 (–0.09 to 0.33)
Merello, 1997	60	1.05 (0.22)	60	1.30 (0.46)		24.4	–0.25 (–0.38 to –0.12)
x Payne, 1996	51	0.02 (0.14)	49	0.00 (0.00)		0.0	Not estimable
Subtotal (95% CI)	281		285			94.5	–0.04 (–0.11 to 0.02)

Test for heterogeneity $\chi^2 = 34.35$, df = 3, $p < 0.00001$
Test for overall effect z = 1.33, $p = 0.18$

02 TEP versus Preperitoneal Mesh							
Champault, 1997	51	3.20 (1.16)	49	7.30 (1.29)		1.8	–4.10 (–4.58 to –3.62)
Subtotal (95% CI)	51		49			1.8	–4.10 (–4.58 to –3.62)

Test for heterogeneity $\chi^2 = 0.0$, df = 0
Test for overall effect z = 16.69, $p < 0.00001$

03 TEP versus Plug and Mesh							
x Khoury, 1998	140	0.00 (0.00)	118	0.29 (0.56)		0.0	Not estimable
Subtotal (95% CI)	140		118			0.0	0.00 (0.00 to 0.00)

Test for heterogeneity $\chi^2 = 0.00$, df = 0
Test for overall effect z = 0.0, $p = 1$

04 TEP versus Mixed Mesh							
MRC multicentre, 1999	302	1.40 (2.10)	301	1.55 (2.03)		3.7	–0.15 (–0.48 to 0.18)
Subtotal (95% CI)	302		301			3.7	–0.15 (–0.48 to 0.18)

Test for heterogeneity $\chi^2 = 0.0$, df = 0
Test for overall effect z = 0.89, $p = 0.4$

Total (95% CI)	774		753			100.0	–0.12 (–0.18 to –0.06)

Test for heterogeneity $\chi^2 = 301.97$, df = 5, $p < 0.00001$
Test for overall effect z = 3.68, $p < 0.0002$

```
        –1      –0.5      0      0.5      1
           Favours treatment   Favours control
```

Comparison: 02 TEP versus Open Mesh
Outcome: 12 Time to return to usual activities (days)

Study	Treatment n/N	Control n/N	HR (95% CI fixed)	Weight %	HR (95% CI fixed)
01 TEP versus Flat Mesh					
Heikkinen (2), 1998	22/22	23/23		5.8	0.56 (0.30 to 1.03)
Merello, 1997	7/7	5/5		1.5	0.34 (0.10 to 1.11)
Payne, 1996	51/51	49/49		10.8	0.28 (0.18 to 0.43)
Subtotal (95% CI)	80/80	77/77		18.1	0.35 (0.25 to 0.50)

Test for heterogeneity $\chi^2 = 3.28$, df = 2, $p = 0.19$
Test for overall effect z = –5.92, $p < 0.00001$

02 TEP versus Preperitoneal Mesh					
Subtotal (95% CI)	0/0	0/0		0.0	Not estimable

Test for heterogeneity $\chi^2 = 0.0$, df = 1
Test for overall effect z = 0.0, $p = 1$

03 TEP versus Plug and Mesh					
Khoury, 1998	136/136	116/116		26.5	0.22 (0.16 to 0.29)
Subtotal (95% CI)	136/136	116/116		26.5	0.22 (0.16 to 0.29)

Test for heterogeneity $\chi^2 = 0.0$, df = 0
Test for overall effect z = –10.51, $p < 0.00001$

04 TEP versus Mixed Mesh					
MRC multicentre, 1999	215/228	183/199		55.4	0.80 (0.66 to 0.97)
Subtotal (95% CI)	215/228	183/199		55.4	0.80 (0.66 to 0.97)

Test for heterogeneity $\chi^2 = 0.0$, df = 0
Test for overall effect z = –2.26, $p = 0.02$

Total (95% CI)	431/444	376/392		100.0	0.49 (0.42 to 0.56)

Test for heterogeneity $\chi^2 = 61.62$, df = 4, $p < 0.00001$
Test for overall effect z = –9.61, $p < 0.00001$

```
   0.01     0.1       1       10      100
           Favours treatment   Favours control
```

n/N refers to the number who have returned to activities within the follow-up period. The remaining few people are censored, i.e. they have not yet returned to activities at the time of follow-up.

Comparison: 02 TEP versus Open Mesh
Outcome: 13 Persisting numbness

Study	Treatment n/N	Control n/N	RR (95% CI fixed)	Weight %	RR (95% CI fixed)
01 TEP versus Flat Mesh					
Heikkinen (2), 1998	0/22	4/23		3.9	0.12 (0.01 to 2.04)
Merello, 1997	0/1	2/2		1.8	0.30 (0.03 to 3.49)
Subtotal (95% CI)	0/23	6/25		5.7	0.17 (0.03 to 1.16)
Test for heterogeneity $\chi^2 = 0.27$, df = 1, $p = 0.6$					
Test for overall effect $z = -1.81$, $p = 0.07$					
02 TEP versus Preperitoneal Mesh					
Subtotal (95% CI)	0/0	0/0		0.0	Not estimable
Test for heterogeneity $\chi^2 = 0.0$, df = 0					
Test for overall effect $z = 0.0$, $p = 1$					
03 TEP versus Plug and Mesh					
Khoury, 1998	1/137	0/117		0.5	2.57 (0.11 to 62.38)
Subtotal (95% CI)	1/137	0/117		0.5	2.57 (0.11 to 62.38)
Test for heterogeneity $\chi^2 = 0.0$, df = 0					
Test for overall effect $z = 0.58$, $p = 0.6$					
04 TEP versus Mixed Mesh					
MRC multicentre, 1999	75/308	104/296		93.9	0.69 (0.54 to 0.89)
Subtotal (95% CI)	75/308	104/296		93.9	0.69 (0.54 to 0.89)
Test for heterogeneity $\chi^2 = 0.0$, df = 0					
Test for overall effect $z = -2.87$, $p = 0.004$					
Total (95% CI)	76/468	110/438		100.0	0.67 (0.53 to 0.86)
Test for heterogeneity $\chi^2 = 2.59$, df = 3, $p = 0.46$					
Test for overall effect $z = -3.15$, $p = 0.002$					

0.001 0.01 0.1 1 10 100 1000
Favours treatment   Favours control

Comparison: 02 TEP versus Open Mesh
Outcome: 14 Persisting pain

Study	Treatment n/N	Control n/N	RR (95% CI fixed)	Weight %	RR (95% CI fixed)
01 TEP versus Flat Mesh					
Heikkinen (2), 1998	0/22	1/23		0.9	0.35 (0.01 to 8.11)
Merello, 1997	0/34	5/17		4.4	0.05 (0.00 to 0.80)
Subtotal (95% CI)	0/56	6/40		5.3	0.10 (0.01 to 0.66)
Test for heterogeneity $\chi^2 = 0.88$, df = 1, $p = 0.35$					
Test for overall effect $z = -2.38$, $p = 0.02$					
02 TEP versus Preperitoneal Mesh					
Subtotal (95% CI)	0/0	0/0		0.0	Not estimable
Test for heterogeneity $\chi^2 = 0.0$, df = 0					
Test for overall effect $z = 0.0$, $p = 1$					
03 TEP versus Plug and Mesh					
Khoury, 1998	2/137	11/117		7.2	0.16 (0.04 to 0.69)
Subtotal (95% CI)	2/137	11/117		7.2	0.16 (0.04 to 0.69)
Test for heterogeneity $\chi^2 = 0.0$, df = 0					
Test for overall effect $z = -2.46$, $p = 0.01$					
04 TEP versus Mixed Mesh					
MRC multicentre, 1999	125/324	142/317		87.5	0.86 (0.72 to 1.04)
Subtotal (95% CI)	125/324	142/317		87.5	0.86 (0.72 to 1.04)
Test for heterogeneity $\chi^2 = 0.0$, df = 0					
Test for overall effect $z = -1.59$, $p = 0.11$					
Total (95% CI)	127/517	159/474		100.0	0.77 (0.64 to 0.92)
Test for heterogeneity $\chi^2 = 9.88$, df = 3, $p = 0.02$					
Test for overall effect $z = -2.84$, $p = 0.004$					

0.001 0.01 0.1 1 10 100 1000
Favours treatment   Favours control

125

Comparison: 02 TEP versus Open Mesh
Outcome: 15 Hernia recurrence

Study	Treatment n/N	Control n/N	RR (95% CI fixed)	Weight %	RR (95% CI fixed)
01 TEP versus Flat Mesh					
Andersson, 2003	2/76	0/85		3.0	5.58 (0.27 to 114.52)
Bringman, 2003	2/92	0/103		3.0	5.59 (0.27 to 114.98)
Colak 2003	2/67	4/67		25.3	0.50 (0.09 to 2.64)
x Heikkinen (2), 1998	0/22	0/23		0.0	Not estimable
x Lal, 2003	0/25	0/25		0.0	Not estimable
x Merello, 1997	0/59	0/57		0.0	Not estimable
Payne, 1996	1/50	0/50		3.2	3.00 (0.13 to 71.93)
Subtotal (95% CI)	7/391	4/410		34.4	1.61 (0.57 to 4.60)
Test for heterogeneity $\chi^2 = 3.35$, df = 3, $p = 0.34$					
Test for overall effect z = 0.89, $p = 0.4$					
02 TEP versus Preperitoneal Mesh					
x Bostanci, 1998	0/32	0/32		0.0	Not estimable
Champault, 1997	3/51	1/49		6.4	2.88 (0.31 to 26.78)
Suter, 2002	1/19	0/20		3.1	3.15 (0.14 to 72.89)
Subtotal (95% CI)	4/102	1/101		9.5	2.97 (0.48 to 18.28)
Test for heterogeneity $\chi^2 = 0.00$, df = 1, $p = 0.96$					
Test for overall effect z = 1.17, $p = 0.2$					
03 TEP versus Plug and Mesh					
Bringman, 2003	2/92	2/104		11.9	1.13 (0.16 to 7.87)
Khoury, 1998	3/137	6/116		41.0	0.42 (0.11 to 1.66)
Subtotal (95% CI)	5/229	8/220		52.9	0.58 (0.20 to 1.73)
Test for heterogeneity $\chi^2 = 0.66$, df = 1, $p = 0.42$					
Test for overall effect z = −0.98, $p = 0.3$					
04 TEP versus Mixed Mesh					
MRC multicentre, 1999	7/285	0/271		3.2	14.27 (0.82 to 248.59)
Subtotal (95% CI)	7/285	0/271		3.2	14.27 (0.82 to 248.59)
Test for heterogeneity $\chi^2 = 0.0$, df = 0					
Test for overall effect z = 1.82, $p = 0.07$					
Total (95% CI)	23/1007	13/1002		100.0	1.61 (0.87 to 2.98)
Test for heterogeneity $\chi^2 = 9.83$, df = 8, $p = 0.28$					
Test for overall effect z = 1.50, $p = 0.13$					

0.01 0.1 1 10 100

Favours treatment   Favours control

Appendix 7(3)

Results of meta-analyses: laparoscopic TAPP versus laparoscopic TEP repair

Comparison: 03 TAPP versus TEP
Outcome: 01 Duration of operation (minutes)

Study	Treatment n	Mean (SD)	Control n	Mean (SD)	WMD (95% CI fixed)	Weight %	WMD (95% CI fixed)
Schrenk, 1996	28	46.00 (9.20)	24	52.30 (13.90)		100.0	−6.30 (−12.82 to 0.22)
Total (95% CI)	28		24			100.0	−6.30 (−12.82 to 0.22)

Test for heterogeneity $\chi^2 = 0.0$, df = 0
Test for overall effect $z = 1.89$, $p = 0.06$

−10   −5   0   5   10
Favours treatment   Favours control

Comparison: 03 TAPP versus TEP
Outcome: 04 Haematoma

Study	Treatment n/N	Control n/N	RR (95% CI fixed)	Weight %	RR (95% CI fixed)
Schrenk, 1996	1/28	0/24		100.0	2.59 (0.11 to 60.69)
Total (95% CI)	1/28	0/24		100.0	2.59 (0.11 to 60.69)

Test for heterogeneity $\chi^2 = 0.0$, df = 0
Test for overall effect $z = 0.59$, $p = 0.6$

0.01   0.1   1   10   100
Favours treatment   Favours control

Comparison: 03 TAPP versus TEP
Outcome: 11 Length of stay (days)

Study	Treatment n	Mean (SD)	Control n	Mean (SD)	WMD (95% CI fixed)	Weight %	WMD (95% CI fixed)
Schrenk, 1996	28	3.70 (1.40)	24	4.40 (0.90)		100.0	−0.70 (−1.33 to −0.07)
Total (95% CI)	28		24			100.0	−0.70 (−1.33 to −0.07)

Test for heterogeneity $\chi^2 = 0.0$, df = 0
Test for overall effect $z = 2.17$, $p = 0.03$

−100   −50   0   50   100
Favours treatment   Favours control

Comparison: 03 TAPP versus TEP
Outcome: 15 Hernia recurrence

Study	Treatment n/N	Control n/N	RR (95% CI fixed)	Weight %	RR (95% CI fixed)
Schrenk, 1996	1/28	0/24		100.0	2.59 (0.11 to 60.69)
Total (95% CI)	1/28	0/24		100.0	2.59 (0.11 to 60.69)

Test for heterogeneity $\chi^2 = 0.0$, df = 0
Test for overall effect $z = 0.59$, $p = 0.6$

0.01   0.1   1   10   100
Favours treatment   Favours control

Appendix 7(4)

Results of meta-analyses: laparoscopic TAPP versus open mesh repair (recurrent hernias)

Comparison: 04 TAPP versus Open Mesh (Recurrent hernias)
Outcome: 01 Duration of operation (minutes)

Study	Treatment n	Mean (SD)	Control n	Mean (SD)	WMD (95% CI fixed)	Weight %	WMD (95% CI fixed)
01 TAPP versus Flat Mesh							
Payne, 1994	6	88.33 (19.15)	2	53.50 (12.02)		5.2	34.83 (12.20 to 57.46)
Wellwood, 1998	20	48.60 (14.77)	25	54.56 (18.52)		28.2	−5.96 (−15.69 to 3.77)
Subtotal (95% CI)	26		27			33.4	0.40 (−8.54 to 9.33)
Test for heterogeneity χ^2 = 10.53, df = 1, p = 0.0012							
Test for overall effect z = 0.09, p = 0.9							
02 TAPP versus Preperitoneal Mesh							
Aitola, 1998	8	49.88 (17.54)	7	42.43 (7.28)		15.1	7.45 (−5.85 to 20.75)
Beets, 1999	42	79.38 (31.67)	37	55.70 (16.48)		22.2	23.68 (12.73 to 34.63)
SCUR, 1999	23	76.52 (30.52)	18	45.83 (17.83)		11.9	30.69 (15.74 to 45.64)
Subtotal (95% CI)	73		62			49.2	20.41 (13.05 to 27.77)
Test for heterogeneity χ^2 = 5.81, df = 2, p = 0.055							
Test for overall effect z = 5.44, p < 0.00001							
03 TAPP versus Plug and Mesh							
Subtotal (95% CI)	0		0			0.0	Not estimable
Test for heterogeneity χ^2 = 0.0, df = 0							
Test for overall effect z = 0.0, p = 1							
04 TAPP versus Mixed Mesh							
MRC multicentre 1999	6	54.17 (14.29)	4	36.25 (4.79)		17.4	17.92 (5.56 to 30.28)
Subtotal (95% CI)	6		4			17.4	17.92 (5.56 to 30.28)
Test for heterogeneity χ^2 = 0.0, df = 0							
Test for overall effect z = 2.84, p = 0.004							
Total (95% CI)	105		93			100.0	13.30 (8.14 to 18.46)
Test for heterogeneity χ^2 = 28.47, df = 5, p < 0.00001							
Test for overall effect z = 5.05, p < 0.00001							

−100   −50   0   50   100

Favours treatment   Favours control

Comparison: 04 TAPP versus Open Mesh (Recurrent hernias)
Outcome: 02 "Opposite" method initiated

Study	Treatment n/N	Control n/N	RR (95% CI fixed)	Weight %	RR (95% CI fixed)
01 TAPP versus Flat Mesh					
x Payne, 1994	0/6	0/2		0.0	Not estimable
Subtotal (95% CI)	0/6	0/2		0.0	Not estimable
Test for heterogeneity χ^2 = 0.0, df = 0					
Test for overall effect z = 0.0, p = 1					
02 TAPP versus Preperitoneal Mesh					
Aitola, 1998	3/10	0/7		52.2	5.09 (0.30 to 85.39)
Beets, 1999	1/42	0/37		47.8	2.65 (0.11 to 63.17)
Subtotal (95% CI)	4/52	0/44		100.0	3.92 (0.49 to 31.68)
Test for heterogeneity χ^2 = 0.09, df = 1, p = 0.76					
Test for overall effect z = 1.28, p = 0.2					
03 TAPP versus Plug and Mesh					
Subtotal (95% CI)	0/0	0/0		0.0	Not estimable
Test for heterogeneity χ^2 = 0.0, df = 0					
Test for overall effect z = 0.0, p = 1					
04 TAPP versus Mixed Mesh					
x MRC multicentre, 1999	0/6	0/4		0.0	Not estimable
Subtotal (95% CI)	0/6	0/4		0.0	Not estimable
Test for heterogeneity χ^2 = 0.0, df = 0					
Test for overall effect z = 0.0, p = 1					
Total (95% CI)	4/64	0/50		100.0	3.92 (0.49 to 31.68)
Test for heterogeneity χ^2 = 0.09, df = 1, p = 0.76					
Test for overall effect z = 1.28, p = 0.2					

0.001   0.01   0.1   1   10   100   1000

Favours treatment   Favours control

129

Comparison: 04 TAPP versus Open Mesh (Recurrent hernias)
Outcome: 03 Conversion

Study	Treatment n/N	Control n/N	RR (95% CI fixed)	Weight %	RR (95% CI fixed)
01 TAPP versus Flat Mesh					
x Payne, 1994	0/6	0/2		0.0	Not estimable
x Wellwood, 1998	0/20	0/25		0.0	Not estimable
Subtotal (95% CI)	0/26	0/27		0.0	Not estimable
Test for heterogeneity $\chi^2 = 0.0$, df = 0					
Test for overall effect z = 0.0, p = 1					
02 TAPP versus Preperitoneal Mesh					
Aitola, 1998	1/10	0/7		50.9	2.18 (0.10 to 46.92)
SCUR, 1999	1/23	0/18		49.1	2.38 (0.10 to 55.07)
Subtotal (95% CI)	2/33	0/25		100.0	2.28 (0.25 to 20.47)
Test for heterogeneity $\chi^2 = 0.00$, df = 1, p = 0.97					
Test for overall effect z = 0.73, p = 0.5					
03 TAPP versus Plug and Mesh					
Subtotal (95% CI)	0/0	0/0		0.0	Not estimable
Test for heterogeneity $\chi^2 = 0.0$, df = 0					
Test for overall effect z = 0.0, p = 1					
04 TAPP versus Mixed Mesh					
x MRC multicentre, 1999	0/6	0/4		0.0	Not estimable
Subtotal (95% CI)	0/6	0/4		0.0	Not estimable
Test for heterogeneity $\chi^2 = 0.0$, df = 0					
Test for overall effect z = 0.0, p = 1					
Total (95% CI)	2/65	0/56		100.0	2.28 (0.25 to 20.47)
Test for heterogeneity $\chi^2 = 0.00$, df = 1, p = 0.97					
Test for overall effect z = 0.73, p = 0.5					

0.001 0.01 0.1 1 10 100 1000

Favours treatment   Favours control

Comparison: 04 TAPP versus Open Mesh (Recurrent hernias)
Outcome: 04 Haematoma

Study	Treatment n/N	Control n/N	RR (95% CI fixed)	Weight %	RR (95% CI fixed)
01 TAPP versus Flat Mesh					
Wellwood, 1998	0/20	6/25		45.2	0.10 (0.01 to 1.60)
Subtotal (95% CI)	0/20	6/25		45.2	0.10 (0.01 to 1.60)
Test for heterogeneity $\chi^2 = 0.0$, df = 0					
Test for overall effect z = −1.64, p = 0.10					
02 TAPP versus Preperitoneal Mesh					
Aitola, 1998	1/10	0/7		4.5	2.18 (0.10 to 46.92)
Beets, 1999	10/42	5/37		41.3	1.76 (0.66 to 4.69)
SCUR, 1999	1/23	0/18		4.3	2.38 (0.10 to 55.07)
Subtotal (95% CI)	12/75	5/62		50.2	1.85 (0.76 to 4.54)
Test for heterogeneity $\chi^2 = 0.05$, df = 2, p = 0.98					
Test for overall effect z = 1.35, p = 0.18					
03 TAPP versus Plug and Mesh					
Subtotal (95% CI)	0/0	0/0		0.0	Not estimable
Test for heterogeneity $\chi^2 = 0.0$, df = 0					
Test for overall effect z = 0.0, p = 1					
04 TAPP versus Mixed Mesh					
MRC multicentre, 1999	1/5	0/3		4.7	2.00 (0.11 to 37.83)
Subtotal (95% CI)	1/5	0/3		4.7	2.00 (0.11 to 37.83)
Test for heterogeneity $\chi^2 = 0.0$, df = 0					
Test for overall effect z = 0.46, p = 0.6					
Total (95% CI)	13/100	11/90		100.0	1.07 (0.51 to 2.21)
Test for heterogeneity $\chi^2 = 4.47$, df = 4, p = 0.35					
Test for overall effect z = 0.17, p = 0.9					

0.001 0.01 0.1 1 10 100 1000

Favours treatment   Favours control

Comparison: 04 TAPP versus Open Mesh (Recurrent hernias)
Outcome: 05 Seroma

Study	Treatment n/N	Control n/N	RR (95% CI fixed)	Weight %	RR (95% CI fixed)
01 TAPP versus Flat Mesh					
Wellwood, 1998	0/20	2/25		19.1	0.25 (0.01 to 4.88)
Subtotal (95% CI)	0/20	2/25		19.1	0.25 (0.01 to 4.88)
Test for heterogeneity $\chi^2 = 0.0$, df = 0					
Test for overall effect $z = -0.92$, $p = 0.4$					
02 TAPP versus Preperitoneal Mesh					
Aitola, 1998	1/10	0/7		4.9	2.18 (0.10 to 46.92)
Beets, 1999	15/38	7/37		60.6	2.09 (0.96 to 4.53)
x SCUR, 1999	0/23	0/18		0.0	Not estimable
Subtotal (95% CI)	16/71	7/62		65.5	2.09 (0.99 to 4.45)
Test for heterogeneity $\chi^2 = 0.00$, df = 1, $p = 0.98$					
Test for overall effect $z = 1.92$, $p = 0.05$					
03 TAPP versus Plug and Mesh					
Subtotal (95% CI)	0/0	0/0		0.0	Not estimable
Test for heterogeneity $\chi^2 = 0.0$, df = 0					
Test for overall effect $z = 0.0$, $p = 1$					
04 TAPP versus Mixed Mesh					
MRC multicentre, 1999	0/5	1/3		15.4	0.22 (0.01 to 4.20)
Subtotal (95% CI)	0/5	1/3		15.4	0.22 (0.01 to 4.20)
Test for heterogeneity $\chi^2 = 0.0$, df = 0					
Test for overall effect $z = 1.00$, $p = 0.3$					
Total (95% CI)	16/96	10/90		100.0	1.45 (0.75 to 2.82)
Test for heterogeneity $\chi^2 = 3.83$, df = 3, $p = 0.28$					
Test for overall effect $z = 1.11$, $p = 0.3$					

0.001 0.01 0.1 1 10 100 1000
Favours treatment   Favours control

Comparison: 04 TAPP versus Open Mesh (Recurrent hernias)
Outcome: 06 Wound/superficial infection

Study	Treatment n/N	Control n/N	RR (95% CI fixed)	Weight %	RR (95% CI fixed)
01 TAPP versus Flat Mesh					
Wellwood, 1998	3/20	5/25		42.7	0.75 (0.20 to 2.77)
Subtotal (95% CI)	3/20	5/25		42.7	0.75 (0.20 to 2.77)
Test for heterogeneity $\chi^2 = 0.0$, df = 0					
Test for overall effect $z = -0.43$, $p = 0.7$					
02 TAPP versus Preperitoneal Mesh					
Aitola, 1998	1/10	0/7		5.6	2.18 (0.10 to 46.92)
Beets, 1999	0/42	4/37		45.9	0.10 (0.01 to 1.77)
x SCUR, 1999	0/23	0/18		0.0	Not estimable
Subtotal (95% CI)	1/75	4/62		51.5	0.32 (0.06 to 1.70)
Test for heterogeneity $\chi^2 = 2.14$, df = 1, $p = 0.14$					
Test for overall effect $z = -1.33$, $p = 0.18$					
03 TAPP versus Plug and Mesh					
Subtotal (95% CI)	0/0	0/0		0.0	Not estimable
Test for heterogeneity $\chi^2 = 0.0$, df = 0					
Test for overall effect $z = 0.0$, $p = 1$					
04 TAPP versus Mixed Mesh					
MRC multicentre, 1999	1/5	0/3		5.8	2.00 (0.11 to 37.83)
Subtotal (95% CI)	1/5	0/3		5.8	2.00 (0.11 to 37.83)
Test for heterogeneity $\chi^2 = 0.0$, df = 0					
Test for overall effect $z = 0.46$, $p = 0.6$					
Total (95% CI)	5/100	9/90		100.0	0.60 (0.24 to 1.54)
Test for heterogeneity $\chi^2 = 2.94$, df = 3, $p = 0.4$					
Test for overall effect $z = -1.06$, $p = 0.3$					

0.001 0.01 0.1 1 10 100 1000
Favours treatment   Favours control

131

Comparison: 04 TAPP versus Open Mesh (Recurrent hernias)
Outcome: 09 Visceral injury

Study	Treatment n/N	Control n/N	RR (95% CI fixed)	Weight %	RR (95% CI fixed)
01 TAPP versus Flat Mesh					
x Wellwood, 1998	0/20	0/25		0.0	Not estimable
Subtotal (95% CI)	0/20	0/25		0.0	Not estimable
Test for heterogeneity $\chi^2 = 0.0$, df = 0					
Test for overall effect z = 0.0, p = 1					
02 TAPP versus Preperitoneal Mesh					
Aitola, 1998	1/10	0/7		100.0	2.18 (0.10 to 46.92)
x SCUR, 1999	0/23	0/18		0.0	Not estimable
Subtotal (95% CI)	1/33	0/25		100.0	2.18 (0.10 to 46.92)
Test for heterogeneity $\chi^2 = 0.0$, df = 0					
Test for overall effect z = 0.50, p = 0.6					
03 TAPP versus Plug and Mesh					
Subtotal (95% CI)	0/0	0/0		0.0	Not estimable
Test for heterogeneity $\chi^2 = 0.0$, df = 0					
Test for overall effect z = 0.0, p = 1					
04 TAPP versus Mixed Mesh					
x MRC multicentre, 1999	0/6	0/4		0.0	Not estimable
Subtotal (95% CI)	0/6	0/4		0.0	Not estimable
Test for heterogeneity $\chi^2 = 0.0$, df = 0					
Test for overall effect z = 0.0, p = 1					
Total (95% CI)	1/59	0/54		100.0	2.18 (0.10 to 46.92)
Test for heterogeneity $\chi^2 = 0.0$, df = 0					
Test for overall effect z = 0.50, p = 0.6					

0.001 0.01 0.1 1 10 100 1000

Favours treatment   Favours control

Comparison: 04 TAPP versus Open Mesh (Recurrent hernias)
Outcome: 11 Length of stay (days)

Study	Treatment n	Mean (SD)	Control n	Mean (SD)	WMD (95% CI fixed)	Weight %	WMD (95% CI fixed)
01 TAPP versus Flat Mesh							
x Payne, 1994	6	0.33 (0.82)	2	0.00 (0.00)		0.0	Not estimable
Wellwood, 1998	20	0.15 (0.37)	25	0.08 (0.28)		60.7	0.07 (–0.13 to 0.27)
Subtotal (95% CI)	26		27			60.7	0.07 (–0.13 to 0.27)
Test for heterogeneity $\chi^2 = 0.00$, df = 0, p = 1							
Test for overall effect z = 0.70, p = 0.5							
02 TAPP versus Preperitoneal Mesh							
Aitola, 1998	10	2.50 (3.75)	7	1.57 (0.54)		0.4	0.93 (–1.43 to 3.29)
Beets, 1999	42	1.10 (0.48)	37	1.38 (0.72)		31.1	–0.28 (–0.55 to –0.01)
SCUR, 1999	23	1.13 (1.22)	18	0.33 (0.49)		7.8	0.80 (0.25 to 1.35)
Subtotal (95% CI)	75		62			39.3	–0.05 (–0.30 to 0.19)
Test for heterogeneity $\chi^2 = 12.63$, df = 2, p = 0.0018							
Test for overall effect z = 0.43, p = 0.7							
03 TAPP versus Plug and Mesh							
Subtotal (95% CI)	0		0			0.0	Not estimable
Test for heterogeneity $\chi^2 = 0.0$, df = 0							
Test for overall effect z = 0.0, p = 1							
04 TAPP versus Mixed Mesh							
x MRC multicentre 1999	5	1.00 (0.00)	3	1.00 (0.00)		0.0	Not estimable
Subtotal (95% CI)	5		3			0.0	0.00 (0.00 to 0.00)
Test for heterogeneity $\chi^2 = 0.0$, df = 0							
Test for overall effect z = 0.0, p = 1							
Total (95% CI)	106		92			100.0	0.02 (–0.13 to 0.17)
Test for heterogeneity $\chi^2 = 13.23$, df = 3, p = 0.0042							
Test for overall effect z = 0.28, p = 0.8							

–4 –2 0 2 4

Favours treatment   Favours control

Comparison: 04 TAPP versus Open Mesh (Recurrent hernias)
Outcome: 12 Time to return to usual activities (days)

Study	Treatment n/N	Control n/N	HR (95% CI fixed)	Weight %	HR (95% CI fixed)
01 TAPP versus Flat Mesh					
Payne, 1994	6/6	2/2		7.4	0.41 (0.10 to 1.66)
Wellwood, 1998	20/20	25/25		34.5	0.48 (0.25 to 0.91)
Subtotal (95% CI)	26/26	27/27		41.8	0.46 (0.26 to 0.83)
Test for heterogeneity $\chi^2 = 0.03$, df = 1, $p = 0.85$					
Test for overall effect $z = -2.58$, $p = 0.010$					
02 TAPP versus Preperitoneal Mesh					
Aitola, 1998	4/4	2/2		5.5	0.62 (0.12 to 3.09)
Beets, 1999	16/16	16/16		28.2	0.63 (0.31 to 1.28)
SCUR, 1999	13/13	10/10		21.0	0.61 (0.27 to 1.38)
Subtotal (95% CI)	33/33	28/28		54.8	0.62 (0.37 to 1.03)
Test for heterogeneity $\chi^2 = 0.0$, df = 2, $p = 1$					
Test for overall effect $z = -1.83$, $p = 0.07$					
03 TAPP versus Plug and Mesh					
Subtotal (95% CI)	0/0	0/0		0.0	Not estimable
Test for heterogeneity $\chi^2 = 0.0$, df = 0					
Test for overall effect $z = 0.0$, $p = 1$					
04 TAPP versus Mixed Mesh					
MRC multicentre, 1999	3/4	3/3		3.4	7.98 (1.02 to 62.28)
Subtotal (95% CI)	3/4	3/3		3.4	7.98 (1.02 to 62.28)
Test for heterogeneity $\chi^2 = 0.0$, df = 0					
Test for overall effect $z = 1.98$, $p = 0.05$					
Total (95% CI)	62/63	58/58		100.0	0.60 (0.41 to 0.87)
Test for heterogeneity $\chi^2 = 6.89$, df = 5, $p = 0.23$					
Test for overall effect $z = -2.66$, $p = 0.008$					

```
            0.001  0.01  0.1    1    10   100  1000
              Favours treatment    Favours control
```

n/N refers to the number who have returned to activities within the follow-up period. The remaining few people are censored, i.e. they have not yet returned to activities at the time of follow-up.

Comparison: 04 TAPP versus Open Mesh (Recurrent hernias)
Outcome: 13 Persisting numbness

Study	Treatment n/N	Control n/N	RR (95% CI fixed)	Weight %	RR (95% CI fixed)
01 TAPP versus Flat Mesh					
x Payne, 1994	0/6	0/2		0.0	Not estimable
Wellwood, 1998	1/20	6/25		54.9	0.21 (0.03 to 1.59)
Subtotal (95% CI)	1/26	6/27		54.9	0.21 (0.03 to 1.59)
Test for heterogeneity $\chi^2 = 0.0$, df = 0					
Test for overall effect $z = -1.51$, $p = 0.13$					
02 TAPP versus Preperitoneal Mesh					
x Beets, 1999	0/42	0/37		0.0	Not estimable
SCUR, 1999	0/16	3/14		38.3	0.13 (0.01 to 2.25)
Subtotal (95% CI)	0/58	3/51		38.3	0.13 (0.01 to 2.25)
Test for heterogeneity $\chi^2 = 0.0$, df = 0					
Test for overall effect $z = -1.41$, $p = 0.16$					
03 TAPP versus Plug and Mesh					
Subtotal (95% CI)	0/0	0/0		0.0	Not estimable
Test for heterogeneity $\chi^2 = 0.0$, df = 0					
Test for overall effect $z = 0.0$, $p = 1$					
04 TAPP versus Mixed Mesh					
MRC multicentre, 1999	2/7	0/3		6.9	2.50 (0.15 to 40.67)
Subtotal (95% CI)	2/7	0/3		6.9	2.50 (0.15 to 40.67)
Test for heterogeneity $\chi^2 = 0.0$, df = 0					
Test for overall effect $z = 0.64$, $p = 0.5$					
Total (95% CI)	3/91	9/81		100.0	0.33 (0.10 to 1.14)
Test for heterogeneity $\chi^2 = 2.65$, df = 2, $p = 0.27$					
Test for overall effect $z = -1.75$, $p = 0.08$					

```
            0.001  0.01  0.1    1    10   100  1000
              Favours treatment    Favours control
```

133

Comparison: 04 TAPP versus Open Mesh (Recurrent hernias)
Outcome: 14 Persisting pain

Study	Treatment n/N	Control n/N	RR (95% CI fixed)	Weight %	RR (95% CI fixed)
01 TAPP versus Flat Mesh					
Wellwood, 1998	9/20	7/24		43.1	1.54 (0.70 to 3.40)
Subtotal (95% CI)	9/20	7/24		43.1	1.54 (0.70 to 3.40)
Test for heterogeneity $\chi^2 = 0.0$, df = 0					
Test for overall effect $z = 1.08$, $p = 0.3$					
02 TAPP versus Preperitoneal Mesh					
Beets, 1999	4/42	3/37		21.6	1.17 (0.28 to 4.91)
SCUR, 1999	0/16	2/14		18.0	0.18 (0.01 to 3.39)
Subtotal (95% CI)	4/58	5/51		39.6	0.72 (0.22 to 2.39)
Test for heterogeneity $\chi^2 = 1.32$, df = 1, $p = 0.25$					
Test for overall effect $z = -0.54$, $p = 0.6$					
03 TAPP versus Plug and Mesh					
Subtotal (95% CI)	0/0	0/0		0.0	Not estimable
Test for heterogeneity $\chi^2 = 0.0$, df = 0					
Test for overall effect $z = 0.0$, $p = 1$					
04 TAPP versus Mixed Mesh					
MRC multicentre, 1999	1/7	2/4		17.3	0.29 (0.04 to 2.25)
Subtotal (95% CI)	1/7	2/4		17.3	0.29 (0.04 to 2.25)
Test for heterogeneity $\chi^2 = 0.0$, df = 0					
Test for overall effect $z = -1.19$, $p = 0.2$					
Total (95% CI)	14/85	14/79		100.0	1.00 (0.54 to 1.85)
Test for heterogeneity $\chi^2 = 3.95$, df = 3, $p = 0.27$					
Test for overall effect $z = 0.00$, $p = 1$					

0.001 0.01 0.1 1 10 100 1000
Favours treatment   Favours control

Comparison: 04 TAPP versus Open Mesh (Recurrent hernias)
Outcome: 15 Hernia recurrence

Study	Treatment n/N	Control n/N	RR (95% CI fixed)	Weight %	RR (95% CI fixed)
01 TAPP versus Flat Mesh					
x Payne, 1994	0/6	0/2		0.0	Not estimable
Wellwood, 1998	0/20	1/25		17.9	0.41 (0.02 to 9.62)
Subtotal (95% CI)	0/26	1/27		17.9	0.41 (0.02 to 9.62)
Test for heterogeneity $\chi^2 = 0.0$, df = 0					
Test for overall effect $z = -0.55$, $p = 0.6$					
02 TAPP versus Preperitoneal Mesh					
Aitola, 1998	4/10	1/7		15.7	2.80 (0.39 to 20.02)
Beets, 1999	6/42	1/37		14.2	5.29 (0.67 to 41.91)
SCUR, 1999	0/23	3/18		52.2	0.11 (0.01 to 2.06)
Subtotal (95% CI)	10/75	5/62		82.1	1.52 (0.57 to 4.05)
Test for heterogeneity $\chi^2 = 4.84$, df = 2, $p = 0.089$					
Test for overall effect $z = 0.84$, $p = 0.4$					
03 TAPP versus Plug and Mesh					
Subtotal (95% CI)	0/0	0/0		0.0	Not estimable
Test for heterogeneity $\chi^2 = 0.0$, df = 0					
Test for overall effect $z = 0.0$, $p = 1$					
04 TAPP versus Mixed Mesh					
x MRC multicentre, 1999	0/5	0/4		0.0	Not estimable
Subtotal (95% CI)	0/5	0/4		0.0	Not estimable
Test for heterogeneity $\chi^2 = 0.0$, df = 0					
Test for overall effect $z = 0.0$, $p = 1$					
Total (95% CI)	10/106	6/93		100.0	1.32 (0.53 to 3.31)
Test for heterogeneity $\chi^2 = 5.56$, df = 3, $p = 0.13$					
Test for overall effect $z = 0.60$, $p = 0.5$					

0.01 0.1 1 10 100
Favours treatment   Favours control

Appendix 7(5)

Results of meta-analyses: laparoscopic TEP versus open mesh repair (recurrent hernias)

Comparison: 05 TEP versus Open Mesh (Recurrent hernias)
Outcome: 01 Duration of operation (minutes)

Study	Treatment n	Mean (SD)	Control n	Mean (SD)	WMD (95% CI fixed)	Weight %	WMD (95% CI fixed)
01 TEP versus Flat Mesh							
Colak, 2003	7	41.42 (5.56)	5	67.40 (11.12)		20.0	−25.98 (−36.56 to −15.40)
x Payne, 1996	4	77.50 (15.00)	1	65.00 (0.00)		0.0	Not estimable
Subtotal (95% CI)	11		6			20.0	−25.98 (−36.56 to −15.40)
Test for heterogeneity $\chi^2 = 0.0$, df = 0							
Test for overall effect $z = 4.81$, $p < 0.00001$							
02 TEP versus Preperitoneal Mesh							
Champault, 1997	20	100.00 (19.00)	23	63.00 (14.00)		22.0	37.00 (26.90 to 47.10)
Subtotal (95% CI)	20		23			22.0	37.00 (26.90 to 47.10)
Test for heterogeneity $\chi^2 = 0.00$, df = 0, $p = 1$							
Test for overall effect $z = 7.18$, $p < 0.00001$							
03 TEP versus Plug and Mesh							
Khoury, 1998	14	29.79 (13.97)	23	34.13 (11.04)		30.3	−4.34 (−12.94 to 4.26)
Subtotal (95% CI)	14		23			30.3	−4.34 (−12.94 to 4.26)
Test for heterogeneity $\chi^2 = 0.0$, df = 0							
Test for overall effect $z = 0.99$, $p = 0.3$							
04 TEP versus Mixed Mesh							
MRC multicentre 1999	47	64.04 (20.29)	36	47.03 (21.09)		27.7	17.01 (8.00 to 26.02)
Subtotal (95% CI)	47		36			27.7	17.01 (8.00 to 26.02)
Test for heterogeneity $\chi^2 = 0.0$, df = 0							
Test for overall effect $z = 3.70$, $p = 0.0002$							
Total (95% CI)	92		88			100.0	6.31 (1.58 to 11.05)
Test for heterogeneity $\chi^2 = 82.54$, df = 3, $p < 0.00001$							
Test for overall effect $z = 2.61$, $p = 0.009$							

−100 −50 0 50 100

Favours treatment   Favours control

Comparison: 05 TEP versus Open Mesh (Recurrent hernias)
Outcome: 02 "Opposite" method initiated

Study	Treatment n/N	Control n/N	RR (95% CI fixed)	Weight %	RR (95% CI fixed)
01 TEP versus Flat Mesh					
x Payne, 1996	0/4	0/1		0.0	Not estimable
Subtotal (95% CI)	0/4	0/1		0.0	Not estimable
Test for heterogeneity $\chi^2 = 0.0$, df = 0					
Test for overall effect $z = 0.0$, $p = 1$					
02 TEP versus Preperitoneal Mesh					
Subtotal (95% CI)	0/0	0/0		0.0	Not estimable
Test for heterogeneity $\chi^2 = 0.0$, df = 0					
Test for overall effect $z = 0.0$, $p = 1$					
03 TEP versus Plug and Mesh					
x Khoury, 1998	0/14	0/23		0.0	Not estimable
Subtotal (95% CI)	0/14	0/23		0.0	Not estimable
Test for heterogeneity $\chi^2 = 0.0$, df = 0					
Test for overall effect $z = 0.0$, $p = 1$					
04 TEP versus Mixed Mesh					
MRC multicentre, 1999	3/49	2/38		100.0	1.16 (0.20 to 6.62)
Subtotal (95% CI)	3/49	2/38		100.0	1.16 (0.20 to 6.62)
Test for heterogeneity $\chi^2 = 0.0$, df = 0					
Test for overall effect $z = 0.17$, $p = 0.9$					
Total (95% CI)	3/67	2/62		100.0	1.16 (0.20 to 6.62)
Test for heterogeneity $\chi^2 = 0.0$, df = 0					
Test for overall effect $z = 0.17$, $p = 0.9$					

0.001 0.01 0.1 1 10 100 1000

Favours treatment   Favours control

Comparison: 05 TEP versus Open Mesh (Recurrent hernias)
Outcome: 03 Conversion

Study	Treatment n/N	Control n/N	RR (95% CI fixed)	Weight %	RR (95% CI fixed)
01 TEP versus Flat Mesh					
x Payne, 1996	0/4	0/1		0.0	Not estimable
Subtotal (95% CI)	0/4	0/1		0.0	Not estimable
Test for heterogeneity $\chi^2 = 0.0$, df = 0					
Test for overall effect $z = 0.0$, $p = 1$					
02 TEP versus Preperitoneal Mesh					
Subtotal (95% CI)	0/0	0/0		0.0	Not estimable
Test for heterogeneity $\chi^2 = 0.0$, df = 0					
Test for overall effect $z = 0.0$, $p = 1$					
03 TEP versus Plug and Mesh					
x Khoury, 1998	0/13	0/23		0.0	Not estimable
Subtotal (95% CI)	0/13	0/23		0.0	Not estimable
Test for heterogeneity $\chi^2 = 0.0$, df = 0					
Test for overall effect $z = 0.0$, $p = 1$					
04 TEP versus Mixed Mesh					
MRC multicentre, 1999	8/46	1/38		100.0	6.61 (0.86 to 50.52)
Subtotal (95% CI)	8/46	1/38		100.0	6.61 (0.86 to 50.52)
Test for heterogeneity $\chi^2 = 0.0$, df = 0					
Test for overall effect $z = 1.82$, $p = 0.07$					
Total (95% CI)	8/63	1/62		100.0	6.61 (0.86 to 50.52)
Test for heterogeneity $\chi^2 = 0.0$, df = 0					
Test for overall effect $z = 1.82$, $p = 0.07$					

```
        0.001  0.01   0.1    1    10   100  1000
           Favours treatment    Favours control
```

Comparison: 05 TEP versus Open Mesh (Recurrent hernias)
Outcome: 04 Haematoma

Study	Treatment n/N	Control n/N	RR (95% CI fixed)	Weight %	RR (95% CI fixed)
01 TEP versus Flat Mesh					
Subtotal (95% CI)	0/0	0/0		0.0	Not estimable
Test for heterogeneity $\chi^2 = 0.0$, df = 0					
Test for overall effect $z = 0.0$, $p = 1$					
02 TEP versus Preperitoneal Mesh					
Subtotal (95% CI)	0/0	0/0		0.0	Not estimable
Test for heterogeneity $\chi^2 = 0.0$, df = 0					
Test for overall effect $z = 0.0$, $p = 1$					
03 TEP versus Plug and Mesh					
Khoury, 1998	0/14	6/22		24.8	0.12 (0.01 to 1.94)
Subtotal (95% CI)	0/14	6/22		24.8	0.12 (0.01 to 1.94)
Test for heterogeneity $\chi^2 = 0.0$, df = 0					
Test for overall effect $z = -1.50$, $p = 0.13$					
04 TEP versus Mixed Mesh					
MRC multicentre, 1999	6/45	14/36		75.2	0.34 (0.15 to 0.80)
Subtotal (95% CI)	6/45	14/36		75.2	0.34 (0.15 to 0.80)
Test for heterogeneity $\chi^2 = 0.0$, df = 0					
Test for overall effect $z = -2.47$, $p = 0.01$					
Total (95% CI)	6/59	20/58		100.0	0.29 (0.13 to 0.66)
Test for heterogeneity $\chi^2 = 0.55$, df = 1, $p = 0.46$					
Test for overall effect $z = -2.95$, $p = 0.003$					

```
        0.001  0.01   0.1    1    10   100  1000
           Favours treatment    Favours control
```

Comparison: 05 TEP versus Open Mesh (Recurrent hernias)
Outcome: 05 Seroma

Study	Treatment n/N	Control n/N	RR (95% CI fixed)	Weight %	RR (95% CI fixed)
01 TEP versus Flat Mesh					
Subtotal (95% CI)	0/0	0/0		0.0	Not estimable
Test for heterogeneity $\chi^2 = 0.0$, df = 0					
Test for overall effect $z = 0.0$, $p = 1$					
02 TEP versus Preperitoneal Mesh					
Subtotal (95% CI)	0/0	0/0		0.0	Not estimable
Test for heterogeneity $\chi^2 = 0.0$, df = 0					
Test for overall effect $z = 0.0$, $p = 1$					
03 TEP versus Plug and Mesh					
x Khoury, 1998	0/14	0/22		0.0	Not estimable
Subtotal (95% CI)	0/14	0/22		0.0	Not estimable
Test for heterogeneity $\chi^2 = 0.0$, df = 0					
Test for overall effect $z = 0.0$, $p = 1$					
04 TEP versus Mixed Mesh					
MRC multicentre, 1999	3/45	4/36		100.0	0.60 (0.14 to 2.51)
Subtotal (95% CI)	3/45	4/36		100.0	0.60 (0.14 to 2.51)
Test for heterogeneity $\chi^2 = 0.0$, df = 0					
Test for overall effect $z = -2.47$, $p = 0.01$					
Total (95% CI)	3/59	4/58		100.0	0.60 (0.14 to 2.51)
Test for heterogeneity $\chi^2 = 0.0$, df = 0					
Test for overall effect $z = -0.70$, $p = 0.5$					

0.001 0.01 0.1 1 10 100 1000
Favours treatment   Favours control

Comparison: 05 TEP versus Open Mesh (Recurrent hernias)
Outcome: 11 Length of stay (days)

Study	Treatment n	Mean (SD)	Control n	Mean (SD)	WMD (95% CI fixed)	Weight %	WMD (95% CI fixed)
01 TEP versus Flat Mesh							
x Payne, 1996	4	0.25 (0.50)	1	0.00 (0.00)		0.0	Not estimable
Subtotal (95% CI)	4		1			0.0	0.00 (0.00 to 0.00)
Test for heterogeneity $\chi^2 = 0.0$, df = 0							
Test for overall effect $z = 0.0$, $p = 1$							
02 TEP versus Preperitoneal Mesh							
Subtotal (95% CI)	0		0			0.0	Not estimable
Test for heterogeneity $\chi^2 = 0.0$, df = 0							
Test for overall effect $z = 0.0$, $p = 1$							
03 TEP versus Plug and Mesh							
Subtotal (95% CI)	0		0			0.0	Not estimable
Test for heterogeneity $\chi^2 = 0.0$, df = 0							
Test for overall effect $z = 0.0$, $p = 1$							
04 TEP versus Mixed Mesh							
MRC multicentre 1999	47	1.74 (1.99)	36	1.50 (1.21)		100.0	0.24 (−0.45 to 0.93)
Subtotal (95% CI)	47		36			100.0	0.24 (−0.45 to 0.93)
Test for heterogeneity $\chi^2 = 0.0$, df = 0							
Test for overall effect $z = 0.68$, $p = 0.5$							
Total (95% CI)	51		37			100.0	0.24 (−0.45 to 0.93)
Test for heterogeneity $\chi^2 = 0.0$, df = 0							
Test for overall effect $z = 0.68$, $p = 0.5$							

−4 −2 0 2 4
Favours treatment   Favours control

137

Comparison: 05 TEP versus Open Mesh (Recurrent hernias)
Outcome: 12 Time to return to usual activities (days)

Study	Treatment n/N	Control n/N	HR (95% CI fixed)	Weight %	HR (95% CI fixed)
01 TEP versus Flat Mesh					
Payne, 1996	4/4	1/1		3.2	1.87 (0.14 to 25.64)
Subtotal (95% CI)	4/4	1/1		3.2	1.87 (0.14 to 25.64)
Test for heterogeneity $\chi^2 = 0.0$, df = 0					
Test for overall effect z = 0.47, p = 0.6					
02 TEP versus Preperitoneal Mesh					
Subtotal (95% CI)	0/0	0/0		0.0	Not estimable
Test for heterogeneity $\chi^2 = 0.0$, df = 0					
Test for overall effect z = 0.0, p = 1					
03 TEP versus Plug and Mesh					
Khoury, 1998	13/13	22/22		21.6	0.10 (0.03 to 0.26)
Subtotal (95% CI)	13/13	22/22		21.6	0.10 (0.03 to 0.26)
Test for heterogeneity $\chi^2 = 0.0$, df = 0					
Test for overall effect z = –4.54, p = 0.00001					
04 TEP versus Mixed Mesh					
MRC multicentre, 1999	32/34	21/23		75.2	0.87 (0.50 to 1.49)
Subtotal (95% CI)	32/34	21/23		75.2	0.87 (0.50 to 1.49)
Test for heterogeneity $\chi^2 = 0.0$, df = 0					
Test for overall effect z = –0.51, p = 0.6					
Total (95% CI)	49/51	44/46		100.0	0.55 (0.35 to 0.89)
Test for heterogeneity $\chi^2 = 14.98$, df = 2, p = 0.0006					
Test for overall effect z = –2.47, p = 0.01					

0.001 0.01 0.1 1 10 100 1000
Favours treatment   Favours control

n/N refers to the number who have returned to activities within the follow-up period. The remaining few people are censored, i.e. they have not yet returned to activities at the time of follow-up.

Comparison: 05 TEP versus Open Mesh (Recurrent hernias)
Outcome: 13 Persisting numbness

Study	Treatment n/N	Control n/N	RR (95% CI fixed)	Weight %	RR (95% CI fixed)
01 TEP versus Flat Mesh					
Subtotal (95% CI)	0/0	0/0		0.0	Not estimable
Test for heterogeneity $\chi^2 = 0.0$, df = 0					
Test for overall effect z = 0.0, p = 1					
02 TEP versus Preperitoneal Mesh					
Subtotal (95% CI)	0/0	0/0		0.0	Not estimable
Test for heterogeneity $\chi^2 = 0.0$, df = 0					
Test for overall effect z = 0.0, p = 1					
03 TEP versus Plug and Mesh					
x Khoury, 1998	0/14	0/22		0.0	Not estimable
Subtotal (95% CI)	0/14	0/22		0.0	Not estimable
Test for heterogeneity $\chi^2 = 0.0$, df = 0					
Test for overall effect z = 0.0, p = 1					
04 TEP versus Mixed Mesh					
MRC multicentre, 1999	16/46	10/35		100.0	1.22 (0.63 to 2.35)
Subtotal (95% CI)	16/46	10/35		100.0	1.22 (0.63 to 2.35)
Test for heterogeneity $\chi^2 = 0.0$, df = 0					
Test for overall effect z = 0.59, p = 0.6					
Total (95% CI)	16/60	10/57		100.0	1.22 (0.63 to 2.35)
Test for heterogeneity $\chi^2 = 0.0$, df = 0					
Test for overall effect z = 0.59, p = 0.6					

0.001 0.01 0.1 1 10 100 1000
Favours treatment   Favours control

Comparison: 05 TEP versus Open Mesh (Recurrent hernias)
Outcome: 14 Persisting pain

Study	Treatment n/N	Control n/N	RR (95% CI fixed)	Weight %	RR (95% CI fixed)
01 TEP versus Flat Mesh					
Subtotal (95% CI)	0/0	0/0		0.0	Not estimable
Test for heterogeneity $\chi^2 = 0.0$, df = 0					
Test for overall effect $z = 0.0$, $p = 1$					
02 TEP versus Preperitoneal Mesh					
Subtotal (95% CI)	0/0	0/0		0.0	Not estimable
Test for heterogeneity $\chi^2 = 0.0$, df = 0					
Test for overall effect $z = 0.0$, $p = 1$					
03 TEP versus Plug and Mesh					
Khoury, 1998	0/14	2/22		8.4	0.31 (0.02 to 5.95)
Subtotal (95% CI)	0/14	2/22		8.4	0.31 (0.02 to 5.95)
Test for heterogeneity $\chi^2 = 0.0$, df = 0					
Test for overall effect $z = -0.78$, $p = 0.4$					
04 TEP versus Mixed Mesh					
MRC multicentre, 1999	24/49	19/37		91.6	0.95 (0.62 to 1.46)
Subtotal (95% CI)	24/49	19/37		91.6	0.95 (0.62 to 1.46)
Test for heterogeneity $\chi^2 = 0.0$, df = 0					
Test for overall effect $z = -0.22$, $p = 0.8$					
Total (95% CI)	24/63	21/59		100.0	0.90 (0.59 to 1.38)
Test for heterogeneity $\chi^2 = 0.58$, df = 1, $p = 0.45$					
Test for overall effect $z = -0.49$, $p = 0.6$					

0.001 0.01 0.1 1 10 100 1000
Favours treatment — Favours control

Comparison: 05 TEP versus Open Mesh (Recurrent hernias)
Outcome: 15 Hernia recurrence

Study	Treatment n/N	Control n/N	RR (95% CI fixed)	Weight %	RR (95% CI fixed)
01 TEP versus Flat Mesh					
Subtotal (95% CI)	0/0	0/0		0.0	Not estimable
Test for heterogeneity $\chi^2 = 0.0$, df = 0					
Test for overall effect $z = 0.0$, $p = 1$					
02 TEP versus Preperitoneal Mesh					
Subtotal (95% CI)	0/0	0/0		0.0	Not estimable
Test for heterogeneity $\chi^2 = 0.0$, df = 0					
Test for overall effect $z = 0.0$, $p = 1$					
03 TEP versus Plug and Mesh					
Khoury, 1998	0/14	2/22		14.8	0.31 (0.02 to 5.95)
Subtotal (95% CI)	0/14	2/22		14.8	0.31 (0.02 to 5.95)
Test for heterogeneity $\chi^2 = 0.0$, df = 0					
Test for overall effect $z = -0.78$, $p = 0.4$					
04 TEP versus Mixed Mesh					
MRC multicentre, 1999	16/46	10/35		85.2	1.22 (0.63 to 2.35)
Subtotal (95% CI)	16/46	10/35		85.2	1.22 (0.63 to 2.35)
Test for heterogeneity $\chi^2 = 0.0$, df = 0					
Test for overall effect $z = 0.59$, $p = 0.6$					
Total (95% CI)	16/60	12/57		100.0	1.08 (0.57 to 2.05)
Test for heterogeneity $\chi^2 = 0.82$, df = 1, $p = 0.37$					
Test for overall effect $z = 0.24$, $p = 0.8$					

0.01 0.1 1 10 100
Favours treatment — Favours control

139

Appendix 7(6)

# Results of meta-analyses: laparoscopic TAPP versus open mesh repair (bilateral hernias)

Comparison: 06 TAPP versus Open Mesh (Bilateral hernias)
Outcome: 01 Duration of operation (minutes)

| Study	Treatment n	Mean (SD)	Control n	Mean (SD)	WMD (95% CI fixed)	Weight %	WMD (95% CI fixed)
01 TAPP versus Flat Mesh							
x Heikkinen, 1997	1	140.00 (0.00)	1	77.00 (0.00)		0.0	Not estimable
Payne, 1994	4	93.00 (11.52)	6	87.50 (16.66)		9.5	5.50 (–11.97 to 22.97)
Sarli, 2001	20	95.00 (32.30)	23	99.00 (28.30)		8.7	–4.00 (–22.28 to 14.28)
Wellwood, 1998	23	62.52 (14.96)	24	67.46 (13.10)		44.9	–4.94 (–12.99 to 3.11)
Subtotal (95% CI)	48		54			63.1	–3.23 (–10.02 to 3.56)
Test for heterogeneity χ^2 = 1.14, df = 2, p = 0.57							
Test for overall effect z = 0.93, p = 0.4							
02 TAPP versus Preperitoneal Mesh							
Aitola, 1998	10	56.90 (13.85)	3	65.00 (5.00)		27.5	–8.10 (–18.38 to 2.18)
Beets, 1999	14	100.36 (35.60)	13	55.69 (13.96)		7.2	44.67 (24.54 to 64.80)
Subtotal (95% CI)	24		16			34.7	2.81 (–6.34 to 11.97)
Test for heterogeneity χ^2 = 20.93, df = 1, p < 0.00001							
Test for overall effect z = 0.60, p = 0.5							
03 TAPP versus Plug and Mesh							
Subtotal (95% CI)	0		0			0.0	Not estimable
Test for heterogeneity χ^2 = 0.0, df = 0							
Test for overall effect z = 0.0, p = 1							
04 TAPP versus Mixed Mesh							
MRC multicentre, 1999	5	94.20 (39.66)	7	57.57 (16.47)		2.1	36.63 (–0.21 to 73.47)
Subtotal (95% CI)	5		7			2.1	36.63 (–0.21 to 73.47)
Test for heterogeneity χ^2 = 0.0, df = 0							
Test for overall effect z = 1.95, p = 0.5							
Total (95% CI)	77		77			100.0	–0.28 (–5.67 to 5.12)
Test for heterogeneity χ^2 = 27.09, df = 5, p = 0.0001							
Test for overall effect z = 0.10, p = 0.9							

–100   –50   0   50   100

Favours treatment   Favours control

Comparison: 06 TAPP versus Open Mesh (Bilateral hernias)
Outcome: 02 "Opposite" method initiated

Study	Treatment n/N	Control n/N	RR (95% CI fixed)	Weight %	RR (95% CI fixed)
01 TAPP versus Flat Mesh					
x Heikkinen, 1997	0/1	0/1		0.0	Not estimable
x Payne, 1994	0/4	0/6		0.0	Not estimable
Subtotal (95% CI)	0/5	0/7		0.0	Not estimable
Test for heterogeneity $\chi^2 = 0.0$, df = 0					
Test for overall effect $z = 0.0$, $p = 1$					
02 TAPP versus Preperitoneal Mesh					
Aitola, 1998	1/10	0/4		57.1	1.36 (0.07 to 27.97)
Beets, 1999	1/14	0/13		42.9	2.80 (0.12 to 63.20)
Subtotal (95% CI)	2/24	0/17		100.0	1.98 (0.23 to 16.83)
Test for heterogeneity $\chi^2 = 0.11$, df = 1, $p = 0.74$					
Test for overall effect $z = 0.63$, $p = 0.5$					
03 TAPP versus Plug and Mesh					
Subtotal (95% CI)	0/0	0/0		0.0	Not estimable
Test for heterogeneity $\chi^2 = 0.0$, df = 0					
Test for overall effect $z = 0.0$, $p = 1$					
04 TAPP versus Mixed Mesh					
x MRC multicentre, 1999	0/5	0/6		0.0	Not estimable
Subtotal (95% CI)	0/5	0/6		0.0	Not estimable
Test for heterogeneity $\chi^2 = 0.0$, df = 0					
Test for overall effect $z = 0.0$, $p = 1$					
Total (95% CI)	2/34	0/30		100.0	1.98 (0.23 to 16.83)
Test for heterogeneity $\chi^2 = 0.11$, df = 1, $p = 0.74$					
Test for overall effect $z = 0.63$, $p = 0.5$					

0.001 0.01 0.1 1 10 100 1000

Favours treatment   Favours control

Comparison: 06 TAPP versus Open Mesh (Bilateral hernias)
Outcome: 03 Conversion

Study	Treatment n/N	Control n/N	RR (95% CI fixed)	Weight %	RR (95% CI fixed)
01 TAPP versus Flat Mesh					
x Heikkinen, 1997	0/1	0/1		0.0	Not estimable
x Payne, 1994	0/4	0/6		0.0	Not estimable
x Sarli, 2001	0/20	0/23		0.0	Not estimable
x Wellwood, 1998	0/23	0/24		0.0	Not estimable
Subtotal (95% CI)	0/48	0/54		0.0	Not estimable
Test for heterogeneity $\chi^2 = 0.0$, df = 0					
Test for overall effect $z = 0.0$, $p = 1$					
02 TAPP versus Preperitoneal Mesh					
x Aitola, 1998	0/10	0/4		0.0	Not estimable
Subtotal (95% CI)	0/10	0/4		0.0	Not estimable
Test for heterogeneity $\chi^2 = 0.0$, df = 0					
Test for overall effect $z = 0.0$, $p = 1$					
03 TAPP versus Plug and Mesh					
Subtotal (95% CI)	0/0	0/0		0.0	Not estimable
Test for heterogeneity $\chi^2 = 0.0$, df = 0					
Test for overall effect $z = 0.0$, $p = 1$					
04 TAPP versus Mixed Mesh					
MRC multicentre, 1999	1/5	0/6		100.0	3.50 (0.17 to 70.95)
Subtotal (95% CI)	1/5	0/6		100.0	3.50 (0.17 to 70.95)
Test for heterogeneity $\chi^2 = 0.0$, df = 0					
Test for overall effect $z = 0.82$, $p = 0.4$					
Total (95% CI)	1/63	0/64		100.0	3.50 (0.17 to 70.95)
Test for heterogeneity $\chi^2 = 0.0$, df = 0					
Test for overall effect $z = 0.82$, $p = 0.4$					

0.001 0.01 0.1 1 10 100 1000

Favours treatment   Favours control

Comparison: 06 TAPP versus Open Mesh (Bilateral hernias)
Outcome: 04 Haematoma

Study	Treatment n/N	Control n/N	RR (95% CI fixed)	Weight %	RR (95% CI fixed)
01 TAPP versus Flat Mesh					
Heikkinen, 1997	0/1	1/1		12.2	0.33 (0.03 to 4.19)
Sarli, 2001	1/20	4/23		30.3	0.29 (0.03 to 2.37)
Wellwood, 1998	2/23	2/24		15.9	1.04 (0.16 to 6.80)
Subtotal (95% CI)	3/44	7/48		58.5	0.50 (0.15 to 1.65)

Test for heterogeneity $\chi^2 = 0.95$, df = 2, $p = 0.62$
Test for overall effect $z = -1.13$, $p = 0.3$

02 TAPP versus Preperitoneal Mesh					
Aitola, 1998	1/10	1/4		11.6	0.40 (0.03 to 4.96)
Beets, 1999	4/14	3/13		25.3	1.24 (0.34 to 4.51)
Subtotal (95% CI)	5/24	4/17		37.0	0.97 (0.32 to 2.99)

Test for heterogeneity $\chi^2 = 0.61$, df = 1, $p = 0.43$
Test for overall effect $z = 0.05$, $p = 1$

03 TAPP versus Plug and Mesh					
Subtotal (95% CI)	0/0	0/0		0.0	Not estimable

Test for heterogeneity $\chi^2 = 0.0$, df = 0
Test for overall effect $z = 0.0$, $p = 1$

04 TAPP versus Mixed Mesh					
MRC multicentre, 1999	1/4	0/3		4.5	2.40 (0.13 to 44.42)
Subtotal (95% CI)	1/4	0/3		4.5	2.40 (0.13 to 44.42)

Test for heterogeneity $\chi^2 = 0.0$, df = 0
Test for overall effect $z = 0.59$, $p = 0.6$

Total (95% CI)	9/72	11/68		100.0	0.76 (0.35 to 1.65)

Test for heterogeneity $\chi^2 = 2.73$, df = 5, $p = 0.74$
Test for overall effect $z = -0.69$, $p = 0.5$

0.001 0.01 0.1 1 10 100 1000
Favours treatment   Favours control

Comparison: 06 TAPP versus Open Mesh (Bilateral hernias)
Outcome: 05 Seroma

Study	Treatment n/N	Control n/N	RR (95% CI fixed)	Weight %	RR (95% CI fixed)
01 TAPP versus Flat Mesh					
x Heikkinen, 1997	0/1	0/1		0.0	Not estimable
Sarli, 2001	2/20	0/23		11.1	5.71 (0.29 to 112.43)
Wellwood, 1998	1/23	1/24		23.3	1.04 (0.07 to 15.72)
Subtotal (95% CI)	3/44	1/48		34.4	2.55 (0.40 to 16.36)

Test for heterogeneity $\chi^2 = 0.70$, df = 1, $p = 0.4$
Test for overall effect $z = 0.99$, $p = 0.3$

02 TAPP versus Preperitoneal Mesh					
Aitola, 1998	2/10	0/4		16.3	2.27 (0.13 to 39.15)
Beets, 1999	6/14	2/13		49.3	2.79 (0.68 to 11.42)
Subtotal (95% CI)	8/24	2/17		65.6	2.66 (0.75 to 9.44)

Test for heterogeneity $\chi^2 = 0.02$, df = 1, $p = 0.9$
Test for overall effect $z = 1.51$, $p = 0.13$

03 TAPP versus Plug and Mesh					
Subtotal (95% CI)	0/0	0/0		0.0	Not estimable

Test for heterogeneity $\chi^2 = 0.0$, df = 0
Test for overall effect $z = 0.0$, $p = 1$

04 TAPP versus Mixed Mesh					
x MRC multicentre, 1999	0/4	0/3		0.0	Not estimable
Subtotal (95% CI)	0/4	0/3		0.0	Not estimable

Test for heterogeneity $\chi^2 = 0.0$, df = 0
Test for overall effect $z = 0.0$, $p = 1$

Total (95% CI)	11/72	3/68		100.0	2.62 (0.92 to 7.48)

Test for heterogeneity $\chi^2 = 0.72$, df = 3, $p = 0.87$
Test for overall effect $z = 1.80$, $p = 0.07$

0.001 0.01 0.1 1 10 100 1000
Favours treatment   Favours control

143

Comparison: 06 TAPP versus Open Mesh (Bilateral hernias)
Outcome: 06 Wound/superficial infection

Study	Treatment n/N	Control n/N	RR (95% CI fixed)	Weight %	RR (95% CI fixed)
01 TAPP versus Flat Mesh					
x Heikkinen, 1997	0/1	0/1		0.0	Not estimable
Sarli, 2001	0/20	3/23		20.9	0.16 (0.01 to 2.98)
Wellwood, 1998	3/23	10/24		62.6	0.31 (0.10 to 1.00)
Subtotal (95% CI)	3/44	13/48		83.5	0.28 (0.09 to 0.81)
Test for heterogeneity $\chi^2 = 0.17$, df = 1, $p = 0.68$					
Test for overall effect $z = -2.34$, $p = 0.02$					
02 TAPP versus Preperitoneal Mesh					
x Aitola, 1998	0/10	0/4		0.0	Not estimable
Beets, 1999	0/14	2/13		16.5	0.19 (0.01 to 3.56)
Subtotal (95% CI)	0/24	2/17		16.5	0.19 (0.01 to 3.56)
Test for heterogeneity $\chi^2 = 0.0$, df = 0					
Test for overall effect $z = -1.12$, $p = 0.3$					
03 TAPP versus Plug and Mesh					
Subtotal (95% CI)	0/0	0/0		0.0	Not estimable
Test for heterogeneity $\chi^2 = 0.0$, df = 0					
Test for overall effect $z = 0.0$, $p = 1$					
04 TAPP versus Mixed Mesh					
x MRC multicentre, 1999	0/4	0/3		0.0	Not estimable
Subtotal (95% CI)	0/4	0/3		0.0	Not estimable
Test for heterogeneity $\chi^2 = 0.0$, df = 0					
Test for overall effect $z = 0.0$, $p = 1$					
Total (95% CI)	3/72	15/68		100.0	0.26 (0.09 to 0.72)
Test for heterogeneity $\chi^2 = 0.24$, df = 2, $p = 0.88$					
Test for overall effect $z = -2.60$, $p = 0.009$					

```
        0.01    0.1     1      10     100
           Favours treatment  Favours control
```

Comparison: 06 TAPP versus Open Mesh (Bilateral hernias)
Outcome: 11 Length of stay (days)

Study	Treatment n	Mean (SD)	Control n	Mean (SD)	WMD (95% CI fixed)	Weight %	WMD (95% CI fixed)
01 TAPP versus Flat Mesh							
x Heikkinen, 1997	1	2.50 (0.00)	1	1.50 (0.00)		0.0	Not estimable
x Payne, 1994	4	0.00 (0.00)	6	0.17 (0.41)		0.0	Not estimable
Wellwood, 1998	23	0.09 (0.29)	24	0.25 (0.44)		88.4	−0.16 (−0.37 to 0.05)
Subtotal (95% CI)	28		31			88.4	−0.16 (−0.37 to 0.05)
Test for heterogeneity $\chi^2 = 0.0$, df = 0							
Test for overall effect $z = 1.48$, $p = 0.14$							
02 TAPP versus Preperitoneal Mesh							
x Aitola, 1998	10	1.30 (0.68)	4	1.00 (0.00)		0.0	Not estimable
Beets, 1999	14	1.21 (0.80)	13	1.85 (0.99)		8.6	−0.64 (−1.32 to 0.04)
Subtotal (95% CI)	24		17			8.6	−0.64 (−1.32 to 0.04)
Test for heterogeneity $\chi^2 = 0.0$, df = 0							
Test for overall effect $z = 1.84$, $p = 0.07$							
03 TAPP versus Plug and Mesh							
Subtotal (95% CI)	0		0			0.0	Not estimable
Test for heterogeneity $\chi^2 = 0.0$, df = 0							
Test for overall effect $z = 0.0$, $p = 1$							
04 TAPP versus Mixed Mesh							
MRC multicentre 1999	4	1.75 (0.96)	3	1.33 (0.58)		3.0	0.42 (−0.73 to 1.57)
Subtotal (95% CI)	4		3			3.0	0.42 (−0.73 to 1.57)
Test for heterogeneity $\chi^2 = 0.0$, df = 0							
Test for overall effect $z = 0.72$, $p = 0.5$							
Total (95% CI)	56		51			100.0	−0.18 (−0.38 to 0.02)
Test for heterogeneity $\chi^2 = 2.83$, df = 2, $p = 0.24$							
Test for overall effect $z = 1.80$, $p = 0.07$							

```
        -4      -2      0      2      4
           Favours treatment  Favours control
```

Comparison: 06 TAPP versus Open Mesh (Bilateral hernias)
Outcome: 12 Time to return to usual activities (days)

Study	Treatment n/N	Control n/N	HR (95% CI fixed)	Weight %	HR (95% CI fixed)
01 TAPP versus Flat Mesh					
x Heikkinen, 1997	0/1	0/1		0.0	Not estimable
Payne, 1994	4/4	6/6		5.0	0.03 (0.00 to 0.25)
Wellwood, 1998	22/22	23/23		54.0	0.39 (0.20 to 0.73)
Subtotal (95% CI)	26/27	29/30		59.0	0.31 (0.17 to 0.57)
Test for heterogeneity $\chi^2 = 5.13$, df = 1, $p = 0.023$					
Test for overall effect $z = -3.73$, $p = 0.0002$					
02 TAPP versus Preperitoneal Mesh					
Aitola, 1998	8/8	4/4		16.3	0.85 (0.26 to 2.76)
Beets, 1999	6/6	4/4		14.2	0.91 (0.26 to 3.20)
Subtotal (95% CI)	14/14	8/8		30.4	0.88 (0.37 to 2.08)
Test for heterogeneity $\chi^2 = 0.01$, df = 1, $p = 0.94$					
Test for overall effect $z = -0.29$, $p = 0.8$					
03 TAPP versus Plug and Mesh					
Subtotal (95% CI)	0/0	0/0		0.0	Not estimable
Test for heterogeneity $\chi^2 = 0.0$, df = 0					
Test for overall effect $z = 0.0$, $p = 1$					
04 TAPP versus Mixed Mesh					
MRC multicentre, 1999	2/2	6/6		10.6	1.56 (0.37 to 6.67)
Subtotal (95% CI)	2/2	6/6		10.6	1.56 (0.37 to 6.67)
Test for heterogeneity $\chi^2 = 0.0$, df = 0					
Test for overall effect $z = 0.60$, $p = 0.5$					
Total (95% CI)	42/43	43/44		100.0	0.51 (0.32 to 0.81)
Test for heterogeneity $\chi^2 = 11.51$, df = 4, $p = 0.021$					
Test for overall effect $z = -2.83$, $p = 0.005$					

0.001 0.01 0.1 1 10 100 1000

Favours treatment   Favours control

n/N refers to the number who have returned to activities within the follow-up period. The remaining few people are censored, i.e. they have not yet returned to activities at the time of follow-up.

Comparison: 06 TAPP versus Open Mesh (Bilateral hernias)
Outcome: 13 Persisting numbness

Study	Treatment n/N	Control n/N	RR (95% CI fixed)	Weight %	RR (95% CI fixed)
01 TAPP versus Flat Mesh					
x Payne, 1994	0/4	0/6		0.0	Not estimable
Wellwood, 1998	1/23	7/24		73.3	0.15 (0.02 to 1.12)
Subtotal (95% CI)	1/27	7/30		73.3	0.15 (0.02 to 1.12)
Test for heterogeneity $\chi^2 = 0.0$, df = 0					
Test for overall effect $z = -1.85$, $p = 0.6$					
02 TAPP versus Preperitoneal Mesh					
x Beets, 1999	0/14	0/13		0.0	Not estimable
Subtotal (95% CI)	0/14	0/13		0.0	Not estimable
Test for heterogeneity $\chi^2 = 0.0$, df = 0					
Test for overall effect $z = 0.0$, $p = 1$					
03 TAPP versus Plug and Mesh					
Subtotal (95% CI)	0/0	0/0		0.0	Not estimable
Test for heterogeneity $\chi^2 = 0.0$, df = 0					
Test for overall effect $z = 0.0$, $p = 1$					
04 TAPP versus Mixed Mesh					
MRC multicentre, 1999	1/5	3/7		26.7	0.47 (0.07 to 3.28)
Subtotal (95% CI)	1/5	3/7		26.7	0.47 (0.07 to 3.28)
Test for heterogeneity $\chi^2 = 0.0$, df = 0					
Test for overall effect $z = -0.77$, $p = 0.4$					
Total (95% CI)	2/46	10/50		100.0	0.23 (0.06 to 0.94)
Test for heterogeneity $\chi^2 = 0.67$, df = 1, $p = 0.41$					
Test for overall effect $z = -2.05$, $p = 0.04$					

0.01 0.1 1 10 100

Favours treatment   Favours control

145

Comparison: 06 TAPP versus Open Mesh (Bilateral hernias)
Outcome: 14 Persisting pain

Study	Treatment n/N	Control n/N	RR (95% CI fixed)	Weight %	RR (95% CI fixed)
01 TAPP versus Flat Mesh					
Wellwood, 1998	10/23	11/24		70.2	0.95 (0.50 to 1.79)
Subtotal (95% CI)	10/23	11/24		70.2	0.95 (0.50 to 1.79)
Test for heterogeneity $\chi^2 = 0.0$, df = 0					
Test for overall effect $z = -0.16$, $p = 0.9$					
02 TAPP versus Preperitoneal Mesh					
Beets, 1999	1/14	2/13		13.5	0.46 (0.05 to 4.53)
Subtotal (95% CI)	1/14	2/13		13.5	0.46 (0.05 to 4.53)
Test for heterogeneity $\chi^2 = 0.0$, df = 0					
Test for overall effect $z = 0.66$, $p = 0.5$					
03 TAPP versus Plug and Mesh					
Subtotal (95% CI)	0/0	0/0		0.0	Not estimable
Test for heterogeneity $\chi^2 = 0.0$, df = 0					
Test for overall effect $z = 0.0$, $p = 1$					
04 TAPP versus Mixed Mesh					
MRC multicentre, 1999	1/5	3/7		16.3	0.47 (0.07 to 3.28)
Subtotal (95% CI)	1/5	3/7		16.3	0.47 (0.07 to 3.28)
Test for heterogeneity $\chi^2 = 0.0$, df = 0					
Test for overall effect $z = -0.77$, $p = 0.4$					
Total (95% CI)	12/42	16/44		100.0	0.80 (0.45 to 1.45)
Test for heterogeneity $\chi^2 = 0.78$, df = 2, $p = 0.68$					
Test for overall effect $z = -0.72$, $p = 0.5$					

0.001 0.01 0.1 1 10 100 1000
Favours treatment   Favours control

Comparison: 06 TAPP versus Open Mesh (Bilateral hernias)
Outcome: 15 Hernia recurrence

Study	Treatment n/N	Control n/N	RR (95% CI fixed)	Weight %	RR (95% CI fixed)
01 TAPP versus Flat Mesh					
x Heikkinen, 1997	0/1	0/1		0.0	Not estimable
x Payne, 1994	0/4	0/6		0.0	Not estimable
Sarli, 2001	0/20	1/23		47.8	0.38 (0.02 to 8.86)
Wellwood, 1998	1/23	0/24		16.7	3.12 (0.13 to 73.02)
Subtotal (95% CI)	1/48	1/54		64.6	1.09 (0.16 to 7.68)
Test for heterogeneity $\chi^2 = 0.86$, df = 1, $p = 0.35$					
Test for overall effect $z = 0.09$, $p = 0.9$					
02 TAPP versus Preperitoneal Mesh					
x Aitola, 1998	0/10	0/4		0.0	Not estimable
Beets, 1999	4/14	1/13		35.4	3.71 (0.47 to 29.06)
Subtotal (95% CI)	4/24	1/17		35.4	3.71 (0.47 to 29.06)
Test for heterogeneity $\chi^2 = 0.0$, df = 0					
Test for overall effect $z = 1.25$, $p = 0.2$					
03 TAPP versus Plug and Mesh					
Subtotal (95% CI)	0/0	0/0		0.0	Not estimable
Test for heterogeneity $\chi^2 = 0.0$, df = 0					
Test for overall effect $z = 0.0$, $p = 1$					
04 TAPP versus Mixed Mesh					
x MRC multicentre, 1999	0/3	0/6		0.0	Not estimable
Subtotal (95% CI)	0/3	0/6		0.0	Not estimable
Test for heterogeneity $\chi^2 = 0.0$, df = 0					
Test for overall effect $z = 0.0$, $p = 1$					
Total (95% CI)	5/75	2/77		100.0	2.02 (0.52 to 7.83)
Test for heterogeneity $\chi^2 = 1.49$, df = 2, $p = 0.47$					
Test for overall effect $z = 1.02$, $p = 0.3$					

0.01 0.1 1 10 100
Favours treatment   Favours control

Appendix 7(7)

Results of meta-analyses: laparoscopic TEP versus open mesh repair (bilateral hernias)

Comparison: 07 TEP versus Open Mesh (Bilateral hernias)
Outcome: 01 Duration of operation (minutes)

Study	Treatment n	Mean (SD)	Control n	Mean (SD)	WMD (95% CI fixed)	Weight %	WMD (95% CI fixed)
01 TEP versus Flat Mesh							
Colak, 2003	21	54.33 (17.37)	6	74.50 (8.09)		34.8	−20.17 (−30.02 to −10.32)
Payne, 1996	9	82.78 (18.73)	6	81.67 (20.17)		8.2	1.11 (−19.14 to 21.36)
Subtotal (95% CI)	30		12			43.0	−16.10 (−24.96 to −7.24)
Test for heterogeneity $\chi^2 = 3.43$, df = 1, $p = 0.064$							
Test for overall effect $z = 3.56$, $p = 0.0004$							
02 TEP versus Preperitoneal Mesh							
Champault, 1997	21	110.00 (25.00)	24	80.00 (13.00)		23.9	30.00 (18.11 to 41.89)
Subtotal (95% CI)	21		24			23.9	30.00 (18.11 to 41.89)
Test for heterogeneity $\chi^2 = 0.0$, df = 0							
Test for overall effect $z = 4.95$, $p < 0.00001$							
03 TEP versus Plug and Mesh							
Khoury, 1998	15	52.00 (16.78)	3	51.67 (16.07)		8.4	0.33 (−19.74 to 20.40)
Subtotal (95% CI)	15		3			8.4	0.33 (−19.74 to 20.40)
Test for heterogeneity $\chi^2 = 0.0$, df = 0							
Test for overall effect $z = 0.03$, $p = 1$							
04 TEP versus Mixed Mesh							
MRC multicentre 1999	27	76.11 (22.73)	28	52.32 (21.39)		24.8	23.79 (12.12 to 35.46)
Subtotal (95% CI)	27		28			24.8	23.79 (12.12 to 35.46)
Test for heterogeneity $\chi^2 = 0.0$, df = 0							
Test for overall effect $z = 3.99$, $p = 0.00006$							
Total (95% CI)	93		67			100.0	6.16 (0.35 to 11.97)
Test for heterogeneity $\chi^2 = 52.20$, df = 4, $p < 0.00001$							
Test for overall effect $z = 2.08$, $p = 0.04$							

−100   −50   0   50   100

Favours treatment   Favours control

Comparison: 07 TEP versus Open Mesh (Bilateral hernias)
Outcome: 02 "Opposite" method initiated

Study	Treatment n/N	Control n/N	RR (95% CI fixed)	Weight %	RR (95% CI fixed)
01 TEP versus Flat Mesh					
x Payne, 1996	0/9	0/6		0.0	Not estimable
Subtotal (95% CI)	0/9	0/6		0.0	Not estimable
Test for heterogeneity $\chi^2 = 0.0$, df = 0					
Test for overall effect z = 0.0, p = 1					
02 TEP versus Preperitoneal Mesh					
Subtotal (95% CI)	0/0	0/0		0.0	Not estimable
Test for heterogeneity $\chi^2 = 0.0$, df = 0					
Test for overall effect z = 0.0, p = 1					
03 TEP versus Plug and Mesh					
x Khoury, 1998	0/16	0/3		0.0	Not estimable
Subtotal (95% CI)	0/16	0/3		0.0	Not estimable
Test for heterogeneity $\chi^2 = 0.0$, df = 0					
Test for overall effect z = 0.0, p = 1					
04 TEP versus Mixed Mesh					
MRC multicentre, 1999	1/28	0/29		100.0	3.10 (0.13 to 73.13)
Subtotal (95% CI)	1/28	0/29		100.0	3.10 (0.13 to 73.13)
Test for heterogeneity $\chi^2 = 0.0$, df = 0					
Test for overall effect z = 0.70, p = 0.5					
Total (95% CI)	1/53	0/38		100.0	3.10 (0.13 to 73.13)
Test for heterogeneity $\chi^2 = 0.0$, df = 0					
Test for overall effect z = 0.70, p = 0.5					

0.001 0.01 0.1 1 10 100 1000
Favours treatment   Favours control

Comparison: 07 TEP versus Open Mesh (Bilateral hernias)
Outcome: 03 Conversion

Study	Treatment n/N	Control n/N	RR (95% CI fixed)	Weight %	RR (95% CI fixed)
01 TEP versus Flat Mesh					
x Payne, 1996	0/9	0/6		0.0	Not estimable
Subtotal (95% CI)	0/9	0/6		0.0	Not estimable
Test for heterogeneity $\chi^2 = 0.0$, df = 0					
Test for overall effect z = 0.0, p = 1					
02 TEP versus Preperitoneal Mesh					
Subtotal (95% CI)	0/0	0/0		0.0	Not estimable
Test for heterogeneity $\chi^2 = 0.0$, df = 0					
Test for overall effect z = 0.0, p = 1					
03 TEP versus Plug and Mesh					
Khoury, 1998	1/15	0/3		62.4	0.75 (0.04 to 15.17)
Subtotal (95% CI)	1/15	0/3		62.4	0.75 (0.04 to 15.17)
Test for heterogeneity $\chi^2 = 0.0$, df = 0					
Test for overall effect z = −0.19, p = 0.9					
04 TEP versus Mixed Mesh					
MRC multicentre, 1999	2/27	0/29		37.6	5.36 (0.27 to 106.79)
Subtotal (95% CI)	2/27	0/29		37.6	5.36 (0.27 to 106.79)
Test for heterogeneity $\chi^2 = 0.0$, df = 0					
Test for overall effect z = 1.10, p = 0.3					
Total (95% CI)	3/51	0/38		100.0	2.48 (0.35 to 17.44)
Test for heterogeneity $\chi^2 = 0.86$, df = 1, p = 0.35					
Test for overall effect z = 0.92, p = 0.4					

0.001 0.01 0.1 1 10 100 1000
Favours treatment   Favours control

Comparison: 07 TEP versus Open Mesh (Bilateral hernias)
Outcome: 04 Haematoma

Study	Treatment n/N	Control n/N	RR (95% CI fixed)	Weight %	RR (95% CI fixed)
01 TEP versus Flat Mesh					
Subtotal (95% CI)	0/0	0/0		0.0	Not estimable
Test for heterogeneity $\chi^2 = 0.0$, df = 0					
Test for overall effect $z = 0.0$, $p = 1$					
02 TEP versus Preperitoneal Mesh					
Subtotal (95% CI)	0/0	0/0		0.0	Not estimable
Test for heterogeneity $\chi^2 = 0.0$, df = 0					
Test for overall effect $z = 0.0$, $p = 1$					
03 TEP versus Plug and Mesh					
Khoury, 1998	1/16	0/3		30.0	0.71 (0.03 to 14.32)
Subtotal (95% CI)	1/16	0/3		30.0	0.71 (0.03 to 14.32)
Test for heterogeneity $\chi^2 = 0.0$, df = 0					
Test for overall effect $z = -0.23$, $p = 0.8$					
04 TEP versus Mixed Mesh					
MRC multicentre, 1999	5/25	2/28		70.0	2.80 (0.60 to 13.17)
Subtotal (95% CI)	5/25	2/28		70.0	2.80 (0.60 to 13.17)
Test for heterogeneity $\chi^2 = 0.0$, df = 0					
Test for overall effect $z = 1.30$, $p = 0.19$					
Total (95% CI)	6/41	2/31		100.0	2.17 (0.57 to 8.24)
Test for heterogeneity $\chi^2 = 0.64$, df = 1, $p = 0.42$					
Test for overall effect $z = 1.14$, $p = 0.3$					

0.001 0.01 0.1 1 10 100 1000
Favours treatment   Favours control

Comparison: 07 TEP versus Open Mesh (Bilateral hernias)
Outcome: 05 Seroma

Study	Treatment n/N	Control n/N	RR (95% CI fixed)	Weight %	RR (95% CI fixed)
01 TEP versus Flat Mesh					
Subtotal (95% CI)	0/0	0/0		0.0	Not estimable
Test for heterogeneity $\chi^2 = 0.0$, df = 0					
Test for overall effect $z = 0.0$, $p = 1$					
02 TEP versus Preperitoneal Mesh					
Subtotal (95% CI)	0/0	0/0		0.0	Not estimable
Test for heterogeneity $\chi^2 = 0.0$, df = 0					
Test for overall effect $z = 0.0$, $p = 1$					
03 TEP versus Plug and Mesh					
x Khoury, 1998	0/16	0/3		0.0	Not estimable
Subtotal (95% CI)	0/16	0/3		0.0	Not estimable
Test for heterogeneity $\chi^2 = 0.0$, df = 0					
Test for overall effect $z = 0.0$, $p = 1$					
04 TEP versus Mixed Mesh					
MRC multicentre, 1999	2/24	4/28		100.0	0.58 (0.12 to 2.91)
Subtotal (95% CI)	2/24	4/28		100.0	0.58 (0.12 to 2.91)
Test for heterogeneity $\chi^2 = 0.0$, df = 0					
Test for overall effect $z = -0.66$, $p = 0.5$					
Total (95% CI)	2/40	4/31		100.0	0.58 (0.12 to 2.91)
Test for heterogeneity $\chi^2 = 0.0$, df = 0					
Test for overall effect $z = -0.66$, $p = 0.5$					

0.001 0.01 0.1 1 10 100 1000
Favours treatment   Favours control

149

Comparison: 07 TEP versus Open Mesh (Bilateral hernias)
Outcome: 06 Wound/superficial infection

Study	Treatment n/N	Control n/N	RR (95% CI fixed)	Weight %	RR (95% CI fixed)
01 TEP versus Flat Mesh					
Subtotal (95% CI)	0/0	0/0		0.0	Not estimable
Test for heterogeneity $\chi^2 = 0.0$, df = 0					
Test for overall effect z = 0.0, p = 1					
02 TEP versus Preperitoneal Mesh					
Subtotal (95% CI)	0/0	0/0		0.0	Not estimable
Test for heterogeneity $\chi^2 = 0.0$, df = 0					
Test for overall effect z = 0.0, p = 1					
03 TEP versus Plug and Mesh					
x Khoury, 1998	0/16	0/3		0.0	Not estimable
Subtotal (95% CI)	0/16	0/3		0.0	Not estimable
Test for heterogeneity $\chi^2 = 0.0$, df = 0					
Test for overall effect z = 0.0, p = 1					
04 TEP versus Mixed Mesh					
MRC multicentre, 1999	0/24	1/28		100.0	0.39 (0.02 to 9.07)
Subtotal (95% CI)	0/24	1/28		100.0	0.39 (0.02 to 9.07)
Test for heterogeneity $\chi^2 = 0.0$, df = 0					
Test for overall effect z = −0.59, p = 0.6					
Total (95% CI)	0/40	1/31		100.0	0.39 (0.02 to 9.07)
Test for heterogeneity $\chi^2 = 0.0$, df = 0					
Test for overall effect z = −0.59, p = 0.6					

0.001 0.01 0.1 1 10 100 1000

Favours treatment   Favours control

Comparison: 07 TEP versus Open Mesh (Bilateral hernias)
Outcome: 11 Length of stay (days)

Study	Treatment n	Mean (SD)	Control n	Mean (SD)	WMD (95% CI fixed)	Weight %	WMD (95% CI fixed)
01 TEP versus Flat Mesh							
x Payne, 1996	9	0.00 (0.00)	6	0.00 (0.00)		0.0	Not estimable
Subtotal (95% CI)	9		6			0.0	0.00 (0.00 to 0.00)
Test for heterogeneity $\chi^2 = 0.0$, df = 0							
Test for overall effect z = 0, p = 1							
02 TEP versus Preperitoneal Mesh							
Subtotal (95% CI)	0		0			0.0	Not estimable
Test for heterogeneity $\chi^2 = 0.0$, df = 0							
Test for overall effect z = 0.0, p = 1							
03 TEP versus Plug and Mesh							
x Khoury, 1998	16	0.00 (0.00)	3	1.00 (1.00)		0.0	Not estimable
Subtotal (95% CI)	16		3			0.0	0.00 (0.00 to 0.00)
Test for heterogeneity $\chi^2 = 0.0$, df = 0							
Test for overall effect z = 0.0, p = 1							
04 TEP versus Mixed Mesh							
MRC multicentre 1999	27	1.59 (0.80)	27	1.74 (0.94)		100.0	−0.15 (−0.62 to 0.32)
Subtotal (95% CI)	27		27			100.0	−0.15 (−0.62 to 0.32)
Test for heterogeneity $\chi^2 = 0.0$, df = 0							
Test for overall effect z = 0.63, p = 0.5							
Total (95% CI)	52		36			100.0	−0.15 (−0.62 to 0.32)
Test for heterogeneity $\chi^2 = 0.0$, df = 0							
Test for overall effect z = 0.63, p = 0.5							

−4 −2 0 2 4

Favours treatment   Favours control

Comparison: 07 TEP versus Open Mesh (Bilateral hernias)
Outcome: 12 Time to return to usual activities (days)

Study	Treatment n/N	Control n/N	HR (95% CI fixed)	Weight %	HR (95% CI fixed)
01 TEP versus Flat Mesh					
Payne, 1996	9/9	6/6		25.9	0.63 (0.23 to 1.73)
Subtotal (95% CI)	9/9	6/6		25.9	0.63 (0.23 to 1.73)
Test for heterogeneity $\chi^2 = 0.0$, df = 0					
Test for overall effect $z = -0.90$, $p = 0.4$					
02 TEP versus Preperitoneal Mesh					
Subtotal (95% CI)	0/0	0/0		0.0	Not estimable
Test for heterogeneity $\chi^2 = 0.0$, df = 0					
Test for overall effect $z = 0.0$, $p = 1$					
03 TEP versus Plug and Mesh					
Khoury, 1998	16/16	3/3		21.1	0.76 (0.25 to 2.33)
Subtotal (95% CI)	16/16	3/3		21.1	0.76 (0.25 to 2.33)
Test for heterogeneity $\chi^2 = 0.0$, df = 0					
Test for overall effect $z = -0.48$, $p = 0.6$					
04 TEP versus Mixed Mesh					
MRC multicentre, 1999	13/16	20/23		53.0	0.89 (0.44 to 1.81)
Subtotal (95% CI)	13/16	20/23		53.0	0.89 (0.44 to 1.81)
Test for heterogeneity $\chi^2 = 0.0$, df = 0					
Test for overall effect $z = -0.32$, $p = 0.8$					
Total (95% CI)	38/41	29/32		100.0	0.79 (0.47 to 1.32)
Test for heterogeneity $\chi^2 = 0.31$, df = 2, $p = 0.86$					
Test for overall effect $z = -0.91$, $p = 0.4$					

```
        0.001  0.01   0.1     1      10    100   1000
              Favours treatment    Favours control
```

n/N refers to the number who have returned to activities within the follow-up period. The remaining few people are censored, i.e. they have not yet returned to activities at the time of follow-up.

Comparison: 07 TEP versus Open Mesh (Bilateral hernias)
Outcome: 13 Persisting numbness

Study	Treatment n/N	Control n/N	RR (95% CI fixed)	Weight %	RR (95% CI fixed)
01 TEP versus Flat Mesh					
Subtotal (95% CI)	0/0	0/0		0.0	Not estimable
Test for heterogeneity $\chi^2 = 0.0$, df = 0					
Test for overall effect $z = 0.0$, $p = 1$					
02 TEP versus Preperitoneal Mesh					
Subtotal (95% CI)	0/0	0/0		0.0	Not estimable
Test for heterogeneity $\chi^2 = 0.0$, df = 0					
Test for overall effect $z = 0.0$, $p = 1$					
03 TEP versus Plug and Mesh					
Khoury, 1998	1/16	0/3		9.1	0.71 (0.03 to 14.32)
Subtotal (95% CI)	1/16	0/3		9.1	0.71 (0.03 to 14.32)
Test for heterogeneity $\chi^2 = 0.0$, df = 0					
Test for overall effect $z = -0.23$, $p = 0.8$					
04 TEP versus Mixed Mesh					
MRC multicentre, 1999	8/23	9/28		90.9	1.08 (0.50 to 2.35)
Subtotal (95% CI)	8/23	9/28		90.9	1.08 (0.50 to 2.35)
Test for heterogeneity $\chi^2 = 0.0$, df = 0					
Test for overall effect $z = 0.20$, $p = 0.8$					
Total (95% CI)	9/39	9/31		100.0	1.05 (0.49 to 2.22)
Test for heterogeneity $\chi^2 = 0.07$, df = 1, $p = 0.79$					
Test for overall effect $z = 0.12$, $p = 0.9$					

```
        0.001  0.01   0.1     1      10    100   1000
              Favours treatment    Favours control
```

151

Comparison: 07 TEP versus Open Mesh (Bilateral hernias)
Outcome: 14 Persisting pain

Study	Treatment n/N	Control n/N	RR (95% CI fixed)	Weight %	RR (95% CI fixed)
01 TEP versus Flat Mesh					
Subtotal (95% CI)	0/0	0/0		0.0	Not estimable
Test for heterogeneity $\chi^2 = 0.0$, df = 0					
Test for overall effect $z = 0.0$, $p = 1$					
02 TEP versus Preperitoneal Mesh					
Subtotal (95% CI)	0/0	0/0		0.0	Not estimable
Test for heterogeneity $\chi^2 = 0.0$, df = 0					
Test for overall effect $z = 0.0$, $p = 1$					
03 TEP versus Plug and Mesh					
Khoury, 1998	1/16	0/3		4.8	0.71 (0.03 to 14.32)
Subtotal (95% CI)	1/16	0/3		4.8	0.71 (0.03 to 14.32)
Test for heterogeneity $\chi^2 = 0.0$, df = 0					
Test for overall effect $z = -0.23$, $p = 0.8$					
04 TEP versus Mixed Mesh					
MRC multicentre, 1999	15/26	17/29		95.2	0.98 (0.63 to 1.54)
Subtotal (95% CI)	15/26	17/29		95.2	0.98 (0.63 to 1.54)
Test for heterogeneity $\chi^2 = 0.0$, df = 0					
Test for overall effect $z = -0.07$, $p = 0.9$					
Total (95% CI)	16/42	17/32		100.0	0.97 (0.62 to 1.52)
Test for heterogeneity $\chi^2 = 0.05$, df = 1, $p = 0.83$					
Test for overall effect $z = -0.13$, $p = 0.9$					

0.01 0.1 1 10 100
Favours treatment   Favours control

Comparison: 07 TEP versus Open Mesh (Bilateral hernias)
Outcome: 15 Hernia recurrence

Study	Treatment n/N	Control n/N	RR (95% CI fixed)	Weight %	RR (95% CI fixed)
01 TEP versus Flat Mesh					
Subtotal (95% CI)	0/0	0/0		0.0	Not estimable
Test for heterogeneity $\chi^2 = 0.0$, df = 0					
Test for overall effect $z = 0.0$, $p = 1$					
02 TEP versus Preperitoneal Mesh					
Suter, 2002	1/19	0/20		51.3	3.15 (0.14 to 72.89)
Subtotal (95% CI)	1/19	0/20		51.3	3.15 (0.14 to 72.89)
Test for heterogeneity $\chi^2 = 0.0$, df = 0					
Test for overall effect $z = 0.72$, $p = 0.5$					
03 TEP versus Plug and Mesh					
x Khoury, 1998	0/16	0/3		0.0	Not estimable
Subtotal (95% CI)	0/16	0/3		0.0	Not estimable
Test for heterogeneity $\chi^2 = 0.0$, df = 0					
Test for overall effect $z = 0.0$, $p = 1$					
04 TEP versus Mixed Mesh					
MRC multicentre, 1999	2/24	0/28		48.7	5.80 (0.29 to 115.21)
Subtotal (95% CI)	2/24	0/28		48.7	5.80 (0.29 to 115.21)
Test for heterogeneity $\chi^2 = 0.0$, df = 0					
Test for overall effect $z = 1.15$, $p = 0.2$					
Total (95% CI)	3/59	0/51		100.0	4.44 (0.52 to 38.01)
Test for heterogeneity $\chi^2 = 0.08$, df = 1, $p = 0.78$					
Test for overall effect $z = 1.36$, $p = 0.17$					

0.001 0.01 0.1 1 10 100 1000
Favours treatment   Favours control

Appendix 8

Details of further studies used for clinical
effectiveness of TAPP versus TEP (non-RCTs)

Study	Country of study	Study design	Data collection	Number of repairs	Patients' characteristics – TAPP	Patients' characteristics – TEP
Baca, 2000[112]	Germany	Case series	Retrospective	2500 TAPP	92% male Average age 59 (range 19–88) years 32% direct, 37% indirect, 2% femoral, 12% combined, 17% recurrent, 22% bilateral Mean follow-up 39 months (range 4 weeks to 7 years) 87% patients included in analysis	Not applicable
Cohen, 1998[113]	Brazil	Concurrent comparison?	Prospective	108 TAPP 100 TEP	100% male Mean age 35 (range 21–73) years – overall only 28% unilateral, 38% bilateral, 33% recurrent	100% male Mean age 35 (range 21–73) years – overall only 9% unilateral, 49% bilateral, 42% recurrent
Felix, 1995[114]	USA	Concurrent comparison	Retrospective	733 TAPP 382 TEP	87% male Mean age 49 (range 12–89) years Median follow-up: 24 months (TAPP) and 9 months (TEP) 60% indirect, 23.6% direct, 15.3% pantaloon, 1% femoral	
Khoury, 1995[115]	Canada	Concurrent comparison	Prospective	60 TAPP 60 TEP	91% male Age range 20–76 years 67% indirect, 28% direct, 3% femoral, 2% combined	Used a distension balloon 93% male Age range 20–73 years 68% indirect, 27% direct, 2% femoral, 3% combined
Leibl, 2000[116]	Germany	Case series	Retrospective	5707 TAPP	Not reported	
Lepere, 2000[117]	France	Concurrent comparison	Retrospective	1290 TAPP 682 TEP	87% male overall 63% unilateral, 37% bilateral, 9% recurrent	87% male overall 74% unilateral, 36% bilateral, 8% recurrent
Tamme, 2003[118]	Germany	Case series	Retrospective	5203 TEP	91% male Median age 53 (range 15–89) years 32% direct, 57% indirect, 8% combined, 3% femoral, 13% recurrent, 35% bilateral	
Van Hee, 1998[119]	Belgium	Concurrent comparison?	Prospective	37 TAPP 69 TEP	100% male Mean age 58 (range 20–79) years 78% unilateral, 22% bilateral, 43% direct, 54% direct, 3% combined, 5% recurrent	97% male Mean age 59 (range 21–84) years 68% unilateral, 32% bilateral, 29% direct, 59% indirect, 12% combined, 10% recurrent
Weiser, 2000[120]	Germany	Non-concurrent comparison	Retrospective	1216 TAPP 1547 TEP	Not reported	Not reported

Appendix 9

Learning curve study eligibility form

NICE review of the effectiveness and cost-effectiveness of laparoscopic surgery for inguinal hernia repair

Study ID: _____ **Refman ID:** _____

Q1. Is data reported for an individual operator rather than an institution?

            Yes   Unclear   No

                Go to   **Exclude**
             Next question

Q2. Is data reported for at least 3 points on the learning curve?

            Yes   Unclear   No

                Go to   **Exclude**
             Next question

Q3. Are the procedures consecutive?

            Yes   Unclear   No

                Go to   **Exclude**
             Next question

Q4. Is data reported for at least one of the relevant 'learning' outcomes?

            Yes   Unclear   No

                Go to   **Exclude**
             Next question

Final decision: Included ☐ Unclear ☐ Excluded ☐

Appendix 10

Learning curve data collection and quality assessment form

NICE review of the effectiveness and cost-effectiveness of laparoscopic surgery for inguinal hernia repair

Reviewer ID: _____

Study Details

Study ID:　　　　　　　　　　　　　　　　　Abstract ☐　　Full text ☐

Authors:

Title:

Publication year or date of interim data collection:

Language:

Type of study:

Setting and Timing

Setting of study: _____

Number of clinics _____　Number of operators _____

No. lap procedures performed prior to study entry _____

Recruitment period: _____

Follow-up period: _____

Other details:

Intervention			
	Surgical Technique	**Type of Anaesthesia**	**No of patients**
Intervention 1:			
Intervention 2:			

Patient Characteristics			
	Intervention 1	**Intervention 2**	**Overall**
Age (years)			
Sex (M/F)			

Outcomes										
Duration of operation	Time point									
	Mins									
	Time point									
	Mins									
Visceral injury	Time point									
	Number									
Vascular injury	Time point									
	Number									
Length of stay	Time point									
	Days									
Return to usual activity	Time point									
	Days									
Hernia recurrence	Time point									
	No									
Persisting pain	Time point									
	No									
Persisting numbness	Time point									
	No									

Appendix 11
Characteristics of learning curve studies

Study	Study type	Surgical technique	Patients (n)	Repairs (n)	Setting	Clinics (n)	Operators (n)	Laparoscopic procedures prior to study (n)	Follow-up period	Characteristics of patients	Characteristics of hernias
Aeberhard, 1999[121]	Prospective audit	TEP	1186	1605 (767 unilateral, 419 bilateral)	Multicentre, Switzerland	29	29?	594	>3 months	Age mean (SD) 54.6 (14.4) years 1095 male/90 female	819 indirect, 338 direct, 231 recurrent, 28 femoral
Lau, 2002[20,127]	Retrospective analysis	TEP	120	120	Single centre, Hong Kong	1	1	14 TAPP, no TEP	1 week	Age mean (SD) 63 (13.9) years 116 male/4 female	80 indirect, 31 direct, 11 recurrent, 2 femoral
Leibl, 2000[122]	Retrospective analysis	TAPP	778	778	Single centre, Germany	10 (2 groups: experts and trainees)	1	Median 30.5	Median 23 months	Age (range) 59 (16–97) years Experts, 58 (18–92) learners	No translation
Liem, 1996[123]	Pilot study	TEP	120	122	Multicentre, The Netherlands	4	4	Only one had done 15 TAPP	Unknown	Age (range) 54 (21–57) years 113 male/7 female	92 indirect, 26 direct, 14 recurrent, 2 bilateral
Ramsay, 2001[124]	Systematic review	TAPP and TEP	702	702	Multicentre, UK	Unknown	27	At least 10 but 'still learning'	Unknown	Unknown	Unknown
Voitk, 1998[125]	Prospective analysis	TAPP	98	164 (first 100 consecutive TAPP procedures)	Single centre, Canada	1	1	>50 chole cystectomy, no laparoscopic hernias	2 weeks/ 3 months	Age mean (range) 57 (24–88) years 90 male/8 female	62 unilateral, 38 bilateral, 21 pantaloon. 58% indirect, 42% direct
Wright, 1998[126]	Report of 2 RCTs	TEP	Unknown	Given for 30 repairs	2 multicentre RCTs – The Netherlands and UK	Unknown	7	Unknown	Unknown	Unknown	Unknown

Appendix 12

Characteristics and summary of results of the
studies reporting both costs and outcomes

Study	Study characteristics	Treatment groups	Baseline characteristics and follow-up	Results	Conclusions
BARD, 2003 (BARD Industry submission 2003)	To assess the cost-effectiveness of the Perfix Plug approach *Design:* decision analytic model making indirect comparisons using pooled data from randomised and non-randomised studies Cost reported in 2002 UK £	Perfix Plug (form of open mesh) Laparoscopic repair	Characteristics of patient population not described. Time horizon of model not stated Cost based on NHS National Reference Costs for 2002 for hernia repair plus the cost of the Prefix plug Key assumption relates to proportion of patients managed as less costly day cases (91% Perfix Plug, 60% laparoscopic repair)	*Costs:* Mean cost per initial procedure Perfix Plug £803, laparoscopic £868 *Recurrence probabilities:* Prefix Plug 0.5, laparoscopic 2.2 One- and two-way analysis performed to look at thresholds. In two-way analysis cost neutrality occurs when the laparoscopic day-case rate is 76% and the recurrence rate is 1.8% Cost per procedure (including recurrences treatment costs) Perfix Plug £809, laparoscopic £894	Perfix Plug approach is cost saving and more effective but the results are driven by number of people managed as day-cases and to very much lesser extent estimates of recurrence
Eno, 2000[135]	To compare outcome of patients who had an open hernia repair or a laparoscopic hernia repair *Design:* retrospective observational study *Setting:* Australia teaching hospital *Country:* Australia *Costing:* costs obtained using the Trendstar Decision Support Information System (John Hunter Hospital). Costs included an average of nursing, medical, allied health, dispensed drugs, imaging, pathology, theatre and prosthesis costs Costs reported AUS$ Year not stated	*Number of patients in each group:* Laparoscopic 69 Open 35 Conversion laparoscopic to open 4 All patients having laparoscopic had general anaesthesia but only 84% of those in the open group Data for the costs of consumables were obtained from the New South Wales Inpatient Statistics Collection 1996–97, 1997–98 Effectiveness data retrieved from patients between June 1997 and May 1998	Patients were between 26 and 80 years old for laparoscopic, average 50 years, and between 17 and 91 years old for open mesh, average 59 years. Patients included those who had an elective hernia repair between 1 June 1997 and 31 May 1998 at John Hunter Hospital Follow-up only during hospitalisation period	*Average length of stay:* laparoscopic 1.1 days (median 1.0, range 0–4) Open repair 1.8 days (median 1.0, range 0–7) $p = 0.001$ (Mann–Whitney U-test) *Operation duration:* Laparoscopic average 68 minutes (range 40–155) Open average 51 minutes (range 30–80) $p = 0.0001$ (Mann–Whitney U-test) *Complications:* Laparoscopic 2 Open group 13 $p = 0.08$ (Fisher's exact test) *Postoperative analgesia:* Laparoscopic: median number of doses 1 (range 0–3) Open repair: median number of doses 2 (range 0–5) $p = 0.022$ (Mann–Whitney U-test) *Hospital costs:* Laparoscopic: AUS$ 3106 Open: AUS$ 2342 No sensitivity analysis was performed	The study identified that only length of stay and the use of analgesia were significantly higher in the open than in the laparoscopic Authors' group state that despite only considering in-hospital costs the additional cost of laparoscopic would fund the performance of at least 13 extra open repairs in the audited hospital

Study	Study characteristics	Treatment groups	Baseline characteristics and follow-up	Results	Conclusions
Ethicon Endo-Surgery, 2003 (Ethicon Endo-Surgery Submission, 2003)	Same as MRC Laparoscopic Groin Hernia Trial but modified to consider the management of bilateral hernias The MRC trial was a multicentre trial based in 26 centres in the UK UK costing: method of bottom-up. Cost reported in 1998 UK £	Same as MRC Laparoscopic Groin Hernia Trial Laparoscopic 468 Open mesh 460 Various regimes of anaesthesia and equipment were used	Same as MRC Laparoscopic Groin Hernia Trial QALY scores are based on EQ5D given at 1 week, 1 month and 3 months Utilities calculated using power curves and UK tariffs for the EQ5D. Assumed that 30% of all patients would have occult contralateral hernias and that these could be identified and treated by laparoscopic repair. Thus presenting the need for subsequent operations	Allowing for treatment of occult contralateral hernias reduced incremental cost per QALY to £15,000 (£55,548 in the previous MRC trial)	Use of laparoscopic repair may be considered cost-effective. Includes an impact for the NHS: £1.3 million pounds and 6900 secondary interventions
Papachristou, 2002[133]	To compare the costs and effectiveness of TAPP compared with TEP and standard open mesh *Design:* observational *Setting:* not stated *Country:* Greece *Costing:* Method of costing not reported Cost reported in Euros Year not stated	*Number of patients in each group:* TAPP 60 TEP 174 Open 86	Patients were between 21 and 82 years old and presented with inguinal hernia No other inclusion/exclusion criteria were stated Follow-up 6 months Only costs relating to the operative episode were collected. These costs included inpatient room, operation room, pharmacy, intravenous fluids, anaesthesia supplies and nutrition services	*Postoperative complications:* TAPP: 13 TEP: 9 Open: 10 *Recurrences:* TAPP: 2 TEP: 1 Open: 0 *Time to normal activities (days) median (range):* TAPP: 8 (6–16) TEP: 6 (4–10) Open: 12 (10–21) *Total average costs:* TAPP: 763.20 euros TEP: 572.50 euros Open: 489 euros No sensitivity analysis was performed	Laparoscopic and open mesh comparable for complications. TEP less operative pain and more rapid return to normal activities Choice between TEP and open mesh depending on surgeon's experience

163

Study	Study characteristics	Treatment groups	Baseline characteristics and follow-up	Results	Conclusions
Pikoulis, 2002[134]	To compare laparoscopic repair and mesh plug technique *Design:* observational (prospective) *Setting:* two major medical centres *Country:* Greece *Costing:* Based on hospital charges Costs reported in US $ Year not stated	*Number of patients in each group:* TAPP 237 Open 234 TAPP: general anaesthesia Open: local, epidural, or spinal anaesthesia All TAPP patients were kept overnight Open patients under local anaesthesia, discharged a few hours later, the remaining patients kept overnight	Patients were between 29 and 78 years old for laparoscopic and 18 and 87 years old for open mesh Patients were excluded if: • were at high risk for general anaesthesia • were pregnant • had multiple lower abdominal operations • had second recurrences. Patients with bilateral groin hernias or femoral hernias and those with both inguinal hernias and cholelithiais were encouraged to undergo laparoscopic Mean follow-up in the study was 17 months	Median operating time (minutes): TAPP 57 (56.37–60.08) Open 33 (33.2–35.7) *Return to light activities (days) mean (SD):* TAPP 5.4(2.4) Open 3.4 (1.5) Return to full-time work (days): TAPP median 8 (range 4–10) Open median 8 (range 4–9) Return to heavy physical activities in days mean (SD): TAPP 19.6 (5.9) Open 18.7 (4.3) Complications: TAPP 117 Open 9 Recurrences: TAPP 6 Open 1 Cost: TAPP mean US$ 1200 Open mean US$ 500 No sensitivity analysis was performed	Mesh repair faster, cheaper, technically easier, does not require general anaesthesia and resulted in fewer short or long-term complications and reduced the recurrence rate

Study	Study characteristics	Treatment groups	Baseline characteristics and follow-up	Results	Conclusions
Stylopoulos, 2003[132]	To study the cost-effectiveness of laparoscopic surgery Design: Markov model using data from 51 RCTs and two databases Costing: Costs reported in 2002 US$ and discounted at 3% rate	Expectant management Laparoscopic Open mesh Open non-mesh	Patients were between 18 and 65+ years old No other inclusion/exclusion criteria were stated The cohort of patients was modelled for 5 years Costs were Medicare charges, all direct medical costs were included, productivity costs were included following guidelines of the Washington Panel. QALYs based on Quality Wellbeing Index and US population valuations	*Costs:* Laparoscopic: $4086 Open mesh: $4290 Open non-mesh: $6200 *QALYs:* Laparoscopic: 9.04 QALYs Open mesh: 8.975 QALYs Open non-mesh: 8.546 QALYs *Early recurrence probability (2 years):* Laparoscopic: 2.192% Open mesh: 2.329% Open non-mesh: 4.737% *Incremental costs per QALY relative to expectant management:* laparoscopic $605 Open mesh $697, Open non-mesh $1711 One- and two-way sensitivity analysis was performed on the assumptions of the model Ambulatory facility cost and recurrence rate for laparoscopic appeared to be the most influential values	From a societal perspective the laparoscopic approach may be cost-effective and greater efforts to make it easier to perform could reduce healthcare costs Note: this analysis assumes a lower rate of recurrences for laparoscopic repair. These data should be considered in the light of the supplementary meta-analysis reported in Appendix 15

Study	Study characteristics	Treatment groups	Baseline characteristics and follow-up	Results	Conclusions
Vale, 2003 (unpublished)	To study the cost-effectiveness of laparoscopic surgery *Design:* Markov model using data from 3 Cochrane reviews conducted as part of the same project *Costing:* costs reported in Euros 2001 and discounted at 6% rate. Exchange rate data reported	TAPP TEP Open non-mesh Open flat mash	Model based on a male patient age 45 years The cohort of the patients was modelled for 5 years Costs were based on the bottom-up costs estimated alongside three recent economic evaluations. Cost data from three sources not pooled but rather the analyses were repeated for each data source Probabilistic sensitivity analysis conducted for a number of scenarios including different cost data sources and type of laparoscopic equipment (reusable or disposable)	Open mesh vs open non-mesh associated with lower cost, less pain, fewer recurrences and less time from usual activities Open flat mesh vs laparoscopic *Costs:* vs TEP mean saving £101 (95% CI £63 to £177) vs TAPP mean saving £161 (95% CI £138 to £203) *Recurrence over 5 years:* vs TEP 2 fewer recurrences per 1000 patients (95% CI –49.5 to 109.0) vs TAPP 1 additional recurrence per 1000 patients (95% CI –30.8 to 56.4) *Return to usual activities:* vs TEP: 4.3 less days (95% CI 0.4 to 8.2) vs TAPP: 3.2 less days (95% CI 1.8 to 4.5) *Pain:* vs TEP: 67 (95% CI 41 to 107) vs TAPP: 32 (95% CI 12 to 57) more people per 1000	Open non-mesh was dominated Laparoscopic repair is not cost-effective compared with open mesh repair in terms of cost per recurrence avoided The extra costs of laparoscopic repair are unlikely to be offset by the short-term benefits (reduced pain, earlier return to usual activities)

Appendix 13

Cost estimates used in the model

Note: The cost for each item may not sum to the totals reported owing to rounding.

TABLE 41 Staff and theatre costs

TAPP and TEP	
Staff	**Cost (£) per minute**
Consultant anaesthetist	0.56
Consultant	0.56
Senior Registrar	0.30
Staff nurse ×2	0.36
Theatre orderly	0.12
Auxiliary	0.12
Total	2.00
Theatre cost	**Cost (£) per minute**
Overheads	4.40
Staff and theatre costs	6.40
OFM, OPM and OPPM	
Staff	**Cost (£) per minute**
Consultant anaesthetist	0.56
Consultant	0.56
Registrar	0.24
Staff nurse ×2	0.36
Theatre orderly	0.12
Auxiliary	0.12
Total	1.94
Theatre cost	**Cost (£) per patient**
Overheads	4.40
Total staff and theatre costs	6.34

TABLE 42 Equipment costs, general anaesthetics, reusables

TAPP and TEP	**Cost per patient (£)**
Drugs	10.36
Other	2.50
Prophylactic antibiotics	7.28
Equipment costs	9.67
Consumables	32.93
Cleaning and sterilisation	59.38
Other laparoscopic equipment	44.46
Total	166.58

TABLE 43 *Operation equipment costs, general anaesthetics, disposables*

TAPP and TEP	Cost per patient (£)
Drugs	9.09
Other	2.50
Prophylactic antibiotics	7.28
Consumables	637.96
Cleaning and sterilisation	86.73
Other laparoscopic equipment	44.46
Total	788.02

TABLE 44 *Operation equipment costs, local anaesthetics*

OFM, OPM and OPPM	Cost per patient (£)
Drugs	5.98
Other items	3.13
Prophylactic antibiotics	7.28
Consumables	41.74
Cleaning and sterilisation	33.15
Reusable equipment	6.33
Total	97.60

TABLE 45 *Hospitalisation costs*

All modalities	Cost per patient (£)
Hospital 'hotel costs' per day	236.57

Appendix 14

Details of the discrete choice experiment

This section is based on work conducted by Emma McIntosh and colleagues.

Outline of the discrete choice experiment

The discrete choice experiment (DCE) approach breaks the commodity being valued (in this case the process and outcomes for a particular type of hernia repair) into a series of attributes. Individuals are then presented with a number of discrete choices and, for each choice, respondents must say which option they prefer. Each type of repair offers both potential advantages and disadvantages in relation to the varying attributes. For example, for each type of surgical repair there may be trade-offs occurring between quality of life, return to usual activities, recurrence rates, pain scores and cost. Furthermore, each individual intervention is associated with different levels for each attribute. It is unclear what 'value' patients place on each of these attributes. Hence, it is unclear which method of inguinal repair provides the greatest welfare gain to patients.

The study was carried out at two centres – London and Glasgow. The attributes and levels for the study were based on the available literature and consensus meetings with clinical collaborators. The attributes and levels outlined had to be representative of the main 'trade-offs' between laparoscopic and open groin hernia repair. In order to obtain welfare estimates, a payment vehicle was also included in the DCE. The DCE used a strength of preference response variable. This variable allows for a graded response rather than a dichotomous choice, which is more usual with DCEs, as it was hypothesised that the strength of preference format may produce more accurate estimates of welfare.

Following the selection of attributes and levels choice scenarios for presentation to respondents were developed. The main design criteria were orthogonality of design (there is no correlation between the levels of an attribute included in a DCE) and level balance (the levels of an attribute occur with equal frequency in the questionnaire). Design software (SPEED, Hague Consulting) was used to identify an orthogonal matrix of scenarios.

A pilot study was conducted to assess the appropriateness of the attributes and levels chosen. This study was also used to determine whether there was evidence that respondents perceived that attributes were correlated, (whether they measured the same thing), or that they were interactions between attributes (whether preferences for one attribute were influenced by the levels of the other interacting attribute). Based on the results of the pilot study the design and content of the postal questionnaire used was finalised. *Table 46* summarises the attributes and levels used to develop the scenarios.

Devising welfare estimates

To estimate benefits from alternative types of hernia repair a benefit equation was first derived from the response data where the independent variables were the difference in the levels of the attributes within each choice and the dependent variable was the strength of preference score. The following equation was thus estimated:

$$\Delta B = \beta_0 + \beta_1\text{'Anaesthetic'} + \beta_2\text{'Complications'} + \beta_3\text{'Postoperativepain'} + \beta_4\text{'Longtermpain'} + \beta_5\text{'Recurrence'} + \beta_6\text{'Cost'} + e + u$$

where ΔB is the change in benefit in moving from treatment option A to treatment option B, and all

TABLE 46 *Attributes and levels used in the DCE*

Attribute	Levels
Type of anaesthetic	0=general, 1=local
Risk of serious complications	0.1%, 0.5%, 1%
Days in pain following surgery	3 days, 7 days, 14 days
Chance of long-term pain up to 1 year	3%, 5%, 13%
Chance of recurrence within 4 years	4%, 16%, 20%
Cost	£500, £1000, £1500

independent variables are the differences in the attributes of the choice experiment. *e* and *u* are the unobservable error terms, where *e* is the error term due to differences amongst observations and *u* is the error term due to differences amongst respondents. The coefficients β_0 to β_6 are the parameters of the model to be estimated. They indicate the relative importance, or weight, of a unit change in that attribute on overall benefit. β_0 is the constant term in the model, reflecting the overall preference for B over A when there is no difference between the levels of attributes across scenarios.

How much of one attribute respondents are willing to give up for improvements in other attributes, i.e. the rate at which individuals trade between these attributes, is shown by the ratio of the coefficients. For example β_1/β_6 shows how much an individual is willing to pay to have their preferred type of anaesthetic (assuming others things equal). Given that the strength of preference responses are ordinal ratings of utility differences between attribute level pairs, a random effects ordered probit was used to estimate the regression equation using the LIMDEP package. Confidence intervals for the welfare estimates were obtained by bootstrapping from the multivariate normal distribution of coefficients and their variance-covariance matrix. The 95% confidence intervals are the 2.5th and 97.5th percentile values from the bootstrapped distribution.

Sample size

The sample of patients for the main postal survey was identified from hospital records as having had a hernia repair in the past. In total, 658 patients were identified from existing databases, the majority of those had been involved in the MRC trials. These patients were then sent a covering

letter, information sheet and copy of the DCE questionnaire for self-completion and freepost reply. A reminder was sent after 2 weeks.

Results of DCE

Of the 658 questionnaires sent out, 320 were returned, a response rate of 49%. Of those returned, 258 were completed (39%). Of those returned uncompleted, 40 provided some form of reasoning for non-response, either by letter or telephone call and 41 questionnaires were uncompleted with no reason given.

Of a possible total of 3354 ($n = 258 \times 13$) response variables there were 250 missing dependent 'response' variables. These were removed from the analysis of choices, leaving 3104 choice responses for analysis, from $n = 246$ respondents (these 246 respondents had total responses ranging from only 1 to the full 13 questions). The results of a consistency test included in the strength of preference questions (based on dominance criteria) showed that 30 respondents (comprising 386 observations in total; 26 respondents $\times$ 13 observations and 4 respondents $\times$ 12 observations) were 'inconsistent' in choosing the 'incorrect' scenario, this is an inconsistency rate of 12.25%. These individuals were identified by a dummy variable in the analysis ('inconsis' = 1) such that the choice models estimated could be tested to see whether the inclusion of these individuals affected the results.

The coefficients and welfare results of the ordered probit model for the strength of preference format are shown in *Table 47*.

Table 48 shows the results of the analysis when those individuals that give inconsistent responses were excluded.

TABLE 47 Random effects ordered probit model: all responders

Variable	Attribute Unit	Coefficients (95% CIs)	SE	P	WTP (£) per unit (95% CI's)
Type of anaesthetic (0 = General, 1 = Local)	*Categorical*	−0.1660 (−0.12541, −0.1801)	0.02345	0.000	327.65 (248, 355)
Risk of serious complications (%)	*0.01%*	−0.3386 (−0.3786, −0.2232)	0.04825	0.000	668.33 (441, 747)
Days in pain following surgery (Days)	*1 Day*	−0.0609 (−0.0652, −0.05124)	0.00342	0.000	120.20 (101.13, 128.66)
Cost (£)	*£*	−0.0005 (−0.00057, −0.00044)	0.000032	0.000	N/A
Chance of long term pain up to 1 year (%)	*1%*	−0.0432 (−0.043247, −0.0645)	0.00502	0.000	85.35 (78.87, 127.37)
Chance of recurrence (%)	*%*	−0.0516 (−0.05877, −0.04653)	0.00221	0.000	101.88 (91.84, 116.00)
Constant		1.62143 (1.546, 1.711)	0.08834	0.000	N/A

Number of observations: 3,104
Unbalanced panel: 246 individuals
Log likelihood function: −3369.97
Restricted log-likelihood: −3714.41
χ^2: 599
Significance level: 0.000
McFadden's R^2: 0.09
% Correct predictions: 40%

TABLE 48 Random effects ordered probit model: 'consistent' responders only

Variable	Attribute Unit	Coefficients	SE	P	WTP (£) per unit
Type of anaesthetic (0 = General, 1 = Local)	*Categorical*	−0.1842774	0.025414	0.000	313.77
Risk of serious complications (%)	*0.01%*	−0.394805	0.050481	0.000	672.23
Days in pain following surgery (Days)	*1 Day*	−0.0672808	0.003524	0.000	114.56
Cost (£)	*£*	−0.000587309	0.000035	0.000	N/A
Chance of long-term pain up to 1 year (%)	*1%*	−0.0496271	0.005271	0.000	84.50
Chance of recurrence (%)	*%*	−0.0599083	0.002601	0.000	102.00
Constant	*/*	1.66248	0.09886	0.000	

Number of observations: 2717
Unbalanced panel: 216 individuals
Log likelihood function: −2890.618
Restricted log-likelihood: −3154.234
χ^2: 527.33
Significance level: 0.000
McFadden's R^2: 0.08
% Correct predictions: 41.5%

Hernia repair – a survey of your preferences

Information sheet

In this questionnaire we are trying to find out what is important to people when having hernia repair surgery. We are asking you because you have already had a hernia repair and you are therefore the best person to ask. Your views are important to us.

It is important to note that this questionnaire is <u>not</u> trying to evaluate the operation you actually had (or about to have), but to find out your views about a number of <u>imaginary</u> hernia repair scenarios.

The information you provide will allow us to produce information on how patients value the different characteristics of hernia repair surgery.

The questionnaire will ask you to <u>imagine</u> you need another hernia repair and then to tell us

which operation you would choose if you were given the choice. All you have to do is pick the imaginary operation you would prefer from a series of choices.

These imaginary operations differ only in terms of the six features listed in the questionnaire. Please take a moment to read the descriptions of how these imaginary operations vary before completing the choices.

This should only take you a few minutes to complete and will help hernia surgeons and researchers to find out what are the most important features of hernia operations.

Many <u>thanks</u> for your help with this research. When you have completed the questionnaire please return it in the <u>Freepost</u> envelope provided.

Discrete choice questionnaire

(Note: the questionnaire displayed is not precisely the one used owing to small formatting edits)

Hernia Repair – A survey of your preferences

University of Aberdeen

In collaboration with Professor Paddy O'Dwyer
Department of Surgery
Western General Infirmary, Glasgow

If you would like to ask any questions about completing this questionnaire please contact:

Emma McIntosh
Research fellow

Tel: 01865 226634

G					

Please read your pink information sheet first.

The imaginary operations will differ only according to the following features, everything else about the operations will be equal.

Type of anaesthetic
Local   *General*

Chance of serious complications giving rise to prolonged hospital stay
This refers to the chance of having a serious complication during surgery, e.g. bladder injury.

☐ 0.1%   ☐ 0.5%   ☐ 1%
(1 per 1000)   (5 per 1000)   (10 per 1000)

Number of days suffering post-operative pain
This refers to the number of days you may experience pain as a result of your operation. You may have to take painkillers such as Aspirin or Paracetamol and there may be occasional times where the pain in noticeable when the painkillers wear off.

☐ *3 days*   ☐ *7 days*   ☐ *14 days*

Cost (£) to you as a result of this episode of care
This refers to the cost to you of the hernia operation and the following post-operative recuperation. Whilst you would never be asked to pay, please try to think of how much you would value this operation as you would value other items you buy.

☐ *£500*   ☐ *£1000*   ☐ *£1500*

Chance of experiencing long-term persisting pain up to 1 year post-operatively
This refers to the chance that you may have pain in your hernia region following surgery for up to 1 year.

☐ *3%*   ☐ *5%*   ☐ *13%*

Chance of recurrence following your operation
This refers to the chance that your hernia may recur (come back) and you may have to have another hernia operation within the next 4 years.

☐ *4%*   ☐ *16%*   ☐ *20%*

Now we would like you to *choose between* alternative possible hernia repair operations by indicating how *strongly* you prefer your favourite. Please try to imagine that you are about to have a hernia operation and you are deciding between possible operations by looking at how the features of each operation differ.

Please look at each imaginary operation and choose between A & B by circling the number which most represents your preference

We are not asking you to find the surgery nearest to the *actual* surgery you had, we are interested in the choices you would make if ever offered these imaginary operations

Please answer every question remembering that there are no right or wrong answers. It is <u>your views</u> that we are interested in.

EXAMPLE

Imaginary Hernia Operation	A	B
Type of anaesthetic	Local	Local
Risk of a **serious complication** giving rise to prolonged hospital stay	1%	0.1%
Number of days suffering **post-operative pain**	14 days	3 days
Cost of operation to you (£)	£1,000	£500
Chance of experiencing **long-term pain** up to 1 year after your operation	13%	3%
Chance of a hernia recurrence	20%	4%

1	**2**	**3**	**4**	**5**	**6**	**7**
A is much better	A is somewhat better	A is slightly better	A & B are equal	B is slightly better	B is somewhat better	B is much better

Please circle the number from 1 to 7 which best reflects your preference
In this example, I circled number 7 because if I imagined I had to have another hernia operation, I think operation B would be much better than operation A. Now please turn over and complete the rest yourself.

Imaginary Operations

	A	B
Type of anaesthetic	General	Local
Risk of a **serious complication** giving rise to prolonged hospital stay	0.1%	0.1%
Number of days suffering **post-operative pain**	3 days	7 days
Cost of operation to you (£)	£500	£1,000
Chance of experiencing **long-term pain** up to 1 year after your operation	5%	13%
Chance of a hernia recurrence	4%	16%

1	**2**	**3**	**4**	**5**	**6**	**7**
A is much better	A is somewhat better	A is slightly better	A & B are equal	B is slightly better	B is somewhat better	B is much better

Imaginary Operations

	A	**B**
Type of anaesthetic	General	Local
Risk of a **serious complication** giving rise to prolonged hospital stay	0.5%	1%
Number of days suffering **post-operative pain**	3 days	3 days
Cost of operation to you (£)	£1,000	£1,500
Chance of experiencing **long-term pain** up to 1 year after your operation	13%	5%
Chance of a hernia recurrence	4%	16%

1	**2**	**3**	**4**	**5**	**6**	**7**
A is much better	A is somewhat better	A is slightly better	A & B are equal	B is slightly better	B is somewhat better	B is much better

Imaginary Operations

	A	**B**
Type of anaesthetic	General	Local
Risk of a **serious complication** giving rise to prolonged hospital stay	0.1%	0.1%
Number of days suffering **post-operative pain**	7 days	3 days
Cost of operation to you (£)	£1,500	£1,000
Chance of experiencing **long-term pain** up to 1 year after your operation	5%	3%
Chance of a hernia recurrence	4%	20%

1	**2**	**3**	**4**	**5**	**6**	**7**
A is much better	A is somewhat better	A is slightly better	A & B are equal	B is slightly better	B is somewhat better	B is much better

Imaginary Operations

	A	B
Type of anaesthetic	General	Local
Risk of a **serious complication** giving rise to prolonged hospital stay	0.1%	0.5%
Number of days suffering **post-operative pain**	14 days	14 days
Cost of operation to you (£)	£500	£1,500
Chance of experiencing **long-term pain** up to 1 year after your operation	13%	13%
Chance of a hernia recurrence	16%	4%

1 **2** **3** **4** **5** **6** **7**

| A is much better | A is somewhat better | A is slightly better | A & B are equal | B is slightly better | B is somewhat better | B is much better |

Imaginary Operations

	A	B
Type of anaesthetic	General	Local
Risk of a **serious complication** giving rise to prolonged hospital stay	1%	0.5%
Number of days suffering **post-operative pain**	3 days	14 days
Cost of operation to you (£)	£1,500	£500
Chance of experiencing **long-term pain** up to 1 year after your operation	13%	5%
Chance of a hernia recurrence	20%	20%

1 **2** **3** **4** **5** **6** **7**

| A is much better | A is somewhat better | A is slightly better | A & B are equal | B is slightly better | B is somewhat better | B is much better |

Imaginary Operations

	A	**B**
Type of anaesthetic	Local	General
Risk of a **serious complication** giving rise to prolonged hospital stay	1%	0.5%
Number of days suffering **post-operative pain**	7 days	7 days
Cost of operation to you (£)	£500	£1,000
Chance of experiencing **long-term pain** up to 1 year after your operation	3%	5%
Chance of a hernia recurrence	4%	20%

1   **2**   **3**   **4**   **5**   **6**   **7**

A is much better	A is somewhat better	A is slightly better	A & B are equal	B is slightly better	B is somewhat better	B is much better

Imaginary Operations

	A	**B**
Type of anaesthetic	General	General
Risk of a **serious complication** giving rise to prolonged hospital stay	0.1%	0.1%
Number of days suffering **post-operative pain**	3 days	7 days
Cost of operation to you (£)	£500	£1,500
Chance of experiencing **long-term pain** up to 1 year after your operation	5%	5%
Chance of a hernia recurrence	4%	4%

1   **2**   **3**   **4**   **5**   **6**   **7**

A is much better	A is somewhat better	A is slightly better	A & B are equal	B is slightly better	B is somewhat better	B is much better

177

Imaginary Operations

	A	B
Type of anaesthetic	General	Local
Risk of a **serious complication** giving rise to prolonged hospital stay	1%	1%
Number of days suffering **post-operative pain**	14 days	7 days
Cost of operation to you (£)	£1,000	£500
Chance of experiencing **long-term pain** up to 1 year after your operation	3%	3%
Chance of a hernia recurrence	4%	4%

1	**2**	**3**	**4**	**5**	**6**	**7**
A is much better	A is somewhat better	A is slightly better	A & B are equal	B is slightly better	B is somewhat better	B is much better

Imaginary Operations

	A	B
Type of anaesthetic	General	Local
Risk of a **serious complication** giving rise to prolonged hospital stay	0.5%	0.1%
Number of days suffering **post-operative pain**	3 days	7 days
Cost of operation to you (£)	£500	£1,000
Chance of experiencing **long-term pain** up to 1 year after your operation	3%	13%
Chance of a hernia recurrence	16%	16%

1	**2**	**3**	**4**	**5**	**6**	**7**
A is much better	A is somewhat better	A is slightly better	A & B are equal	B is slightly better	B is somewhat better	B is much better

Imaginary Operations

	A	B
Type of anaesthetic	General	Local
Risk of a **serious complication** giving rise to prolonged hospital stay	0.1%	1%
Number of days suffering **post-operative pain**	14 days	3 days
Cost of operation to you (£)	£1,500	£1,500
Chance of experiencing **long-term pain** up to 1 year after your operation	3%	5%
Chance of a hernia recurrence	20%	16%

1   **2**   **3**   **4**   **5**   **6**   **7**

A is much better	A is somewhat better	A is slightly better	A & B are equal	B is slightly better	B is somewhat better	B is much better

Imaginary Operations

	A	B
Type of anaesthetic	General	Local
Risk of a **serious complication** giving rise to prolonged hospital stay	1%	0.5%
Number of days suffering **post-operative pain**	7 days	14 days
Cost of operation to you (£)	£500	£1,500
Chance of experiencing **long-term pain** up to 1 year after your operation	13%	13%
Chance of a hernia recurrence	20%	4%

1   **2**   **3**   **4**   **5**   **6**   **7**

A is much better	A is somewhat better	A is slightly better	A & B are equal	B is slightly better	B is somewhat better	B is much better

Imaginary Operations

	A	B
Type of anaesthetic	General	Local
Risk of a **serious complication** giving rise to prolonged hospital stay	0.5%	0.5%
Number of days suffering **post-operative pain**	7 days	14 days
Cost of operation to you (£)	£1,500	£500
Chance of experiencing **long-term pain** up to 1 year after your operation	3%	5%
Chance of a hernia recurrence	16%	20%

1	**2**	**3**	**4**	**5**	**6**	**7**
A is much better	A is somewhat better	A is slightly better	A & B are equal	B is slightly better	B is somewhat better	B is much better

Imaginary Operations

	A	B
Type of anaesthetic	Local	General
Risk of a **serious complication** giving rise to prolonged hospital stay	0.1%	1%
Number of days suffering **post-operative pain**	3 days	14 days
Cost of operation to you (£)	£1,000	£1,000
Chance of experiencing **long-term pain** up to 1 year after your operation	3%	5%
Chance of a hernia recurrence	20%	16%

1	**2**	**3**	**4**	**5**	**6**	**7**
A is much better	A is somewhat better	A is slightly better	A & B are equal	B is slightly better	B is somewhat better	B is much better

How difficult/easy did you find the choices above? (*please circle*)

Very Difficult				**Moderate**				**Very Easy**	
1	2	3	4	5	6	7	8	9	10

Now that you have completed the choices please <u>rank</u> the features in the order of importance to you when you were making your choices. Please rank them on a scale of 1–6 where 1 = the most important and 6 = the least important. Or if they were not important to you please leave the box blank.

Ranking

Risk of a serious complication ☐
Number of days of post-operative pain ☐
Cost of the operation ☐
Chance of long term pain ☐
Chance of a recurrence ☐
Type of anaesthetic ☐

Please tick (✓) whether you would prefer **local ( )** or **general ( )** anaesthetic

Finally, we find it very useful to have information about you.
All answers are <u>completely confidential</u>.

Gender   Female ☐   **Age** [   ] years
              Male ☐

Do you have any children? Yes ☐ No ☐

If *yes*, how many live in your household? [   ]

Qualifications None ☐
       O-grade/GCSE ☐
Higher/A-level/SYS/OND ☐   *Please indicate the*
Diploma/HND/HNC ☐   *highest level only*
              Undergraduate degree ☐
              Post-graduate degree ☐
              Other (please specify below) ☐

              ....

Income   **Could you please estimate the annual income of your household before deducting tax and national insurance (if you receive any benefits or pensions include them as income)** *(Please tick one box only)*.

Less than £9,999	☐	**£30,000 – £34,999**	☐
£10,000 – £14,999	☐	**£35,000 – £39,999**	☐
£15,000 – £19,999	☐	**£40,000 – £44,999**	☐
£20,000 – £24,999	☐	**£45,000 – £49,999**	☐
£25,000 – £29,999	☐	**Greater than £50,000**	☐

How many adults are there in your household? [   ]

Questions about your <u>actual</u> hernia operation

What type of hernia repair did you have?

Open mesh ☐   Open non-mesh ☐   Key hole ☐

Don't remember ☐

181

What date did you have your hernia surgery? (if you can't remember please just note the month and/or year) ____ / ____ / ____

How many days of pain did you suffer after your hernia operation? ☐

How many days did it take you to return to your normal activities? ☐

Finally, on a scale of 1–10, where 1 = very unsatisfied and 10 = very satisfied, please state how you rated your hernia operation ☐

Thank you for completing this questionnaire.
Please post it back in the enclosed <u>Freepost</u> addressed envelope

Appendix 15

Supplementary report

Summary

Background

In April 2004, a trial conducted by Neumayer and colleagues was published in the *New England Journal of Medicine*. This trial reported data on 2164 randomised participants as compared with the 5560 randomised participants in the 37 eligible trials considered by the main Assessment Report. The laparoscopic group was made up of 90% TEP and 10% TAPP procedures but disaggregated data were not reported. For the purpose of this report, the trial has been classified as a comparison of TEP with open flat mesh.

Quality of additional study

The new trial appeared to be of generally good quality with a minimum duration of follow-up of 2 years.

Summary of benefits

Additional outcome data were available for wound/superficial infection, vascular injury, visceral injury, port-site hernia, persisting pain and hernia recurrence. The main change from the main Assessment Report is that recurrence is now statistically significantly more likely following TEP repair. One suggested explanation of this was the inexperience of some surgeons. A further finding is the increased risk of serious complications following laparoscopic repair, although these data are difficult to assess. The findings of the supplementary analysis for the other outcomes were essentially similar to those in the main Assessment Report.

Costs

Owing to the higher risk of recurrence for TEP repair, the estimated cost of TEP repair at 5 and 25 years increased slightly from £1113 to £1122 and from £1135 to £1149, respectively.

Cost-effectiveness

If recurrence is the only measure of effectiveness of importance, then in the supplementary (and main analyses) TEP and TAPP repair are dominated by open flat mesh. In terms of cost per QALY, the probability that TEP repair is cost-effective is still relatively high. This principally reflects the lower risk of persisting pain after laparoscopic repair. In the supplementary analysis, TEP is less likely to be considered cost-effective and the principal beneficiary of this is TAPP, rather than open flat mesh

Sensitivity analysis

The sensitivity analysis illustrates that the differences between TEP and TAPP repair are not great. For example, the estimates of QALYs for TAPP and TEP were similar when the relative risk of long-term pain from Neumayer and colleagues was used.

Limitations of the calculations (assumptions made)

This supplementary report does not represent a systematic update and it was based solely on the published report by Neumayer and colleagues. Furthermore, lack of disaggregated data led to the assumption that the results of Neumayer and colleagues apply solely to TEP repair.

Neumayer and colleagues report a higher rate of complications for laparoscopic repair. However, it is possible that they might relate partly to TAPP repair. For persisting pain it is likely that the risk of persisting pain is lower following TEP repair and the non-statistically significant results reported in the meta-analysis were a statistical artefact caused by the analytical approach used.

Other important issues regarding implications

Post hoc analyses in Neumayer and colleagues' trial suggested that the excess of recurrences in the laparoscopic group could be explained by the performance of surgeons who had performed fewer than 250 laparoscopic procedures.

Need for further research

To overcome some of the limitations of the analysis, further, disaggregated data from Neumayer and colleagues are required.

The Assessment Report will require a systematic revision once the results of further, currently ongoing, large trials are reported.

Introduction

The evidence available for the comparison of laparoscopic and open mesh methods of inguinal hernia repair has continued to accumulate since the submission of the Assessment Report in December 2003 (hereafter called the main Assessment Report).[1] By far the largest piece of new evidence is the trial by Neumayer and colleagues published in the *New England Journal of Medicine* in April 2004.[2] This trial was conducted in 14 Veterans Affairs hospitals in the USA and the report includes data on the outcomes of 2164 randomised participants. To put this in context, there were 5560 randomised participants in the 37 eligible trials considered in the main Assessment Report.[1]

Neumayer and colleagues did report data on a number of outcomes considered in the main Assessment Report, but not all. Outcome measures for which there was not information included opposite method initiated, conversions, return to usual activities and QoL. The brevity of the trial report hampers the interpretation of the data that are reported. In particular, 90% of participants in the laparoscopic arm received TEP repair with the remainder receiving TAPP repair. Data are not reported separately for these procedures and it is unclear whether or not events are proportionally distributed between the two methods of laparoscopic repair. As an interim expedient, the trial has been classified as a comparison of TEP with open flat mesh when incorporated into the meta-analysis and economic evaluation. As discussed later, the new trial report principally has an impact on the overviews of data describing complications and hernia recurrence. Knowing the operation actually performed would have greatly helped the interpretation of these changes.

Effectiveness

Methods for reviewing effectiveness
Data extraction strategy
Data extraction was performed independently by two reviewers using the data extraction form presented in Appendix 3 of the main Assessment Report.[1] Where a difference of opinion existed, the two reviewers consulted an arbiter.

Quality assessment strategy
The system for classifying methodological quality is described in detail in the section 'Quality assessment strategy' (p. 10) (and Appendix 3) of

the main Assessment Report.[1] Two reviewers working independently assessed the study report for methodological quality and any disagreements were resolved by consensus or arbitration.

Data synthesis
The method for data synthesis is described in detail in the section 'Data synthesis' (p. 10) of the main Assessment Report.[1] Where possible, any new data reported in the study were added to the existing data in the meta-analysis.

Results
Methodological quality of included study
Randomisation was carried out by a computer-generated, permuted-block sequence and stratified according to the type of hernia, whether the hernia was unilateral or bilateral and the study site. However, the method of allocation concealment was unclear. Some 12.6% of participants were lost to follow-up in the laparoscopic group compared with 15% of participants in the open group. Analysis was by ITT but it was unclear if the outcome assessor was blinded. The minimum follow-up was 2 years. Hernia recurrence was based on serial assessment by a surgeon not involved in the original operation, with confirmation from an independent surgeon, ultrasound examination or at operation. A further issue was that it was difficult to judge from the report the severity of some of the complications and to avoid the possibility of double counting. The initial operation was reported to have been performed by a surgeon who had experience of at least 25 laparoscopic repairs and had submitted a videotaped laparoscopic procedure that had been reviewed by a surgeon member of the study's executive committee.

Assessment of effectiveness
Outcome data were available for wound/superficial infection, vascular injury, visceral injury, port-site hernia, persisting pain and hernia recurrence. The results of the meta-analyses are summarised in *Table 1* and reported more fully later.

Wound/superficial infection
Neumayer and colleagues contributed three times as much data to the meta-analysis of this outcome than the other six included studies combined. The results of the supplementary analysis are consistent with those from the main Assessment Report with fewer wound/superficial infections for TEP compared with open flat mesh, although this difference is not statistically significant.

TABLE I Summary of relative effect sizes and CIs for those outcomes for which Neumayer and colleagues[2] contributed data

Outcome (trials in supplementary analysis)	Analysis	RR	95% CI	*p*-Value
Wound/superficial infection (7)	Main	0.55	0.20 to 1.53	0.47
	Supplementary	0.65	0.34 to 1.22	0.18
Vascular injury (5)	Main	1.07	0.15 to 7.45	0.90
	Supplementary	1.89	0.40 to 8.83	0.42
Visceral injury (4)	Main	1.07	0.07 to 16.89	1.0
	Supplementary	1.04	0.15 to 7.33	0.97
Port site hernia (2)	Main		Not estimable	
	Supplementary	5.03	0.24 to 104.54	0.30
Persisting pain (3)	Main	0.10	0.01 to 0.66	0.02
	Supplementary	0.36	0.08 to 1.65	0.19
Recurrence (8)	Main	1.61	0.57 to 4.60	0.4
	Supplementary	2.00	1.43 to 2.81	<0.0001

Vascular injury

Overall, in the supplementary analysis there were 4/1179 (0.3%) potentially serious vascular injuries in the TEP groups and 2/1176 (0.17%) in the open groups. This compares with 2/190 (1.05%) and 2/182 (1.09%) in the main Assessment Report for the TEP and open groups, respectively. Neumayer and colleagues' report[2] mentions two vascular injuries that led to reoperation in the laparoscopic group. It should be noted that in the supplementary analysis it was assumed that these two additional injuries occurred during TEP repair, and it is not yet known whether this was the case.

Visceral injury

In the supplementary analysis, this outcome was reported by four trials with Neumayer and colleagues contributing ~85% of the available data.[2] In the main analysis there were 1/170 and 1/177 reports of potentially serious visceral injuries for TEP and open flat mesh groups, respectively. Corresponding data for the supplementary analysis were 2/1159 (0.17%) and 2/1171 (0.17%). The extra case in the laparoscopic group was an intestinal injury that was judged to be causally linked with the patient's death. The case in the open group was of bowel obstruction in a femoral hernia 2 years after the index operation with the presumption that the femoral hernia had been missed during the index operation. Two other deaths within 30 days of laparoscopic surgery were also judged to be procedure related.

Port-site hernia

Port-site hernias can only occur with laparoscopic repair. From the two trials that reported this outcome (total of 1011 TEP repairs) there were two cases (0.19%) of port-site hernia. Both of these cases occurred amongst the 989 individuals who received laparoscopic repair in Neumayer and colleagues' trial.[2]

Persisting pain

Overall, there were fewer cases of persisting pain at 1 year in both the main and supplementary analyses. However, the sparse data available in the main analysis, which related to just over 100 patients, suggested that this difference was statistically significant. The results following the addition of the data from Neumayer and colleagues,[2] although consistent with that of the earlier studies, appear not to be statistically significant. However, this is a statistical artefact; there was significantly less persistent pain after laparoscopic repair in Neumayer and colleagues' trial,[2] and there were no cases of persisting pain in the laparoscopic groups of the other two trials. The explanation is that to cope with zero cases in the laparoscopic groups of the other two trials the REVMAN program adds 0.5 to each side of the analysis and this is the reason why the summary statistic generated is non-significant. To put this another way, the data from the new trial are consistent with the other trials of laparoscopic repair in showing a significantly lower rate of persisting pain after laparoscopic repair.

Hernia recurrence

In the main analysis there was a non-significantly higher recurrence rate after TEP repair, largely reflecting the MRC Laparoscopic Groin Hernia Trial.[3] Much higher rates of recurrence were reported by Neumayer and colleagues[2] (10% in the laparoscopic group at 2 years). These data now

'dominate' the meta-analysis such that the summary estimate from the new analysis is a highly statistically significant higher rate after TEP compared with open flat mesh (RR 2.00; 95% CI 1.43 to 2.81) and with open-mesh (RR 1.93; 95% CI 1.42 to 2.63).

Cost-effectiveness

As in the main Assessment Report, data for the supplementary analysis are presented for two time horizons, 5 and 25 years. All costs are presented in 2001–02 UK pounds. Costs and benefits are discounted at 6% and 1.5%, respectively.

Methods

This supplementary analysis uses the same methods described in detail in Chapter 5 of the main Assessment Report.[1] In this document only additional methods, assumptions or data are reported.

Supplementary model parameters
Baseline parameters

The baseline parameter values for the supplementary analysis are the same as those presented in *Table 18* of the main Assessment Report.[1] In the main analysis, baseline risks of recurrence were obtained from the Swedish Hernia Registry (Nilsson E, Swedish Registry: personal communication, 2003). These data report lower rates of recurrence at 2 years than suggested by the data provided by Neumayer and colleagues.[2] The method adopted by Neumayer and colleagues to diagnose hernias [described in the section Current service costs (p. 5)] may account for the higher event rate. Nonetheless, the impact of a higher baseline risk of recurrence on cost-effectiveness has been considered as part of the sensitivity analysis.

Relative effect sizes

Estimates of relative effect size were based on evidence were provided by the main and revised meta-analyses. These data were chosen using the same methodology as was outlined in Chapter 5 of the main Assessment Report.[1]

Table 2 reports the point estimate of the relative effect sizes used in the supplementary analysis (*Table 19* in the main Assessment Report details the main data). Also included in this table are the 95% CIs surrounding the point estimates and estimates for the time to return to usual activities for each intervention. Uncertainty was characterised by log-normal distributions for RRs

and time to return to usual activities. Normal distributions were used for WMDs.

In the supplementary analysis, data for recurrent hernias were based on data for the comparison of TEP with flat mesh rather than TEP versus mixed mesh, as used in the main Assessment Report.[1] The rationale behind this is that the new data were available for the comparison of TEP with flat mesh from Neumayer and colleagues.[2] As reported in the main Assessment Report, absolute parameter values for each intervention were derived by applying the relative rates obtained from the meta-analyses to estimates of the absolute rate for a baseline comparator.

Resource use and costs

The same estimates as were used for the analysis reported in the main Assessment Report were used for this supplementary analysis. These data are reported in detail in *Table 20* of the main Assessment Report.[1]

Estimation of QALYs

No additional utility data were available from Neumayer and colleagues.[2] Therefore, the same utility data as used in the main Assessment Report were used in the supplementary analysis (see *Tables 21* and *22* of the main Assessment Report[1]). Data were available on the risk of pain from Neumayer and colleagues and this does have some influence on the utility scores that were derived for each state of the model. *Table 3* provides the estimated utility scores for each state which are used in this supplementary analysis (this table corresponds to Table 23 in the main Assessment Report[1]).

Assessment of cost-effectiveness

The results of the supplementary base case analysis are based on the estimated costs and outcomes faced by a cohort of 57-year-old males (the mean age of patients receiving a primary repair of inguinal hernia in England and Wales). The central outcomes of the analysis are first presented in terms of a balance sheet. Within the economic model the different outcomes are combined into a single measure of relative efficiency measured in terms of the incremental cost per QALY. Data on the incremental cost per QALY are presented in two ways. First, mean costs and QALYs for the alternative interventions are presented and incremental cost per QALYs calculated where appropriate. These data are presented for two time horizons, 5 and 25 years. The second way in which the cost-effectiveness of the alternative interventions is presented is in

TABLE 2 *Relative effect sizes used in the supplementary model*

Parameter	Point estimate	Limits of 95% CI		Distribution
		Low	**High**	
RR for long-term pain (primary and subsequent)				
TAPP vs OFM	0.68	0.52	0.89	Log-normal
TEP vs OFM	0.36	0.08	1.65	Log-normal
RR for numbness (primary and subsequent)				
TAPP vs OFM	0.10	0.03	0.32	Log-normal
TEP vs OFM	0.17	0.33	1.16	Log-normal
RR for recurrences (primary)				
TAPP vs OFM	1.68	0.73	3.88	Log-normal
TEP vs OFM	2.00	1.43	2.81	Log-normal
RR for recurrences (subsequent)				
TAPP vs OFM	0.41	0.02	9.61	Log-normal
TEP vs OFM	0.91	0.54	1.51	Log-normal
WMD for operation time (primary) (minutes)				
TAPP vs OFM	10.9	9.4	12.5	Normal
TEP vs OFM	4.3	1.3	7.3	Normal
WMD for operation time (subsequent) (minutes)				
TAPP vs OFM	0.40	−8.5	9.3	Normal
TEP vs OFM	−26.0	−36.6	−15.4	Normal
WMD for length of stay (inpatients) (primary) (days)				
TAPP vs OFM	0.10	0.04	0.17	Normal
TEP vs OFM	−0.04	−0.11	0.02	Normal
WMD for length of stay (inpatients) (secondary) (days)				
TAPP vs OFM	0.07	−0.13	0.27	Normal
TEP vs OFM	0.24	−0.45	0.93	Normal
Return to usual activities (primary and secondary) (days)				
OFM	11	10	11	Log-normal
TAPP	8	7	9	Log-normal
TEP	7	7	7	Log-normal
OFM, open flat mesh.				

TABLE 3 *Utility values attached to each state of the model for the first cycle*[a]

Procedure	Initial operation	No recurrence	Reoperation	Recurrence, no reoperation	Death
TAPP	0.924	0.950	0.871	0.837	0.000
TEP	0.925	0.950	0.871	0.836	0.000
Open flat mesh	0.918	0.946	0.867	0.836	0.000

[a] Rates of recurrence, long-term pain and numbness vary over time and therefore using the methodology reported in Chapter 5 of the main Assessment Report the utilities associated with some states also vary slightly over time.

187

terms of the probability that an intervention is cost-effective for different threshold values for society's willingness to pay for a QALY (these data could have been presented as CEACs, but for brevity a tabular format has been adopted).

Sensitivity analysis and subgroup analysis
Baseline risk of recurrence

Neumayer and colleagues report a cumulative rate of recurrence following TEP at 2 years of 10.1%.[2] This contrasts to an estimated rate of between 2.5% and 3.0% for TEP based on the Swedish Registry data. In this sensitivity analysis, the baseline risk of recurrence has been adjusted so that at 2 years it is more consistent with the results of Neumayer and colleagues. The rationale for this sensitivity analysis is that at a higher baseline risk it would be expected that open flat mesh would be more likely to be considered cost-effective.

Utility estimates used for long-term pain and numbness

As has been stated previously, the utility estimates used within the model come from one trial.[3] The data from this trial were reanalysed to provide utility estimates for long-term persisting pain and numbness. These data are likely to be key determinants of QALYs but as these data relate to 3 months postsurgery they may not be more generally applicable. In this sensitivity analyses it was assumed that there is no disutility associated with long-term pain and numbness, either alone or in combination. This sensitivity analysis therefore shows whether the gain in utility caused solely by the shorter recovery period following an operation (and any reoperations) following laparoscopic repair is worthwhile.

Effect of relative risk of long-term pain

As described in the section 'Effectiveness' (p. 184), the calculation of a pooled relative risk for long-term pain was problematic. In this sensitivity analysis the RR for Neumayer and colleagues (0.69, 95% CI 0.54 to 0.88)[2] is used in preference to the pooled RR (0.36, 95% CI 0.08 to 1.65) from the supplementary analysis.

Effect of serious complications

The base case of the model has assumed that the serious complications would be principally captured in terms of longer operation time and length of stay. The extreme assumption that all serious complications result in immediate death was used to test the extent to which this sufficiently captures the effect on outcomes. However, this sensitivity analysis was not ultimately performed as the data reported by Neumayer and colleagues was not reported in a disaggregated form. Therefore, it is unclear to what extent the data apply to those individuals who received TEP (90% of the sample) or TAPP.

Results

Tables 4 and *5* presents the balance sheet for the comparison of TEP with open flat mesh for 5- and 25-year time horizons. TEP is associated with more time at usual activities but this is achieved at higher cost, risk of rare but serious complications and recurrences. The costs presented in *Tables 4* and *5* are based on reusable laparoscopic equipment.

The data presented in *Tables 4* and *5* allow implicit valuations about how the alternative outcomes can be traded off. Should recurrence be the only

TABLE 4 *Balance sheet for the comparison of TEP repair with open flat mesh for a 5-year time horizon*[a]

Favours TEP	Favours open flat mesh
More time at usual activities after 5 years TEP: 3.85 (95% CI 2.89 to 4.88) more days	**Potentially lower costs over 5 years** Mean saving £114; 95% CI £81 to £176)
	Potentially more serious complications TEP: 0.2 more serious complications per 1000 patients
	More recurrences compared with OFM TEP: 2 more recurrence per 100 patients over 5 years (95% CI 1 to 7)
Similar risk of long-term pain and numbness recurrence compared with OFM Long-term pain: 9.5 (95%CI –9.4 to 24.0) fewer people per 1000 Numbness: 18.5 fewer patients per 1000 (95% CI –2.9 to 34.1)	
[a] Ranges are the 2.5 and 97.5 percentile points from the range of values produced by the Monte Carlo simulations.	

TABLE 5 *Balance sheet for the comparison of TEP repair with open flat mesh for a 25-year time horizon*[a]

Favours TEP	Favours open flat mesh
More time at usual activities after 25 years 3.81 (95% CI 2.74 to 4.91) more days	**Potentially lower costs over 25 years** Mean saving £126 (95% CI £87 to £222)
	Potentially more serious complications TEP: 0.2 more serious complications TEP per 1000 patients
	More recurrences compared with OFM TEP: 5 more recurrences per 100 patients over 25 years (95% CI 2 to 14)
Similar risk of long-term pain and numbness compared with OFM Long-term pain: 9.5 (95%CI –9.4 to 29.7) fewer people per 1000 Numbness: 18.5 fewer patients per 1000 (95% CI –2.9 to 34.1)	

[a] Ranges are the 2.5 and 97.5 percentile points from the range of values produced by the Monte Carlo simulations.

outcome of interest then the data presented in these tables (and in *Tables 28* and *29* in the main Assessment Report) indicate that TEP is more costly and less effective than open flat mesh and therefore open flat mesh is the dominant intervention (TAPP is also dominated as it is more costly and there is no evidence of a difference in effectiveness).

The different outcomes reported in *Tables 4* and *5* are explicitly combined within the estimates of incremental cost per QALY. The results of both the deterministic and stochastic analyses are presented in *Table 6*. Also presented in this table are the results of the main Assessment Report in order to facilitate comparison.

As *Tables 4* and *5* show, the inclusion of data from Neumayer and colleagues, because of the assumptions made, has an effect only on estimates of cost, long-term pain, return to usual activities and recurrences for TEP. In terms of return to usual activities and cost, the effect has been to move these outcome values very slightly in a direction favouring open flat mesh. The impact of the data on long-term pain and recurrence has been more marked. The supplementary analysis suggests that TEP is now associated with more recurrences.

In terms of QALYs, in the supplementary base-case analysis, the mean incremental cost per QALY has increased but it is still within a range that society might consider acceptable (*Table 6*). It appears that TEP is less likely to be considered cost-effective in the supplementary

analysis. The principal beneficiary of this change is TAPP.

The effect of increasing the baseline risk of recurrence had a marked effect on the likelihood that TEP was considered cost-effective, with again the main beneficiary being TAPP rather than OFM.

The substitution of the RR of pain from Neumayer and colleagues[2] in preference to the pooled RR from the supplementary analysis results in TAPP becoming increasingly likely to be considered the most cost-effective option and open flat mesh being highly unlikely to be consider cost-effective. The reason for this result is that in this sensitivity analysis the RR for long-term pain is 0.68 (95% CI 0.52 to 0.89) for TAPP versus open flat mesh compared with 0.69 (95% CI 0.54 to 0.88) for TEP versus open flat mesh. This illustrates that the results are highly sensitive to rates of pain and the associated utility score. This finding is also illustrated by the sensitivity analysis where pain and numbness are associated with no disutility.

Comparison of the results of the sensitivity analysis for both the main and supplementary analyses shows a similar picture to that provided by the base-case analysis. In all cases the incremental cost per QALY of TEP compared with open flat mesh increases and the likelihood that TEP is considered cost-effective falls. What is clear from these analyses is that changes in parameter estimates for the risks of recurrence and long-term pain in favour of open flat mesh are not sufficient to remove the likelihood that TEP could be considered cost-effective.

TABLE 6 Comparison of alternative treatments for both the main and supplementary base-case analysis and sensitivity analyses (TAPP, TEP and open flat mesh comparison)

	Procedure	Cost (£)	QALYs	Incremental cost per QALY (£)	Probability cost-effectiveness for different threshold values for society's willingness to pay for a QALY (%)			
					£10,000	£20,000	£30,000	£50,000
Main: Base-case model for a 5-year time horizon (3 comparators)	TAPP	1190	4.44	Dominated (12,196 vs OFM)	3.7	10.8	11.3	12.1
	TEP	1113	4.45	4928	85.0	88.9	88.7	87.9
	OFM	1009	4.42		11.3	0.3	0.0	0.0
Supplementary: Base case for a 5-year time horizon (3 comparators)	TAPP	1190	4.439	Dominated (12,196 vs OFM)	6.3	24.1	29.3	34.2
	TEP	1122	4.441	6725	65.6	74.1	70.3	65.7
	OFM	1009	4.424		28.1	1.8	0.4	0.1
Main: Base-case model for a 25-year time horizon (3 comparators)	TAPP	1211	16.226	Dominated (5219 vs OFM)	13.0	15.2	15.8	16.1
	TEP	1135	16.244	2092	85.5	85.2	84.8	84.9
	OFM	1022	16.190		0.4	0.0	0.0	0.0
Supplementary: Base case for a 25-year time horizon (3 comparators)	TAPP	1211	16.226	Dominated (5219 vs OFM)	32.5	38.0	39.7	42.3
	TEP	1149	16.232	2994	65.6	61.6	60.2	57.6
	OFM	1022	16.190		1.9	0.4	0.1	0.1
Supplementary: Increased baseline risk of recurrence	TAPP	1345	16.205	Dominated (8219 vs OFM)	40.0	49.6	51.3	52.3
	TEP	1310	16.207	6497	41.2	46.3	46.9	46.5
	OFM	1110	16.176		18.8	4.1	2.0	1.2
Supplementary: RR of pain from Neumayer and colleagues	TAPP	1211	16.226	13,789 (5219 vs OFM)	51.3	65.3	70.1	73.8
	TEP	1149	16.222	3999	44.7	33.9	29.6	25.9
	OFM	1022	16.190		4.0	0.8	0.3	0.3
Main: Assuming that there is no disutility associated with pain or numbness	TAPP	1211	16.26	2,173,247	0.0	0.2	1.7	8.6
	TEP	1135	16.26	98,584	0.3	3.6	13.4	30.8
	OFM	1022	16.26		99.7	96.2	84.9	60.6
Supplementary: Assuming that there is no disutility associated with pain or numbness	TAPP	1211	16.258	97,763 (159,480 vs OFM)	0.1	0.4	1.8	6.8
	TEP	1149	16.257	230,988	0.0	0.1	2.0	14.2
	OFM	1022	16.257		99.0	99.5	96.2	79.0

Discussion

Main results

Effectiveness

The main change in the estimates of effects following the incorporation of data from Neumayer and colleagues' trial is in the meta-analysis of hernia recurrence. Overall, recurrence rates were much higher in the new trial than in previous trials, and were twice as high after laparoscopic repair than open repair. Reflecting this, the estimated RR following TEP compared with open flat mesh is now 2.00 (95% CI 1.43 to 2.81).

The high recurrence rates overall in Neumayer and colleagues' trial are likely to be due, in part at least, to the method of diagnosis. It would have been helpful to have had access to data that separated recurrences that were diagnosed following patient report from those diagnosed at clinical examination, and those confirmed at operation from those diagnosed by ultrasound. The results of Neumayer and colleagues' trial[2] have similarities with the MRC Laparoscopic Groin Hernia Trial (which had previously been out of line with the other trials).[3] In that trial, there were seven recurrences in the laparoscopic group (again mixed TAPP and TEP) compared with none at 1 year follow-up in the open mesh group. One suggested explanation for this was inexperience of some of the surgeons. This seemed to be supported by the findings of long-term follow-up of patients recruited by the most experienced surgeon in that trial: at 5 years there were equal numbers of recurrence in the two groups.[4] *Post hoc* analyses in Neumayer and colleagues' trial suggested that the excess of recurrences in the laparoscopic group was explained by the performance of surgeons who had performed fewer than 250 laparoscopic procedures. Amongst the 20/78 surgeons who had performed more than this number, recurrences in the two trial groups were similar.

Another notable finding was a death related to a visceral injury during laparoscopic repair and two cases of reoperation because of haemorrhage, again in the laparoscopic group (although it is not known for any of these cases which laparoscopic technique was used). The report also suggests higher rates of less serious complications after laparoscopic repair but the report is difficult to assess in this respect.

In contrast to recurrence and complications, the results for other measures of outcome were essentially similar to those in the main report.

Costs and cost-effectiveness

If the only measure of effectiveness that is judged important is recurrences, then in the supplementary (and main analyses) TEP and TAPP repair are dominated by open flat mesh. When other relevant outcomes are aggregated into QALYs then in the base-case analysis the probability that TEP repair is cost-effective is still relatively high at threshold values that society is willing to pay for a QALY. This result indicates that an increase in recurrence rates for TEP repair is not sufficient to offset the gains from less long-term pain and numbness.

Nonetheless, in the supplementary analysis, TEP is less likely to be considered cost-effective and the principal beneficiary of this is TAPP rather than open flat mesh. The sensitivity analysis conducted illustrates two issues. The first is that the differences between TEP and TAPP repair are not great. For example, when the RR of long-term pain from Neumayer and colleagues was used in the analysis, the estimates of QALYs for TAPP and TEP repair were similar and the chance of open flat mesh repair being considered cost-effective was very low. Second, the sensitivity analysis illustrates that the results are much more sensitive to the risk of pain and its associated utility than the risk of recurrence.

Assumptions, limitations and uncertainties

Although the trial reported by Neumayer and colleagues represents the single largest published trial comparing laparoscopic with open mesh repair, this supplementary report does not represent a systematic update. No attempt has been made to identify other studies published since the previous search was conducted in June 2003. Although it is likely that such studies do exist, it is very unlikely that they will be of the same size, and hence impact, as the Neumayer and colleagues' trial (although we do know that large trials conducted in Sweden should be reported soon). Furthermore, the supplementary analysis relied solely on the published report by Neumayer and colleagues. In the time available, no attempt was made to elicit extra data that have been collected but not as yet reported.

The reliance on published data led to the assumption that the results of Neumayer and colleagues apply solely to TEP repair. This assumption was made because 90% of the laparoscopic patients received TEP repair and disaggregated data were not reported. The

TABLE 7 *Comparison of TEP and open flat mesh for both the main and supplementary analyses*

	Procedure	Incremental cost per QALY (£)	Probability cost-effectiveness for different threshold values for society's willingness to pay for a QALY (%)			
			£10,000	**£20,000**	**£30,000**	**£50,000**
Main: Base-case model for a 5-year time horizon (TEP vs OFM)	TEP	4928	85.8	95.9	97.2	98.2
	OFM		14.2	4.1	2.8	1.8
Supplementary: Base case for a 5-year time horizon (TEP vs OFM)	TEP	6725	67.4	90.4	93.6	95.6
	OFM		32.6	9.6	6.4	4.4
Main: Base-case model for a 25-year time horizon (TEP vs OFM)	TEP	2092	93.6	96.7	97.9	98.4
	OFM		6.4	3.3	2.1	1.6
Supplementary: Base case for a 25-year time horizon (TEP vs OFM)	TEP	2994	86.2	92.3	93.8	95.0
	OFM		13.8	7.7	6.2	5.0

consequence of this assumption is that TEP now appears less favourable when directly compared with open flat mesh and indirectly compared with TAPP than it did in the main Assessment Report. Neumayer and colleagues report a higher rate of complications for laparoscopic repair. These complications are, however, still rare and it is possible that they might relate in part or solely to TAPP repair. Until further, disaggregated data are obtained from the authors, it is unclear how best to interpret these data.

The finding that there is now an increase in the likelihood that TAPP might be considered cost-effective might be due to the limited data available for the comparisons of TAPP with open flat mesh rather than a relative decline in performance of TEP compared with TAPP. It is possible that the data available for the TAPP versus open flat mesh may still be sufficiently imprecise when compared with the data available for TEP versus open flat mesh for erroneous conclusions to be drawn. For this reason, in *Table 7* data are presented that show the pairwise comparison of TEP with open flat mesh (the data for TAPP versus open flat mesh are not considered).

As *Table 7* shows, with the addition of the data from Neumayer and colleagues TEP has, when compared with open flat mesh, a slightly reduced likelihood that it would be considered cost-effective at threshold values for a cost per QALY that society might consider acceptable.

Conclusions

Implications for the NHS
- If the sole purpose of hernia repair is to avoid recurrence and/or rare serious complications, then open flat mesh repair would be the preferred method.
- The new trial report by Neumayer and colleagues, like other trials, shows less persistent pain after laparoscopic repair. For this reason, in terms of cost per QALY, the addition of data from Neumayer and colleagues does not greatly affect the results from the main Assessment Report.
- TEP repair will provide additional benefits at a cost that may be deemed acceptable to society.

Implications for research
- Further data on those outcomes considered, but not yet reported by Neumayer and colleagues, are required.
- Where possible, additional disaggregated data from Neumayer and colleagues are required to address some of the uncertainties highlighted above, particularly related to recurrence and complications.
- The Assessment Report should be updated when the results of currently ongoing trials become available.

References

1. McCormack K, Wake B, Perez J, Fraser C, Cook J, McIntosh E, *et al*. Laparoscopic surgery for inguinal

hernia repair: systematic review of effectiveness and economic evaluation. *Health Technol Assess* 2005;**9**(14).

2. Neumayer L, Giobbie-Hurder A, Jonasson O, Fitzgibbons R, Dunlop D, Gibbs J, *et al.*, for the Veterans Affairs Cooperative Studies Program 456 Investigators. Open mesh versus laparoscopic mesh repair of inguinal hernia. *N Engl J Med* 2004; **350**:1819–27.

3. MRC Laparoscopic Groin Hernia Trial Group. Laparoscopic versus open repair of groin hernia: a randomised comparison. *Lancet* 1999;**354**: 185–90.

4. Wright D, Paterson C, Scott N, Hair A, O'Dwyer PJ. Five-year follow-up of patients undergoing laparoscopic or open groin hernia repair: a randomized controlled trial. *Ann Surg* 2002; **235**:333–7.

Appendix 1: detailed quality assessment results for included primary studies

Study	Method of randomisation	Concealment of allocation	Blinding of outcome assessor	Loss to follow-up	Analysis by ITT
Neumayer, 2004[2]	Computer randomisation	Unclear	Unclear	Yes	Yes

Appendix 2: characteristics of additional study for effectiveness

Study	Study details	Intervention/comparator	Intervention population characteristics	Comparator population characteristics	Outcomes
Neumayer, 2004[2]	Multicentre RCT 2164 participants Follow-up = 2 years Full text	Laparoscopic (90% TEP, 10% TAPP) (*n* = 1087 randomised; data relate to 994) versus open flat mesh (*n* = 1077 randomised; data relate to 989)	99.1% general anaesthetic 0.7% regional anaesthetic 0.2% local anaesthetic 17.7% bilateral 9.7% recurrent Direct – unknown Indirect – unknown Age mean (SD) 58.6 (12.8) years 994 male/0 female	61.0% general anaesthetic 27.5% regional anaesthetic 11.5% local anaesthetic 17.9% bilateral 8.9% recurrent Direct – unknown Indirect – unknown Age mean (SD) 58.4 (12.7) years 989 male/0 female	Intraoperative complications Postoperative complications Hernia recurrence Persisting pain Mortality

Appendix 3: main and supplementary meta-analyses

Main

Comparison: 02 TEP versus Open Mesh
Outcome: 06 Wound/superficial infection

Study	Treatment n/N	Control n/N	RR (95% CI fixed)	Weight %	RR (95% CI fixed)
01 TEP versus Flat Mesh					
Andersson, 2003	0/81	2/84		10.0	0.21 (0.01 to 4.25)
Bringman, 2003	1/92	4/103		15.4	0.28 (0.03 to 2.46)
Colak, 2003	0/67	2/67		10.2	0.20 (0.01 to 4.09)
Heikkinen (2), 1998	2/22	0/23		2.0	5.22 (0.26 to 102.93)
Lal, 2003	1/25	1/25		4.1	1.00 (0.07 to 15.12)
x Merello, 1997	0/39	0/25		0.0	Not estimable
Subtotal (95% CI)	4/326	9/327		41.6	0.55 (0.20 to 1.53)
Test for heterogeneity $\chi^2 = 3.58$, df = 4, $p = 0.47$					
Test for overall effect $z = -1.15$, $p = 0.3$					
02 TEP versus Preperitoneal Mesh					
Bostanci, 1998	0/32	1/32		6.1	0.33 (0.01 to 7.89)
Subtotal (95% CI)	0/32	1/32		6.1	0.33 (0.01 to 7.89)
Test for heterogeneity $\chi^2 = 0.0$, df = 0					
Test for overall effect $z = -0.68$, $p = 0.5$					
03 TEP versus Plug and Mesh					
Bringman, 2003	1/92	3/104		11.5	0.38 (0.04 to 3.56)
x Khoury, 1998	0/136	0/117		0.0	Not estimable
Subtotal (95% CI)	1/228	3/221		11.5	1.08 (0.04 to 3.56)
Test for heterogeneity $\chi^2 = 0.0$, df = 0					
Test for overall effect $z = -0.85$, $p = 0.4$					
04 TEP versus Mixed Mesh					
MRC multicentre, 1999	8/292	10/291		40.8	0.80 (0.32 to 1.99)
Subtotal (95% CI)	8/292	10/291		40.8	0.80 (0.32 to 1.99)
Test for heterogeneity $\chi^2 = 0.0$, df = 0					
Test for overall effect $z = -0.49$, $p = 0.6$					
Total (95% CI)	13/878	23/871		100.0	0.62 (0.33 to 1.16)
Test for heterogeneity $\chi^2 = 4.27$, df = 7, $p = 0.75$					
Test for overall effect $z = -1.49$, $p = 0.14$					

0.001 0.01 0.1 1 10 100 1000

Favours treatment   Favours control

Main

Comparison: 02 TEP versus Open Mesh
Outcome: 08 Vascular injury

Study	Treatment n/N	Control n/N	RR (95% CI fixed)	Weight %	RR (95% CI fixed)
01 TEP versus Flat Mesh					
Andersson, 2003	2/81	2/87		49.4	1.07 (0.15 to 7.45)
x Colak, 2003	0/67	0/67		0.0	Not estimable
x Heikkinen (2), 1998	0/22	0/23		0.0	Not estimable
x Merello, 1997	0/20	0/5		0.0	Not estimable
Subtotal (95% CI)	2/190	2/182		49.4	1.07 (0.15 to 7.45)
Test for heterogeneity $\chi^2 = 0.0$, df = 0					
Test for overall effect $z = 0.07$, $p = 0.9$					
02 TEP versus Preperitoneal Mesh					
Simmermacher, 2000	2/80	2/82		50.6	1.03 (0.15 to 7.10)
Subtotal (95% CI)	2/80	2/82		50.6	1.03 (0.15 to 7.10)
Test for heterogeneity $\chi^2 = 0.0$, df = 0					
Test for overall effect $z = 0.03$, $p = 1$					
03 TEP versus Plug and Mesh					
x Khoury, 1998	0/136	0/117		0.0	Not estimable
Subtotal (95% CI)	0/136	0/117		0.0	Not estimable
Test for heterogeneity $\chi^2 = 0.0$, df = 0					
Test for overall effect $z = 0.0$, $p = 1$					
04 TEP versus Mixed Mesh					
x MRC multicentre, 1999	0/338	0/336		0.0	Not estimable
Subtotal (95% CI)	0/338	0/336		0.0	Not estimable
Test for heterogeneity $\chi^2 = 0.0$, df = 0					
Test for overall effect $z = 0.0$, $p = 1$					
Total (95% CI)	4/744	4/717		100.0	1.05 (0.27 to 4.12)
Test for heterogeneity $\chi^2 = 0.00$, df = 1, $p = 0.97$					
Test for overall effect $z = 0.07$, $p = 0.9$					

```
         0.001  0.01   0.1     1     10    100   1000
              Favours treatment    Favours control
```

Supplementary

Review: Laparoscopic techniques versus open techniques for inguinal hernia repair (NICE update 2003)
Comparison: 02 TEP versus Open Mesh
Outcome: 06 Wound/superficial infection

Study or sub-category	Treatment n/N	Control n/N	RR (fixed) 95% CI	Weight %	RR (fixed) 95% CI
01 TEP versus Flat Mesh					
Andersson, 2003	0/81	2/84		6.37	0.21 (0.01 to 4.25)
Merello, 1997	0/39	0/25			Not estimable
Heikkinen (2), 1998	2/22	0/23		1.27	5.22 (0.26 to 102.93)
Bringman, 2003	1/92	4/103		9.80	0.28 (0.03 to 2.46)
Colak, 2003	0/67	2/67		6.49	0.20 (0.01 to 4.09)
Lal, 2003	1/25	1/25		2.60	1.00 (0.07 to 15.12)
NEJM, 2004	10/989	14/994		36.26	0.72 (0.32 to 1.61)
Subtotal (95% CI)	1315	1321		62.79	0.65 (0.34 to 1.22)
Total events: 14 (Treatment), 23 (Control)					
Test for heterogeneity χ^2 = 3.74, df = 5 (p = 0.59), I^2 = 0%					
Test for overall effect z = 1.35 (p = 0.18)					
02 TEP versus Preperitoneal Mesh					
Bostanci, 1998	0/32	1/32		3.89	0.33 (0.01 to 7.89)
Subtotal (95% CI)	32	32		3.89	0.33 (0.01 to 7.89)
Total events: 0 (Treatment), 1 (Control)					
Test for heterogeneity not applicable					
Test for overall effect z = 0.68 (p = 0.50)					
03 TEP versus Plug and Mesh					
Khoury, 1998	0/136	0/117			Not estimable
Bringman, 2003	1/92	3/104		7.31	0.38 (0.04 to 3.56)
Subtotal (95% CI)	228	221		7.31	0.38 (0.04 to 3.56)
Total events: 1 (Treatment), 3 (Control)					
Test for heterogeneity not applicable					
Test for overall effect z = 0.85 (p = 0.39)					
04 TEP versus Mixed Mesh					
MRC multicentre, 1999	8/292	10/291		26.01	0.80 (0.32 to 1.99)
Subtotal (95% CI)	292	291		26.01	0.80 (0.32 to 1.99)
Total events: 8 (Treatment), 10 (Control)					
Test for heterogeneity not applicable					
Test for overall effect z = 0.49 (p = 0.63)					
Total (95% CI)	1867	1865		100.0	0.65 (0.40 to 1.08)
Total events: 23 (Treatment), 37 (Control)					
Test for heterogeneity χ^2 = 4.33, df = 8 (p = 0.83), I^2 = 0%					
Test for overall effect z = 1.67 (p = 0.09)					

0.001   0.01   0.1   1   10   100   1000

Favours treatment   Favours control

Supplementary

Review: Laparoscopic techniques versus open techniques for inguinal hernia repair (NICE update 2003)
Comparison: 02 TEP versus Open Mesh
Outcome: 08 Vascular injury

Study or sub-category	Treatment n/N	Control n/N	RR (fixed) 95% CI	Weight %	RR (fixed) 95% CI
01 TEP versus Flat Mesh					
Andersson, 2003	2/81	2/87		43.81	1.07 (0.15 to 7.45)
Merello, 1997	0/20	0/5			Not estimable
Heikkinen (2), 1998	0/22	0/23			Not estimable
Colak, 2003	0/67	0/67			Not estimable
NEJM, 2004	2/989	0/994		11.33	5.03 (0.24 to 104.54)
Subtotal (95% CI)	1179	1176		55.13	1.89 (0.40 to 8.83)
Total events: 4 (Treatment), 2 (Control)					
Test for heterogeneity $\chi^2 = 0.73$, df = 1 ($p = 0.39$), $I^2 = 0\%$					
Test for overall effect z = 0.81 ($p = 0.42$)					
02 TEP versus Preperitoneal Mesh					
Simmermacher, 2000	2/80	2/82		44.87	1.03 (0.15 to 7.10)
Subtotal (95% CI)	80	82		44.87	1.03 (0.15 to 7.10)
Total events: 2 (Treatment), 2 (Control)					
Test for heterogeneity not applicable					
Test for overall effect z = 0.03 ($p = 0.98$)					
03 TEP versus Plug and Mesh					
Khoury, 1998	0/136	0/117			Not estimable
Subtotal (95% CI)	0	0			Not estimable
Total events: 0 (Treatment), 0 (Control)					
Test for heterogeneity not applicable					
Test for overall effect not applicable					
04 TEP versus Mixed Mesh					
MRC multicentre, 1999	0/338	0/336			Not estimable
Subtotal (95% CI)	0	0			Not estimable
Total events: 0 (Treatment), 0 (Control)					
Test for heterogeneity not applicable					
Test for overall effect not applicable					
Total (95% CI)	1733	1711		100.0	1.50 (0.45 to 4.95)
Total events: 6 (Treatment), 4 (Control)					
Test for heterogeneity $\chi^2 = 0.87$, df = 2 ($p = 0.65$), $I^2 = 0\%$					
Test for overall effect z = 0.66 ($p = 0.51$)					

0.001 0.01 0.1 1 10 100 1000

Favours treatment   Favours control

Main

Comparison: 02 TEP versus Open Mesh
Outcome: 09 Vascular injury

Study	Treatment n/N	Control n/N	RR (95% CI fixed)	Weight %	RR (95% CI fixed)
01 TEP versus Flat Mesh					
Andersson, 2003	1/81	1/87		39.1	1.07 (0.07 to 16.89)
x Colak, 2003	0/67	0/67		0.0	Not estimable
x Heikkinen (2), 1998	0/22	0/23		0.0	Not estimable
Subtotal (95% CI)	1/170	1/177		39.1	1.07 (0.07 to 16.89)
Test for heterogeneity $\chi^2 = 0.0$, df = 0					
Test for overall effect $z = 0.05$, $p = 1$					
02 TEP versus Preperitoneal Mesh					
Subtotal (95% CI)	0/0	0/0		0.0	Not estimable
Test for heterogeneity $\chi^2 = 0.0$, df = 0					
Test for overall effect $z = 0.0$, $p = 1$					
03 TEP versus Plug and Mesh					
x Khoury, 1998	0/136	0/117		0.0	Not estimable
Subtotal (95% CI)	0/136	0/117		0.0	Not estimable
Test for heterogeneity $\chi^2 = 0.0$, df = 0					
Test for overall effect $z = 0.0$, $p = 1$					
04 TEP versus Mixed Mesh					
MRC multicentre, 1999	0/338	1/336		60.9	0.33 (0.01 to 8.11)
Subtotal (95% CI)	0/338	1/336		60.9	0.33 (0.01 to 8.11)
Test for heterogeneity $\chi^2 = 0.0$, df = 0					
Test for overall effect $z = -0.68$, $p = 0.5$					
Total (95% CI)	1/644	2/630		100.0	0.62 (0.08 to 4.62)
Test for heterogeneity $\chi^2 = 0.30$, df = 1, $p = 0.58$					
Test for overall effect $z = -0.46$, $p = 0.6$					

0.001 0.01 0.1 1 10 100 1000
Favours treatment   Favours control

Supplementary

Review: Laparoscopic techniques versus open techniques for inguinal hernia repair (NICE update 2003)
Comparison: 02 TEP versus Open Mesh
Outcome: 09 Vascular injury

Study or sub-category	Treatment n/N	Control n/N	RR (fixed) 95% CI	Weight %	RR (fixed) 95% CI
01 TEP versus Flat Mesh					
Andersson, 2003	1/81	1/87		27.82	1.07 (0.07 to 16.89)
Heikkinen (2), 1998	0/22	0/23			Not estimable
Colak, 2003	0/67	0/67			Not estimable
NEJM, 2004	1/989	1/994		28.78	1.01 (0.06 to 16.05)
Subtotal (95% CI)	1159	1171		56.60	1.04 (0.15 to 7.33)
Total events: 2 (Treatment), 2 (Control)					
Test for heterogeneity $\chi^2 = 0.00$, df = 1 ($p = 0.97$), $I^2 = 0\%$					
Test for overall effect $z = 0.04$ ($p = 0.97$)					
02 TEP versus Preperitoneal Mesh					
Subtotal (95% CI)	0	0			Not estimable
Total events: 0 (Treatment), 0 (Control)					
Test for heterogeneity not applicable					
Test for overall effect not applicable					
03 TEP versus Plug and Mesh					
Khoury, 1998	0/136	0/117			Not estimable
Subtotal (95% CI)	0	0			Not estimable
Total events: 0 (Treatment), 0 (Control)					
Test for heterogeneity not applicable					
Test for overall effect not applicable					
04 TEP versus Mixed Mesh					
MRC multicentre, 1999	0/338	1/336		43.40	0.33 (0.01 to 8.11)
Subtotal (95% CI)	338	336		43.40	0.33 (0.01 to 8.11)
Total events: 0 (Treatment), 1 (Control)					
Test for heterogeneity not applicable					
Test for overall effect $z = 0.68$ ($p = 0.50$)					
Total (95% CI)	1633	1624		100.0	0.73 (0.15 to 3.68)
Total events: 2 (Treatment), 3 (Control)					
Test for heterogeneity $\chi^2 = 0.36$, df = 2 ($p = 0.83$), $I^2 = 0\%$					
Test for overall effect $z = 0.38$ ($p = 0.70$)					

0.001 0.01 0.1 1 10 100 1000
Favours treatment   Favours control

Supplementary

Review: Laparoscopic techniques versus open techniques for inguinal hernia repair (NICE update 2003)
Comparison: 02 TEP versus Open Mesh
Outcome: 10 Port site hernia

Study or sub-category	Treatment n/N	Control n/N	RR (fixed) 95% CI	Weight %	RR (fixed) 95% CI
01 TEP versus Flat Mesh					
Heikkinen (2), 1998	0/22	0/23			Not estimable
NEJM, 2004	2/989	0/994		100.0	5.03 (0.24 to 104.54)
Subtotal (95% CI)	1011	1017		100.0	5.03 (0.24 to 104.54)
Total events: 2 (Treatment), 0 (Control)					
Test for heterogeneity not applicable					
Test for overall effect z = 1.04 (p = 0.30)					
02 TEP versus Preperitoneal Mesh					
Subtotal (95% CI)	0	0			Not estimable
Total events: 0 (Treatment), 0 (Control)					
Test for heterogeneity not applicable					
Test for overall effect not applicable					
03 TEP versus Plug and Mesh					
Khoury, 1998	0/136	0/117			Not estimable
Subtotal (95% CI)	0	0			Not estimable
Total events: 0 (Treatment), 0 (Control)					
Test for heterogeneity not applicable					
Test for overall effect not applicable					
04 TEP versus Mixed Mesh					
MRC multicentre, 1999	0/285	0/271			Not estimable
Subtotal (95% CI)	0	0			Not estimable
Total events: 0 (Treatment), 0 (Control)					
Test for heterogeneity not applicable					
Test for overall effect not applicable					
Total (95% CI)	1432	1405		100.0	5.03 (0.24 to 104.54)
Total events: 2 (Treatment), 0 (Control)					
Test for heterogeneity not applicable					
Test for overall effect z = 1.04 (p = 0.30)					

0.001 0.01 0.1 1 10 100 1000
Favours treatment   Favours control

Main

Comparison: 02 TEP versus Open Mesh
Outcome: 14 Persisting pain

Study	Treatment n/N	Control n/N	RR (95% CI fixed)	Weight %	RR (95% CI fixed)
01 TEP versus Flat Mesh					
Heikkinen (2), 1998	0/22	1/23		0.9	0.35 (0.01 to 8.11)
Merello, 1997	0/34	5/17		4.4	0.05 (0.00 to 0.80)
Subtotal (95% CI)	0/56	6/40		5.3	0.10 (0.01 to 0.66)
Test for heterogeneity χ^2 = 0.88, df = 1, p = 0.35					
Test for overall effect z = −2.38, p = 0.02					
02 TEP versus Preperitoneal Mesh					
Subtotal (95% CI)	0/0	0/0		0.0	Not estimable
Test for heterogeneity χ^2 = 0.0, df = 0					
Test for overall effect z = 0.0 , p = 1					
03 TEP versus Plug and Mesh					
Khoury, 1998	2/137	11/117		7.2	0.16 (0.04 to 0.69)
Subtotal (95% CI)	2/137	11/117		7.2	0.16 (0.04 to 0.69)
Test for heterogeneity χ^2 = 0.0, df = 0					
Test for overall effect z = −2.46, p = 0.01					
04 TEP versus Mixed Mesh					
MRC multicentre, 1999	125/324	142/317		87.5	0.86 (0.72 to 1.04)
Subtotal (95% CI)	125/324	142/317		87.5	0.86 (0.72 to 1.04)
Test for heterogeneity χ^2 = 0.0, df = 0					
Test for overall effect z = −1.59, p = 0.11					
Total (95% CI)	127/517	159/474		100.0	0.77 (0.64 to 0.92)
Test for heterogeneity χ^2 = 9.88, df = 3, p = 0.02					
Test for overall effect z = −2.84, p = 0.004					

0.001 0.01 0.1 1 10 100 1000
Favours treatment   Favours control

Supplementary

Review: Laparoscopic techniques versus open techniques for inguinal hernia repair (NICE update 2003)
Comparison: 02 TEP versus Open Mesh
Outcome: 14 Persisting pain

Study or sub-category	Treatment n/N	Control n/N	RR (fixed) 95% CI	Weight %	RR (fixed) 95% CI
01 TEP versus Flat Mesh					
Merello, 1997	0/34	5/17		1.98	0.05 (0.00 to 0.80)
Heikkinen (2), 1998	0/22	1/23		1.62	0.35 (0.01 to 8.11)
NEJM, 2004	97/989	142/994		43.40	0.69 (0.54 to 0.88)
Subtotal (95% CI)	1045	1034		47.00	0.36 (0.08 to 1.65)
Total events: 97 (Treatment), 148 (Control)					
Test for heterogeneity χ^2 = 3.64, df = 2 (p = 0.16), I^2 = 45.0%					
Test for overall effect z = 1.32 (p = 0.19)					
02 TEP versus Preperitoneal Mesh					
Subtotal (95% CI)	0	0			Not estimable
Total events: 0 (Treatment), 0 (Control)					
Test for heterogeneity not applicable					
Test for overall effect not applicable					
03 TEP versus Plug and Mesh					
Khoury, 1998	2/137	11/117		6.55	0.16 (0.04 to 0.69)
Subtotal (95% CI)	137	117		6.55	0.16 (0.04 to 0.69)
Total events: 2 (Treatment), 11 (Control)					
Test for heterogeneity not applicable					
Test for overall effect z = 2.46 (p = 0.01)					
04 TEP versus Mixed Mesh					
MRC multicentre, 1999	125/324	142/317		46.46	0.86 (0.72 to 1.04)
Subtotal (95% CI)	324	317		46.46	0.86 (0.72 to 1.04)
Total events: 125 (Treatment), 142 (Control)					
Test for heterogeneity not applicable					
Test for overall effect z = 1.59 (p = 0.11)					
Total (95% CI)	1506	1468		100.0	0.65 (0.43 to 0.98)
Total events: 224 (Treatment), 301 (Control)					
Test for heterogeneity χ^2 = 11.30, df = 4 (p = 0.02), I^2 = 64.6%					
Test for overall effect z = 2.08 (p = 0.04)					

0.001   0.01   0.1   1   10   100   1000

Favours treatment   Favours control

Main

Comparison: 02 TEP versus Open Mesh
Outcome: 15 Hernia recurrence

Study	Treatment n/N	Control n/N	RR (95% CI fixed)	Weight %	RR (95% CI fixed)
01 TEP versus Flat Mesh					
Andersson, 2003	2/76	0/85		3.0	5.58 (0.27 to 114.52)
Bringman, 2003	2/92	0/103		3.0	5.59 (0.27 to 114.98)
Colak, 2003	2/67	4/67		25.3	0.50 (0.09 to 2.64)
x Heikkinen (2), 1998	0/22	0/23		0.0	Not estimable
x Lal, 2003	0/25	0/25		0.0	Not estimable
x Merello, 1997	0/59	0/57		0.0	Not estimable
Payne, 1996	1/50	0/50		3.2	3.00 (0.13 to 71.93)
Subtotal (95% CI)	7/391	4/410		34.4	1.61 (0.57 to 4.60)
Test for heterogeneity $\chi^2 = 3.35$, df = 3, $p = 0.34$					
Test for overall effect z = 0.89, $p = 0.4$					
02 TEP versus Preperitoneal Mesh					
x Bostanci, 1998	0/32	0/32		0.0	Not estimable
Champault, 1997	3/51	1/49		6.4	2.88 (0.31 to 26.78)
Suter, 2002	1/19	0/20		3.1	3.15 (0.14 to 72.89)
Subtotal (95% CI)	4/102	1/101		9.5	2.97 (0.48 to 18.28)
Test for heterogeneity $\chi^2 = 0.00$, df = 1, $p = 0.96$					
Test for overall effect z = 1.17, $p = 0.2$					
03 TEP versus Plug and Mesh					
Bringman, 2003	2/92	2/104		11.9	1.13 (0.16 to 7.87)
Khoury, 1998	3/137	6/116		41.0	0.42 (0.11 to 1.66)
Subtotal (95% CI)	5/229	8/220		52.9	0.58 (0.20 to 1.73)
Test for heterogeneity $\chi^2 = 0.66$, df = 1, $p = 0.42$					
Test for overall effect z = –0.98, $p = 0.3$					
04 TEP versus Mixed Mesh					
MRC multicentre, 1999	7/285	0/271		3.2	14.27 (0.82 to 248.59)
Subtotal (95% CI)	7/285	0/271		3.2	14.27 (0.82 to 248.59)
Test for heterogeneity $\chi^2 = 0.0$, df = 0					
Test for overall effect z = 1.82, $p = 0.07$					
Total (95% CI)	23/1007	13/1002		100.0	1.61 (0.87 to 2.98)
Test for heterogeneity $\chi^2 = 9.83$, df = 8, $p = 0.28$					
Test for overall effect z = 1.50, $p = 0.13$					

0.01　　0.1　　1　　10　　100

Favours treatment　　　　Favours control

Supplementary

Review: Laparoscopic techniques versus open techniques for inguinal hernia repair (NICE update 2003)
Comparison: 02 TEP versus Open Mesh
Outcome: 14 Hernia recurrence

Study or sub-category	Treatment n/N	Control n/N	RR (fixed) 95% CI	Weight %	RR (fixed) 95% CI
01 TEP versus Flat Mesh					
Andersson, 2003	2/76	0/85		0.82	5.58 (0.27 to 114.52)
Payne, 1996	1/50	0/50		0.87	3.00 (0.13 to 71.92)
Merello, 1997	0/59	0/57			Not estimable
Heikkinen (2), 1998	0/22	0/23			Not estimable
Bringman, 2003	2/92	0/103		0.82	5.59 (0.27 to 114.97)
Colak, 2003	2/67	4/67		6.95	0.50 (0.09 to 2.64)
Lal, 2003	0/25	0/25			Not estimable
NEJM, 2004	87/862	41/834		72.46	2.05 (1.43 to 2.94)
Subtotal (95% CI)	1253	1244		81.93	2.00 (1.43 to 2.81)
Total events: 94 (Treatment), 45 (Control)					
Test for heterogeneity $\chi^2 = 3.64$, df = 4 ($p = 0.46$), $I^2 = 0\%$					
Test for overall effect $z = 4.01$ ($p < 0.0001$)					
02 TEP versus Preperitoneal Mesh					
Champault, 1997	3/51	1/49		1.77	2.88 (0.31 to 26.78)
Bostanci, 1998	0/32	0/32			Not estimable
Suter, 2002	1/19	0/20		0.85	3.15 (0.14 to 72.88)
Subtotal (95% CI)	102	101		2.62	2.97 (0.48 to 18.28)
Total events: 4 (Treatment), 1 (Control)					
Test for heterogeneity $\chi^2 = 0.00$, df = 1 ($p = 0.96$), $I^2 = 0\%$					
Test for overall effect $z = 1.17$ ($p = 0.24$)					
03 TEP versus Plug and Mesh					
Khoury, 1998	3/137	6/116		11.30	0.42 (0.11 to 1.66)
Bringman, 2003	2/92	2/104		3.26	1.13 (0.16 to 7.86)
Subtotal (95% CI)	229	220		14.56	0.58 (0.20 to 1.73)
Total events: 5 (Treatment), 8 (Control)					
Test for heterogeneity $\chi^2 = 0.66$, df = 1 ($p = 0.42$), $I^2 = 0\%$					
Test for overall effect $z = 0.98$ ($p = 0.33$)					
04 TEP versus Mixed Mesh					
MRC multicentre, 1999	7/285	0/271		0.89	14.27 (0.82 to 248.58)
Subtotal (95% CI)	285	271		0.89	14.27 (0.82 to 248.58)
Total events: 7 (Treatment), 0 (Control)					
Test for heterogeneity not applicable					
Test for overall effect $z = 1.82$ ($p = 0.07$)					
Total (95% CI)	1869	1836		100.0	1.93 (1.42 to 2.63)
Total events: 110 (Treatment), 54 (Control)					
Test for heterogeneity $\chi^2 = 10.82$, df = 9 ($p = 0.29$), $I^2 = 16.8\%$					
Test for overall effect $z = 4.16$ ($p < 0.0001$)					

0.01　0.1　1　10　100

Favours treatment　　Favours control

203

◆

Health Technology Assessment reports
published to date

No. 15
Ethical issues in the design and conduct of randomised controlled trials.
A review by Edwards SJL, Lilford RJ, Braunholtz DA, Jackson JC, Hewison J, Thornton J.

No. 16
Qualitative research methods in health technology assessment: a review of the literature.
By Murphy E, Dingwall R, Greatbatch D, Parker S, Watson P.

No. 17
The costs and benefits of paramedic skills in pre-hospital trauma care.
By Nicholl J, Hughes S, Dixon S, Turner J, Yates D.

No. 18
Systematic review of endoscopic ultrasound in gastro-oesophageal cancer.
By Harris KM, Kelly S, Berry E, Hutton J, Roderick P, Cullingworth J, *et al*.

No. 19
Systematic reviews of trials and other studies.
By Sutton AJ, Abrams KR, Jones DR, Sheldon TA, Song F.

No. 20
Primary total hip replacement surgery: a systematic review of outcomes and modelling of cost-effectiveness associated with different prostheses.
A review by Fitzpatrick R, Shortall E, Sculpher M, Murray D, Morris R, Lodge M, *et al*.

Volume 3, 1999

No. 1
Informed decision making: an annotated bibliography and systematic review.
By Bekker H, Thornton JG, Airey CM, Connelly JB, Hewison J, Robinson MB, *et al*.

No. 2
Handling uncertainty when performing economic evaluation of healthcare interventions.
A review by Briggs AH, Gray AM.

No. 3
The role of expectancies in the placebo effect and their use in the delivery of health care: a systematic review.
By Crow R, Gage H, Hampson S, Hart J, Kimber A, Thomas H.

No. 4
A randomised controlled trial of different approaches to universal antenatal HIV testing: uptake and acceptability. Annex: Antenatal HIV testing – assessment of a routine voluntary approach.
By Simpson WM, Johnstone FD, Boyd FM, Goldberg DJ, Hart GJ, Gormley SM, *et al*.

No. 5
Methods for evaluating area-wide and organisation-based interventions in health and health care: a systematic review.
By Ukoumunne OC, Gulliford MC, Chinn S, Sterne JAC, Burney PGJ.

No. 6
Assessing the costs of healthcare technologies in clinical trials.
A review by Johnston K, Buxton MJ, Jones DR, Fitzpatrick R.

No. 7
Cooperatives and their primary care emergency centres: organisation and impact.
By Hallam L, Henthorne K.

No. 8
Screening for cystic fibrosis.
A review by Murray J, Cuckle H, Taylor G, Littlewood J, Hewison J.

No. 9
A review of the use of health status measures in economic evaluation.
By Brazier J, Deverill M, Green C, Harper R, Booth A.

No. 10
Methods for the analysis of quality-of-life and survival data in health technology assessment.
A review by Billingham LJ, Abrams KR, Jones DR.

No. 11
Antenatal and neonatal haemoglobinopathy screening in the UK: review and economic analysis.
By Zeuner D, Ades AE, Karnon J, Brown J, Dezateux C, Anionwu EN.

No. 12
Assessing the quality of reports of randomised trials: implications for the conduct of meta-analyses.
A review by Moher D, Cook DJ, Jadad AR, Tugwell P, Moher M, Jones A, *et al*.

No. 13
'Early warning systems' for identifying new healthcare technologies.
By Robert G, Stevens A, Gabbay J.

No. 14
A systematic review of the role of human papillomavirus testing within a cervical screening programme.
By Cuzick J, Sasieni P, Davies P, Adams J, Normand C, Frater A, *et al*.

No. 15
Near patient testing in diabetes clinics: appraising the costs and outcomes.
By Grieve R, Beech R, Vincent J, Mazurkiewicz J.

No. 16
Positron emission tomography: establishing priorities for health technology assessment.
A review by Robert G, Milne R.

No. 17 (Pt 1)
The debridement of chronic wounds: a systematic review.
By Bradley M, Cullum N, Sheldon T.

No. 17 (Pt 2)
Systematic reviews of wound care management: (2) Dressings and topical agents used in the healing of chronic wounds.
By Bradley M, Cullum N, Nelson EA, Petticrew M, Sheldon T, Torgerson D.

No. 18
A systematic literature review of spiral and electron beam computed tomography: with particular reference to clinical applications in hepatic lesions, pulmonary embolus and coronary artery disease.
By Berry E, Kelly S, Hutton J, Harris KM, Roderick P, Boyce JC, *et al*.

No. 19
What role for statins? A review and economic model.
By Ebrahim S, Davey Smith G, McCabe C, Payne N, Pickin M, Sheldon TA, *et al*.

No. 20
Factors that limit the quality, number and progress of randomised controlled trials.
A review by Prescott RJ, Counsell CE, Gillespie WJ, Grant AM, Russell IT, Kiauka S, *et al*.

No. 21
Antimicrobial prophylaxis in total hip replacement: a systematic review.
By Glenny AM, Song F.

No. 22
Health promoting schools and health promotion in schools: two systematic reviews.
By Lister-Sharp D, Chapman S, Stewart-Brown S, Sowden A.

No. 23
Economic evaluation of a primary care-based education programme for patients with osteoarthritis of the knee.
A review by Lord J, Victor C, Littlejohns P, Ross FM, Axford JS.

Volume 4, 2000

No. 1
The estimation of marginal time preference in a UK-wide sample (TEMPUS) project.
A review by Cairns JA, van der Pol MM.

No. 2
Geriatric rehabilitation following fractures in older people: a systematic review.
By Cameron I, Crotty M, Currie C, Finnegan T, Gillespie L, Gillespie W, *et al*.

No. 3
Screening for sickle cell disease and thalassaemia: a systematic review with supplementary research.
By Davies SC, Cronin E, Gill M, Greengross P, Hickman M, Normand C.

No. 4
Community provision of hearing aids and related audiology services.
A review by Reeves DJ, Alborz A, Hickson FS, Bamford JM.

No. 5
False-negative results in screening programmes: systematic review of impact and implications.
By Petticrew MP, Sowden AJ, Lister-Sharp D, Wright K.

No. 6
Costs and benefits of community postnatal support workers: a randomised controlled trial.
By Morrell CJ, Spiby H, Stewart P, Walters S, Morgan A.

No. 7
Implantable contraceptives (subdermal implants and hormonally impregnated intrauterine systems) versus other forms of reversible contraceptives: two systematic reviews to assess relative effectiveness, acceptability, tolerability and cost-effectiveness.
By French RS, Cowan FM, Mansour DJA, Morris S, Procter T, Hughes D, *et al*.

No. 8
An introduction to statistical methods for health technology assessment.
A review by White SJ, Ashby D, Brown PJ.

No. 9
Disease-modifying drugs for multiple sclerosis: a rapid and systematic review.
By Clegg A, Bryant J, Milne R.

No. 10
Publication and related biases.
A review by Song F, Eastwood AJ, Gilbody S, Duley L, Sutton AJ.

No. 11
Cost and outcome implications of the organisation of vascular services.
By Michaels J, Brazier J, Palfreyman S, Shackley P, Slack R.

No. 12
Monitoring blood glucose control in diabetes mellitus: a systematic review.
By Coster S, Gulliford MC, Seed PT, Powrie JK, Swaminathan R.

No. 13
The effectiveness of domiciliary health visiting: a systematic review of international studies
and a selective review of the British literature.
By Elkan R, Kendrick D, Hewitt M, Robinson JJA, Tolley K, Blair M, *et al*.

No. 14
The determinants of screening uptake and interventions for increasing uptake: a systematic review.
By Jepson R, Clegg A, Forbes C, Lewis R, Sowden A, Kleijnen J.

No. 15
The effectiveness and cost-effectiveness of prophylactic removal of wisdom teeth.
A rapid review by Song F, O'Meara S, Wilson P, Golder S, Kleijnen J.

No. 16
Ultrasound screening in pregnancy: a systematic review of the clinical effectiveness, cost-effectiveness and women's views.
By Bricker L, Garcia J, Henderson J, Mugford M, Neilson J, Roberts T, *et al*.

No. 17
A rapid and systematic review of the effectiveness and cost-effectiveness of the taxanes used in the treatment of advanced breast and ovarian cancer.
By Lister-Sharp D, McDonagh MS, Khan KS, Kleijnen J.

No. 18
Liquid-based cytology in cervical screening: a rapid and systematic review.
By Payne N, Chilcott J, McGoogan E.

No. 19
Randomised controlled trial of non-directive counselling, cognitive–behaviour therapy and usual general practitioner care in the management of depression as well as mixed anxiety and depression in primary care.
By King M, Sibbald B, Ward E, Bower P, Lloyd M, Gabbay M, *et al*.

No. 20
Routine referral for radiography of patients presenting with low back pain: is patients' outcome influenced by GPs' referral for plain radiography?
By Kerry S, Hilton S, Patel S, Dundas D, Rink E, Lord J.

No. 21
Systematic reviews of wound care management: (3) antimicrobial agents for chronic wounds; (4) diabetic foot ulceration.
By O'Meara S, Cullum N, Majid M, Sheldon T.

No. 22
Using routine data to complement and enhance the results of randomised controlled trials.
By Lewsey JD, Leyland AH, Murray GD, Boddy FA.

No. 23
Coronary artery stents in the treatment of ischaemic heart disease: a rapid and systematic review.
By Meads C, Cummins C, Jolly K, Stevens A, Burls A, Hyde C.

No. 24
Outcome measures for adult critical care: a systematic review.
By Hayes JA, Black NA, Jenkinson C, Young JD, Rowan KM, Daly K, *et al*.

No. 25
A systematic review to evaluate the effectiveness of interventions to promote the initiation of breastfeeding.
By Fairbank L, O'Meara S, Renfrew MJ, Woolridge M, Sowden AJ, Lister-Sharp D.

No. 26
Implantable cardioverter defibrillators: arrhythmias. A rapid and systematic review.
By Parkes J, Bryant J, Milne R.

No. 27
Treatments for fatigue in multiple sclerosis: a rapid and systematic review.
By Brañas P, Jordan R, Fry-Smith A, Burls A, Hyde C.

No. 28
Early asthma prophylaxis, natural history, skeletal development and economy (EASE): a pilot randomised controlled trial.
By Baxter-Jones ADG, Helms PJ, Russell G, Grant A, Ross S, Cairns JA, *et al*.

No. 29
Screening for hypercholesterolaemia versus case finding for familial hypercholesterolaemia: a systematic review and cost-effectiveness analysis.
By Marks D, Wonderling D, Thorogood M, Lambert H, Humphries SE, Neil HAW.

No. 30
A rapid and systematic review of the clinical effectiveness and cost-effectiveness of glycoprotein IIb/IIIa antagonists in the medical management of unstable angina.
By McDonagh MS, Bachmann LM, Golder S, Kleijnen J, ter Riet G.

No. 31
A randomised controlled trial of prehospital intravenous fluid replacement therapy in serious trauma.
By Turner J, Nicholl J, Webber L, Cox H, Dixon S, Yates D.

No. 32
Intrathecal pumps for giving opioids in chronic pain: a systematic review.
By Williams JE, Louw G, Towlerton G.

No. 33
Combination therapy (interferon alfa and ribavirin) in the treatment of chronic hepatitis C: a rapid and systematic review.
By Shepherd J, Waugh N, Hewitson P.

No. 34
A systematic review of comparisons of effect sizes derived from randomised and non-randomised studies.

By MacLehose RR, Reeves BC, Harvey IM, Sheldon TA, Russell IT, Black AMS.

No. 35
Intravascular ultrasound-guided interventions in coronary artery disease: a systematic literature review, with decision-analytic modelling, of outcomes and cost-effectiveness.

By Berry E, Kelly S, Hutton J, Lindsay HSJ, Blaxill JM, Evans JA, *et al.*

No. 36
A randomised controlled trial to evaluate the effectiveness and cost-effectiveness of counselling patients with chronic depression.

By Simpson S, Corney R, Fitzgerald P, Beecham J.

No. 37
Systematic review of treatments for atopic eczema.

By Hoare C, Li Wan Po A, Williams H.

No. 38
Bayesian methods in health technology assessment: a review.

By Spiegelhalter DJ, Myles JP, Jones DR, Abrams KR.

No. 39
The management of dyspepsia: a systematic review.

By Delaney B, Moayyedi P, Deeks J, Innes M, Soo S, Barton P, *et al.*

No. 40
A systematic review of treatments for severe psoriasis.

By Griffiths CEM, Clark CM, Chalmers RJG, Li Wan Po A, Williams HC.

Volume 5, 2001

No. 1
Clinical and cost-effectiveness of donepezil, rivastigmine and galantamine for Alzheimer's disease: a rapid and systematic review.

By Clegg A, Bryant J, Nicholson T, McIntyre L, De Broe S, Gerard K, *et al.*

No. 2
The clinical effectiveness and cost-effectiveness of riluzole for motor neurone disease: a rapid and systematic review.

By Stewart A, Sandercock J, Bryan S, Hyde C, Barton PM, Fry-Smith A, *et al.*

No. 3
Equity and the economic evaluation of healthcare.

By Sassi F, Archard L, Le Grand J.

No. 4
Quality-of-life measures in chronic diseases of childhood.

By Eiser C, Morse R.

No. 5
Eliciting public preferences for healthcare: a systematic review of techniques.

By Ryan M, Scott DA, Reeves C, Bate A, van Teijlingen ER, Russell EM, *et al.*

No. 6
General health status measures for people with cognitive impairment: learning disability and acquired brain injury.

By Riemsma RP, Forbes CA, Glanville JM, Eastwood AJ, Kleijnen J.

No. 7
An assessment of screening strategies for fragile X syndrome in the UK.

By Pembrey ME, Barnicoat AJ, Carmichael B, Bobrow M, Turner G.

No. 8
Issues in methodological research: perspectives from researchers and commissioners.

By Lilford RJ, Richardson A, Stevens A, Fitzpatrick R, Edwards S, Rock F, *et al.*

No. 9
Systematic reviews of wound care management: (5) beds; (6) compression; (7) laser therapy, therapeutic ultrasound, electrotherapy and electromagnetic therapy.

By Cullum N, Nelson EA, Flemming K, Sheldon T.

No. 10
Effects of educational and psychosocial interventions for adolescents with diabetes mellitus: a systematic review.

By Hampson SE, Skinner TC, Hart J, Storey L, Gage H, Foxcroft D, *et al.*

No. 11
Effectiveness of autologous chondrocyte transplantation for hyaline cartilage defects in knees: a rapid and systematic review.

By Jobanputra P, Parry D, Fry-Smith A, Burls A.

No. 12
Statistical assessment of the learning curves of health technologies.

By Ramsay CR, Grant AM, Wallace SA, Garthwaite PH, Monk AF, Russell IT.

No. 13
The effectiveness and cost-effectiveness of temozolomide for the treatment of recurrent malignant glioma: a rapid and systematic review.

By Dinnes J, Cave C, Huang S, Major K, Milne R.

No. 14
A rapid and systematic review of the clinical effectiveness and cost-effectiveness of debriding agents in treating surgical wounds healing by secondary intention.

By Lewis R, Whiting P, ter Riet G, O'Meara S, Glanville J.

No. 15
Home treatment for mental health problems: a systematic review.

By Burns T, Knapp M, Catty J, Healey A, Henderson J, Watt H, *et al.*

No. 16
How to develop cost-conscious guidelines.

By Eccles M, Mason J.

No. 17
The role of specialist nurses in multiple sclerosis: a rapid and systematic review.

By De Broe S, Christopher F, Waugh N.

No. 18
A rapid and systematic review of the clinical effectiveness and cost-effectiveness of orlistat in the management of obesity.

By O'Meara S, Riemsma R, Shirran L, Mather L, ter Riet G.

No. 19
The clinical effectiveness and cost-effectiveness of pioglitazone for type 2 diabetes mellitus: a rapid and systematic review.

By Chilcott J, Wight J, Lloyd Jones M, Tappenden P.

No. 20
Extended scope of nursing practice: a multicentre randomised controlled trial of appropriately trained nurses and preregistration house officers in pre-operative assessment in elective general surgery.

By Kinley H, Czoski-Murray C, George S, McCabe C, Primrose J, Reilly C, *et al.*

No. 21
Systematic reviews of the effectiveness of day care for people with severe mental disorders: (1) Acute day hospital versus admission; (2) Vocational rehabilitation; (3) Day hospital versus outpatient care.

By Marshall M, Crowther R, Almaraz-Serrano A, Creed F, Sledge W, Kluiter H, *et al.*

No. 22
The measurement and monitoring of surgical adverse events.

By Bruce J, Russell EM, Mollison J, Krukowski ZH.

No. 23
Action research: a systematic review and guidance for assessment.

By Waterman H, Tillen D, Dickson R, de Koning K.

No. 24
A rapid and systematic review of the clinical effectiveness and cost-effectiveness of gemcitabine for the treatment of pancreatic cancer.

By Ward S, Morris E, Bansback N, Calvert N, Crellin A, Forman D, *et al.*

No. 25
A rapid and systematic review of the evidence for the clinical effectiveness and cost-effectiveness of irinotecan, oxaliplatin and raltitrexed for the treatment of advanced colorectal cancer.
By Lloyd Jones M, Hummel S, Bansback N, Orr B, Seymour M.

No. 26
Comparison of the effectiveness of inhaler devices in asthma and chronic obstructive airways disease: a systematic review of the literature.
By Brocklebank D, Ram F, Wright J, Barry P, Cates C, Davies L, *et al*.

No. 27
The cost-effectiveness of magnetic resonance imaging for investigation of the knee joint.
By Bryan S, Weatherburn G, Bungay H, Hatrick C, Salas C, Parry D, *et al*.

No. 28
A rapid and systematic review of the clinical effectiveness and cost-effectiveness of topotecan for ovarian cancer.
By Forbes C, Shirran L, Bagnall A-M, Duffy S, ter Riet G.

No. 29
Superseded by a report published in a later volume.

No. 30
The role of radiography in primary care patients with low back pain of at least 6 weeks duration: a randomised (unblinded) controlled trial.
By Kendrick D, Fielding K, Bentley E, Miller P, Kerslake R, Pringle M.

No. 31
Design and use of questionnaires: a review of best practice applicable to surveys of health service staff and patients.
By McColl E, Jacoby A, Thomas L, Soutter J, Bamford C, Steen N, *et al*.

No. 32
A rapid and systematic review of the clinical effectiveness and cost-effectiveness of paclitaxel, docetaxel, gemcitabine and vinorelbine in non-small-cell lung cancer.
By Clegg A, Scott DA, Sidhu M, Hewitson P, Waugh N.

No. 33
Subgroup analyses in randomised controlled trials: quantifying the risks of false-positives and false-negatives.
By Brookes ST, Whitley E, Peters TJ, Mulheran PA, Egger M, Davey Smith G.

No. 34
Depot antipsychotic medication in the treatment of patients with schizophrenia: (1) Meta-review; (2) Patient and nurse attitudes.
By David AS, Adams C.

No. 35
A systematic review of controlled trials of the effectiveness and cost-effectiveness of brief psychological treatments for depression.
By Churchill R, Hunot V, Corney R, Knapp M, McGuire H, Tylee A, *et al*.

No. 36
Cost analysis of child health surveillance.
By Sanderson D, Wright D, Acton C, Duree D.

Volume 6, 2002

No. 1
A study of the methods used to select review criteria for clinical audit.
By Hearnshaw H, Harker R, Cheater F, Baker R, Grimshaw G.

No. 2
Fludarabine as second-line therapy for B cell chronic lymphocytic leukaemia: a technology assessment.
By Hyde C, Wake B, Bryan S, Barton P, Fry-Smith A, Davenport C, *et al*.

No. 3
Rituximab as third-line treatment for refractory or recurrent Stage III or IV follicular non-Hodgkin's lymphoma: a systematic review and economic evaluation.
By Wake B, Hyde C, Bryan S, Barton P, Song F, Fry-Smith A, *et al*.

No. 4
A systematic review of discharge arrangements for older people.
By Parker SG, Peet SM, McPherson A, Cannaby AM, Baker R, Wilson A, *et al*.

No. 5
The clinical effectiveness and cost-effectiveness of inhaler devices used in the routine management of chronic asthma in older children: a systematic review and economic evaluation.
By Peters J, Stevenson M, Beverley C, Lim J, Smith S.

No. 6
The clinical effectiveness and cost-effectiveness of sibutramine in the management of obesity: a technology assessment.
By O'Meara S, Riemsma R, Shirran L, Mather L, ter Riet G.

No. 7
The cost-effectiveness of magnetic resonance angiography for carotid artery stenosis and peripheral vascular disease: a systematic review.
By Berry E, Kelly S, Westwood ME, Davies LM, Gough MJ, Bamford JM, *et al*.

No. 8
Promoting physical activity in South Asian Muslim women through 'exercise on prescription'.
By Carroll B, Ali N, Azam N.

No. 9
Zanamivir for the treatment of influenza in adults: a systematic review and economic evaluation.
By Burls A, Clark W, Stewart T, Preston C, Bryan S, Jefferson T, *et al*.

No. 10
A review of the natural history and epidemiology of multiple sclerosis: implications for resource allocation and health economic models.
By Richards RG, Sampson FC, Beard SM, Tappenden P.

No. 11
Screening for gestational diabetes: a systematic review and economic evaluation.
By Scott DA, Loveman E, McIntyre L, Waugh N.

No. 12
The clinical effectiveness and cost-effectiveness of surgery for people with morbid obesity: a systematic review and economic evaluation.
By Clegg AJ, Colquitt J, Sidhu MK, Royle P, Loveman E, Walker A.

No. 13
The clinical effectiveness of trastuzumab for breast cancer: a systematic review.
By Lewis R, Bagnall A-M, Forbes C, Shirran E, Duffy S, Kleijnen J, *et al*.

No. 14
The clinical effectiveness and cost-effectiveness of vinorelbine for breast cancer: a systematic review and economic evaluation.
By Lewis R, Bagnall A-M, King S, Woolacott N, Forbes C, Shirran L, *et al*.

No. 15
A systematic review of the effectiveness and cost-effectiveness of metal-on-metal hip resurfacing arthroplasty for treatment of hip disease.
By Vale L, Wyness L, McCormack K, McKenzie L, Brazzelli M, Stearns SC.

No. 16
The clinical effectiveness and cost-effectiveness of bupropion and nicotine replacement therapy for smoking cessation: a systematic review and economic evaluation.
By Woolacott NF, Jones L, Forbes CA, Mather LC, Sowden AJ, Song FJ, *et al*.

No. 17
A systematic review of effectiveness and economic evaluation of new drug treatments for juvenile idiopathic arthritis: etanercept.
By Cummins C, Connock M, Fry-Smith A, Burls A.

No. 18
Clinical effectiveness and cost-effectiveness of growth hormone in children: a systematic review and economic evaluation.
By Bryant J, Cave C, Mihaylova B, Chase D, McIntyre L, Gerard K, *et al*.

No. 19
Clinical effectiveness and cost-effectiveness of growth hormone in adults in relation to impact on quality of life: a systematic review and economic evaluation.
By Bryant J, Loveman E, Chase D, Mihaylova B, Cave C, Gerard K, *et al*.

No. 20
Clinical medication review by a pharmacist of patients on repeat prescriptions in general practice: a randomised controlled trial.
By Zermansky AG, Petty DR, Raynor DK, Lowe CJ, Freementle N, Vail A.

No. 21
The effectiveness of infliximab and etanercept for the treatment of rheumatoid arthritis: a systematic review and economic evaluation.
By Jobanputra P, Barton P, Bryan S, Burls A.

No. 22
A systematic review and economic evaluation of computerised cognitive behaviour therapy for depression and anxiety.
By Kaltenthaler E, Shackley P, Stevens K, Beverley C, Parry G, Chilcott J.

No. 23
A systematic review and economic evaluation of pegylated liposomal doxorubicin hydrochloride for ovarian cancer.
By Forbes C, Wilby J, Richardson G, Sculpher M, Mather L, Reimsma R.

No. 24
A systematic review of the effectiveness of interventions based on a stages-of-change approach to promote individual behaviour change.
By Riemsma RP, Pattenden J, Bridle C, Sowden AJ, Mather L, Watt IS, *et al*.

No. 25
A systematic review update of the clinical effectiveness and cost-effectiveness of glycoprotein IIb/IIIa antagonists.
By Robinson M, Ginnelly L, Sculpher M, Jones L, Riemsma R, Palmer S, *et al*.

No. 26
A systematic review of the effectiveness, cost-effectiveness and barriers to implementation of thrombolytic and neuroprotective therapy for acute ischaemic stroke in the NHS.
By Sandercock P, Berge E, Dennis M, Forbes J, Hand P, Kwan J, *et al*.

No. 27
A randomised controlled crossover trial of nurse practitioner versus doctor-led outpatient care in a bronchiectasis clinic.
By Caine N, Sharples LD, Hollingworth W, French J, Keogan M, Exley A, *et al*.

No. 28
Clinical effectiveness and cost – consequences of selective serotonin reuptake inhibitors in the treatment of sex offenders.
By Adi Y, Ashcroft D, Browne K, Beech A, Fry-Smith A, Hyde C.

No. 29
Treatment of established osteoporosis: a systematic review and cost–utility analysis.
By Kanis JA, Brazier JE, Stevenson M, Calvert NW, Lloyd Jones M.

No. 30
Which anaesthetic agents are cost-effective in day surgery? Literature review, national survey of practice and randomised controlled trial.
By Elliott RA Payne K, Moore JK, Davies LM, Harper NJN, St Leger AS, *et al*.

No. 31
Screening for hepatitis C among injecting drug users and in genitourinary medicine clinics: systematic reviews of effectiveness, modelling study and national survey of current practice.
By Stein K, Dalziel K, Walker A, McIntyre L, Jenkins B, Horne J, *et al*.

No. 32
The measurement of satisfaction with healthcare: implications for practice from a systematic review of the literature.
By Crow R, Gage H, Hampson S, Hart J, Kimber A, Storey L, *et al*.

No. 33
The effectiveness and cost-effectiveness of imatinib in chronic myeloid leukaemia: a systematic review.
By Garside R, Round A, Dalziel K, Stein K, Royle R.

No. 34
A comparative study of hypertonic saline, daily and alternate-day rhDNase in children with cystic fibrosis.
By Suri R, Wallis C, Bush A, Thompson S, Normand C, Flather M, *et al*.

No. 35
A systematic review of the costs and effectiveness of different models of paediatric home care.
By Parker G, Bhakta P, Lovett CA, Paisley S, Olsen R, Turner D, *et al*.

Volume 7, 2003

No. 1
How important are comprehensive literature searches and the assessment of trial quality in systematic reviews? Empirical study.
By Egger M, Jüni P, Bartlett C, Holenstein F, Sterne J.

No. 2
Systematic review of the effectiveness and cost-effectiveness, and economic evaluation, of home versus hospital or satellite unit haemodialysis for people with end-stage renal failure.
By Mowatt G, Vale L, Perez J, Wyness L, Fraser C, MacLeod A, *et al*.

No. 3
Systematic review and economic evaluation of the effectiveness of infliximab for the treatment of Crohn's disease.
By Clark W, Raftery J, Barton P, Song F, Fry-Smith A, Burls A.

No. 4
A review of the clinical effectiveness and cost-effectiveness of routine anti-D prophylaxis for pregnant women who are rhesus negative.
By Chilcott J, Lloyd Jones M, Wight J, Forman K, Wray J, Beverley C, *et al*.

No. 5
Systematic review and evaluation of the use of tumour markers in paediatric oncology: Ewing's sarcoma and neuroblastoma.
By Riley RD, Burchill SA, Abrams KR, Heney D, Lambert PC, Jones DR, *et al*.

No. 6
The cost-effectiveness of screening for *Helicobacter pylori* to reduce mortality and morbidity from gastric cancer and peptic ulcer disease: a discrete-event simulation model.
By Roderick P, Davies R, Raftery J, Crabbe D, Pearce R, Bhandari P, *et al*.

No. 7
The clinical effectiveness and cost-effectiveness of routine dental checks: a systematic review and economic evaluation.
By Davenport C, Elley K, Salas C, Taylor-Weetman CL, Fry-Smith A, Bryan S, *et al*.

No. 8
A multicentre randomised controlled trial assessing the costs and benefits of using structured information and analysis of women's preferences in the management of menorrhagia.
By Kennedy ADM, Sculpher MJ, Coulter A, Dwyer N, Rees M, Horsley S, *et al*.

No. 9
Clinical effectiveness and cost–utility of photodynamic therapy for wet age-related macular degeneration: a systematic review and economic evaluation.
By Meads C, Salas C, Roberts T, Moore D, Fry-Smith A, Hyde C.

No. 10
Evaluation of molecular tests for prenatal diagnosis of chromosome abnormalities.
By Grimshaw GM, Szczepura A, Hultén M, MacDonald F, Nevin NC, Sutton F, *et al*.

No. 11
First and second trimester antenatal screening for Down's syndrome: the results of the Serum, Urine and Ultrasound Screening Study (SURUSS).
By Wald NJ, Rodeck C, Hackshaw AK, Walters J, Chitty L, Mackinson AM.

No. 12
The effectiveness and cost-effectiveness of ultrasound locating devices for central venous access: a systematic review and economic evaluation.
By Calvert N, Hind D, McWilliams RG, Thomas SM, Beverley C, Davidson A.

No. 13
A systematic review of atypical antipsychotics in schizophrenia.
By Bagnall A-M, Jones L, Lewis R, Ginnelly L, Glanville J, Torgerson D, *et al*.

No. 14
Prostate Testing for Cancer and Treatment (ProtecT) feasibility study.
By Donovan J, Hamdy F, Neal D, Peters T, Oliver S, Brindle L, *et al*.

No. 15
Early thrombolysis for the treatment of acute myocardial infarction: a systematic review and economic evaluation.
By Boland A, Dundar Y, Bagust A, Haycox A, Hill R, Mujica Mota R, *et al*.

No. 16
Screening for fragile X syndrome: a literature review and modelling.
By Song FJ, Barton P, Sleightholme V, Yao GL, Fry-Smith A.

No. 17
Systematic review of endoscopic sinus surgery for nasal polyps.
By Dalziel K, Stein K, Round A, Garside R, Royle P.

No. 18
Towards efficient guidelines: how to monitor guideline use in primary care.
By Hutchinson A, McIntosh A, Cox S, Gilbert C.

No. 19
Effectiveness and cost-effectiveness of acute hospital-based spinal cord injuries services: systematic review.
By Bagnall A-M, Jones L, Richardson G, Duffy S, Riemsma R.

No. 20
Prioritisation of health technology assessment. The PATHS model: methods and case studies.
By Townsend J, Buxton M, Harper G.

No. 21
Systematic review of the clinical effectiveness and cost-effectiveness of tension-free vaginal tape for treatment of urinary stress incontinence.
By Cody J, Wyness L, Wallace S, Glazener C, Kilonzo M, Stearns S, *et al*.

No. 22
The clinical and cost-effectiveness of patient education models for diabetes: a systematic review and economic evaluation.
By Loveman E, Cave C, Green C, Royle P, Dunn N, Waugh N.

No. 23
The role of modelling in prioritising and planning clinical trials.
By Chilcott J, Brennan A, Booth A, Karnon J, Tappenden P.

No. 24
Cost–benefit evaluation of routine influenza immunisation in people 65–74 years of age.
By Allsup S, Gosney M, Haycox A, Regan M.

No. 25
The clinical and cost-effectiveness of pulsatile machine perfusion versus cold storage of kidneys for transplantation retrieved from heart-beating and non-heart-beating donors.
By Wight J, Chilcott J, Holmes M, Brewer N.

No. 26
Can randomised trials rely on existing electronic data? A feasibility study to explore the value of routine data in health technology assessment.
By Williams JG, Cheung WY, Cohen DR, Hutchings HA, Longo MF, Russell IT.

No. 27
Evaluating non-randomised intervention studies.
By Deeks JJ, Dinnes J, D'Amico R, Sowden AJ, Sakarovitch C, Song F, *et al*.

No. 28
A randomised controlled trial to assess the impact of a package comprising a patient-orientated, evidence-based self-help guidebook and patient-centred consultations on disease management and satisfaction in inflammatory bowel disease.
By Kennedy A, Nelson E, Reeves D, Richardson G, Roberts C, Robinson A, *et al*.

No. 29
The effectiveness of diagnostic tests for the assessment of shoulder pain due to soft tissue disorders: a systematic review.
By Dinnes J, Loveman E, McIntyre L, Waugh N.

No. 30
The value of digital imaging in diabetic retinopathy.
By Sharp PF, Olson J, Strachan F, Hipwell J, Ludbrook A, O'Donnell M, *et al*.

No. 31
Lowering blood pressure to prevent myocardial infarction and stroke: a new preventive strategy.
By Law M, Wald N, Morris J.

No. 32
Clinical and cost-effectiveness of capecitabine and tegafur with uracil for the treatment of metastatic colorectal cancer: systematic review and economic evaluation.
By Ward S, Kaltenthaler E, Cowan J, Brewer N.

No. 33
Clinical and cost-effectiveness of new and emerging technologies for early localised prostate cancer: a systematic review.
By Hummel S, Paisley S, Morgan A, Currie E, Brewer N.

No. 34
Literature searching for clinical and cost-effectiveness studies used in health technology assessment reports carried out for the National Institute for Clinical Excellence appraisal system.
By Royle P, Waugh N.

No. 35
Systematic review and economic decision modelling for the prevention and treatment of influenza A and B.
By Turner D, Wailoo A, Nicholson K, Cooper N, Sutton A, Abrams K.

No. 36
A randomised controlled trial to evaluate the clinical and cost-effectiveness of Hickman line insertions in adult cancer patients by nurses.
By Boland A, Haycox A, Bagust A, Fitzsimmons L.

No. 37
Redesigning postnatal care: a randomised controlled trial of protocol-based midwifery-led care focused on individual women's physical and psychological health needs.
By MacArthur C, Winter HR, Bick DE, Lilford RJ, Lancashire RJ, Knowles H, *et al*.

No. 38
Estimating implied rates of discount in healthcare decision-making.
By West RR, McNabb R, Thompson AGH, Sheldon TA, Grimley Evans J.

No. 39
Systematic review of isolation policies in the hospital management of methicillin-resistant *Staphylococcus aureus*: a review of the literature with epidemiological and economic modelling.
By Cooper BS, Stone SP, Kibbler CC, Cookson BD, Roberts JA, Medley GF, *et al*.

No. 40
Treatments for spasticity and pain in multiple sclerosis: a systematic review.
By Beard S, Hunn A, Wight J.

No. 41
The inclusion of reports of randomised trials published in languages other than English in systematic reviews.
By Moher D, Pham B, Lawson ML, Klassen TP.

No. 42
The impact of screening on future health-promoting behaviours and health beliefs: a systematic review.
By Bankhead CR, Brett J, Bukach C, Webster P, Stewart-Brown S, Munafo M, *et al*.

Volume 8, 2004

No. 1
What is the best imaging strategy for acute stroke?
By Wardlaw JM, Keir SL, Seymour J, Lewis S, Sandercock PAG, Dennis MS, *et al*.

No. 2
Systematic review and modelling of the investigation of acute and chronic chest pain presenting in primary care.
By Mant J, McManus RJ, Oakes RAL, Delaney BC, Barton PM, Deeks JJ, *et al*.

No. 3
The effectiveness and cost-effectiveness of microwave and thermal balloon endometrial ablation for heavy menstrual bleeding: a systematic review and economic modelling.
By Garside R, Stein K, Wyatt K, Round A, Price A.

No. 4
A systematic review of the role of bisphosphonates in metastatic disease.
By Ross JR, Saunders Y, Edmonds PM, Patel S, Wonderling D, Normand C, *et al*.

No. 5
Systematic review of the clinical effectiveness and cost-effectiveness of capecitabine (Xeloda®) for locally advanced and/or metastatic breast cancer.
By Jones L, Hawkins N, Westwood M, Wright K, Richardson G, Riemsma R.

No. 6
Effectiveness and efficiency of guideline dissemination and implementation strategies.
By Grimshaw JM, Thomas RE, MacLennan G, Fraser C, Ramsay CR, Vale L, *et al*.

No. 7
Clinical effectiveness and costs of the Sugarbaker procedure for the treatment of pseudomyxoma peritonei.
By Bryant J, Clegg AJ, Sidhu MK, Brodin H, Royle P, Davidson P.

No. 8
Psychological treatment for insomnia in the regulation of long-term hypnotic drug use.
By Morgan K, Dixon S, Mathers N, Thompson J, Tomeny M.

No. 9
Improving the evaluation of therapeutic interventions in multiple sclerosis: development of a patient-based measure of outcome.
By Hobart JC, Riazi A, Lamping DL, Fitzpatrick R, Thompson AJ.

No. 10
A systematic review and economic evaluation of magnetic resonance cholangiopancreatography compared with diagnostic endoscopic retrograde cholangiopancreatography.
By Kaltenthaler E, Bravo Vergel Y, Chilcott J, Thomas S, Blakeborough T, Walters SJ, *et al*.

No. 11
The use of modelling to evaluate new drugs for patients with a chronic condition: the case of antibodies against tumour necrosis factor in rheumatoid arthritis.
By Barton P, Jobanputra P, Wilson J, Bryan S, Burls A.

No. 12
Clinical effectiveness and cost-effectiveness of neonatal screening for inborn errors of metabolism using tandem mass spectrometry: a systematic review.
By Pandor A, Eastham J, Beverley C, Chilcott J, Paisley S.

No. 13
Clinical effectiveness and cost-effectiveness of pioglitazone and rosiglitazone in the treatment of type 2 diabetes: a systematic review and economic evaluation.
By Czoski-Murray C, Warren E, Chilcott J, Beverley C, Psyllaki MA, Cowan J.

No. 14
Routine examination of the newborn: the EMREN study. Evaluation of an extension of the midwife role including a randomised controlled trial of appropriately trained midwives and paediatric senior house officers.
By Townsend J, Wolke D, Hayes J, Davé S, Rogers C, Bloomfield L, *et al*.

No. 15
Involving consumers in research and development agenda setting for the NHS: developing an evidence-based approach.
By Oliver S, Clarke-Jones L, Rees R, Milne R, Buchanan P, Gabbay J, *et al*.

No. 16
A multi-centre randomised controlled trial of minimally invasive direct coronary bypass grafting versus percutaneous transluminal coronary angioplasty with stenting for proximal stenosis of the left anterior descending coronary artery.
By Reeves BC, Angelini GD, Bryan AJ, Taylor FC, Cripps T, Spyt TJ, *et al*.

No. 17
Does early magnetic resonance imaging influence management or improve outcome in patients referred to secondary care with low back pain? A pragmatic randomised controlled trial.
By Gilbert FJ, Grant AM, Gillan MGC, Vale L, Scott NW, Campbell MK, *et al*.

No. 18
The clinical and cost-effectiveness of anakinra for the treatment of rheumatoid arthritis in adults: a systematic review and economic analysis.
By Clark W, Jobanputra P, Barton P, Burls A.

No. 19
A rapid and systematic review and economic evaluation of the clinical and cost-effectiveness of newer drugs for treatment of mania associated with bipolar affective disorder.
By Bridle C, Palmer S, Bagnall A-M, Darba J, Duffy S, Sculpher M, *et al*.

No. 20
Liquid-based cytology in cervical screening: an updated rapid and systematic review and economic analysis.
By Karnon J, Peters J, Platt J, Chilcott J, McGoogan E, Brewer N.

No. 21
Systematic review of the long-term effects and economic consequences of treatments for obesity and implications for health improvement.
By Avenell A, Broom J, Brown TJ, Poobalan A, Aucott L, Stearns SC, *et al*.

No. 22
Autoantibody testing in children with newly diagnosed type 1 diabetes mellitus.
By Dretzke J, Cummins C, Sandercock J, Fry-Smith A, Barrett T, Burls A.

No. 23
Clinical effectiveness and cost-effectiveness of prehospital intravenous fluids in trauma patients.
By Dretzke J, Sandercock J, Bayliss S, Burls A.

No. 24
Newer hypnotic drugs for the short-term management of insomnia: a systematic review and economic evaluation.
By Dündar Y, Boland A, Strobl J, Dodd S, Haycox A, Bagust A, *et al*.

No. 25
Development and validation of methods for assessing the quality of diagnostic accuracy studies.
By Whiting P, Rutjes AWS, Dinnes J, Reitsma JB, Bossuyt PMM, Kleijnen J.

No. 26
EVALUATE hysterectomy trial: a multicentre randomised trial comparing abdominal, vaginal and laparoscopic methods of hysterectomy.
By Garry R, Fountain J, Brown J, Manca A, Mason S, Sculpher M, *et al*.

No. 27
Methods for expected value of information analysis in complex health economic models: developments on the health economics of interferon-β and glatiramer acetate for multiple sclerosis.
By Tappenden P, Chilcott JB, Eggington S, Oakley J, McCabe C.

No. 28
Effectiveness and cost-effectiveness of imatinib for first-line treatment of chronic myeloid leukaemia in chronic phase: a systematic review and economic analysis.
By Dalziel K, Round A, Stein K, Garside R, Price A.

No. 29
VenUS I: a randomised controlled trial of two types of bandage for treating venous leg ulcers.
By Iglesias C, Nelson EA, Cullum NA, Torgerson DJ on behalf of the VenUS Team.

No. 30
Systematic review of the effectiveness and cost-effectiveness, and economic evaluation, of myocardial perfusion scintigraphy for the diagnosis and management of angina and myocardial infarction.
By Mowatt G, Vale L, Brazzelli M, Hernandez R, Murray A, Scott N, *et al*.

No. 31
A pilot study on the use of decision theory and value of information analysis as part of the NHS Health Technology Assessment programme.
By Claxton K, Ginnelly L, Sculpher M, Philips Z, Palmer S.

No. 32
The Social Support and Family Health Study: a randomised controlled trial and economic evaluation of two alternative forms of postnatal support for mothers living in disadvantaged inner-city areas.
By Wiggins M, Oakley A, Roberts I, Turner H, Rajan L, Austerberry H, *et al*.

No. 33
Psychosocial aspects of genetic screening of pregnant women and newborns: a systematic review.
By Green JM, Hewison J, Bekker HL, Bryant, Cuckle HS.

No. 34
Evaluation of abnormal uterine bleeding: comparison of three outpatient procedures within cohorts defined by age and menopausal status.
By Critchley HOD, Warner P, Lee AJ, Brechin S, Guise J, Graham B.

No. 35
Coronary artery stents: a rapid systematic review and economic evaluation.
By Hill R, Bagust A, Bakhai A, Dickson R, Dündar Y, Haycox A, *et al*.

No. 36
Review of guidelines for good practice in decision-analytic modelling in health technology assessment.
By Philips Z, Ginnelly L, Sculpher M, Claxton K, Golder S, Riemsma R, *et al*.

No. 37
Rituximab (MabThera®) for aggressive non-Hodgkin's lymphoma: systematic review and economic evaluation.
By Knight C, Hind D, Brewer N, Abbott V.

No. 38
Clinical effectiveness and cost-effectiveness of clopidogrel and modified-release dipyridamole in the secondary prevention of occlusive vascular events: a systematic review and economic evaluation.
By Jones L, Griffin S, Palmer S, Main C, Orton V, Sculpher M, *et al*.

No. 39
Pegylated interferon α-2a and -2b in combination with ribavirin in the treatment of chronic hepatitis C: a systematic review and economic evaluation.
By Shepherd J, Brodin H, Cave C, Waugh N, Price A, Gabbay J.

No. 40
Clopidogrel used in combination with aspirin compared with aspirin alone in the treatment of non-ST-segment-elevation acute coronary syndromes: a systematic review and economic evaluation.
By Main C, Palmer S, Griffin S, Jones L, Orton V, Sculpher M, *et al*.

No. 41
Provision, uptake and cost of cardiac rehabilitation programmes: improving services to under-represented groups.
By Beswick AD, Rees K, Griebsch I, Taylor FC, Burke M, West RR, *et al*.

No. 42
Involving South Asian patients in clinical trials.
By Hussain-Gambles M, Leese B, Atkin K, Brown J, Mason S, Tovey P.

No. 43
Clinical and cost-effectiveness of continuous subcutaneous insulin infusion for diabetes.
By Colquitt JL, Green C, Sidhu MK, Hartwell D, Waugh N.

No. 44
Identification and assessment of ongoing trials in health technology assessment reviews.
By Song FJ, Fry-Smith A, Davenport C, Bayliss S, Adi Y, Wilson JS, *et al*.

No. 45
Systematic review and economic evaluation of a long-acting insulin analogue, insulin glargine
By Warren E, Weatherley-Jones E, Chilcott J, Beverley C.

No. 46
Supplementation of a home-based exercise programme with a class-based programme for people with osteoarthritis of the knees: a randomised controlled trial and health economic analysis.
By McCarthy CJ, Mills PM, Pullen R, Richardson G, Hawkins N, Roberts CR, *et al*.

No. 47
Clinical and cost-effectiveness of once-daily versus more frequent use of same potency topical corticosteroids for atopic eczema: a systematic review and economic evaluation.
By Green C, Colquitt JL, Kirby J, Davidson P, Payne E.

No. 48
Acupuncture of chronic headache disorders in primary care: randomised controlled trial and economic analysis.
By Vickers AJ, Rees RW, Zollman CE, McCarney R, Smith CM, Ellis N, *et al*.

No. 49
Generalisability in economic evaluation studies in healthcare: a review and case studies.
By Sculpher MJ, Pang FS, Manca A, Drummond MF, Golder S, Urdahl H, *et al*.

No. 50
Virtual outreach: a randomised controlled trial and economic evaluation of joint teleconferenced medical consultations.
By Wallace P, Barber J, Clayton W, Currell R, Fleming K, Garner P, *et al*.

213

Health Technology Assessment Programme

Prioritisation Strategy Group

Members

Chair,
Professor Tom Walley,
Director, NHS HTA Programme,
Department of Pharmacology &
Therapeutics,
University of Liverpool

Professor Bruce Campbell,
Consultant Vascular & General
Surgeon, Royal Devon & Exeter
Hospital

Professor Shah Ebrahim,
Professor in Epidemiology
of Ageing, University of
Bristol

Dr John Reynolds, Clinical
Director, Acute General
Medicine SDU, Radcliffe
Hospital, Oxford

Dr Ron Zimmern, Director,
Public Health Genetics Unit,
Strangeways Research
Laboratories, Cambridge

HTA Commissioning Board

Members

Programme Director,
Professor Tom Walley,
Director, NHS HTA Programme,
Department of Pharmacology &
Therapeutics,
University of Liverpool

Chair,
Professor Shah Ebrahim,
Professor in Epidemiology of
Ageing, Department of Social
Medicine, University of Bristol

Deputy Chair,
Professor Jenny Hewison,
Professor of Health Care
Psychology, Academic Unit of
Psychiatry and Behavioural
Sciences, University of Leeds
School of Medicine

Dr Jeffrey Aronson
Reader in Clinical
Pharmacology, Department of
Clinical Pharmacology,
Radcliffe Infirmary, Oxford

Professor Ann Bowling,
Professor of Health Services
Research, Primary Care and
Population Studies,
University College London

Professor Andrew Bradbury,
Professor of Vascular Surgery,
Department of Vascular Surgery,
Birmingham Heartlands
Hospital

Professor John Brazier, Director
of Health Economics,
Sheffield Health Economics
Group, School of Health &
Related Research,
University of Sheffield

Dr Andrew Briggs, Public
Health Career Scientist, Health
Economics Research Centre,
University of Oxford

Professor Nicky Cullum,
Director of Centre for Evidence
Based Nursing, Department of
Health Sciences, University of
York

Dr Andrew Farmer, Senior
Lecturer in General Practice,
Department of Primary Health
Care, University of Oxford

Professor Fiona J Gilbert,
Professor of Radiology,
Department of Radiology,
University of Aberdeen

Professor Adrian Grant,
Director, Health Services
Research Unit, University of
Aberdeen

Professor F D Richard Hobbs,
Professor of Primary Care &
General Practice, Department of
Primary Care & General
Practice, University of
Birmingham

Professor Peter Jones, Head of
Department, University
Department of Psychiatry,
University of Cambridge

Professor Sallie Lamb, Research
Professor in Physiotherapy/Co-
Director, Interdisciplinary
Research Centre in Health,
Coventry University

Professor Julian Little,
Professor of Epidemiology,
Department of Medicine and
Therapeutics, University of
Aberdeen

Professor Stuart Logan,
Director of Health & Social
Care Research, The Peninsula
Medical School, Universities of
Exeter & Plymouth

Professor Tim Peters, Professor
of Primary Care Health Services
Research, Division of Primary
Health Care, University of
Bristol

Professor Ian Roberts, Professor
of Epidemiology & Public
Health, Intervention Research
Unit, London School of
Hygiene and Tropical Medicine

Professor Peter Sandercock,
Professor of Medical Neurology,
Department of Clinical
Neurosciences, University of
Edinburgh

Professor Mark Sculpher,
Professor of Health Economics,
Centre for Health Economics,
Institute for Research in the
Social Services, University of York

Professor Martin Severs,
Professor in Elderly Health
Care, Portsmouth Institute of
Medicine

Dr Jonathan Shapiro, Senior
Fellow, Health Services
Management Centre,
Birmingham

Ms Kate Thomas,
Deputy Director,
Medical Care Research Unit,
University of Sheffield

Professor Simon G Thompson,
Director, MRC Biostatistics
Unit, Institute of Public Health,
Cambridge

Ms Sue Ziebland,
Senior Research Fellow,
Cancer Research UK,
University of Oxford

Diagnostic Technologies & Screening Panel

Members

Chair,
Dr Ron Zimmern, Director of the Public Health Genetics Unit, Strangeways Research Laboratories, Cambridge

Ms Norma Armston, Freelance Consumer Advocate, Bolton

Professor Max Bachmann Professor Health Care Interfaces, Department of Health Policy and Practice, University of East Anglia

Professor Rudy Bilous Professor of Clinical Medicine & Consultant Physician, The Academic Centre, South Tees Hospitals NHS Trust

Dr Paul Cockcroft, Consultant Medical Microbiologist/Laboratory Director, Public Health Laboratory, St Mary's Hospital, Portsmouth

Professor Adrian K Dixon, Professor of Radiology, Addenbrooke's Hospital, Cambridge

Dr David Elliman, Consultant in Community Child Health, London

Professor Glyn Elwyn, Primary Medical Care Research Group, Swansea Clinical School, University of Wales Swansea

Dr John Fielding, Consultant Radiologist, Radiology Department, Royal Shrewsbury Hospital

Dr Karen N Foster, Clinical Lecturer, Dept of General Practice & Primary Care, University of Aberdeen

Professor Antony J Franks, Deputy Medical Director, The Leeds Teaching Hospitals NHS Trust

Mr Tam Fry, Honorary Chairman, Child Growth Foundation, London

Dr Edmund Jessop, Medical Adviser, National Specialist Commissioning Advisory Group (NSCAG), Department of Health, London

Dr Jennifer J Kurinczuk, Consultant Clinical Epidemiologist, National Perinatal Epidemiology Unit, Oxford

Dr Susanne M Ludgate, Medical Director, Medical Devices Agency, London

Dr William Rosenberg, Senior Lecturer and Consultant in Medicine, University of Southampton

Dr Susan Schonfield, CPHM Specialised Services Commissioning, Croydon Primary Care Trust

Dr Margaret Somerville, Director of Public Health, Teignbridge Primary Care Trust

Professor Lindsay Wilson Turnbull, Scientific Director, Centre for MR Investigations & YCR Professor of Radiology, University of Hull

Professor Martin J Whittle, Head of Division of Reproductive & Child Health, University of Birmingham

Dr Dennis Wright, Consultant Biochemist & Clinical Director, Pathology & The Kennedy Galton Centre, Northwick Park & St Mark's Hospitals, Harrow

Pharmaceuticals Panel

Members

Chair,
Dr John Reynolds, Clinical Director, Acute General Medicine SDU, Oxford Radcliffe Hospital

Professor Tony Avery, Professor of Primary Health Care, University of Nottingham

Professor Stirling Bryan, Professor of Health Economics, Health Services Management Centre, University of Birmingham

Mr Peter Cardy, Chief Executive, Macmillan Cancer Relief, London

Dr Christopher Cates, GP and Cochrane Editor, Bushey Health Centre

Professor Imti Choonara, Professor in Child Health, University of Nottingham, Derbyshire Children's Hospital

Mr Charles Dobson, Special Projects Adviser, Department of Health

Dr Robin Ferner, Consultant Physician and Director, West Midlands Centre for Adverse Drug Reactions, City Hospital NHS Trust, Birmingham

Dr Karen A Fitzgerald, Pharmaceutical Adviser, Bro Taf Health Authority, Cardiff

Mrs Sharon Hart, Managing Editor, *Drug & Therapeutics Bulletin*, London

Dr Christine Hine, Consultant in Public Health Medicine, Bristol South & West Primary Care Trust

Professor Stan Kaye, Professor of Medical Oncology, Consultant in Medical Oncology/Drug Development, The Royal Marsden Hospital

Ms Barbara Meredith, Project Manager Clinical Guidelines, Patient Involvement Unit, NICE

Dr Frances Rotblat, CPMP Delegate, Medicines Control Agency, London

Professor Jan Scott, Professor of Psychological Treatments, Institute of Psychiatry, University of London

Mrs Katrina Simister, New Products Manager, National Prescribing Centre, Liverpool

Dr Richard Tiner, Medical Director, Association of the British Pharmaceutical Industry

Dr Helen Williams, Consultant Microbiologist, Norfolk & Norwich University Hospital NHS Trust

Current and past membership details of all HTA 'committees' are available from the HTA website (www.ncchta.org)

Therapeutic Procedures Panel

Members

**Chair,
Professor Bruce Campbell,**
Consultant Vascular and
General Surgeon, Royal Devon
& Exeter Hospital

Dr Mahmood Adil, Head of
Clinical Support & Health
Protection, Directorate of
Health and Social Care (North),
Department of Health,
Manchester

Dr Aileen Clarke,
Reader in Health Services
Research, Public Health &
Policy Research Unit,
Barts & the London School of
Medicine & Dentistry,
Institute of Community Health
Sciences, Queen Mary,
University of London

Mr Matthew William Cooke,
Senior Clinical Lecturer and
Honorary Consultant,
Emergency Department,
University of Warwick, Coventry
& Warwickshire NHS Trust,
Division of Health in the
Community, Centre for Primary
Health Care Studies, Coventry

Dr Carl E Counsell, Senior
Lecturer in Neurology,
University of Aberdeen

Dr Keith Dodd, Consultant
Paediatrician, Derbyshire
Children's Hospital

Professor Gene Feder, Professor
of Primary Care R&D, Barts &
the London, Queen Mary's
School of Medicine and
Dentistry, University of London

Professor Paul Gregg,
Professor of Orthopaedic
Surgical Science, Department of
Orthopaedic Surgery,
South Tees Hospital NHS Trust

Ms Bec Hanley, Freelance
Consumer Advocate,
Hurstpierpoint

Ms Maryann L. Hardy,
Lecturer,
Division of Radiography,
University of Bradford

Professor Alan Horwich,
Director of Clinical R&D, The
Institute of Cancer Research,
London

Dr Phillip Leech, Principal
Medical Officer for Primary
Care, Department of Health,
London

Dr Simon de Lusignan,
Senior Lecturer, Primary Care
Informatics, Department of
Community Health Sciences,
St George's Hospital Medical
School, London

Dr Mike McGovern, Senior
Medical Officer, Heart Team,
Department of Health, London

Professor James Neilson,
Professor of Obstetrics and
Gynaecology, Dept of Obstetrics
and Gynaecology,
University of Liverpool,
Liverpool Women's Hospital

Dr John C Pounsford,
Consultant Physician, North
Bristol NHS Trust

Dr Vimal Sharma,
Consultant Psychiatrist & Hon
Snr Lecturer,
Mental Health Resource Centre,
Victoria Central Hospital,
Wirral

Dr L David Smith, Consultant
Cardiologist, Royal Devon &
Exeter Hospital

Professor Norman Waugh,
Professor of Public Health,
University of Aberdeen

Current and past membership details of all HTA 'committees' are available from the HTA website (www.ncchta.org)

Expert Advisory Network

Members

Professor Douglas Altman,
Director of CSM & Cancer
Research UK Med Stat Gp,
Centre for Statistics in
Medicine, University of Oxford,
Institute of Health Sciences,
Headington, Oxford

Professor John Bond,
Director, Centre for Health
Services Research,
University of Newcastle upon
Tyne, School of Population &
Health Sciences,
Newcastle upon Tyne

Mr Shaun Brogan,
Chief Executive, Ridgeway
Primary Care Group, Aylesbury

Mrs Stella Burnside OBE,
Chief Executive,
Office of the Chief Executive.
Trust Headquarters,
Altnagelvin Hospitals Health &
Social Services Trust,
Altnagelvin Area Hospital,
Londonderry

Ms Tracy Bury,
Project Manager, World
Confederation for Physical
Therapy, London

Mr John A Cairns,
Professor of Health Economics,
Health Economics Research
Unit, University of Aberdeen

Professor Iain T Cameron,
Professor of Obstetrics and
Gynaecology and Head of the
School of Medicine,
University of Southampton

Dr Christine Clark,
Medical Writer & Consultant
Pharmacist, Rossendale

Professor Collette Mary Clifford,
Professor of Nursing & Head of
Research, School of Health
Sciences, University of
Birmingham, Edgbaston,
Birmingham

Professor Barry Cookson,
Director,
Laboratory of Healthcare
Associated Infection,
Health Protection Agency,
London

Professor Howard Stephen Cuckle,
Professor of Reproductive
Epidemiology, Department of
Paediatrics, Obstetrics &
Gynaecology, University of
Leeds

Professor Nicky Cullum,
Director of Centre for Evidence
Based Nursing, University of York

Dr Katherine Darton,
Information Unit, MIND – The
Mental Health Charity, London

Professor Carol Dezateux,
Professor of Paediatric
Epidemiology, London

Mr John Dunning,
Consultant Cardiothoracic
Surgeon, Cardiothoracic
Surgical Unit, Papworth
Hospital NHS Trust, Cambridge

Mr Jonothan Earnshaw,
Consultant Vascular Surgeon,
Gloucestershire Royal Hospital,
Gloucester

Professor Martin Eccles,
Professor of Clinical
Effectiveness, Centre for Health
Services Research, University of
Newcastle upon Tyne

Professor Pam Enderby,
Professor of Community
Rehabilitation, Institute of
General Practice and Primary
Care, University of Sheffield

Mr Leonard R Fenwick,
Chief Executive, Newcastle
upon Tyne Hospitals NHS Trust

Professor David Field,
Professor of Neonatal Medicine,
Child Health, The Leicester
Royal Infirmary NHS Trust

Mrs Gillian Fletcher,
Antenatal Teacher & Tutor and
President, National Childbirth
Trust, Henfield

Professor Jayne Franklyn,
Professor of Medicine,
Department of Medicine,
University of Birmingham,
Queen Elizabeth Hospital,
Edgbaston, Birmingham

Ms Grace Gibbs,
Deputy Chief Executive,
Director for Nursing, Midwifery
& Clinical Support Servs,
West Middlesex University
Hospital, Isleworth

Dr Neville Goodman,
Consultant Anaesthetist,
Southmead Hospital, Bristol

Professor Alastair Gray,
Professor of Health Economics,
Department of Public Health,
University of Oxford

Professor Robert E Hawkins,
CRC Professor and Director of
Medical Oncology, Christie CRC
Research Centre, Christie
Hospital NHS Trust, Manchester

Professor F D Richard Hobbs,
Professor of Primary Care &
General Practice, Department of
Primary Care & General
Practice, University of
Birmingham

Professor Allen Hutchinson,
Director of Public Health &
Deputy Dean of ScHARR,
Department of Public Health,
University of Sheffield

Dr Duncan Keeley,
General Practitioner (Dr Burch
& Ptnrs), The Health Centre,
Thame

Dr Donna Lamping,
Research Degrees Programme
Director & Reader in Psychology,
Health Services Research Unit,
London School of Hygiene and
Tropical Medicine, London

Mr George Levvy,
Chief Executive, Motor
Neurone Disease Association,
Northampton

Professor James Lindesay,
Professor of Psychiatry for the
Elderly, University of Leicester,
Leicester General Hospital

Professor Rajan Madhok,
Medical Director & Director of
Public Health, Directorate of
Clinical Strategy & Public
Health, North & East Yorkshire
& Northern Lincolnshire Health
Authority, York

Professor David Mant,
Professor of General Practice,
Department of Primary Care,
University of Oxford

Professor Alexander Markham,
Director, Molecular Medicine
Unit, St James's University
Hospital, Leeds

Dr Chris McCall,
General Practitioner,
The Hadleigh Practice,
Castle Mullen

Professor Alistair McGuire,
Professor of Health Economics,
London School of Economics

Dr Peter Moore,
Freelance Science Writer,
Ashtead

Dr Andrew Mortimore,
Consultant in Public Health
Medicine, Southampton City
Primary Care Trust

Dr Sue Moss,
Associate Director, Cancer
Screening Evaluation Unit,
Institute of Cancer Research,
Sutton

Professor Jon Nicholl,
Director of Medical Care
Research Unit, School of Health
and Related Research,
University of Sheffield

Mrs Julietta Patnick,
National Co-ordinator, NHS
Cancer Screening Programmes,
Sheffield

Professor Robert Peveler,
Professor of Liaison Psychiatry,
University Mental Health
Group, Royal South Hants
Hospital, Southampton

Professor Chris Price,
Visiting Chair – Oxford,
Clinical Research, Bayer
Diagnostics Europe,
Cirencester

Ms Marianne Rigge,
Director, College of Health,
London

Dr Eamonn Sheridan,
Consultant in Clinical Genetics,
Genetics Department,
St James's University Hospital,
Leeds

Dr Ken Stein,
Senior Clinical Lecturer in
Public Health, Director,
Peninsula Technology
Assessment Group,
University of Exeter

Professor Sarah Stewart-Brown,
Director HSRU/Honorary
Consultant in PH Medicine,
Department of Public Health,
University of Oxford

Professor Ala Szczepura,
Professor of Health Service
Research, Centre for Health
Services Studies, University of
Warwick

Dr Ross Taylor,
Senior Lecturer,
Department of General Practice
and Primary Care,
University of Aberdeen

Mrs Joan Webster,
Consumer member, HTA –
Expert Advisory Network

Current and past membership details of all HTA 'committees' are available from the HTA website (www.ncchta.org)